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Editorial on the Research Topic
Myokines, Adipokines, Cytokines in Muscle Pathophysiology
INTRODUCTION
Individual striated muscle fibers communicate in both a paracrine and endocrine fashion and are
also involved in the crosstalk with other tissues and organs such as the adipose tissue, immune
system, liver, pancreas, bones, and brain (Delezie andHandschin, 2018). The striatedmuscle, which
accounts for∼40% of body mass, presents high biosynthetic activity, and extensive vascularization,
features that endorse current thinking that muscle is the largest endocrine system of the body
(Benatti and Pedersen, 2015). There are hundreds of muscle secretory products, collectively
known as myokines, including proteins, miRNA, and exosomes (Barone et al., 2016). Muscle
secretion is significantly affected by muscle contraction (Son et al., 2018) due to the activation
of mechanotransduction pathways (Coletti et al., 2016a). It has been suggested that the adipose
tissue is also an endocrine organ, producing adipokines- leptin, and other hormones, in addition to
cytokines (Galic et al., 2010). The inflammatory infiltrate in fat depots affects the course of several
diseases, including cancer (Batista et al., 2012; Sawicka and Krasowska, 2016; Neto et al., 2018;
Opatrilova et al., 2018), and an extensive review on the role of adipokines in disease has been
published elsewhere (Orzechowski et al., 2014).
Myokines, adipokines, and cytokines are major therapeutic targets in both muscular and
non-muscular diseases (Lindegaard et al., 2013;Manole et al., 2018), and understanding of their role
in tissue crosstalk represents a subject of great interest in current biology.We have therefore chosen
to address this paradigm within this Frontiers special issue on “Myokines, Adipokines, Cytokines
in Muscle Pathophysiology.”
PROMOTING MUSCLE REGENERATION IN MUSCLE DISEASES
Inflammation impairs muscle regeneration, by affecting pro-myogenic genes, including NFAT5. In
a cellular model of myositis, Herbelet et al. showed that impaired NFAT5 expression and nuclear
translocation induced by the inflammatory cytokines IL-1 and INF-gamma. In patients with
polymyositis and dermatomyositis, NFAT5 was unaffected, whereas in inclusion body myositis,
NFAT5 was not expressed at all. This state is characterized by sub-clinical inflammation and
oxidative stress is found in individuals consuming High Fat Diets (HFD) and contributes to the
pathogenesis of the metabolic dysfunction observed in obesity. This has been demonstrated by
Andrich et al. in rats consuming HFD for 14 days. HFD reduced GSH levels in the musculature, an
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indicator of altered antioxidant defense, but also, increased IL-6
gene expression. Rossi et al. reviewed the role of inflammation
in skeletal muscle remodelling, highlighting that hypoxia
and IL-6, upon strength training, augment macrophage and
neutrophil recruitment.
HGF/c-met plays an important role in infiltrating
macrophages during muscle regeneration (Choi et al.). HGF
regulates macrophage transition from the inflammatory to the
anti-inflammatory phenotype and acts on various cell types,
including muscle progenitors, coordinating muscle regeneration.
It is noteworthy that severe conditions in which the muscle
wastes away, such as cachexia, occur in the absence of overt
local inflammation, and the atrophic muscle is not enriched in
inflammatory cells (Berardi et al., 2008). Therefore, inflammatory
cytokines in cachexia lead to protein breakdown and apoptosis,
without establishing a chronic degeneration-inflammation cycle
related to the detrimental action of local inflammatory cells (de
Castro et al., 2019).
STEM CELLS TO THE RESCUE
Stem cell-mediated muscle regeneration is regulated by
circulating hormones and growth factors, by signals released by
damaged muscle fibers, and by the extracellular matrix (Musarò
et al., 2007). Myostatin (MST) and activin bind the activin
receptor-2B (AcvR2B), with the effect of negatively regulating
muscle growth and myogenesis (Lee and McPherron, 2001).
Formicola et al. demonstrated that inhibition of the AcvR2B
receptor rescues muscle regenerative potential, in parallel with
the downregulation of ectopic fat deposition and fibrosis.
Muscle SC proliferation is affected in vivo by the expression of
the histone deacetylase HDAC4, which acts as a transcriptional
activator or repressor (Marroncelli et al., 2018). The paper by
Renzini et al. demonstrated that the deletion of HDAC4 affects
muscle regeneration and suggested that HDAC4 controls muscle
regeneration in vivo via soluble factors.
Satellite cells are important, but not unique players in muscle
regeneration. In another contribution, Biferali et al. review
the role of fibro–adipogenic progenitors (FAPs) in muscle
regeneration. After muscle injury, FAPs undergo massive
expansion, followed by subsequent macrophage-mediated
clearance. During this critical time window, FAPs establish a
dynamic network of interactions supporting SC differentiation.
PARACRINE AND ENDOCRINE
MEDIATORS IN MUSCLE PATHOLOGIES
A comprehensive review written by Penna et al. discusses the
role of several pro-inflammatory cytokines produced by tumors
and how they contribute to cachexia in cancer. Pro-cachectic
factors also exert direct effects on muscle cells in vitro, as shown
by Baccam et al., who demonstrated that tumor-derived-factors
induce the activin-mediated atrophy of myotubes. A high level
of circulating activin is an adverse prognostic factor in cancer
patients (Loumaye et al., 2017), yet, the direct role of activin,
beyond that of a marker of cachexia, has not been demonstrated.
Follistatin, the physiological activin inhibitor produced by the
myotubes upon mechanical stimulation, protects these cells from
atrophy. These findings are in agreement with those reported in
this same Frontiers special issue by Formicola et al..
The clinical relevance of muscle activity-dependent protective
factors is highlighted in inactive patients, submitted to
hemodialysis (HD), who show reduced levels of the beta-
aminoisobutyric acid (BAIBA), a factor that has beneficial
effects on muscle metabolism in an autocrine/paracrine
manner. In HD patients, BAIBA levels were reduced in inactive
individuals (Molfino et al.), confirming the importance of
supplying nutritional support (Garcia et al., 2019) and/or
exercise intervention in patients who have had long periods of
physical inactivity.
Microgravity induces muscle atrophy in astronauts and
Teodori et al. have investigated the role of miRNAs in
the immune response to simulated microgravity in silico,
revealing that microgravity induced conflicting signals that were
responsible for muscle atrophy.
MUSCLE AS AN ENDOCRINE ORGAN
Over 600 myokines are released by the skeletal muscle (Görgens
et al., 2015). The already long list of myokines keeps evolving, as
new candidates are proposed to be classified into this category.
This Frontiers special issue also includes several contributions on
the subject, including a comprehensive review of the myokines
released as a response to muscle contraction, by Lee and Jun. The
potential of myokine to counteract muscle wasting under various
conditions is further discussed by Piccirillo et al..
Adamo et al. have suggested that the skeletal muscle produces
two hormones classically known as neurohypophyseal factors,
i.e., vasopressin and oxytocin. The skeletal muscle may be both a
source, as well as a target of these hormones. In a very provocative
way, the findings reviewed by Adamo et al. challenge the classical
view of endocrine glands as unique, anatomically defined sources
of a given factor.
The skeletal muscle is important source of Fibroblast growth
factor 21 (FGF21). Whether the action of one such factor is
beneficial or detrimental for the muscle is still unclear, especially
in humans. By examining the circulating levels of FGF21 in
several physiological or pathological conditions we may gather
further insight on its relevance and therapeutic value for treating
metabolic diseases (Tezze et al.).
HUMORAL MEDIATORS OF THE ORGAN
CROSS-TALK
The perspective of white adipose tissue (WAT) has evolved
from one in which it is a mere site for fatty acid storage
and metabolism, to the current concept that WAT is a
major endocrine organ with a specific role in the control of
inflammation. Taking this into account, more recent studies have
explored how adipocytes and WAT stromavascular components
affect the striated muscle and a plethora of other tissues,
especially in pathological conditions (Riccardi et al., 2020).
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Two articles in this issue address and discuss the crosstalk
between muscle and adipose tissue: first a review on the
myokine regulating both brown and white adipose tissue biology:
myostatin, IL-6, IL-15, Irisin, FGF21, Angiopoietin-like protein
(ANGPTL) and BAIBA (Leal et al.); second, a report on exercise-
induced myokines release, affecting, adipokine release by WAT
(Mika et al.).
It is well-established that exercise has beneficial effects on
the heart. To highlight novel mechanisms within this context,
Bellafiore et al. investigated the signaling molecules that regulate
capillary growth in the healthy myocardium as a result of
exercise. VEGFR-1/Flt-1, VEGFR-2/Flk-1, HIF-1α, and iNOS, act
as myokines regulating angiogenesis in response to endurance
training, consistent with the observed stimulation of capillary
network development in healthy hearts, following physical
exercise (Brown and Hudlicka, 2003).
The existence of organ crosstalk, involving multiple sources
of the same molecule, such as of a specific cytokine, and
the pleiotropic effects of many of these mediators, generate
paradoxical effects and make it difficult to have a holistic view
of the physiopathology of muscle, fat, and the immune system.
An example of this complexity is IL-6, which is secreted by the
muscle upon exercise but also by the immune cells and WAT
during inflammation, inducing both hypertrophy and atrophy
of the skeletal muscle while, at the same time, being responsive
to exercise in the muscle and fat (Rosa Neto et al., 2009). An
excellent review by Pedersen and Febbraio (2008) both sheds-
light and reconciles different views regarding IL-6 and its role in
the metabolism in health and disease. The full characterization
of the specific signaling pathways activated in different organs
and conditions is of pivotal importance for understanding the
effects of cytokine in different tissues. The Janus kinase (JAK) or
signal transducer and activator of transcription (STAT) pathway,
is a key intracellular mediator of a variety of factors, including
the IL-6 family (Moresi et al.). IL-6-mediated activation of
the JAK/STAT pathway may have opposing effects, promoting
muscle hypertrophy and satellite proliferation, on one hand, and
favoring muscle wasting, on the other hand.
EXERCISE ENDOCRINOLOGICAL
EFFECTS
It has been established that exercise plays a major role in
the prevention of human diseases through endocrinological,
metabolic, genetic, and even epigenetic mechanisms (Coletti
et al., 2016b; Grazioli et al., 2017). However, not all types
of exercise are equal. Hody et al. reviewed the benefits and
the risks of eccentric contractions, such as downhill running.
For its unique features, eccentric exercise has been proposed
for innovative rehabilitative protocols, despite the fact—and
actually for the very reason that—it is a muscle-damaging
exercise protocol. Isaacs et al. have reported that the exertion
caused by rhabdomyolysis induced plyometric exercise is
associated with different extents of muscle damage and that
it is related to pain in healthy subjects. This heterogeneity
correlates with a selective increase of C-reactive protein,
which should be considered when prescribing exercise for
pathological conditions.
In addition to damage and inflammatory markers, exercise
induces the release of extracellular vesicles from the muscle.
Trovato et al. unveiled and extensively examined the role of
vesicles in myokine delivery. The ways in which exercise-
related myokines (exerkines) are involved in tissue crosstalk
during physical exercise is a topic of interest and is likely to
attract further research attention in the future. Exercise affects
vasopressin and oxytocin expression in the neurons of the
paraventricular nucleus (Farina et al., 2014) and induces a five-
fold increase in the circulating levels of the neurohypophyseal
hormone vasopressin (Melin et al., 1980). This increase is
associated with the beneficial effects of exercise on muscle
homeostasis and suggests a model whereby physical activity
stimulates muscle secretion of the neurohypophyseal hormones,
which increases muscle responsiveness to the same hormones
through the up-regulation of their receptors (Adamo et al.).
Taken together, this evidence reveals the molecular bases of the
humoral crosstalk betweenmuscles and the brain during exercise,
reflecting the Latin motto mens sana in corpore sano, i.e., “a
sound mind in a sound body.”
There are age-dependent differences in adaptation to
exercise (Harber et al., 2012). Aged mice that are deficient
in Nicotinamide Riboside Kinase 2 (NMRK2) have shown a
maladaptive metabolic response to exercise in both types of
striated muscle (Deloux et al.). These are not the first findings
to indicate the age-dependent effects of exercise and training
adaptation on muscle metabolism. For instance, young Serum
Response Factor KO mice do adapt normally to endurance
exercise (Djemai et al., 2019) despite the fact that these mice
show muscle functional deficits with aging (Lahoute et al.,
2008).
Mika, Macaluso et al. showed that exercise and linoleic
acid change hepatic fatty acid composition by increasing n-3
polyunsaturated and branched chain fatty acid incorporation.
These findings are particularly interesting in light of the beneficial
effects of linoleic supplements in muscle pathology (Macaluso
et al., 2012; Carotenuto et al., 2016a,b,c).
Taken together, the articles in this special issue demonstrate
that myokines, adipokines, and cytokines are central players in
muscle physiopathology. The striated muscle must, therefore,
be studied and managed using multidisciplinary approaches to
consider organ crosstalk and in order to propose state-to-the-
art, tailored therapeutic interventions that encompass the full
complexity and unique characteristics of each patient.
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Aims: Regeneration in skeletal muscle relies on regulated myoblast migration and
differentiation, in which the transcription factor nuclear factor of activated T-cells
5 (NFAT5) participates. Impaired muscle regeneration and chronic inflammation are
prevalent in myositis. Little is known about the impact of inflammation on NFAT5
localization and expression in this group of diseases. The goal of this study was
to investigate NFAT5 physiology in unaffected myoblasts exposed to cytokine or
hyperosmolar stress and in myositis.
Methods: NFAT5 intracellular localization and expression were studied in vitro using
a cell culture model of myositis. Myoblasts were exposed to DMEM solutions enriched
with pro-inflammatory cytokines IFN-γ with IL-1β or hyperosmolar DMEM obtained by
NaCl supplementation. NFAT5 localization was visualized using immunohistochemistry
(IHC) and Western blotting (WB) in fractionated cell lysates. NFAT5 expression was
assessed byWB and RT-qPCR. In vivo localization and expression of NFAT5were studied
in muscle biopsies of patients diagnosed with polymyositis (n = 6), dermatomyositis
(n = 10), inclusion body myositis (n = 11) and were compared to NFAT5 localization and
expression in non-myopathic controls (n = 13). Muscle biopsies were studied by means
of quantitative IHC and WB of total protein extracts.
Results: In unaffected myoblasts, hyperosmolar stress ensues in NFAT5 nuclear
translocation and increased NFAT5 mRNA and protein expression. In contrast,
pro-inflammatory cytokines did not lead to NFAT5 nuclear translocation nor increased
expression. Cytokines IL-1β with IFN-γ induced colocalization of NFAT5 with histone
deacetylase 6 (HDAC6), involved in cell motility. In muscle biopsies from dermatomyositis
9
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and polymyositis patients, NFAT5 colocalized with HDAC6, while in IBM, this was often
absent.
Conclusions: Our data suggest impaired NFAT5 localization and expression in
unaffected myoblasts in response to inflammation. This disturbed myogenic NFAT5
physiology could possibly explain deleterious effects on muscle regeneration in myositis.
Keywords: NFAT5, myoblasts, hyperosmolar stress, pro-inflammatory cytokines, myositis
INTRODUCTION
Idiopathic inflammatory myopathies (IIM) are auto-
immune muscle diseases comprising polymyositis (PM),
dermatomyositis (DM), inclusion body myositis (IBM),
overlap myositis (OM), and immune mediated necrotizing
myopathy (IMNM) (Dalakas, 1991; Dalakas and Hohlfeld, 2003;
Hoogendijk et al., 2004; De Bleecker et al., 2013). These diseases
are characterized by chronic inflammation and presence of
pro-inflammatory cytokines. DM is a complement mediated
endotheliopathy whereas IBM and PM are cytotoxic T-cell
mediated diseases (De Bleecker and Engel, 1995). In IBM,
protein misfolding and autophagosome dysfunction do occur
(Benveniste et al., 2015). In IIM, affected muscle fibers suffer
necrosis (Loell and Lundberg, 2011). Attempts to regenerate
muscle tissue in IIM are compromised. Impaired proliferation
and altered fusion capacity has been described in primary cell
cultures from patients diagnosed with IIM (Cseri et al., 2015).
Skeletal muscle tissue regeneration occurs in five phases:
degeneration by necrosis, transient inflammation, regeneration,
remodeling, and functional repair (Musarò, 2014). After
activation, muscle stem cells become myoblasts, which will
fuse with damaged myofibers or with each other, forming new
myofibers (Hawke and Garry, 2001; Musarò, 2014). Transient
promyogenic inflammation is tightly regulated and perturbation
in the magnitude of the pro-inflammatory cytokines induces
chronic inflammation, which is deleterious to muscle repair.
One of the possible mechanisms explored in the past to explain
this effect is the activation of nuclear factor- B (NF- B) by
pro-inflammatory cytokines, interfering with the expression of
muscle proteins in differentiatingmyoblasts (Langen et al., 2001).
Nuclear factor of activated T-cells 5 (NFAT5) belongs to
the Rel family of transcription factors and is closely related to
NF- B (López-Rodríguez et al., 2001). It is expressed in skeletal
muscle, kidney cells, lymphocytes, thymus and testes (Miyakawa
Abbreviations: BLAST, Basic local alignment search tool; DM, dermatomyositis;
DMEMCyto, DMEM supplemented with pro-inflammatory cytokines IFN-γ +
IL-1β; DMEM18, DMEM enriched with NaCl, increasing osmolarity by 18mM;
DMEM60, DMEM enriched with NaCl, increasing osmolarity by 60mM; FITC,
fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
HDAC6, histone deacetylase 6; HSP70, heat shock protein 70; HSP90, heat shock
protein 90; IBM, inclusion body myositis; IF, immunofluorescence microscopy;
IFN-γ, interferon gamma; IIM, idiopathic inflammatory myopathies; IL-1β,
interleukin 1 beta; LTβ, lymphotoxin beta; MIQE, minimum information for
publication of quantitative real-time PCR experiments; NaCl, sodium chloride;
NCAM, neural cell adhesion molecule; NFAT5, nuclear factor of activated T-cells
5; PARP, poly (ADP-ribose) polymerase; PM, polymyositis; RT-qPCR, quantitative
real-time PCR; siRNA, silencing RNA; UMyo, unaffected myoblasts; WB, Western
blotting.
et al., 1998; López-Rodríguez et al., 1999; Trama et al., 2000).
Five different isotypes have been described for NFAT5: NFAT5a,
NFAT5b, NFAT5c, NFAT5d1, and NFAT5d2 (Eisenhaber et al.,
2011). Approximately half of endogenous NFAT5 under isotonic
conditions is isoformNFAT5a, attached to the plasma membrane
by palmitoylation and myristoylation. NFAT5b and NFAT5c are
diffusely present in the cytoplasm. In NFAT5a, only the plasma-
membrane bound fraction is sensitive to osmolar changes,
diffusing to the nucleus upon stimulation (Eisenhaber et al.,
2011). NFAT5 in general is tonicity sensitive in skeletal muscle
cells and is involved in myoblast migration and differentiation
(O’Connor et al., 2007). Cell motility and migration is regulated
by histone deacetylase 6 (HDAC6). Besides, NFAT5 regulates
heat-shock protein 90 (Hsp90), involved in IIM (Boyault et al.,
2007; Zhang et al., 2007; De Paepe et al., 2012).
In virtually all cells, maintaining cellular homeostasis is
met with nuclear translocation of NFAT5 and production of
organic osmolytes (Evans et al., 2009), restoring homeostasis
without disturbing cell function. The NFAT5 pathway can be
activated by osmotic shock or receptor activation, yielding a
different gene activation program (Kim N. H. et al., 2014).
Extracellular hypertonicity drains intracellular water to the
extracellular medium causing cell shrinkage (Lang et al., 1998)
and DNA damage. This is counteracted by electrolyte uptake
(i.e., regulatory volume increase) leading to high intracellular
ionic strength (Lang et al., 1998; Alfieri and Petronini, 2007).
The latter is neutralized by uptake and production of osmolytes
such as sorbitol, betaine and taurine (Brown, 1976, 1978; Lang
et al., 1998) after NFAT5 translocation to the nucleus (Ko et al.,
2000; Dahl et al., 2001). NFAT5 attempts to rescue osmolarity by
restoring cell volume and protecting DNA of incoming K+ and
Na+ ions (Ferraris et al., 1996; Miyakawa et al., 1998). NFAT5 is
an activator of tumor necrosis factor (TNF), lymphotoxin β (LTβ)
and heat shock protein 70 (HSP70) transcription (Woo et al.,
2002; Esensten et al., 2005; Creus et al., 2012). Both TNF-α, LTβ
and HSP70 are involved in IIM (De Bleecker et al., 1999; Creus
et al., 2012; De Paepe et al., 2012).
In this study we have hypothesized that there is impaired
NFAT5 localization and expression in myoblasts exposed to
pro-inflammatory cytokines IFN-γ with IL-1β since IIM are
characterized by chronic inflammation, deleterious to muscle
regeneration. In myoblasts exposed to hyperosmolar conditions,
we expect NFAT5 translocation to the nucleus and increased
NFAT5 protein expression. According to our hypothesis, we
expect impaired NFAT5 localization and expression in muscle
biopsies from patients diagnosed with IIM. Exploring the
putative colocalization of NFAT5 with HDAC6, involved in cell
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motility, in both myoblasts and muscle biopsies may further our
understanding of NFAT5’s cellular interactions in skeletal muscle
tissue under pro-inflammatory or hyperosmolar conditions.
MATERIALS AND METHODS
In Vitro Culture of Myoblasts from
Non-myopathic Individuals
Two primary myoblast cell cultures obtained from the Myobank
Banque D’ADN, France, were used for in vitro experimentation
and were kept under passage 12, to avoid cellular senescence.
Myoblasts obtained from unaffected individuals were labeled
“UMyo.” Hence, cell cultures UMyo1 and UMyo2 originated
from unaffected individuals (Supplementary Table 1). Consent
was obtained from all subjects and the study was approved by
local Ethic Committees. All cultures were grown in DMEM
containing glucose and 1% L-glutamine (Life technologies,
Carlsbad, USA), supplemented with 10% FCS (Cambrex,
Bioscience, Walkersville, USA), penicillin (50 IU/ml) +
streptomycin (50 mg/ml) (Gibco, Invitrogen, Carlsbad, USA)
(“DMEM”). Myogenicity was assessed in UMyo by IHC using an
antibody against CD56 (neural cell adhesion molecule, NCAM)
(Supplementary Table 2 and Supplementary Figure 1A, UMyo1).
UMyo7 and UMyo8 were obtained from the Laboratory
of Experimental and Clinical Neuroimmunology in Göttingen,
Germany. These cultures were grown in Skeletal Muscle Cell
Growth Medium + Supplement Mix (Promocell, Heidelberg,
Germany) at 37◦C and 5% CO2.
Exposure of Unaffected Myoblasts to
Pro-inflammatory Cytokines IFN-γ with
IL-1β or Hyperosmolar NaCl
Concentrations
UMyo1 and UMyo2 were transferred at 80% confluence to 8-
chamber slides for IHC studies and to 175-cm2 flasks with
DMEM for WB and RT-qPCR. Two 175-cm2 flasks were used
per condition to obtain sufficient amounts of cells for protein
and mRNA extraction. To mimic inflammatory conditions seen
in myositis, myoblasts were exposed to a mixture of pro-
inflammatory cytokines IFN-γ with IL-1β diluted in DMEM
to respective concentrations of 300 U/ml and 20 ng/ml (R&D
Systems, Minneapolis, USA) for 7 or 24 h (Schmidt et al., 2008).
Unstimulated myoblasts served as controls.
To examine the impact of differentiation on NFAT5
physiology in myoblasts, UMyo7 and UMyo8 were transferred to
8-chamber slides (LabTek II, Nunc, Penfield, USA) with DMEM
supplemented with 0.5% chick embryo extract (CEE, Accurate,
Westbury, USA). At 80% confluence, fusion was induced by
adding heat-treated horse serum for 48 h.
In DMEM, osmolarity was 110mM (280 mOsm/L) with a
NaCl concentration of 6.40 mg/ml. Preparing hyperosmolar
DMEM solutions was performed by adding 1.10 mg/ml NaCl,
to obtain an increase of 18mM, raising the concentration of
the solution to 128mM (333 mOsm/L). This solution is referred
to as “DMEM18” and corresponds to the change in osmolarity
after addition of cytokines to DMEM. Addition of 3.50 mg/ml
NaCl to DMEM to obtain an increase of 60mM of the solution,
resulted in a final osmolarity of 443 mOsm/L. The increase in
60mMwas based on Na+ concentrations in blood in the range of
135–145mM combined with the recent insight pointing to excess
salt intake as a worsening factor in autoimmune diseases (Sigaux
et al., 2017). This solution is designated as “DMEM60.” DMEM
supplemented with cytokine mixture IFN-γ with IL-1β displayed
an osmolarity of 339 mOsm/L and was labeled as “DMEMCyto.”
To study the impact of cytokines only, addition of DMEM18
(333 mOsm/L) to untreated cells yielded hyperosmolar controls.
This hyperosmolar condition was used as control to compensate
for the osmolar change induced in DMEMCyto. Osmolarity of
the media supplemented with NaCl or cytokines was measured
using an osmometer (Osmometer Automatic, Knauer, RS45105-
0, Berlin, Germany).
Patients
Diagnostic limb muscle biopsies (n = 27) were performed after
written informed consent had been obtained from patients or
their legal representatives with PM (n = 6), DM (n = 10), IBM
(n = 11) from the University Hospitals of Ghent and Antwerp
(Belgium) and the Institute of Neuropathology, RWTH Aachen
Medical School (Germany). All patients fulfilled the conventional
criteria for diagnosis (Dalakas and Hohlfeld, 2003; De Bleecker
et al., 2013). From the cryoblocks remaining after diagnostic
work-up, 6µm transversal sections were obtained for IHC and
protein extraction. PM is only diagnosed when non-necrotic
invaded muscle fibers are present in the diagnostic biopsy and
patients have reacted to immunotherapy. At the time of biopsy,
all patients were free of immunotherapy and all of them had
a progressive disease. The patients’ medical files were searched
for concomitant diseases (Supplementary Table 3). As NFAT5
is elevated in diabetic patients (Yang et al., 2006), this has to
be taken into account during the analysis of the results. The
same cautious approach is required if other autoimmune diseases
are present. Muscle biopsies from healthy individuals with no
clinical, electromyographic, or histologic evidence of myopathy
and free from any known other disease served as controls (n =
13). The study was approved by the Ghent University Hospital
Medical Ethics Committee and the RWTH Aachen Medical
School Ethics Committee.
Muscle Biopsies, Quantitative
Immunofluorescent Double and Triple
Staining, Confocal Microscopy, and Image
Analysis
Frozen 6µm transversal muscle tissue sections were used
for double immunofluorescence (IF) performed as described
previously (De Bleecker et al., 2002). Supplementary Table 2
summarizes antibodies and concentrations used during staining
for 1 h. Secondary staining was performed for 1 h with secondary
antibodies linked to the fluorescence markers AlexaFluor-
488 (green), FITC (green), AlexaFluor-555 (red) (Invitrogen,
Waltham, USA) or Cy3 (red) (Jackson ImmunoResearch
Laboratories West Grove, USA). Sections were imaged with
a Leica SP8 AOBS confocal microscope (Leica, Mannheim,
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Germany). Images were taken using a 63X HCX PL Apo 1.4
NA oil objective. Z-sections were made at the resolution limit,
in this case 126 nm, to produce a high-resolution stack suitable
for colocalization measurements. Images were acquired in a
sequential mode, scanned as 246 X 246 nm per pixel. To test for
antibody specificity, NFAT5 siRNA studies were completed. As
NFAT5 Rabbit yielded unspecific binding in myonuclei, NFAT5
Goat was selected as the antibody of choice (Supplementary
Figure 1B). NFAT5 Goat binds to all five NFAT5 isoforms.
Amino acid sequence analysis by BLAST (Basic Local Alignment
Search Tool, NIH, Bethesda, USA) of the NFAT5 Rabbit antibody
yielded recognition of two proteins, rendering the antibody
aspecific to NFAT5 (LLVSLQNQGN NLTGSF). The NFAT5
Goat was specific to NFAT5 (MPSDFISLLS ADLDLESPKS
LYSRESVYDL LPKELQLPPS RETSVASMSQ).
Quantitative Western Blotting (WB)
Total protein extracts were prepared from 175-cm² flasks
using appropriate lysis buffer (Laemmli 1x; 2-Mercaptoethanol
0.1%, Bromophenol Blue 0.01%, Glycerol 10%, SDS 2%, Tris-
HCl 60mM pH 6.8) followed by sonification. For patients’
biopsies, protein extracts were prepared by homogenizing frozen
muscle samples in 2 volumes of extraction buffer (50mM
TrisHCl, 2mM EDTA pH 7.4) supplemented with protease
inhibitor (TM mini protease inhibitor cocktail; Roche, Bazel,
Switzerland). To pellet debris, samples were centrifuged at
2,000 g for 10min. Proteins were transferred to nitrocellulose
membranes by electroblotting and incubated with primary
antibodies (Hendrix et al., 2010) (Supplementary Table 4)
and anti-GADPH (Abcam, Cambridge, Massachusetts, USA) to
correct for protein concentration between samples. PARP was
used as a nuclear control in WB of fractionated cell lysates
(BD Biosciences, Franklin Lakes, New Jersey, USA) and GAPDH
as a cytosolic marker. Immunoreaction was visualized using
chemiluminescence (WesternBrightTM Sirius, Advansta, Menlo
Park, California, USA) and Proxima 2650 (Isogen Life Science,
De Meern, The Netherlands).
In cell cultures, cell fractionation into nuclear and cytosolic
parts was performed by adding a hypotonic buffer (20mM
HEPES, 20% glycerol, 10mM NaCl, 1.5mM MgCl2, 0.2mM
EDTA, 0.1% Triton x-100 and MQ) for cell lysis. Nuclei were
separated into a pellet after gentle centrifugation at 800 rpm
for 10′. After resuspending the pellet in a hypertonic buffer (cf.
hypotonic buffer with 500mM NaCl instead of 10mM NaCl),
rotating it and spinning down, a supernatant containing the
nuclear fraction was obtained. NFAT5 antibody selectivity for
WB was assessed using siRNA NFAT5 (h): sc-43968 (Santa Cruz
Biotechnology, Santa Cruz, California, USA) in one cell culture
at 20 nM starting from a stock solution at 10µM. Scrambled
RNA (scRNA) was used as internal control for siRNA specificity.
ScRNA was prepared by diluting 2 µL in 2mL serum free
DMEM following the supplier’s protocol. Lipofectamine 2000
(Invitrogen) was used for transfection by diluting 75mL in 2mL
serum free DMEM followed by incubation for 5′ at RT. As
lipofectamine was produced in duplicate, each vial was added to
the respective siRNA and scRNA solutions and gently mixed for
20′ at RT. In one 75 cm2 flask with confluent layer, the siRNA
with lipofectamine was added. In the second 75 cm2 flask with
confluent layer, scRNAwith lipofectamine was added. Both flasks
were incubated for 24 h at 37◦C with 5% CO2. We used a DMEM
solution with an osmolarity increased to 135mMand results were
obtained by WB of total cell extractions.
RT-qPCR
One 175-cm2 flask per treatment condition was grown to
full confluency and cell cultures were exposed to cytokines
or hyperosmolar stress for 7 or 24 h. Total lysis of cell
cultures was obtained by following a well-described protocol
(Vandesompele et al., 2002) with a minimum purity of 1.9/2
measured by the A260/A280 ratio on BioDropTM Touch
Duo PC (Harvard Bioscience Inc., Holliston, Massachusetts,
USA). Results in line with the MIQE guidelines (Bustin
et al., 2009) were considered relevant after calculation with
qBase+ Software version 2.6 (www.qbaseplus.com) (Biogazelle,
Zwijnaarde, Belgium) (Hellemans et al., 2007). geNorm was used
to determine the most stable reference genes from a set of tested
candidate reference genes (Supplementary Table 5).
Statistical Analysis
For statistical analysis of quantitative confocal microscopy
images, the Mann Whitney U test was performed in SPSS 23.0
(IBM, Armonk, New York, USA), p < 0.05 were considered
statistically significant. The statistical analysis of colocalization
in confocal images was performed with Volocity 6.1.3 (Perkin
Elmer, Coventry, UK). Background levels were obtained by
measuring the voxel count of the signal outside the cells
and subtracted. Colocalization indexes M1 (NFAT5) and M2
(HDAC6) (which indicate the quantity of colocalization in
each individual channel), Mander’s Overlap coefficient (R)
and Pearson’s correlation coefficient (r) were calculated using
the appropriate algorithm in the Volocity software package.
Pearson’s correlation was solely chosen as a thresholding method
because measurements above background in both channels are
included in the calculations (Costes et al., 2004). M1 stands for
the quantity of red signal in the green channel, and M2 for the
quantity of green signal in the red channel. One-way ANOVA
with Tukey’s multiple comparison test was applied to the values
obtained from RT-qPCR analyzed by qBase+.
RESULTS
InUMyo,myoblast myogenicity was investigated by IHC. Double
IF staining withNFAT5 andNCAMyielded superposition of both
dyes after merging the immunofluorescent detection channels
(Supplementary Figure 1A).
All results described below were obtained in cell cultures
UMyo1 and UMyo2 where differentiation occurred by
spontaneous fusion, without any differentiation medium
(Supplementary Figure 2). In both cell cultures, myoblasts with
single myonuclei could be observed as well as nascent myotubes
harboring different myonuclei per cell, albeit to a lesser extent.
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NFAT5 Localization in Unaffected
Hyperosmolar Stressed Myoblasts
The impact of osmolar stress on NFAT5 localization was
studied in cultured myoblasts. Two primary myoblast cultures
from non-myopathic individuals (UMyo) were exposed to
hyperosmolar DMEM. NFAT5 localization was studied by IHC
and WB of fractionated cell lysates. In WB, PARP was used
as a marker for the nuclear fraction, GAPDH as a cytosolic
marker. Results are displayed in Figure 1. Variation in results
amongst different cell cultures are displayed in Supplementary
Figure 3.
By IHC and WB in UMyo1, NFAT5 was merely localized
in the cytoplasm of untreated myoblasts (n = 3). Exposure to
increasing hyperosmolar conditions showed a decrease in NFAT5
cytoplasmic staining (n = 3) and NFAT5 immunoreactivity in
the cytosolic fraction (n = 1). NFAT5 nuclear staining increased
(n = 3) along with NFAT5 immunoreactivity in the nuclear
fraction (n = 1). In WB specifically, PARP was merely expressed
in the nuclear fraction and GAPDH immunoreactivity was
mainly visible in the cytosolic compartment (Figure 1).
Variation in NFAT5 localization in UMyo was explored by
IHC after exposure to DMEM60. In all UMyo cultures, NFAT5
cytoplasmic staining appeared in a punctate pattern in untreated
conditions. NFAT5 nuclear staining was observed in all UMyo
after hyperosmolar stress (Supplementary Figure 3A). In UMyo7
and UMyo8, where DMEM was supplemented with heat-treated
horse serum, addition of heat-treated horse serum did not
influence NFAT5 localization as visualized in UMyo8 exposed to
DMEM18 or DMEM60 (Supplementary Figure 1C).
Impaired NFAT5 Nuclear Localization in
Unaffected Myoblasts Exposed to
Pro-inflammatory Cytokines IFN-γ with
IL-1β
The influence of cytokine stress on NFAT5 localization
was studied in cultured myoblasts. Two primary myoblast
cultures from non-myopathic individuals were exposed to
DMEM enriched with pro-inflammatory cytokine mixture IFN-
γ (300 U/ml) with IL-1β (20 ng/ml) (DMEMCyto). NFAT5
localization was studied by IHC and WB of fractionated cell
lysates. In WB, PARP was used as a marker for the nuclear
fraction, GAPDH as a cytosolic marker. To study the impact of
cytokines alone, addition of DMEM18 to untreated cells yielded
hyperosmolar controls. This hyperosmolar condition was used
as control to compensate for the osmolar change induced in
DMEMCyto. Results are displayed in Figure 2.
By IHC andWB in UMyo1, control myoblasts showed NFAT5
cytoplasmic and nuclear staining and NFAT5 immunoreactivity
in the cytosolic and nuclear compartments (cf. 3.1). In UMyo1
exposed to pro-inflammatory cytokines IFN-γ with IL-1β,
NFAT5 nuclear staining (n = 3) and immunoreactivity (n = 1)
were strongly decreased in almost all cells (Figure 2).
NFAT5 Expression in Unaffected Myoblasts
Exposed to Hyperosmolar or Cytokine
Stress
NFAT5 expression was studied by means of WB and RT-
qPCR. Firstly, RT-qPCR explored the presence of NFAT5 mRNA
FIGURE 1 | NFAT5 localization in unaffected myoblasts after 24 h exposure to hyperosmolar conditions. (A) Immunofluorescent staining was performed in UMyo1
(unaffected myoblasts) with NFAT5 Goat antibody, followed by a Cy3 (red)-labeled secondary antibody. Myonuclei were counterstained with DAPI staining (blue). White
arrows point at increased NFAT5 nuclear staining in UMyo1 exposed to DMEM18 or DMEM60 (DMEM with a total increase in osmolarity of 18 or 60mM) (n = 3).
(B) By WB, NFAT5 immunoreactivity increased in the nuclear fraction of UMyo1 after hyperosmolar stress. Cytosolic NFAT5 immunoreactivity decreased with
increasing hyperosmolar stress (n = 1).
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FIGURE 2 | NFAT5 localization in unaffected myoblasts after 24 h exposure to DMEM supplemented with pro-inflammatory cytokines IFN-γ with IL-1β.
(A) Immunofluorescent staining was performed in UMyo1 (unaffected myoblasts) with NFAT5 Goat antibody, followed by a Cy3 (red)-labeled secondary antibody.
Myonuclei were counterstained with DAPI staining (blue). NFAT5 nuclear staining was often absent in UMyo1 exposed to DMEMCyto (DMEM enriched with IFN-γ with
IL-1β). The white arrow points at increased NFAT5 nuclear staining in UMyo1 exposed to DMEM18 (DMEM with a total increase in osmolarity of 18mM) (n = 3). (B) By
WB, NFAT5 immunoreactivity decreased in the cytosolic and nuclear fraction of UMyo1 (n = 1).
after 7 and 24 h of exposure to cytokine or hyperosmolar
stress. Secondly, WB was performed on total cell lysates
exposed to hyperosmolar or cytokine stress for 24 h, to study
protein expression. The results are presented in Figure 3 and
Supplementary Figure 3B.
In UMyo1, a fold change in NFAT5 mRNA expression
of 7.04 (±1.53) (p < 0.001) was measured for NFAT5 after
7 h of exposure to DMEM60, with subsequent significant
increase in NFAT5 protein level (n = 3). Following conditions
yielded no significant increase in NFAT5 mRNA expression:
exposure for 24 h to DMEM60, 7 or 24 h exposure to
DMEMCyto. Exposure for 24 h to DMEMCyto had a
minor influence on NFAT5 protein expression (n = 3)
(Figure 3).
Variation in NFAT5 protein expression amongst cell
cultures was studied by WB of total cell lysates of
UMyo1 and UMyo2. DMEM60 increased significantly
NFAT5 protein expression (n = 3) (Supplementary
Figure 3B).
NFAT5 Colocalization with HDAC6 in
Unaffected Myoblasts Exposed to
Pro-inflammatory Cytokines IFN-γ with
IL-1β
By confocal microscopy, NFAT5 colocalization with HDAC6 was
studied in UMyo1 exposed to hyperosmolar or cytokine stress.
Colocalization of red and green dyes yielded a yellow to orange
signal. Colocalization was measured across the whole image by
Volocity and depicted in a diagram. Results are displayed in
Figure 4.
In UMyo1 exposed to DMEM18 or DMEM60, both red
(NFAT5) and green (HDAC6) signals were distinctly present
after superposition. Colocalization with HDAC6 was absent
(Figures 4A,C). Exposure to DMEMCyto induced NFAT5
colocalization with HDAC6, visible as a yellowish coloration
in the cytoplasm of the cells, after merging the red and green
detection channels. Displaying the colocalization indexes of
NFAT5 and HDAC6 in a graph after exposure to DMEM18,
DMEM60 or DMEMCyto yielded the same results (arrows,
Figures 4B,C).
NFAT5 Colocalizes with HDAC6 in PM and
DM, but Not in IBM
As visualized by IHC, 2/6 patients diagnosed with PM had a very
discrete, diffuse NFAT5 surface staining. In DM, similar features
were observed as in PM. In IBM, 4/8 patients expressed a positive
muscle fiber surface NFAT5 staining. In IIM, NCAM (CD56)
positive fibers (regenerating fibers) showed an absence of NFAT5
muscle fiber surface staining. The vast majority of inflammatory
cells were negative for NFAT5 in IIM biopsies (Figure 5A and
Supplementary Table 6).
By quantitative analysis of confocal microscopy images,
NFAT5 and HDAC6 colocalized in PM (p < 0.01) and DM
(p < 0.001), but not in IBM (Figures 5A,B). By WB of total
lysates of patients’ biopsies, NFAT5 was expressed in unaffected
individuals free of any disease, where NFAT5 expression ranged
from once to twice amount of NFAT5 protein. One individual was
randomly selected as the standard individual (black arrow) and
used in WB of PM, DM and IBM patients’ biopsies, allowing for
a comparison between blots. In PM, two out of three patients had
a NFAT5 protein expression similar to controls. One patient had
a decreased NFAT5 protein expression. In DM, NFAT5 protein
expression was in the same range as controls and only one
individual had no detectable levels of NFAT5 protein. In IBM,
two out of three patients had no detectable levels of NFAT5
protein (Figure 5C).
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FIGURE 3 | NFAT5 mRNA and protein expression in unaffected myoblasts exposed to hyperosmolar or pro-inflammatory conditions. (A) In UMyo1 (unaffected
myoblasts), exposure to DMEM60 for 7 h significantly increased NFAT5 mRNA expression (p < 0.001). In contrast, NFAT5 mRNA was not increased in UMyo1 after
24 h hyperosmolar treatment and after 7 or 24 h exposure to DMEMCyto (n = 3). Untreated UMyo1 were used as control. (B) By WB of total cell lysates, an increase
in NFAT5 protein levels was measured in UMyo1 after 24 h hyperosmolar challenge (n = 3).
Figure 6 presents a schematic overview of the obtained
results in NFAT5 physiology in unaffected myoblasts exposed to
hyperosmolar or cytokine enriched DMEM solutions.
DISCUSSION
This study describes two main findings in NFAT5 physiology
in unaffected muscle stem cells. Firstly, NFAT5 is translocated
to the myonuclei and upregulated in myoblast cell cultures
from unaffected individuals exposed to hyperosmolar DMEM
solutions. Specifically in DMEM with an osmolarity increased by
60mM,myoblasts display increased expression of NFAT5mRNA
and protein (IHC, WB, RT-qPCR). Secondly, after exposure of
unaffected myoblasts to DMEM supplemented with cytokines
IFN-γ with IL-1β, NFAT5 translocation to the myonuclei is
not detectable. Instead, NFAT5 colocalizes with HDAC6 in the
cytoplasm of myoblasts. NFAT5mRNA and protein levels are not
increased.
NFAT5 localization has been described in the past as being
merely nuclear in myoblasts, after staining with NFAT5 Rabbit
antibody for IHC (O’Connor et al., 2007). In the current
study, NFAT5 is merely localized in the cytoplasm of myoblasts
after staining with NFAT5 Goat for IHC. This observation
may be explained by NFAT5 antibody specificity. NFAT5 Goat
displays specific binding. NFAT5 staining is absent from both the
cytoplasm and the nucleus after siRNA NFAT5 studies. NFAT5
Rabbit seems to display aspecific binding in the nucleus and to a
lesser extend in the cytoplasm of myoblasts after siRNA NFAT5.
Our first observation corroborates with exposure of myoblasts
to mannitol, a membrane-impermeant osmotic protein, where
the NFAT5 reporter increases with increasing hyperosmolar
mannitol concentrations (O’Connor et al., 2007). In the present
study, adding hyperosmolar NaCl changes the cell environment
to a hyperosmolar stressful setting. This leads to water drainage
out of the cell by osmosis (Lang et al., 1998). To counteract
this deleterious effect, NFAT5 is activated and translocates to
the myonucleus where it binds with DNA (Ko et al., 2000; Dahl
et al., 2001), with subsequent upregulation of NFAT5 mRNA
and NFAT5 protein. NFAT5 is not colocalizing with HDAC6 in
this study. This may point to a normal NFAT5 physiology in
unaffected myoblasts after exposure to hyperosmolar conditions.
In the second observation, NFAT5 translocation could not be
detected in unaffected myoblasts triggered by DMEM enriched
with cytokines IFN-γ with IL-1β (IHC and WB). IFN-γ has
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FIGURE 4 | Study of NFAT5 colocalization with HDAC6 in unaffected myoblasts exposed to hyperosmolar or pro-inflammatory conditions. (A,B) Immunofluorescent
staining was performed in UMyo1 (unaffected myoblasts) with NFAT5 Goat antibody and HDAC6 antibody, followed respectively by a Cy3 (red)-labeled secondary
antibody and Alexa-488 (green)-labeled secondary antibody. Myonuclei were counterstained with DAPI staining (blue). NFAT5 with HDAC6 colocalization was only
observed in UMyo1 exposed for 24 h to DMEMCyto. Colocalization of red and green dyes yielded a yellow to orange signal (white arrow). (C) Colocalization
measurements were performed in UMyo1 by means of Volocity across all images. The graph represents colocalization indexes of NFAT5 and HDAC6 after exposure to
DMEM18, DMEM60 and DMEMCyto for 24 h. NFAT5 with HDAC6 colocalization was only observed in UMyo1 exposed for 24 h to DMEMCyto (white arrow) (n = 3).
been detected in muscle tissue of all the major subtypes of IIM
(Figarella-Branger et al., 2003; Preuße et al., 2012). IFN-γ, IL-
1β, and TNF-α were found to be markedly increased in IBM
muscle compared to PM and DM tissue (Schmidt et al., 2008).
Cytoplasmic NFAT5 was detected by IHC and WB, whereas
NFAT5 was absent from the nucleus both in IHC and WB.
By means of quantitative IHC, cytoplasmic NFAT5 colocalized
with HDAC6. In NFAT5 physiology, entry into the nucleus
depends of the nuclear localization system (NLS) localized in
an amino acid cluster with residues 202 to 204. Mutations
in this cluster abolish nuclear import of NFAT5 (Tong et al.,
2006). NFAT5 amino acid modifications have been described
for NFAT5, such as increased phosphorylation at threonine
135 (Gallazzini et al., 2011) or sumoylation after hyperosmolar
stress (Kim J. A. et al., 2014). In the current study, NFAT5
may not be able to translocate to the nucleus after cytokine
stimulation by alteration of the NLS or by conformational change
of NFAT5. In unaffected myoblasts, this might be a mechanism
to orchestrate the cell’s appropriate response to hyperosmotic vs.
pro-inflammatory conditions leading to a different downstream
factor activation scheme (De Paepe et al., 2016). NF- B is
upregulated in myoblasts after exposure to pro-inflammatory
cytokines. Under these conditions, it interferes with proteins
involved in myogenesis (Langen et al., 2001). In this study,
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FIGURE 5 | Study of NFAT5 localization and expression in control, PM, DM, and IBM biopsies (A,B) Immunofluorescent staining was performed in control, PM, DM,
and IBM biopsies with NFAT5 Goat antibody and HDAC6 antibody, followed respectively by a Cy3 (red)-labeled secondary antibody and Alexa-488 (green)-labeled
secondary antibody. Myonuclei were counterstained with DAPI staining (blue). In PM, and DM, NFAT5 colocalized with HDAC6, as displayed in the rectangular
subsets. This is visible as yellow structures next to the nucleus. Absence of NFAT5 colocalization with HDAC6 was noticed in IBM. By quantitative analysis of confocal
microscopy images, NFAT5 and HDAC6 colocalized in PM (p < 0.01) and DM (p < 0.001), but not in IBM. (C) By WB of total protein extraction of biopsies from
control individuals and patients diagnosed with PM, DM, and IBM, different NFAT5 protein levels were measured. PM merely displayed NFAT5 protein levels in the
same range as controls. In DM, 1/3 patients had no detectable NFAT5 protein levels. In IBM, 2/3 patients had no detectable levels of NFAT5 protein.
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FIGURE 6 | Schematic overview of NFAT5 localization and expression in unaffected myoblasts exposed to hyperosmolar or pro-inflammatory conditions. In
unaffected myoblasts under isotonic conditions, NFAT5 is located in the cytoplasm were it is attached to the plasma membrane and resides in the cytoplasm.
Increased osmolarity in these myoblasts induced NFAT5 translocation to the nucleus, with subsequent NFAT5 mRNA and protein level increase (upper myoblast). In
unaffected myoblasts exposed to pro-inflammatory cytokines IFN-γ with IL-1β, NFAT5 was not translocating to the nucleus and NFAT5 mRNA and protein level were
not increased (lower myoblast).
exposure of unaffected myoblasts to DMEM garnished with
IFN-γ + IL-1β results in NFAT5 being localized in the cytoplasm
and colocalizing with HDAC6, possibly pointing to NFAT5
interacting with HDAC6. HDAC6 is involved in cell motility and
regulates heat shock protein 90 (Boyault et al., 2007; Zhang et al.,
2007). Besides, HDAC6 is downregulated in embryonic stem cells
during differentiation toward themyogenic cell lineage (Lee et al.,
2015).
By WB of fractionated cell extracts in UMyo, three bands for
NFAT5 are noticed, located around 170 kDa. In UMyo control
cells, two bands are located in the cytoplasmic compartment
and one band in the myonucleus. After hyperosmolar treatment,
the two bands located in the cytoplasmic fraction disappear.
The five following isotypes have been described for NFAT5:
NFAT5a, NFAT5b, NFAT5c, NFAT5d1, and NFAT5d2 obtained
by alternative splicing. Eisenhaber et al. (2011) describe diffusion
to the nucleus of the plasma-membrane bound fraction of
NFAT5a after exposure to salt stress of 350 mosm/L. This
condition induces nuclear translocation of all isoforms following
a linear curve with time, with complete migration to the nucleus
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of NFAT5b and NFAT5c (Eisenhaber et al., 2011). By consensus,
isoform NFAT5c has been chosen as the canonical sequence and
has a molecular weight of 166 kDa. Isoform NFAT5a weights
158 kDa (Germann et al., 2012). Isoform NFAT5b displays a
molecular weight of 11 kDa (Germann et al., 2012). NFAT5
isoforms d1 and d2, also called NFAT5z1 and NFAT5z2 or
NFAT5d and NFAT5e, have very similar molecular weights of
respectively 167.7 kDa and 167.8 kDa (Xiao et al., 2015).
NFAT5 is a key regulator of both myoblast migration and
differentiation during skeletal muscle myogenesis. Migratory
defects in NFAT5+/− myoblasts are described alongside a
decreased number of differentiated myoblasts during early
differentiation in dominant-negative NFAT5 cells (O’Connor
et al., 2007). Myofiber regeneration is a hallmark of DM and PM
and regeneration is known to be impaired in IBM (Morosseti
et al., 2006). Undetectable NFAT5 protein levels in almost all IBM
patients is noticed in this current study, when studying NFAT5
expression by WB.
Combination of cytokine with hyperosmolar NaCl, possibly
explaining the interplay between both conditions, led to complete
cell death and was not pursued.
In summary, we describe normal NFAT5 localization and
expression in unaffected myoblasts exposed to hyperosmolar
stress with NFAT5 translocation to the nucleus, increased NFAT5
mRNA and protein levels. In unaffected myoblasts exposed to
cytokine stress, NFAT5 localization and expression are impaired,
with NFAT5 mainly located in the cytoplasm. In PM and DM
patients’ biopsies, NFAT5 remains within the normal range,
whereas in IBM, an absence of NFAT5 expression can be seen.
As NFAT5 is a core protein to myogenesis, our findings may help
further our understanding of impaired muscle regeneration in
myositis.
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Degenerative myopathies typically display a decline in satellite cells coupled with a
replacement of muscle fibers by fat and fibrosis. During this pathological remodeling,
satellite cells are present at lower numbers and do not display a proper regenerative
function. Whether a decline in satellite cells directly contributes to disease progression
or is a secondary result is unknown. In order to dissect these processes, we used a
genetic model to reduce the satellite cell population by ∼70–80% which leads to a
nearly complete loss of regenerative potential. We observe that while no overt tissue
damage is observed following satellite cell depletion, muscle fibers atrophy accompanied
by changes in the stem cell niche cellular composition. Treatment of these mice with an
Activin receptor type-2B (AcvR2B) pathway blocker reverses muscle fiber atrophy as
expected, but also restores regenerative potential of the remaining satellite cells. These
findings demonstrate that in addition to controlling fiber size, the AcvR2B pathway acts
to regulate the muscle stem cell niche providing a more favorable environment for muscle
regeneration.
Keywords: muscle atrophy, muscle regeneration, muscle stem cell niche, satellite cells, TGFβ signaling
INTRODUCTION
Chronic degenerative muscle diseases eventually lead to a collapse in the ability of muscle to
regenerate. In the case of Duchenne muscular dystrophy (DMD), afflicted boys show subtle
motor defects during early postnatal life that rapidly increase with age leading to paralysis and
premature death (Parker et al., 2005; Tabebordbar et al., 2013). It has been proposed that the loss
of regenerative capacity in DMD results from an exhaustion of the muscle progenitor satellite
cell pool during disease progression (Blau et al., 1983, 1985; Heslop et al., 2000; Jiang et al.,
2014; Lu et al., 2014). During the early phase of DMD, muscle undergoes continuous rounds
of degeneration/regeneration but eventually regenerative competence declines accompanied by
a decrease in satellite cell number (Wallace and McNally, 2009; Mann et al., 2011; Tabebordbar
et al., 2013). Following a genetically induced depletion of satellite cells, muscle damage leads to a
22
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replacement of myofibers by fibrosis and fat deposition (Lepper
et al., 2011; Murphy et al., 2011; Sambasivan et al., 2011).
Whether the decline in satellite cells contributes to disease
progression is unclear, in part since dissecting the relative
contribution of a decreased satellite cell number in mouse DMD
models is hampered by the fact that these models do not reflect
the severity of disease progression in boys (Hoffman et al., 1987;
Coulton et al., 1988; Tabebordbar et al., 2013).
We wished to address whether a reduction in the number of
satellite cells has a direct effect upon the muscle tissue in the
absence of injury and in turn, whether changes in the muscle
tissue have an adverse effect upon satellite cell function. This
question is particularly relevant as it has been demonstrated that
small numbers of satellite cells engraft with high efficiency into
healthy skeletal muscle (Collins et al., 2005; Sacco et al., 2008),
thus a decline but not complete elimination of the satellite cell
pool should be sustainable. Furthermore, satellite cells obtained
from mdx mice, a model for Duchenne, contribute robustly
when engrafted into healthy muscle (Boldrin et al., 2015). These
observations raise the question as to why a reduced satellite cell
population cannot replace damaged muscle fibers in diseased
muscle?
A number of secreted growth factors have been shown
to regulate satellite cell function. Different combinations of
TGFβ superfamily receptors and ligands control muscle growth,
progenitor activation, fibrosis and ectopic bone and fat formation
(Yamaguchi, 1995; Glass, 2010; Sako et al., 2010; Serrano et al.,
2011; Bonaldo and Sandri, 2013; Sartori et al., 2013). Myostatin
(MST) is a high affinity ligand for the activin receptor-2B
(AcvR2B) and a potent negative regulator of muscle growth that
blocks myogenic progression (McPherron et al., 1997; Thomas
et al., 2000; Lee and McPherron, 2001). Myostatin-null mice
display a pronounced increase in muscle mass coupled with
reduced fibrosis following injury (McPherron and Lee, 2002;
McCroskery et al., 2005). MST has been shown to stimulate
fibrosis (McCroskery et al., 2005; Artaza et al., 2008; Z Hosaka
et al., 2012) whereas suppression of MST, using a soluble form
of the AcvR2B, has been used to treat congenital myopathies,
sarcopenia and cachexia resulting in reduced fibrosis (Wagner
et al., 2002; Siriett et al., 2006; Morrison et al., 2009; Cadena
et al., 2010; Zhou et al., 2010; George Carlson et al., 2011;
Lawlor et al., 2011; Pistilli et al., 2011; Chiu et al., 2013; Lach-
Trifilieff et al., 2014). Follistatin (FST) binds to and blocks MST
activity results in muscle hypertrophy (Lee and McPherron,
2001; Amthor et al., 2004; Lee et al., 2010). Other growth
factors such as insulin-like growth factor 1 (IGF-1) are potent
activators of muscle growth that act in part by blocking the
downstreamMST-induced pathway (Bodine et al., 2001; Rommel
et al., 2001; Trendelenburg et al., 2009; Oberbauer, 2013).
While manipulation of the AcvR2B pathway provides a basis
for development of therapeutic approaches for degenerative
myopathies (Glass, 2010; Zhou and Lu, 2010; Ceco and McNally,
2013; Tabebordbar et al., 2013), it remains unaddressed whether
these therapies act via a primary effect upon myofibers or target
additional cell types including satellite cells and/or the stem
cell niche. Satellite cells are highly responsive to neighboring
cell populations in vivo (Ten Broek et al., 2010; Yin et al.,
2013) includingmyofibers, vessels, pericytes, and fibroadipogenic
progenitors (FAPs) (Joe et al., 2010; Uezumi et al., 2010;
Dellavalle et al., 2011; Pannérec et al., 2012, 2013) as well as
invading macrophages following injury (Kharraz et al., 2013;
Tabebordbar et al., 2013; Yin et al., 2013; Farup et al., 2015).
While FAPs generate fat in diseased muscle, a depletion of
interstitial cells including FAPs results in poor regeneration
(Murphy et al., 2011), indicating that interstitial cells play a
critical role in proper muscle regeneration (Murphy et al.,
2011).
In this study, we used a genetic mouse model for depleting
satellite cells that relies upon diphtheria toxin targeted cell death
to satellite cells (Sambasivan et al., 2011). In this model, injured
muscle undergoes pronounced fibrosis and fat formation coupled
with a near complete loss of fiber regeneration (Lepper et al.,
2011; Murphy et al., 2011; Sambasivan et al., 2011). We found
that diphtheria toxin injection resulted consistently in ∼70–80%
satellite cell reduction, thereby providing a baseline by which we
could directly assess the effects of satellite cell reduction in the
absence of injury and/or underlying disease state. In addition,
this model allows for a reduction of satellite cells in a single
muscle group as opposedmuscles that provide essential functions
such as the diaphragm. We found that satellite cell depletion
resulted inmuscle fiber atrophy in the absence of injury.Whereas
inhibition of the AcvR2B results in muscle fiber hypertrophy in
muscle containing an intact satellite cell population (Morrison
et al., 2009; Pistilli et al., 2011), we observed that satellite cell
depleted muscles undergo a limited hypertrophic response in
which muscle fiber size is only restored to levels found in intact
untreated muscles. In addition to changes in the muscle fibers,
we observed that PW1+ interstitial cells undergo a marked
increase in cell number following AcvR2B pathway inhibition
suggesting that the stem cell niche is responsive. This prompted
us to test whether this change in the stem cell niche would
have an impact upon the regenerative potential in muscle
containing fewer satellite cells. We report here that treatment
of satellite cell depleted muscle with an AcvR2B inhibitor prior
to injury rescues regenerative potential concomitant with a
near complete inhibition of ectopic fat formation and fibrosis.
Using genetic lineage tracing, we found that the regenerated
fibers originated from the residual pool of satellite cells in the
satellite cell-depleted mice. These data reveal that a decline in
satellite cells has a profound effect on the tissue environment
compromising myogenic competence and that inhibition of the




Animal models used were C57Bl6J mice (Elevage Janvier);
PW1IRESnLacZ transgenic reporter mice (PW1nlacZ) (Besson et al.,
2011); knock-in heterozygous Pax7DTR/+ mice, in which the
diphtheria toxin receptor (DTR) is expressed under the control
of the Pax7 promoter (Sambasivan et al., 2011); Tg:Pax7CreERT2
mice, carrying a BAC where a tamoxifen-inducible Cre
recombinase/estrogen receptor fusion protein, CreERT2
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(Metzger and Chambon, 2001), is expressed under the control of
Pax7 (Mourikis et al., 2012); ROSA26mTomato/mGFP (ROSAmTmG)
mice (Muzumdar et al., 2007) (Jackson Laboratories). Pax7DTR/+
mice were crossed with Tg:Pax7CreERT2 and ROSAmTmG to
obtain Pax7DTR/+:Pax7CreERT2:ROSAmTmG animals.
Ethics Statement
Approval for the animal (mouse) work performed in this
study was obtained through review by the French Ministry of
Education, Agreement #A751320.
RAP-031 Treatment
Five-weeks old C57Bl6 or PW1nLacZ males and 10-weeks old
Pax7DTR/+ or Pax7DTR/+:Pax7CreERT2:ROSAmTmG mice were
injected intra-peritoneally with RAP-031 or vehicle (TBS) 10mg
per kg−1.
Tamoxifen Treatment
Six weeks-old Pax7DTR/+:Pax7CreERT2:ROSAmTmG mice were
injected intra-peritoneally every day for 4 days with tamoxifen
(250–300ml, 20 mg/ml; Sigma Aldrich) diluted in sunflower seed
oil/5% ethanol.
Toxins Injections
Mice were anesthetized by intra-peritoneal injection of ketamine
(100mg.kg−1) and xylazine (10mg.kg−1) in sterile saline
solution. A total volume of 15–30 µl was used for one
single intramuscular injection of diphtheria toxin (DT) from
Corynebacterium diphtheria (Sigma Aldrich) at 1 ng.g−1 of body
weight or PBS into the TA muscle using 30G Hamilton syringe.
Muscle injury was induced by intramuscular injection of 40 µl of
cardiotoxin from Naja mossambica (Latoxan) at a concentration
of 10µM.
Western Blot Analysis
TA muscles were homogenized in a lysis buffer (150mM NaCl,
50mM Hepes pH7.6, 1% NP-40, 0.5% Sodium deoxycholate,
5mMEDTA) supplemented with 1mMPMSF, protease inhibitor
cocktail (Roche, Cat. No. 04693124001), 20mM NaF, 10mM
b-glycerophosphate, 5mM Na-pyrophosphate, and 1mM Na-
orthovanadate. Equal amount of protein were separated by
electrophoresis (Novex NuPAGE Bis-Tris protein gel 12%) and
transferred to a PVDF membrane in 20% methanol transfer
buffer. Membranes were probed with p-SMAD2 (S465/467)/
Smad3 (S423/425), SMAD2/3 total (Cell signaling) and GAPDH
(Abcam). Anti-body binding was visualized using horse-
radish peroxidase (HRP)-conjugated species-specific secondary
antibodies (Jackson ImmunoResearch) followed by enhanced
chemiluminescence (Pierce).
FACS Analysis
For fluorescence activated cell sorting (FACS), hindlimb muscles
from 7 weeks old PW1nLacZ mice were digested (Mitchell
et al., 2010) and FACS sorted as described previously (Pannérec
et al., 2013): briefly, muscles were minced and incubated
with a solution of collagenase/dispase for 90min at 37◦C,
then cells were washed three times in BSA 0.2% (Jackson
Immunoresearch) diluted in Hank’s Balanced Salt Solution
(HBSS) (Life Technologies) and then incubated for 1 h on ice
with the following primary antibodies at a concentration of 10
ng.ml−1: rat anti-mouse CD45-APC (BD Biosciences), rat anti-
mouse Ter119-APC (BD Biosciences), rat anti-mouse CD34-
E450 (eBiosciences), rat anti-mouse Sca1-A700 (eBiosciences),
and rat anti-mouse PDGFRα-PE (CD104a, eBiosciences). Cells
were washed and incubated with C12FDG, 60µM, (Life
Technologies) 1 h at 37◦C and analyzed and sorted on
a FACSAria (Becton Dickinson) with appropriate isotype
matching controls as previously reported (Pannérec et al.,
2013). Ter119pos and CD45pos cells were negatively selected and
the remaining cells were gated based on the other markers:
satellite cells were sorted in the CD34posSca1neg fraction,
while PDGFRαpos and PDGFRαneg PICs were sorted in the
CD34posSca1posC12FDG
pos(PW1pos) fraction (Pannérec et al.,
2013). At least 3 independent experiments were performed for
CTL and RAP-031-injected mice groups.
Cell Culture
For transwell co-culture experiments, FACS-sorted cell
populations were maintained in high serum medium (GM)
as described previously (Pannérec et al., 2013). Satellite cells
were plated in the lower chamber at a density of 100 cells/cm2.
PICs were plated on the membrane of the insert well (1µm
pore size, BD Biosciences) at 3,000 cells per cm2. Cells were
grown for 1 day in GM before adding the following factors:
recombinant myostatin (R&D Systems) was added at 0, 20, 200,
or 2,000 ng.mL−1; human follistatin blocking antibody (αFST)
(R&D Systems), mouse IGF-1 blocking antibody (αIGF1) (R&D
Systems) and isotype matched IgG (R&D Systems) were used at
4 µg.mL−1 (R&D Systems). After 2 days, cells were fixed with
4% (w/v) paraformaldehyde (Sigma Aldrich) and the number of
cells per colony was counted. At least 3 independent experiments
were performed for each condition.
Gene Expression Analysis
RNA extracts were prepared from freshly FACS sorted cells
using RNeasy micro-kit (Qiagen). cDNA was generated by
random-primed reverse transcription using the SuperScript First
Strand kit (Life Technologies). cDNAs were analyzed by semi-
quantitative PCR using the ReddyMix PCRMaster Mix (Thermo
Scientific) under the following cycling conditions: 94◦C for 5min
followed by 32 cycles of amplification (94◦C for 30 s, 60◦C for 30 s
and 72◦C for 1min) and a final incubation at 72◦C for 10min.
Primers are listed in Supplementary Table 1.
Histological Analyses
Tibialis anterior (TA), soleus, plantaris, and gastrocnemius
muscles were removed, weighed and snap frozen
in liquid nitrogen-cooled isopentane (Sigma Aldrich) as
previously described (Mitchell et al., 2010; Pannérec et al., 2013).
In the case of Pax7DTR/+:Pax7CreERT2:ROSAmTmG mice, TA
muscles were fixed 2 h in 4% (w/v) paraformaldehyde (Sigma
Aldrich), incubated overnight in 20% (w/v) sucrose (Sigma
Aldrich) and frozen in liquid nitrogen-cooled isopentane (Sigma
Aldrich). Muscles were cryosectioned (7µm) before processing.
Cryosections were stained with haematoxilin and eosin (H&E)
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(Sigma Aldrich). Fat tissue was detected by Oil-Red O staining
(Sigma Aldrich): cryosections were fixed in 10% formalin (Sigma
Aldrich) for 5min at 4◦C, rinsed in water and then 100%
propylene glycol (Sigma Aldrich) for 10min, stained with Oil red
O (Sigma Aldrich) for 10min at 60◦C, placed in 85% propylene
glycol for 2min and rinsed in water. Nuclei were counterstained
with Mayer’s Hematoxylin Solution (Sigma). Collagen deposition
was detected by Sirius Red staining (Sigma Aldrich): cryosections
were stained with Mayer’s haematoxylin (Sigma Aldrich) for
10min, rinsed in running tap water for 20min, then stained
with 1.3% (w/v) Picro-sirius Red solution (Sigma Aldrich) for
45min and washed twice in acidified water. The fat and fibrotic
index was calculated as percent area of fat (red-colored Oil-Red
O-stained areas) and collagen (pink-colored areas) of the total
tissue area using NIH Image J Software (http://rsbweb.nih.gov/
ij/) as reported previously (Tanano et al., 2003; Mozzetta et al.,
2013).
For immunofluorescence, TA cryosections were fixed in 4%
(w/v) paraformaldehyde and processed for immunostaining as
described previously (Mitchell et al., 2010; Pannérec et al., 2013).
Primary antibodies were: PW1 (Relaix et al., 1996) (rabbit,
1:3,000), Pax7 (mouse, Developmental Studies Hybridoma Bank,
1:15), M-Cadherin (mouse, Nanotools, 1:100), Ki67 (mouse, BD
Biosciences, 1:100), Ki67 (rabbit, Abcam, 1:100, GFP (chicken,
Abcam, 1:500), laminin (rabbit, Sigma, 1:100). Antibody binding
was revealed using species-specific secondary antibodies coupled
to Alexa Fluor 488 (Molecular Probes), Cy3 or Cy5 (Jackson
Immunoresearch). Nuclei were counterstained with DAPI
(Sigma Aldrich). For quantitative analyses of immunostained
tissues, positive cells for at least 300 myofibers were counted
in at least 5 randomly chosen fields per muscle section, n = 3
animals for each group. Fiber size distribution was measured
from cryosections obtained from the mid-belly of TA stained
with laminin, images were captured on a Zeiss AxioImagerZ1
microscope, and morphometric analysis was performed using
MetaMorph7.5 (Molecular Devices). For uninjured muscles, at
least 400 fibers from randomly chosen fields were analyzed per
muscle section, n = 3 animals for each group. For injured
muscles, between 200 and 575 fibers from randomly chosen fields
were analyzed per muscle section, n= 3 animals for each group.
Statistical Analysis
All statistics were performed with an unpaired Student’s t-test
using the GraphPad software. Values represent the mean± s.e.m.
∗p < 0.05 ∗∗p < 0.01 ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001.
RESULTS
Satellite Cell Depletion Results in Muscle
Fiber Atrophy and Reduces Hypertrophy in
Response to AcvR2B Pathway Inhibition
We used the Pax7DTR/+ mouse model in which the DT receptor
is expressed under the control of Pax7 such that injection of DT
results in a substantial depletion of the satellite cell population
(Sambasivan et al., 2011). Ten week-old Pax7DTR/+ mice were
injected with DT in the Tibialis Anterior (TA) (CTL DT mice)
and PBS in the contralateral muscle as a control (CTL PBS mice)
and allowed to recover for 4 weeks (Figure 1A). We observed
that DT-induced satellite cell depletion resulted in a marked
reduction (20%) in fiber size indicating that satellite cells are
required to maintain proper fiber size in resting muscle (median
value of fiber area distribution: CTL PBS = 1058.67 ± 141.49
µm2; CTL DT = 831.33 ± 85.38 µm2) (Figures 1C,D). It has
been shown previously that a soluble form of the AcvR2B (RAP-
031) containing the ligand-binding site inhibits AcvR2B signaling
by functioning as a decoy receptor in vivo and that this inhibition
results in marked hypertrophy due to inhibition of MST and
activin activity (Akpan et al., 2009; Koncarevic et al., 2010;
George Carlson et al., 2011; Pistilli et al., 2011). We therefore
tested RAP-031 in muscle containing an intact population of
satellite cells (PBS-injected control referred to here as “intact”)
and DT-induced satellite cell depleted mice. Mice were injected
intraperitoneally with RAP-031 or vehicle (CTL) twice a week
for 2 weeks (Figure 1A). In order to confirm AcvR2B inhibition
following RAP-031 administration, we performed Western Blot
analyses on TA muscle extracts, which revealed a 50% reduction
of the ratio between the phosphorylated form of Smad2 (pSmad2)
and the total amount of Smad2 in RAP-031 treated animals,
regardless of the status of the satellite cell pool (both in PBS and
DTmuscles), thus confirming inhibition of the AcvR2B signaling
following RAP-031 administration (Figure 1B). Moreover, as
reported by others (Cadena et al., 2010; George Carlson et al.,
2011; Pistilli et al., 2011), intact muscle exposed to RAP-031
displayed a pronounced increase in fiber size (median value
of fiber area distribution: CTL PBS = 1058.67 ± 141.49 µm2;
RAP PBS = 1435.00 ± 105.67 µm2) (Figures 1C,D). However,
in satellite cell-depleted muscle, RAP-031 treatment rescued
the reduction of muscle fiber size previously induced by DT
injection, but failed to generate a net fiber hypertrophic effect
(median value of fiber area distribution: RAP DT = 969.00 ±
61.25 µm2) (Figures 1C,D). Taken together, these data indicate
that a reduced satellite cell compartment limits muscle fiber
hypertrophy in response to AcvR2B inhibition.
Depletion of the Satellite Cell
Compartment Alters the Stem Cell Niche
Fiber hypertrophy is typically accompanied by an increase in
myonuclear content in intact muscle, a process referred to as
nuclear accretion (Smith et al., 2001; Pallafacchina et al., 2013).
We observed that RAP-031 treatment of intact muscles resulted
in a marked increase in sublaminal nuclear content as compared
to vehicle-injected mice (Figure 1E) consistent with previous
studies (Smith et al., 2001; McCroskery et al., 2003; Zhou et al.,
2010; Wang and McPherron, 2012). In contrast, we did not
observe a change in sublaminal nuclei content in DT RAP-
031 mice as compared to controls (Figure 1E) indicating that
in presence of a reduced satellite cell pool, other progenitors
with myogenic capacities (pericytes, myoPICs) are not recruited
into the myofibers. We do note a minor increase in sublaminal
nuclei following satellite cell depletion in the absence of RAP-
031 exposure (Figure 1E), however this is likely due to a reduced
fiber volume, nonetheless, we cannot rule out that a portion of
the surviving satellite cells or other resident progenitor cells fuse
with the muscle fibers in response to satellite cell depletion or
DT-treatment.
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FIGURE 1 | RAP-031 treatment rescues the reduction of muscle fiber size induced by satellite cell depletion and increases PICs in satellite cell-depleted muscle. (A)
Strategy: the right TA of 10 week-old Pax7DTR/+ males was injected with diphteria toxin (DT) to deplete satellite cells while the contralateral muscle was injected with
PBS 2 weeks before RAP-031 treatment. Mice were intraperitoneally injected with RAP-031 or vehicle (CTL) twice a week for 2 weeks and sacrificed 14 days after the
first injection. (B) Western Blot of TA protein extracts with antibodies against phospho-Smad2/3, total Smad2/3 and GAPDH. (i) Representative image of the blots.
Molecular size in kDa is shown on the right side. (ii) Ratio between levels of phospho-Smad2 and levels of total Smad2. The graph shows a marked reduction in the
ratio pSmad2/Smad2 in RAP-031 muscles, indicating an inhibition of the AcvR2B pathway following systemic RAP-031 treatment. N = 2 muscles per group. (C)
Cross-sections images of TA muscles from CTL (Upper) or RAP-031 (Lower) mice injected with PBS (Left) or DT (Right) stained with hematoxylin and eosin. Scale bar,
60µm. (D) Fiber size distribution in CTL PBS (gray), CTL DT (purple), RAP-031 PBS (blue), and RAP-031 DT (orange) TAs. RAP-031 treatment rescued the reduction
of muscle fiber size induced by satellite cell depletion. Values represent the mean number ± s.e.m. per 100 fibers for each size. N = 3 animals for each group. Median
of fiber area distributions are shown in the graphs. (E) Quantification of the number of sublaminal nuclei per 100 fibers in TA from CTL and RAP-031 mice injected with
PBS or DT. RAP-031 treatment did not result in myonuclei addition when satellite cells are depleted. Values represent the mean number ± s.e.m. per 100 fibers. At
(Continued)
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FIGURE 1 | least 300 fibers from randomly chosen fields were counted for each animal, n = 3 animals were considered for each group. (F,G) Quantification of satellite
cells (E) and PICs (F) per 100 fibers in TA from CTL and RAP-031 mice injected with PBS or DT. (H) Ratio between PICs (green) and satellite cells (red) per 100 fibers
in TA from CTL and RAP-031 mice injected with PBS or DT was profoundly altered in DT-injected mice after RAP-031 treatment. In (E–G), satellite cells were
determined as M-Cadherinpos cells underneath the basal lamina, PICs were determined as interstitial PW1pos M-Cadherinneg cells. In (E–G), values represent the
mean number of positive cells ± s.e.m. per 100 fibers. At least 300 fibers from randomly chosen fields were counted for each animal, n = 3 animals were considered
for each group. For all values, *p < 0.05, **p < 0.01, and ***p < 0.001.
We next sought to determine the status of satellite cells
and other resident progenitor cell populations in response to
satellite cell depletion in the presence or absence of RAP-
031 exposure. Muscle tissue sections from PBS or DT-injected
muscles from vehicle and RAP-031 treated mice were stained
for PW1/Peg3 (to label PICs) and M-Cadherin (to label satellite
cells) (Supplementary Figure 1). As expected (Sambasivan et al.,
2011), satellite cell numbers were markedly decreased following
DT injection to levels of ∼25–30% as compared to levels
in intact muscles (Figure 1F). Furthermore, whereas RAP-031
treatment induced a 2-fold increase in satellite cell number in
intact muscles (Figure 1F), we did not observe an increase in
satellite cell number in satellite cell depleted muscles in response
to RAP-031 treatment (Figure 1F). These results suggest that
once the satellite cell number is below a specific or threshold
level, their response to AcvR2B inhibition is abrogated. As
shown previously (Sambasivan et al., 2011) and observed in
this study, PICs are clearly detectable following satellite cell
depletion and we observed a modest increase in PICs number
following satellite cell depletion as compared to intact muscles
(Figure 1G). Furthermore, we observed that PICs undergo a 2-
fold increase in intact muscles and a 4-fold increase in satellite
cell depleted muscles following RAP-031 treatment (Figure 1G),
indicating that PICs increase in number in response to AcvR2B
inhibition in all conditions and that this response is increased
when satellite cell numbers are reduced. Whether the increase in
PICs is due to a proliferation of previously existing PICs or de
novo PW1 expression in a subset of interstitial cells is not known
and requires the generation of novel transgenic mouse models
to specifically track PICs. Since we observed a deregulation of
the number and proportion of muscle cell populations in our
experimental conditions, we wished to better characterize the
status of the muscle stem cell niche. We therefore checked for
the expression of a marker of myogenic cell activation (MyoD)
and a marker of cell proliferation (Ki67) in combination with
markers for satellite cells (PW1, Pax7) and PICs (PW1) via
immunostaining in TA cryosections. We did not detect MyoD
expression in TA from any of the conditions tested (data not
shown), indicating that neither DT-induced satellite cell pool
depletion nor AcvR2B inhibition induced myogenic activation
of satellite cells or any other muscle progenitors. In addition, we
detected only rare Ki67pos cells in all the conditions examined,
among which few Ki67pos PICs and no Ki67pos satellite cell in
DT RAP-031 mice (data not shown), indicating that satellite cells
and a majority of PICs were in quiescent cell cycle state (G0
resting phase) at the end of the observation period, both in the
PBS and DT-injected mice, and regardless of AcvR2B inhibition
treatment.
We had shown previously that PICs and satellite cells are
present in a ∼1:1 ratio in resting muscle throughout postnatal
life, whereas the constitutive loss of Pax7, which leads to a
concomitant decrease of satellite cells and an increase in PICs
such that the ratio of PICs and satellite cells is altered (Mitchell
et al., 2010). We observed that the increase in PICs is present
at birth prior to any detectable loss of satellite cells indicating
that a change in the PIC population is an early event following
compromised satellite cell function in the Pax7 mutant mouse
(Mitchell et al., 2010). Furthermore, we have shown that PICs
encompass the fibroadipogenic progenitors (FAPs) as well
as a population of myogenically competent interstitial cells
(myoPICs) (Pannérec et al., 2013). Since FAPs have already been
shown to exert a promyogenic effect upon activated satellite
cells but also underlie the fibrotic and adipogenic response in
muscle tissue in pathological settings (Joe et al., 2010; Uezumi
et al., 2010, 2011), we set out to determine whether these
populations were altered in response to satellite cell depletion.
Consistent with our previous observations, we observed that
PICs and satellite cells are present in a ∼1:1 ratio in normal
resting muscle (Figure 1H). Following AcvR2B inhibition,
this ratio does not display a significant change despite the
increase in cell number suggesting a tight regulation of the
stem cell niche in both normal and hypertrophic muscle. In
contrast, depletion of the satellite cell compartment resulted
in an alteration of the PIC/satellite cells ratio in favor of
PICs (∼7:1) however, we observed that RAP-031 treatment
resulted in a PIC/satellite cells ratio of ∼17:1 in satellite
cell-depleted muscle (Figure 1H). Analyses performed on
younger mice (5 week-old) (Supplementary Figure 2A) also
showed an increase in both satellite cells and PICs following
RAP-031 treatment (Supplementary Figure 2B), however
PICs displayed a more pronounced increase as compared
to satellite cells, leading to an altered ratio in favor of PICs
(Supplementary Figure 2C). Moreover, we observed that
the proportions of FAPs (PW1posPDGFRαpos) and myoPICs
(PW1posPDGFRαneg) were unchanged in RAP-031 as compared
to vehicle-injected mice (Supplementary Figures 2D–F),
indicating that both PW1 expressing interstitial populations
were equally increased after AcvR2B blockade. Taken together,
these data indicate that AcvR2B pathway inhibition has a
profound impact on the muscle stem cell niche in intact as well
as in satellite cell-depleted muscles.
AcvR2B Inhibition Restores the
Regenerative Capacity and Inhibits
Fibrosis/Adipogenesis in Muscle
Containing Few Satellite Cells
Satellite cell depletion results in a severely compromised
regenerative response coupled with pronounced fibrosis and
fat deposition (Lepper et al., 2011; Sambasivan et al., 2011)
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and this outcome is strikingly similar to late stage degenerative
myopathies (Maier and Bornemann, 1999; Shefer et al., 2006;
Tabebordbar et al., 2013). FAPs have been proposed to exert a
promyogenic role on satellite cells during regeneration but also
to directly contribute to fat and fibrosis in diseased muscle (Joe
et al., 2010; Uezumi et al., 2010; Murphy et al., 2011), therefore
we sought to determine whether the changes observed in the PICs
population, which includes the FAPs, in both intact and satellite
cell depleted muscles following RAP-031 treatment reflected a
general change in the stem cell niche that in turn may provide
a more favorable regenerative environment. Previously we
showed that PICs and satellite cells have distinct transcriptomes
(Pannérec et al., 2013). Closer examination of these previous data
revealed a striking reciprocal expression of TGFβ ligands and
their receptors in PICs and satellite cells although these earlier
studies were performed on cells isolated from juvenile muscles
and without separating the population based upon PDGFRα
expression (Pannérec et al., 2013). Nonetheless, the close
overlap between juvenile and adult satellite cell transcriptomes
(Pannérec et al., 2013) prompted us to examine the expression
of specific TGFβ family members and receptors in adult satellite
cells, FAPs and myoPICs. Semi-quantitative PCR analyses
revealed that adult satellite cells express activinA and MST
(Supplementary Figure 3A), which are factors known to inhibit
myogenesis and induce muscle atrophy (McPherron et al., 1997;
Lee et al., 2010). In contrast, FAPs expressed FST and IGF-1
(Supplementary Figure 3A), which have been demonstrated to
exert a promyogenic effect on muscle fibers and activated satellite
cells (Glass, 2010; Lee et al., 2010) (Supplementary Figure 3A).
We note that the myoPICs do not show this reciprocal expression
of TGFβ family members, although they express different
extracellular and intracellular players of the TGFβ pathway
(Supplementary Figure 3A), suggesting a response to TGFβ
pathway manipulation. Furthermore, we observed that satellite
cell capacity to form clones in vitro is dramatically reduced
when these cells are cultured in presence of increasing doses of
exogenous MST (Supplementary Figures 3B,C), consistent with
previous observations (McCroskery et al., 2003). We found that
the decline of satellite cell clone-forming capacity in presence
of MST can be reversed by the concomitant co-culture with
PICs (Supplementary Figures 3B,C) and that this rescue can be
abrogated by the addition of blocking antibodies against FST
and IGF-1 to the medium (Supplementary Figure 3C). Taken
together, these data are consistent with a model in which the
PICs are a key cellular constituent of the satellite stem cell
niche and serve to provide a promyogenic effect in healthy
muscle in response to injury (Joe et al., 2010; Uezumi et al.,
2010; Murphy et al., 2011; Mozzetta et al., 2013). We found
here that PICs are strongly increased in number in satellite cell-
depleted muscle following RAP-031 treatment as compared to
CTL DT-injected mice (Figure 1G), while satellite cell number
did not change and remained at a level of 30% of the intact
muscle population (Figure 1F). Satellite cell-depleted TAmuscles
and control (PBS-injected) contralateral muscles were therefore
injured by cardiotoxin (Ctx) 1 day before the last RAP-031 or
vehicle injection and the level of regeneration was assessed at 2
weeks following injury. As expected, all RAP-031-treated (n =
9) and CTL (n = 9) TA muscles injected with PBS displayed
robust myofiber regeneration while CTL satellite cell-depleted
muscles displayed severely compromised regeneration coupled
with fat deposition and fibrosis (Figure 2A). We observed rare
and highly restricted regions of newly regenerated fibers in
only 2 of the 5 CTL satellite cell depleted muscles (CTL DT)
suggesting that restricted surviving satellite cells can bemobilized
locally but fail to contribute significantly toward replacingmuscle
tissue. In contrast, RAP-031 treatment of satellite cell-depleted
muscles resulted in a marked rescue in overall regeneration
coupled with a near complete inhibition of fat formation and
fibrosis in 7 out of 9 samples (Figure 2A). We note that
depletion of satellite cells in vehicle-injected mice resulted in
a strong decrease in the number of centrally nucleated fibers
after injury compared to muscles injected with PBS (8.8-fold),
whereas this decrease was less than 1.5-fold in RAP-031 DT
mice as compared to CTL PBS muscles (Figure 2B). Despite
the rescue in regenerative capacity following RAP-031 treatment,
satellite cell-depleted muscles exhibited a 30% reduced fiber
size as compared to normal intact muscles (median value of
fiber area distribution: CTL PBS = 1,455.13 ± 175.68 µm2;
RAP DT = 1003.80 ± 136.18 µm2) (Figure 2C), indicating
that AcvR2B pathway inhibition via RAP-031 administration
before injury is able to rescue overall regeneration capacity
in satellite cell-depleted muscles, but does not rescue satellite
cell depletion-induced muscle mass loss after injury. We note
that while RAP-031 treatment is able to increase fiber size
in homeostatic intact muscles (Figure 1D), it does not induce
muscle fiber hypertrophy after injury (median value of fiber
area distribution: CTL PBS = 1,455.13 ± 175.68 µm2; RAP
PBS = 1,208.55 ± 190.74 µm2) (Figure 2C) suggesting that the
AcvR2B signaling pathway in resting and regenerating muscle
acts differently. Moreover, in RAP-031 satellite cell-depleted
muscle, regeneration was coupled with a marked decrease of fat
as well as fibrotic zones to levels comparable to CTL intact muscle
(Figure 2D).
We next compared the number of satellite cells in injured
and uninjured muscles. As expected (Wang and Rudnicki,
2012; Yin et al., 2013), satellite cells were increased in CTL
PBS-injected muscle after injury (Figure 2E). In contrast,
satellite cell numbers were below the level of detection in
CTL DT-injected contralateral muscles after injury (Figure 2E),
indicating that the failure of regeneration was accompanied by
a complete loss of satellite cell self-renewal after Ctx injection.
We found that RAP-031 treatment did not significantly change
the amount of satellite cells present in the regenerated intact
muscle (Figure 2E) indicating that regeneration of RAP-031
treated muscle is accompanied by the re-establishment of
the normal intact satellite cell population number. Similarly,
satellite cell-depleted muscles pretreated with RAP-031 gave
rise to new muscle with a satellite cell population that
was restored to ∼30% of the intact muscle population
(Figure 2E). These data demonstrate that inhibition of the
AcvR2B pathway in muscle tissue containing a reduced
population of satellite cells is able to rescue regeneration but
that the satellite cell population is only restored to pre-injured
levels.
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FIGURE 2 | AcvR2B pathway inhibition improves overall fiber regeneration and ameliorates tissue homeostasis in injured satellite cell-depleted muscles.
(A) Cross-sections of TA muscle from CTL (Upper) and RAP-031 (Lower) Pax7DTR/+ mice injected with DT or PBS stained with haematoxylin and eosin (Left), Oil-Red
O (Middle) and Sirius Red (Right). Regeneration is more efficient in RAP-031 DT mice as compared to CTL DT mice, with a marked reduction in fat and fibrotic tissue
deposition. Scale bar, 85µm. (B) Quantitative analysis of regenerative capacity of TA muscles shown in (A). The number of centrally nucleated fibers per field in TAs
from CTL mice injected with PBS was considered as the baseline (zero) and values represent the fold change ± s.e.m. normalized accordingly. Muscle fiber
regeneration is significantly rescued in RAP-031 DT mice as compared to CTL DT mice. Five randomly chosen fields from one mid-belly TA section were analyzed for
each animal, n = 3 animals were analyzed for each group. (C) Fiber size distribution in CTL PBS (gray), RAP-031 PBS (blue), and RAP-031 DT (orange) TAs. Satellite
cell-depleted muscles exposed to RAP-031 before injury exhibited regenerated fibers with a reduced size as compared to intact muscles. Values represent the mean
number ± s.e.m. per 100 fibers for each size. N = 3 animals for each group. (D) Quantitative analysis of fat (i) and fibrotic (ii) areas of muscles showed in (A). One
mid-belly TA section was analyzed with ImageJ software for each animal and n = 3 animals were analyzed for each group. Fat areas were determined by Oil-Red O
staining and fibrotic areas were determined by Sirius-Red staining. Values represent the percentage of fat (i) or fibrotic (ii) area on whole muscle area.
(E) Quantification of satellite cells per 100 fibers in TA from uninjured (blue) and injured (yellow) Pax7DTR/+ CTL and RAP-031 mice injected with PBS or DT. Satellite
cells were undetectable after injury in CTL DT muscle, however RAP-031 treatment was able to prevent satellite cell loss. Satellite cells were determined as Pax7pos
cells underneath the basal lamina. At least 5 randomly chosen fields, corresponding to at least 300 fibers, were counted for each animal, n = 3 animals were
considered for each group. *p < 0.05, **p < 0.01, ****p < 0.001.
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AcvR2B Inhibition Rescues Residual
Satellite Cell Regenerative Capacity
Our results raised the question as to whether the regeneration
we observed in RAP-031 treated satellite cell-depleted muscle
was primarily due to the activation of the residual satellite
cells or due to the recruitment of non-satellite cell myogenic
populations. We demonstrated previously that PICs contain
a population of myogenic cells and several studies have
shown the presence of myogenic cells other than satellite
cells in normal muscle tissue however their participation in
regeneration is unproven (Mitchell et al., 2010; Pannérec et al.,
2013). To determine the origin of regenerating myofibers, we
crossed Pax7DTR/+ mice with Tg:Pax7CreERT2 mice (Mourikis
et al., 2012) and with reporter line ROSA26mTomato/mGFP
(ROSAmTmG) (Muzumdar et al., 2007). The resulting
Pax7DTR/+:Pax7CreERT2:ROSAmTmG mice express a tamoxifen-
inducible Cre (Metzger and Chambon, 2001) such that
Pax7-expressing satellite cells and their progeny are specifically
marked by membranous GFP (mGFP), while all the other cells
are marked bymembranous Tomato (mTomato) (Mourikis et al.,
2012). To verify the efficiency of Cre-mediated labeling of the
satellite cell population, 6 week-old Pax7CreERT2:ROSAmTmG
mice were injected with tamoxifen and sacrificed 6 weeks
later (Supplementary Figure 4A). We stained TA muscles
for mGFP and Pax7 and observed that all Pax7-positive
cells were positive for mGFP (Supplementary Figure 4B)
indicating that the expression of mGFP labeled the entirety of
the Pax7pos satellite cell population. In addition, we observed
mGFPpos sublaminal monuclear cells that did not express
Pax7 at detectable levels indicating that mGFP labeling
identified a larger set of satellite cells, which displayed low
or undetectable levels of Pax7 at the time of the analysis
(Supplementary Figure 4B). Taken together, we conclude that
nearly 100% of the satellite cell population was marked by mGFP
expression such that the Pax7DTR/+:Pax7CreERT2:ROSAmTmG
mice provides a genetic tool for determining whether newly
regenerated fibers are derived from satellite cells in which case
fibers are predicted to express mGFP whereas the presence
of mGFPnegmTomatopos regenerating fibers would indicate a
contribution of non-satellite progenitor cells. We then used 6
week-old Pax7DTR/+:Pax7CreERT2:ROSAmTmG mice injected
with tamoxifen to activate mGFP expression in satellite cells
followed by a single injection of DT in the right TA and PBS
in the contralateral muscle 4 weeks after the last tamoxifen
injection. Muscles were allowed to recover for 2 weeks and then
treated with RAP-031. Muscles were injured by cardiotoxin
1 day before the last RAP-031 injection and the regeneration
was assessed 2 weeks later (Figure 3A). In satellite cell-depleted
muscles from RAP-031 mice, we observed that the majority of
centrally nucleated fibers (>80%) were mGFPpos (Figures 3B,C),
comparable to vehicle (CTL) PBS and RAP-031 PBS conditions
(Figures 3B,C), indicating that the reduced pool of satellite
cells can be mobilized by RAP-031 treatment in satellite cell
depleted muscles after injury. While these data confirm previous
studies demonstrating that the satellite cells are the major muscle
progenitor (Relaix and Zammit, 2012) we note that ∼15% of the
centrally-nucleated fibers in intact muscle are exclusively marked
by mTomato (Figure 3D), strongly suggesting a contribution
of non-satellite cells. Interestingly, we observed a 10% increase
in the number of mGFPnegmTomatopos centrally nucleated
fibers and a concomitant 10% decrease of mGFPpos centrally
nucleated fibers in intact muscles from RAP-031 treated mice as
compared to CTL mice (Figures 3C,D), suggesting that AcvR2B
pathway inhibition stimulates non-satellite cell recruitment.
Alternatively, there may be a small population of satellite cells
that are resistant to Cre labeling that accounts for the generation
of tomato positive fibers.
DISCUSSION
In addition to playing a key role during myofiber regeneration,
satellite cells can fuse to existing myofibers during muscle
hypertrophy leading to a stabilization of the larger myofiber mass
(Amthor et al., 2009; McCarthy et al., 2011; Lee et al., 2012;
Wang and McPherron, 2012). In this study, we found that a
∼70–80% reduction in the number of satellite cells triggers a
decrease in myofiber size suggesting a role for satellite cells in
maintaining fiber size. Interestingly, previous studies showed
that depletion of satellite cells in adult mice (4-month old)
did not reduce muscle fiber size nor exacerbate age-related
sarcopenia (Fry et al., 2015; Murach et al., 2017), however
depletion performed at 2.5 months of age (this study) resulted
in fiber size reduction. Moreover, we found that myofiber
hypertrophy is limited in muscles containing fewer satellite cells
following AcvR2B pathway inhibition. Our observations are
therefore consistent with a previous study in which satellite cell
depletion in young mice (2.5 months old) abrogates subsequent
mechanical overload-induced fiber hypertrophy (Murach et al.,
2017), while satellite cells are usually reported to be dispensable in
hypertrophy processes at later ages (>4 months) (Murach et al.,
2017, 2018). Taken together, these data suggest an active, age-
dependent role for satellite cells in normal late postnatal muscle
growth.
The central question of this study was why a reduced satellite
cell population cannot properly regenerate and our observations
here suggest that the microenvironment is altered in response
to a decline in satellite cells. Previous reports demonstrated that
as few as 10 satellite cells can generate hundreds of myofibers
when engrafted in healthy muscle. It has also been proposed that
the diseased muscle environment does not favor optimal satellite
cell function (Mann et al., 2011; Serrano et al., 2011; Pannérec
et al., 2012; Tabebordbar et al., 2013; Yin et al., 2013). Consistent
with this proposal, it has been shown that regenerative capacity
declines sharply when the satellite cell pool declines to 50% of
initial satellite cell complement in the double mouse mutant for
utrophin and dystrophin (Lu et al., 2014). Our results confirm
satellite cells contribute to muscle homeostasis.
The importance of niche cells has been demonstrated in
multiple tissues which serve as cellular partners to govern
progenitor activation, self-renewal and survival (Leatherman,
2013). We demonstrated previously that PW1/Peg3 expression
can be used to identify a large array of adult progenitor/stem
cells including associated niche cells (Besson et al., 2011). As one
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FIGURE 3 | Regeneration in satellite cell-depleted muscles following AcvR2B pathway inhibition is mainly executed by the residual satellite cells. (A) Strategy: 6
week-old Pax7DTR/+:Pax7CreERT2:ROSAmTmG mice were injected with tamoxifen to label satellite cells. 4 weeks later, the right TA was injected with DT to deplete
the satellite cell pool. The contralateral muscle was injected with PBS. After 2 weeks, mice were injected with either RAP-031 or vehicle (CTL) twice a week for 2
weeks. The day before the last injection of RAP-031 or vehicle both TAs were injured by cardiotoxin injection. Mice were sacrificed 2 weeks after injury. (B)
Representative images of cross-sections from injured TA muscles of CTL (Upper) and RAP-031 (Lower) mice injected with DT or PBS as described in (A),
immunostained for mGFP (green) to identify satellite cell-derived fibers and Pax7 (orange) to identify satellite cells. mTomato fluorescence is shown in red, DAPI
staining (blue) identifies nuclei. The majority of regenerating fibers are satellite cell-derived (green) regardless of treatment. White arrowheads: satellite cells. Scale bar,
30µm. (C,D) Quantification of the number of mGFPpos (C) and mGFPnegmTomatopos (D) fibers per 100 centrally nucleated fibers for CTL and RAP-03 mice injected
with PBS or DT, as described in (A). Values represent the mean number of positive fibers ± s.e.m. per 100 centrally nucleated fibers. Random images were captured
at 20X magnification and at least 5 different fields for each section were counted, n = 3 animals were considered for each group. *p < 0.05, **p < 0.01.
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FIGURE 4 | Proposed cellular model of satellite cell and stem cell niche interactions. Top Row- In resting muscle containing an intact population of satellite cells (Left),
pro-myogenic signals (green arrow) from PICs/FAPs (green), and anti-adipogenic signals (red arrow) from satellite cells (red) are kept in a tight balance, which is
maintained after injury (Right). Second Row- Following AcvR2B inhibition, PICs and satellite cell populations expand, however pro- and anti-myogenic balance in
maintained before and after injury. Third Row- Satellite cell depletion disrupts the balance and overall levels of factors regulating the niche (Left) and signaling within
the niche is completely deregulated following injury (Right). This results in a complete loss of satellite cells and consequently a loss of satellite cell derived
anti-adipogenic signals allowing FAP progression into fat and fibrosis (Right). Fourth Row- AcvR2B inhibitor treatment of satellite cell depleted muscle reinforces the
niche (Left) and allows for satellite cell myogenic progression/self-renewal and consequently the maintenance of a minimal balance of factors required to restore the
muscle tissue and stem cell niche (Right).
example, PW1/Peg3 is expressed in the hair follicle bulge cells
that are a major reservoir of skin progenitors as well as in closely
associated dermal papilla cells (Besson et al., 2011, 2017) which
have a dual role as mesenchymal stem cells and as critical niche
support cells (Driskell et al., 2011; Wong et al., 2012). We suggest
that the expression of PW1/Peg3 in the satellite cells and a subset
of interstitial cells including most notably the FAPs, defines a
similar niche in skeletal muscle.
While our lineage tracing analyses confirms that satellite
cells are the major source of regenerated muscle in all cases,
several non-satellite cell populations have been shown to have
pronounced myogenic activity (Pannérec et al., 2012). In intact
skeletal muscle, ∼15% of the regenerated muscle fibers do
not express the satellite cell lineage marker following damage
and increase to ∼25% following AcvR2B pathway inhibition.
Since all Pax7-positive cells express GFP following tamoxifen
injection, our data suggest that non-satellite cell progenitors
participate directly in muscle regeneration but require an intact
satellite cell compartment although lineage-specific markers for
the myoPIC population is required to assess the origin of these
cells.
It has been described previously that satellite cells
inhibit adipogenic differentiation of FAPs and that FAPs
are promyogenic for satellite cells (Joe et al., 2010; Uezumi
et al., 2010, 2011). We report here that in normal resting
muscle, satellite cells express myogenic inhibitory factors such
as MST and activinA, whereas FAPs express promyogenic
factors including FST and IGF-1. These observations provide
a framework (Figure 4) in which satellite cells are present in a
niche which includes the FAPs and that the balance of pro- and
anti-myogenic signals keeps myogenesis and fibro/adipogenesis
tightly regulated.
The AcvR2B pathway has been a focus for the development
of therapeutics for degenerative muscle diseases due to the
recognition that these molecules antagonize myostatin and
activin activity (Glass, 2010; Zhou and Lu, 2010; Ceco and
McNally, 2013). A recent study has revealed that histone
deacetylase (HDAC) inhibitors provide a promising route to
treat muscular dystrophy in murine models via the induction
of follistatin in interstitial muscle cells consistent with our
results here showing that muscle mass is regulated by complex
interactions between multiple cells types (Mozzetta et al., 2013).
It is of interest that the beneficial effects of HDAC inhibitors
decrease efficacy with age (Mozzetta et al., 2013). Similarly, we
report here that AcvR2B inhibition in young mice (5 weeks)
causes an increase in the PIC/satellite cell ratio disrupting the
typical 1:1 ratio, while a 1:1 ratio is maintained in 10-week-
old mice. Taken together, these data indicate that changes in
regenerative capacity and stem cell competence during postnatal
life reflect a loss of plasticity in the stem cell niche.
CONCLUSIONS
Our results point to a mechanistic convergence for satellite cells
governing both regeneration and the maintenance of muscle
fiber size. Whereas 20–30% of the normal population of satellite
cells is insufficient to give rise to new muscle following damage,
this reduced population can execute the regeneration program
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if the AcvR2B pathway is pharmacologically targeted. We
propose that pharmacological targeting of the AcvR2B pathway
restores a balance of regulatory factors within the muscle stem
cell niche, in part through the regulation of cells that exert
a promyogenic effect as well as cells capable of generating
fibrotic and fat tissue, such as PICs/FAPs, that can interfere
with the proper reassembly of muscle tissue (Figure 4), rather
than directly promoting regeneration through the activation of
satellite cells. This idea is also supported by our observation that
AcvR2B inhibition treatment before injury does not alter the
activation status of either the satellite cell population nor other
cells types (such as PICs/FAPs) suggesting that all the cellular
components of the muscle stem cell niche are important for
proper regeneration. The capacity to restore the regenerative
potential of muscle containing a reduced progenitor population
through pharmacological intervention will impact the design of
future therapeutic approaches for degenerative myopathies.
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Supplementary Figure 1 | Representative pictures of immuno-stainings in
uninjured TA muscles. Representative images of cross-sections from uninjured TA
muscles of CTL (Upper) and RAP-031 (Lower) mice injected with DT or PBS,
immunostained for PW1 (green), M-cadherin (red), Laminin (orange). DAPI staining
(blue) identifies nuclei. Satellite cells (white arrowheads) are identified as
M-cadherinpos cells. PICs (yellow arrowheads) are identified as PW1pos interstitial
cells. Scale bar, 20µm.
Supplementary Figure 2 | RAP-031 treatment of intact muscle from young mice
alters the muscle stem cell niche. (A) Strategy: 5 week-old male wild-type mice
were injected intraperitoneally with RAP-031 or vehicle (CTL) every 3 days and
sacrificed 2 weeks after the first injection. (B) Quantification of satellite cells and
PICs per 100 fibers in CTL and RAP-031 TA muscles showed an increase of both
cells types after RAP-031 treatment. (C) Quantification of progenitor cells shown
in (B) for CTL and RAP-031 Tibialis Anterior revealed an altered ratio between
PICs (green) and satellite cells (red) in RAP-031 vs. CTL. For (B,C) PICs were
determined as interstitial PW1posPax7neg cells, satellite cells as Pax7pos cells
underneath the basal lamina. (D,E) Flow cytometric analyses of single cells from
7-week old limb muscles from CTL (D) or RAP-031-injected (E) PW1nLacZ mice
following the protocol described in (A). Cells were stained for CD45, Ter119,
CD34, Sca1, PDGFRα, and C12FDG (to reveal PW1 expression via
β-galactosidase activity), as reported in Pannérec et al. (2013). CD45negTer119neg
were selected. The gates used to isolate FAPs
(CD34posSca1posPW1posPDGFRαpos) and myoPICs
(CD34posSca1posPW1posPDGFRαneg) are shown. Satellite cells (SAT) are also
shown in red (CD34posSca1neg). (F) Number of FAPs (PW1posPDGFRαpos) and
myoPICs (PW1posPDGFRαpos) from CTL and RAP-031 mice as presented as the
mean percentage ± s.e.m. per 100 PICs (CD34posSca1posPW1pos) cells from at
least 3 independent experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
Supplementary Figure 3 | Adult PICs and satellite cells express TGFβ
pathway related genes. (A) Semi-quantitative PCR of selected genes involved
in the TGFβ and IGF-1 pathway in freshly sorted adult satellite cells (SAT),
FAPs (PW1posPDGFRαpos), and myoPICs (PW1posPDGFRαneg) sorted as
shown in (Supplementary Figure 1D). PC, Positive Control: whole muscle
extract from 7 week-old PW1nLacZ mice, except for activin α subunit, IGF-1
IEa and IEb (whole liver extract from 7 week-old PW1nLacZ mice) and for
TGFβR2 (whole brain extract from 7 week-old PW1nLacZ mice). (B) Schematic
transwell membrane system used: PICs (green) were plated in the upper well
on a semipermeable membrane (insert) and satellite cells (red) were plated in
the lower chamber. (C) Quantitative analyses of satellite cell proliferation in
growth medium containing 0, 20, 200 ng/ml, or 2µg/ml of recombinant
myostatin. Satellite cells were cultured alone (red bars) or in the presence of
PICs and isotype-matched IgG (gray bars). Satellite cells and PICs were
co-cultured in presence of a blocking antibody to follistatin (αFST, blue bars) or
to IGF-1 (αIGF-1, black bars) or blocking antibodies to IGF-1 and FST
together (αFST + aIGF1, white bars). Large colonies (>12 cells) were counted
and shown as a percentage of the number of total colonies.
Supplementary Figure 4 | Efficiency of inducible Pax7-driven Cre mediated
recombination of RosamTomatomGFP locus. (A) 6 week-old
Pax7CreERT2:ROSAmTmG mice were injected with tamoxifen every day for 4 days
and sacrificed 6 weeks later. (B) Quantification analysis of satellite cells in mice
treated as in (A). (i) 100% of Pax7pos satellite cells express mGFP. Values
represent the mean number of GFPpos and GFPneg cells ± s.e.m. per 100
Pax7pos cells. (ii) The majority (>80%) of GFPpos mononuclear cells co-express
Pax7, however <20% of the GFPpos mononuclear cells are not co-labeling with
Pax7. Values represent the mean number of Pax7pos and Pax7neg cells ± s.e.m.
per 100 GFPpos mononuclear cells. For quantification, immunostaining for Pax7
and GFP was performed on TA muscle section from n = 4 mice and at least 5
different randomly chosen fields were counted for each section, corresponding to
an average number of fibers of >120 per section.
Supplementary Table 1 | List of primers used for semi-qPCR.
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Background: Skeletal muscle aging is marked by the development of a sarcopenic
phenotype, a global decline of muscle energetic capacities, and an intolerance to
exercise. Among the metabolic disorders involved in this syndrome, NAD metabolism
was shown to be altered in skeletal muscle, with an important role for the NAMPT enzyme
recycling the nicotinamide precursor. An alternative pathway for NAD biosynthesis has
been described for the nicotinamide riboside vitamin B3 precursor used by the NMRK
kinases, including the striated muscle-specific NMRK2.
Aim: With this study, our goal is to explore the ability of 16-month-old Nmrk2−/− mice
to perform endurance exercise and study the consequences on muscle adaptation to
exercise.
Methods: 10 control and 6 Nmrk2−/− mice were used and randomly assigned to
sedentary and treadmill endurance training groups. After 9 weeks of training, heart and
skeletal muscle samples were harvested and used for gene expression analysis, NAD
levels measurements and immunohistochemistry staining.
Results: Endurance training triggered a reduction in the expression of Cpt1b and
AcadL genes involved in fatty acid catabolism in the heart of Nmrk2−/− mice, not in
control mice. NAD levels were not altered in heart or skeletal muscle, nor at baseline
neither after exercise training in any group.Myh7 gene encoding for the slow MHC-I was
more strongly induced by exercise in Nmrk2−/− mice than in controls. Moreover, IL-15
expression levels is higher in Nmrk2−/− mice skeletal muscle at baseline compared to
controls. No fiber type switch was observed in plantaris after exercise, but fast fibers
diameter was reduced in aged control mice, not in Nmrk2−/− mice. No fiber type switch
or diameter modification was observed in soleus muscle.
Conclusion: In this study, we demonstrated for the first time a phenotype in old
Nmrk2−/− mice in response to endurance exercise training. Although NMRK2 seems to
37
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be predominantly dispensable to maintain global NAD levels in heart and skeletal muscle,
we demonstrated a maladaptive metabolic response to exercise in cardiac and skeletal
muscle, showing that NMRK2 has a specific and restricted role in NAD signaling
compared to the NAMPT pathway.
Keywords: heart, skeletal muscle, aging, NAD, NMRK2, exercise, endurance training
INTRODUCTION
Skeletal muscles are highly plastic organs that adapt their shape
and performance to the physiological demand. In a simplified
way, resistance training leads to hypertrophy of fibers while
endurance training stimulates oxidative metabolism in fibers.
This plasticity however is progressively lost with aging, which
is associated both with a reduction in muscle mass and strength
at baseline (sarcopenia) and a reduced gain in performance and
muscle remodeling in response to resistance exercise (Kumar
et al., 2009). Muscle aging is also associated with reduced
endurance exercise capacity that is attributed not only to
decreased cardiovascular performance but also to an intrinsic
decrease in the quality and quantity of muscle cell mitochondria
(Lanza and Nair, 2010; Johnson et al., 2013). Hence, sarcopenic
muscles are supposed to differ in the various biochemical
pathways involved in exercise response (Ziaaldini et al., 2017).
Yet, despite these limitations, regular exercise remains one of
the most effective strategy to counteract sarcopenia and lower
chronic inflammatory cytokines overload although optimization
of the protocols and a better understanding of the mechanisms
involved in the lower response of sarcopenic muscles resistance
training are still required (Cruz-Jentoft et al., 2014; Denison et al.,
2015; Ziaaldini et al., 2017; Monteiro-Junior et al., 2018).
Among the molecular mechanisms involved in the aging
process, alterations in the metabolism of the Nicotinamide
Adenine Dinucleotide (NAD+) has been shown to play a
major role in most tissues, including heart and skeletal muscles
(Mericskay, 2016; Yoshino et al., 2018).
NAD has the particularity of being both a coenzyme and
a signaling molecule. As a coenzyme, NAD is recycled from
oxidized NAD+ to reduced NADH in the oxido-reduction
reactions of the energy metabolism, without net consumption
of the total NAD pool in these processes. As a signaling
molecule, NAD is a co-substrate molecule hydrolyzed by several
cellular enzymes, notably the sirtuins (SIRT) deacetylases, the
polyADPribose polymerases (PARP) and the CD38 and CD157
ADPribose cyclases (Mericskay, 2016; Yoshino et al., 2018).
These pathways act as sensors of energetic and redox state
to regulate energy metabolism (SIRT1, SIRT3), oxidative stress
response and cell survival (PARP1) and Ca2+ signaling (CD38)
in all cell types. In aged mouse skeletal muscle, there is more
than 50% decline in NAD+ levels that alters SIRT1 activity
and reduced the level of nuclear and mitochondrial encoded
mitochondrial proteins (Gomes et al., 2013).
The sirtuins, PARP1 and CD38/CD157 proteins all
cleave the NAD+ into nicotinamide (NAM) and adenine
diphosphate-ribose (ADPR) for their enzymatic activities.
Different salvage pathway exist that compensate for this cellular
consumption of NAD+ (Mericskay, 2016; Yoshino et al., 2018).
A major pathway in muscle is initiated by the nicotinamide
phosphoribosyl transferase (NAMPT). NAMPT uses the NAM
derived from the activity of NAD+ consuming enzymes but
also nutritional NAM (vitamin B3), to generate nicotinamide
mononucleotide (NMN) that is then fused to the ADP moiety
of ATP by the nicotinamide adenilyl transferases (NMNAT, 1 to
3) to form the dinucleotide. Genetic depletion of the NAMPT
enzyme in adult skeletal muscles leads to fiber degeneration and
progressive loss of both muscle strength and treadmill endurance
(Frederick et al., 2016). The contribution of the deamidated
precursors, nicotinic acid and tryptophan to NAD+ synthesis is
minimal in skeletal muscles (Mori et al., 2014).
More recently, an alternative pathway for the synthesis of
NMN was discovered based on the phosphorylation of the
nucleoside form of the NAM base, the nicotinamide riboside
(NR), by the NR kinases NRK1 and NRK2 (official symbol
NMRK1 and NMRK2; Bieganowski and Brenner, 2004; Belenky
et al., 2007). NMRK2 is expressed predominantly in skeletal
muscles whereas NMRK1 seems to be ubiquitously expressed
but more abundant in liver and kidneys (Ratajczak et al., 2016;
Fletcher et al., 2017). Nmrk2−/− mice (12–14 weeks) showed
no alteration in total NAD levels in skeletal muscles and no
phenotype at baseline or after 6 weeks of endurance exercise
protocol as regard muscle fiber cross-sectional area and muscle
fiber type distribution (Fletcher et al., 2017).
Considering that NAD metabolism becomes crucial during
aging, we explored in the present study the ability of middle-
age Nmrk2−/− mice (16 month) to perform endurance exercise
training and the impact of this training on muscle fiber cross-
sectional area, muscle fiber type distribution and myokines
expression in different muscles.
MATERIALS AND METHODS
Animals and Endurance Training
All experiments with animals conformed to the Directive
2010/63/EU of the European Parliament and were approved by
the ethics committee Charles Darvin #5 and authorized by the
Ministry of Research in application of the French Rural Code,
notably the articles R. 214-87 to R. 214-126 (agreement 00369.03:
Role of the kinase NMRK2 in skeletal muscles). The animal
experiments were performed in the UPMC university Center for
Experimental Exploration, UMS 028, 105 Boulevard de l’Hôpital,
Paris 75013, holding the agreement # A751315.
Constitutive Nmrk2 knocked-out mice were obtained and
genotyped in a C57BL/6NTac genetic background as previously
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described (Vaur et al., 2017). Homozygous Nmrk2−/− mice
were viable and fertile. For this study, 16 sixteen-month old
female mice were used (n = 10 C57BL/6N wild-type mice
and n = 6 Nmrk2−/− mice). Half of the animals were then
randomly assigned to sedentary or endurance training groups
(n = 5 C57BL/6N wild-type mice and n = 3 Nrmk2−/− mice
for each condition). Mice were acclimated to the treadmill for 3
consecutive days, and first submitted to an exercise performance
test involving a warm up phase at 5 to 15 cm/s for 15min,
followed by an acute exercise phase where the speed of the
treadmill was progressively increased until reaching signs of
exhaustion (more than 5 shocks within 60 s, or more than
5 consecutive seconds on the shock grid with attempting to
reengage on the treadmill). Endurance training protocol was
carried out for 9 weeks and was composed of a warm up phase
at 5 to 15 cm/s for 15min followed by 0 to 45min at 15 cm/s and
after that 45min in which speed was progressively increased from
15 to 30 cm/s. Protocol was strictly identical for every animal used
in this study.
RT-qPCR Analysis
Total RNA were extracted from tissue samples using
TRI Reagent R© (Molecular Research Center) and a tissue
homogenizer (Precellys R©, Bertin Instruments) following the
manufacturer instructions. RNA concentrations were quantified
by spectrophotometry using NanoDrop 2000 (Thermo Fisher
Scientific). cDNAs were reversed transcripted from 2 µg of
RNA using the iScriptTM Reverse Transcription kit (Biorad).
Quantitative PCR reactions were carried out on CFXTM
Real-Time PCR Detection System (Biorad), in triplicates
for each sample in a 7.5 µL volume containing 3.75 µL of
SsoAdvancedTM Universal SYBR R© Green Supermix, 0.5µM of
each forward and reverse primers and 2.5 µL of 1:20 diluted
cDNA. Primers sequences used in this study are available
on request. The expression of Hprt (Hypoxanthine-guanine
phosphoribosyltransferase) gene or the mean of the expression
of Rplp0 (Ribosomal Protein, Large, P0) and Ywhaz (Tyrosine
3-Monooxygenase/Tryptophan 5-Monooxygenase Activation
Protein Zeta) genes were used as a reference for normalization
in heart and gastrocnemius muscle, and plantaris and soleus
muscles, respectively.
NAD Extraction and Quantification
Metabolites were extracted by homogenizing tissue samples in
a buffered ethanol solution (75% ethanol/25% HEPES 10mM
pH 7.1, 10 µL/mg of tissue) with a tissue homogenizer
(Precellys R©, Bertin Instruments). Extracts were heated at 80◦C
for 5min, chilled on ice and centrifuged for at 15000 g
for 15min at 4◦C. NAD levels were quantified using an
MTT-formazan recycling assay. Samples extracts were diluted
in water to a final volume of 25 µL. After adding 100
µL of reaction buffer (600mM ethanol, 0.5mM 3-(4.5-
dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT),
2mMphenazine ethosulfate (PES), 120mMBicine (pH7.8), yeast
alcohol dehydrogenase 0.05 mg/mL (SIGMA A3263), kinetics
of the reaction was assessed by measuring OD at 550 nm every
30 s for 40min using a TECAN Infinite F500 microplate reader.
Samples NAD concentrations were determined by comparing
the slope of the reaction (OD/s) to a range of standard NAD+
concentrations.
Immunofluorescent Staining
Immediately after sacrifice, fast (plantaris) and slow-twitch
(soleus) muscles where embed in Tissue-Tek (Sakura, USA) and
frozen in liquid nitrogen-cooled isopentane at −150◦C. They
when then stored at −80◦C and sliced into 8µm cryosections
with CM1860 Cryostat, (Leica). Immunohistochemical staining
of Myosin Heavy Chain (MHC) isoforms was performed using
mouse monoclonal antibodies BAD5 (MHC-I specific, alternate
name β-MHC, IgG2b, 1:100 dilution), SC-71 (MHC-IIA specific,
IgG1, 1:100 dilution) and BF-F3 (MHC-IIB specific, IgM, 1:100
dilution) respectively, obtained from Developmental Studies
Hybridoma Bank (DSHB, University of Iowa). Laminin staining
was also performed for labeling basement membranes using
a rabbit polyclonal antibody (L9393, Sigma). Briefly, muscle
sections were fixed with 4% PFA for 5min, washed twice (5min
each) in PBS, permeabilized in 0.1% Triton for 10min, washed
twice in PBS, saturated in 5% IgG-free BSA for 45min, washed
once in PBS, incubated with 1:100 mouse FAB for 20min,
washed once in PBS. Primary antibodies were then incubated
overnight at 4◦C. After washing 3 times in 0.1% Tween20 in
PBS, secondary antibodies were used to selectively bind to each
primary antibody: goat anti-mouse IgG2b conjugated with Alexa
Fluor R© 350, goat anti-mouse IgG1 conjugated with Alexa Fluor R©
555, goat anti-mouse IgM conjugated with Alexa Fluor R© 488, and
goat anti-rabbit conjugated with Alexa Fluor R© 633, all diluted at
1:400 in 5% IgG-free BSA. After 3 washes in 0.1% Tween20 in
PBS, muscle section were mounted using 70% glycerol. Pictures
were taken using and inverted fluorescence microscope (DMi8,
Leica). Pure MHC-IIX fibers were not stained by these antibodies
and appeared black. Fiber type distribution and MinFeret were
assessed using ImageJ software.
Statistical Analysis
Animals were assigned to sedentary or endurance training groups
by randomization. Shapiro–Wilk test were applied to test for
normality of distribution before to use parametric test. To
assess statistical significance between control and Nmrk2−/−
mice at exhaustion test, t-tests for independent samples were
performed. For RT-qPCR analysis, NAD levels and fiber type
and MinFeret comparisons, two-way ANOVA for independent
samples were performed, followed by post-hoc Tukey tests for
multiple comparison when an interaction between the genotype
and the endurance training factors was established. Global
MinFeret distribution statistical differences were assessed using
Chi-square test. Values are expressed as mean± SEM.
RESULTS
Endurance Training and Muscle
Performance in Nmrk2−/− Mice
Considering the old age of the mice, 16 months at the beginning
of the endurance training protocol, and the potential effect of
Nmrk2 deficiency on exercise capacities, training protocol was
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adapted by starting at a very low speed (15cm/s, 100m run
per session) that was progressively increased to reach 30 cm/s
(890m per session) at the end of the protocol. All animals
were able to follow the complete training (Figure 1A). To
assess if there was any difference in term of exercise capacity
and endurance between control and Nmrk2−/− mice, animals
were submitted to a treadmill exhaustion test 1 week after the
beginning of the protocol. Nmrk2 −/− mice reached exhaustion
after 24.0 ± 2.3min vs. 22.6 ± 1.8min for control mice
(Figure 1B), at a speed of 39.0 ± 2.3 cm/s vs. 36.7 ± 1.8 cm/s for
control mice (Figure 1C), with no statistical difference between
the groups. After 9 weeks of training, there was no significant
body weight change in trained control and Nmrk2−/− mice
(Figure 1D).
Effects of Endurance Training on Cardiac
Gene Expression and NAD Levels
To gain insight on NAD metabolism modulation in heart by
exercise in old mice, we first analyzed the gene expression profile
of several main enzymes responsible for its biosynthesis and
consumption. Nmrk2 gene expression was absent as expected
in Nmrk2−/− mice, but not modified by training in control
mice. Nmrk1 and Nampt expressions were not modulated by
endurance training in control and in Nmrk2−/− mice, neither
was the expression of the sirtuins Sirt1 and Sirt3 (Figure 2A).
FIGURE 1 | Daily running distance during endurance training, endurance test
and body weight evolution. (A) Evolution of the daily running distance imposed
to control and Nmrk2−/− mice during the 9 weeks of endurance training. (B,
C) Maximum speed (B) and time (C) reached at exhaustion during endurance
test. (D) Evolution of body weight along the training protocol. N = 5 in
each sedentary and trained control group, and N = 3 in each sedentary and
trained Nmrk2−/− group. Statistical analysis: (B,C), t-test for independant
samples. (D) two-way ANOVA for independent samples.
In line with those observations, we did not observe a difference
regarding NAD levels in cardiac muscle (Figure 2B). Pgc1a,
known to be activated in the heart by exercise, was slightly
increased without reaching statistical significance, when there
was no induction in Nmrk2−/− mice (Figure 2C). Cardiac stress
marker Bnf was not clearly modulated by exercise or lack of
NMRK2 (Figure 2D). TheMyh7 gene encoding the slow β-MHC
was increased in only one sedentary Nmrk2−/− mouse that did
not show any other major diffference in other tested genes in
the heart and skeletal muscle compared to the rest of the group.
Interestingly, Cpt1b and AcadL genes, involved in fatty acids
catabolism, were significantly lowered by exercise in Nmrk2−/−
mice, but not control mice (p < 0.05, Figure 2E). No clear effects
could be identified on Pdk2 and Pdk4 expression, two isoforms
of PDK, which negatively regulates glycolysis, neither on glucose
transporters Glut1 and Glut4 (Figure 2F).
Effects of Endurance Training on Skeletal
Muscle Gene Expression and NAD Levels
Nmrk2 being highly expressed in skeletal muscle, we also
investigated NAD metabolism modulation enzymes in
gastrocnemius muscle. No effect was observed regarding Nampt
or Sirt1 and Sirt3 genes expression, but Nmrk1 was reduced in
Nmrk2−/− mice in comparison to controls (genotype effect,
p < 0.01, Figure 3A). In parallel with these observations, no
major modulation of total NAD levels was observed (Figure 3C).
We also studied the expression levels of myosin heavy-chain
isoforms, known to be modulated by endurance training in
young mice. Interestingly, Myh7 gene coding for the slow
MHC-I isoform was strongly induced by exercise in Nrmk2−/−
mice (p < 0.01, Figure 3B), to a higher level compared to
trained control mice (p < 0.05) when no statistically significant
effect of exercise was found in control mice. No modulation of
other MHC isoforms gene expression was observed (Myh2 for
MHC-II1,Myh1 for MHC-IIX orMyh4 for MHC-IIB).
Considering the emerging role of skeletal muscle in autocrine
and paracrine signaling, we also analyzed the expression of
several myokines in slow (soleus) and fast-twitch (plantaris)
muscles. In soleus muscle, an effect of training and genotype
was observed for IL-15 expression, a myokine that mediates
muscle-fat crosstalk, seems to be higher in trained Nmrk2−/−
mice but no interaction could be identified (Figure 3D). Sparc,
a myokine linked to muscle atrophy, and Fndc5, a precursor of
irisin correlated to browning of adipose tissue, were not modified
by exercise, even in control animals. No modifications of the
expression of these 3 genes was observed in plantaris muscle
although the global profile was strikingly similar to the one
observed in the soleus muscle (Figure 3E).
Modulation of MHC Isoforms Distribution
and Minferet Diameter in Fast and Mixed
Muscles
To go further in the understanding of the effects of NMRK2
deficiency on skeletal muscle adaptation to exercise, we analyzed
the distribution of MHC isoforms and minimal Feret diameter
of fibers in fast plantaris muscle and the mixed more oxidative
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FIGURE 2 | Gene expression analysis and global NAD levels in left ventricle. (A) Relative quantification by RT-qPCR of Nmrk1, Nmrk2, Nampt, Sirt1, and Sirt3 mRNA
levels in left ventricule. (B) Myocardial NAD levels. (C–F) Relative quantification by RT-qPCR of Pgc1α (C), Bnf and Myh7 (D), Cpt1b and AcadL (E), Pdk2, Pdk4,
Glut1, and Glut4 (F) mRNA levels in left ventricule. n = 5 in control and trained control groups, n = 3 in Nmrk2−/− and trained Nmrk2−/− groups. Results are
expressed as mean values ± SEM. Statistical analysis: two-way ANOVA for independent samples. ip < 0.05 for interaction, ###p < 0.001 for genotype effect,
§p < 0.05 and §§p < 0.01 for endurance training effect. *p<0.05 from Tukey’s multiple comparisons test when applicable.
FIGURE 3 | Gene expression analysis and global NAD levels in skeletal muscle. (A,B) Relative quantification by RT-qPCR of Nmrk1, Nmrk2, Nampt, Sirt1, Sirt3 (A),
and Myh7, Myh2, Myh1, and Myh4 myosin isoforms (B) mRNA levels in gastrocnemius muscle. (C) Gastrocnemius NAD levels. (D,E) Relative quantification by
RT-qPCR of IL-15, Sparc, and Fndc5 myokines mRNA levels in soleus (D) and plantaris muscle (E) respectively. Results are expressed as mean values ± SEM.
Statistical analysis: two-way ANOVA for independent samples. ip < 0.05 for interaction, ##p < 0.01 and ###p < 0.001 for genotype effect, §p < 0.05 and
§§p < 0.01 for endurance training effect. *p < 0.05 and **p < 0.01 from Tukey’s multiple comparisons test when applicable.
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soleus muscles by immuno-histochemical staining. In plantaris
muscle, no fiber type switch with exercise could be detected
(Figures 4A–E). As expected, no type I fibers were detected in
this fast muscle. MinFeret diameter trend to be reduced with
exercise in control mice, reaching statistical significance for
MHC-IIX fibers, when no changes were observed in Nmrk2−/−
mice (Figure 4F). Analysis of MinFeret diameter distributions
of all muscle fibers showed a statistically significant shift of
distribution toward thinner muscle fibers with training in control
mice (p < 0.0001, Figure 4G), when no effect of training was
observed with Nmrk2−/− mice (Figure 4H).
In the soleus muscle, there was no difference in term of fiber
type repartition between control and Nmrk2−/− mice, and no
fiber type switching was observed with exercise in any group
(Figures 5A–E). Note that no Type IIb fast twitch glycolytic
fibers were detected in this muscle as expected. No difference
either was found regarding all muscle fibers MinFeret diameter
distributions, in term of genotype or exercise effect (Figures
F–H).
DISCUSSION
The stimulation of NAD+ synthesis by the NR vitamin B3, the
substrate of NMRK enzymes, has been shown to be beneficial for
muscle physiology and mitochondrial function in the context of
aging or genetic myopathies in many studies (Mouchiroud et al.,
2013; Cerutti et al., 2014; Khan et al., 2014; Frederick et al., 2016;
Ryu et al., 2016; Zhang et al., 2016). One exception being a short
report that NR mildly decreases exercise performance in rats in a
swimming exhaustion test although no muscle phenotyping or
molecular analyses were performed to understand this lack of
response (Kourtzidis et al., 2016).
We have shown recently that Nmrk2 levels are strongly
induced in the context dilated cardiomyopathy triggered by
heart-specific deletion of the SRF transcription factor and that
NR-supplemented diet or voluntary wheel running delays the
onset of heart failure in this model (Deloux et al., 2017; Diguet
et al., 2018). NMRK2, a striated muscle specific kinase has
recently been shown to be required inmuscle cells, in redundancy
with the more ubiquitous NMRK1, to respond to the boosting
effect of NR on NAD level (Fletcher et al., 2017). Here, we
showed that aged NMRK2 deficient mice present an altered
response to exercise training. In the heart, Cpt1b and AcadL
genes, involved in β-oxidation, were reduced with exercise in
Nmrk2−/− mice. In gastrocnemius muscle, Nmrk1 levels were
reduced in NMRK2 deficient mice, and slowMHC isoformMyh7
was more strongly induced by exercise in Nmrk2−/− mice than
in controls. Endurance training reduced the diameter of fibers in
control mice but not in Nmrk2−/− mice.
FIGURE 4 | MHC isoforms distribution and MinFeret diameter in plantaris muscle. (A-D) Myosin isoforms and laminin immunofluorescence histochemistry (MHC-I
(MYH7) in blue, MHC-IIA (MYH2) in red, MHC-IIB (MYH4) in green, laminin in magenta) on 8-µm transversal cryosections of plantaris muscle from 18 weeks old mice,
WT or Nmrk2−/−, sedentary or trained. Scale bars = 200µm for whole muscle images, 60µM for magnified images. (E) Fiber type proportions calculated from whole
muscle sections. Fibers negative or mixed for Type I, IIA, or IIB MHC isoforms where assigned to a separated category, in comparaison to pure MHC isoforms positive
fibers. (F) Fibers MinFeret diameter (µM). (G,H) Global MinFeret distributions whithin control and trained control mice (G), and Nmrk2−/− and trained Nmrk2−/− mice
(H). n = 5 in control and trained control groups, n = 3 in Nmrk2−/− and trained Nmrk2−/− groups. Results are expressed as mean values ± SEM. Statistical analysis
(E, F), two-way ANOVA for independent samples. ip < 0.05 for interaction, §p < 0.05 for endurance training effect. *p < 0.05 from Tukey’s multiple comparisons test
when applicable. (G,H), Chi-square test for MinFeret distribution comparisons.
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FIGURE 5 | MHC isoforms distribution and MinFeret diameter in soleus muscle. (A–D) Myosin isoforms and laminin immunofluorescence histochemistry [MHC-I
(MYH7) in blue, MHC-IIA (MYH2) in red, MHC-IIB (MYH4) in green, laminin in magenta] on 8-µm transversal cryosections of soleus muscle from 18 weeks old mice,
WT or Nmrk2−/−, sedentary or trained. Scale bars = 200µm for whole muscle images, 60µM for magnified images. (E) Fiber type proportions calculated from whole
muscle sections. Fibers negative or mixed for Type I, IIA, or IIB MHC isoforms where assigned to a separated category, in comparaison to pure MHC isoforms positive
fibers. (F) Fibers MinFeret diameter (µM). (G,H) Global MinFeret distributions whithin control and trained control mice (G), and Nmrk2−/− and trained Nmrk2−/− mice
(H). n = 5 in control and n = 4 in trained control groups, n = 3 in Nmrk2 −/− and trained Nmrk2−/− groups. Results are expressed as mean values ± SEM.
Statistical analysis (E,F), two-way ANOVA for independent samples. (G,H), Chi-square test for MinFeret distribution comparisons.
In cardiac and skeletal muscle, NAD levels has been described
to be highly regulated by NAMPT, that acts as a rate limiting
enzyme recycling NAM into NMN to form NAD+ (Mori
et al., 2014). NMRK1 and NMRK2 enzymes were identified
more recently as alternative enzyme using NR as an alternative
precursor to salvage NAD+ levels (Bieganowski and Brenner,
2004). Here we show that global steady tissue levels of NAD are
not altered in the heart and skeletal muscle despite the absence of
NMRK2. This result is in agreement with a recently published
study in young Nmrk2−/− mice that also reported there was
no alteration of global NAD levels in quadriceps muscle in the
KO mice in comparison to controls, with concentrations around
400 pmol/mg of tissue, which are identical to our findings in 18
month-old mice (Fletcher et al., 2017). In contrast, however, the
authors did not observe a difference in term ofNmrk1 expression
in young Nmrk2−/− mice, when we found a clear reduction at
18-month of age. However Nampt expression is maintained at
this age in Nmrk2−/− mice, which is apparently sufficient to
sustain global levels of NAD. Interestingly, while NAD levels
were strongly reduced in the skeletal muscle-specific Nampt−/−
mice that were intolerant to exercise, NR had a potent rescuing
effect on exercise intolerance, fiber size and ATP production
despite having no impact on total NAD tissue levels and very
minor effect on mitochondrial NAD pool (Frederick et al., 2016).
These finding show that the NMN produced from NR by NMRK
enzymes is not equivalent to the NMN produced by NAMPT
to synthesize NAD. So, while it is clear now that NMRK2 is
dispensable for the maintenance of global tissue NAD levels, it
suggests that NMRK2 is involved in the synthesis of a subfraction
of the NAD pool that is efficiently used by the muscle cells.
Skeletal muscle adaptations to exercise varies depending on
the type of exercise. To focus on endurance exercise, different
studies have clearly demonstrated in human that endurance
training induces a switch from glycolytic to a more oxidative
phenotype (Andersen and Henriksson, 1977). In young rats, 10
weeks running program triggers a similar shift toward slower
oxidative isoforms of myosin in plantaris muscle, when no shift
was reported in soleus muscle (Fitzsimons et al., 1990). Here,
we show that in aged mice, treadmill running exercise increases
the expression of Myh7 gene, which encodes a slow contractile
isoform of myosin heavy chain (MHCI) that uses less ATP per
unit of work because of its lower myosin ATPase activity, relative
to fast myosin isoforms, and is thus more metabolically efficient
in the context of endurance training. Interestingly, the increase
in Myh7 expression was significantly stronger in Nmrk2−/−
mice compared to controls, suggesting that NMRK2 signaling
is normally blunting the expression of slow myosin in muscle
or reciprocally that the lack of NMRK2 reults in a higher need
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for the muscle to reduce the energy required for contraction.
We also found that endurance exercise led to a reduction of
the mean diameter of muscle fibers in the plantaris but not the
soleus of control mice whereas this phenomenon did not occur in
Nmrk2−/− mice. It is important to notice that Nmrk2 expression
is 2 times higher in plantaris muscle compared to soleus (Fletcher
et al., 2017), which may explain while it function is more easily
put in evidence in this muscle.
Considering the emerging role of skeletal muscle in autocrine
and paracrine signaling, we also analyzed the expression of
several myokines known to be activated by exercise. Among
them, IL-15 is a cytokine secreted by skeletal muscle that
promotes endurance adaptations via a stimulation of the
oxidative energy metabolism and the Sirt1/PGC1a axis in young
mice (Quinn et al., 2013). IL-15 levels are increased by exercise
in humans (Rinnov et al., 2014). On the other skeletal muscle
aging and sarcopenia are associated with low levels of IL-15
(Yalcin et al., 2018). Here, we show that exercise reduced IL-15
mRNA level in aged control and Nmrk2−/− mice. On the other
hand, we showed that the IL-15 gene expression is upregulated
at baseline in the soleus of Nmrk2−/− mice. Since we observed
a trend to have thinner muscle fibers in plantaris but not soleus
muscle of Nmrk2−/− compared to controls, it suggests that the
local increase in IL-15 production in the soleus may contribute
to preserve muscle mass. The link between NMRK2-dependent
NAD metabolism and IL-15 signaling in oxidative metabolism
will deserve to be further explored in the future. In the same line,
our observation that genes involved in fatty acids β-oxidation
(FAO) are abnormally repressed in the heart of Nmrk2−/− mice
upon training while it is well known that FAO is increased during
exercise to respond to the higher energy demand (Jeppesen
and Kiens, 2012) suggest a maladaptative metabolic response in
absence of NMRK2.
In conclusion, we demonstrated for the first time a phenotype
in old Nmrk2−/− mice in response to endurance training
suggesting that NMRK2 deficient mice are prone to develop
muscle dysfunction with aging.
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Physical exercise has beneficial effects on metabolic diseases, and a combined
therapeutic regimen of regular exercise and pharmaceutical treatment is often
recommended for their clinical management. However, the mechanisms by which
exercise produces these beneficial effects are not fully understood. Myokines, a group
of skeletal muscle (SkM) derived peptides may play an important part in this process.
Myokines are produced, expressed and released by muscle fibers under contraction
and exert both local and pleiotropic effects. Myokines such as IL-6, IL-10, and IL-1ra
released during physical exercise mediate its health benefits. Just as exercise seems
to promote the myokine response, physical inactivity seems to impair it, and could
be a mechanism to explain the association between sedentary behavior and many
chronic diseases. Myokines help configure the immune-metabolic factor interface and
the health promoting effects of physical exercise through the release of humoral factors
capable of interacting with other tissues, mainly adipose tissue (AT). AT itself secretes
proinflammatory cytokines (adipokines) as a result of physical inactivity and it is well
recognized that AT inflammation can lead to the development of metabolic diseases,
such as type 2 diabetes mellitus (T2DM) and atherosclerosis. On the other hand, the
browning phenotype of AT has been suggested to be one of the mechanisms through
which physical exercise improves body composition in overweight/obese individuals.
Although, many cytokines are involved in the crosstalk between SkM and AT, in respect
of these effects, it is IL-6, IL-15, irisin, and myostatin which seem to have the decisive
role in this “conversation” between AT and SkM. This review article proposes to bring
together the latest “state of the art” knowledge regarding Myokines and muscle-adipose
tissue crosstalk. Furthermore, it is intended to particularly focus on the immune-metabolic
changes from AT directly mediated by myokines.
Keywords: IL-6, irisin, browning, inflammation, immunometabolism, exercise-factor
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INTRODUCTION
General Characterization
Physical inactivity is a global health problem, and recent data
indicate that approximately one-third of the world’s adult
population is physically inactive. This means that these
individuals do not perform the minimum 150min a week of
moderate to vigorous aerobic physical activity recommended
by the World Health Organization (Ruiz-Casado et al., 2017).
Physical inactivity is directly related to higher risk rates for major
non-communicable diseases (NCDs). NCDs are a set of diseases
of long duration and generally slow progression. The four main
types of noncommunicable diseases are cardiovascular diseases
(e.g., heart attacks and stroke), cancer, chronic respiratory
diseases (e.g., chronic obstructive pulmonary disease and asthma)
and type 2 diabetes mellitus (T2DM; WHO, 2014). In 2008,
NCDs, such as coronary heart disease, T2DM and colon and
breast cancers were responsible for about five million deaths or
about 9% of total global premature mortality (Figure 1; Lee et al.,
2012; Lobelo et al., 2014).
The benefits of physical exercise as a protective factor against
NCDs have been documented since 450 BC, with Hippocrates,
the “father of Western medicine,” stating that “Walking is
man’s best medicine” and “If there is a deficiency in food
and exercise the body will fall sick” (Febbraio, 2017). Several
biological mechanisms may be responsible for the reduction
of risk factors for chronic diseases and premature death
associated with physical exercise (Warburton et al., 2006) and
there is currently a consensus in the literature that regular
physical exercise is directly related to: (1) improvements in
body composition, including reduced abdominal adiposity and
body weight (Thomas et al., 2013; Smith, 2018); (2) improved
lipoprotein protein profiles, through reduced triglyceride and
low-density lipoproteins [LDL] levels, and increased high density
lipoprotein [HDL] levels (Warburton et al., 2006; Mitsui et al.,
2012); (3) greater efficiency in glucose homeostasis and insulin
sensitivity (Tan et al., 2018); (4) reduced blood pressure
(Sharman et al., 2015; Imazu et al., 2017); (5) reduced systemic
inflammation (Lira et al., 2009; Rosa Neto et al., 2009; Batista
et al., 2010) and (6) increased cardiac function (Barauna et al.,
2005; Laterza et al., 2007; Batista et al., 2008).
Unhealthy lifestyles comprising unhealthy diet combined
with lack of physical activity may result in increased blood
pressure, increased blood glucose, elevated blood lipids and
obesity. These are called metabolic risk factors that lead to
cardiovascular disease, the leading NCDs in terms of premature
deaths (GBD 2015 Risk Factors Collaborators, 2016). There are
four metabolic markers referred to as risk factors for NCDs: (1)
raised blood pressure; (2) overweight/obesity; (3) hyperglycemia
and (4) hyperglicidemia. High blood pressure (19% of overall
deaths) followed by overweight and obesity and increased blood
glucose are related to the higher metabolic risk factors that
culminate in death (GBD 2015 Risk Factors Collaborators, 2016).
Obesity is considered a global epidemiological health problem
and is associated with the development of numerous metabolic
diseases, such as: insulin resistance (Martin et al., 2015), Type
II Diabetes (Pulgaron and Delamater, 2014), atherosclerosis
(Lovren et al., 2015), non-alcoholic hepatic steatosis (Li et al.,
2014; Negrin et al., 2014), hypertension (Paley and Johnson,
2018) and coronary heart disease (Warburton et al., 2006;
Figure 1).
Physical exercise is an important non-pharmacological
treatment option not only as a preventive agent, but also in
the treatment of numerous metabolic diseases, such as type
II diabetes, hypertension, and cardiovascular disease (Nunan
et al., 2013; Mahtani et al., 2015). The mechanisms involved
in the benefits generated by physical exercise against metabolic
diseases are related to the increase in total energy expenditure and
consequent reduction in the accumulation of fat mass, including
a reduction in total body mass (Lancaster and Febbraio, 2014).
For decades, it has been known that there is a direct relationship
between obesity and inflammation and the development of NCDs
(Cani and Jordan, 2018). Numerous studies have sought to
elucidate which components of the immune system, as well as
which molecules from local inflammation, could be related to
the development of NCDs (Lancaster and Febbraio, 2014). In
obesity, the immune cell profile in AT is substantially altered,
for example, there is an accumulation of proinflammatory
macrophages, neutrophils, and CD8+ T lymphocytes, while
regulatory and eosinophilic T cells are substantially reduced.
This process contributes to inflammation that culminates in the
development of systemic insulin resistance (Osborn and Olefsky,
2012; Mraz and Haluzik, 2014).
Considering the role of physical exercise as a direct
modulating agent of the benefits related to the general
improvement of physiological variables involved in NCDs in
recent years, several studies have characterized the role of skeletal
striated muscle in this context (Pedersen and Febbraio, 2012;
Pedersen, 2013). It is well established that SkM constitutes a key
organ for the oxidation of lipid, acting as an elaborate energy
production and consumption system that influences the whole
body’s energy metabolism (Iizuka et al., 2014). SkM tissue is
composed of several cell types including muscle fibers, stem cells,
fibroblasts, pericytes, adipocytes, motor neurons, and connective
tissue. In addition, the muscular satellite cells play an important
role in the cellular signaling process with neighboring cells,
thus being a bioactive secretory factor (Sheehan et al., 2000).
For almost half a century, researchers have hypothesized that
musculoskeletal cells have a humoral factor, which is activated
by increased demand for glucose during muscle contractions
(Nielsen and Pedersen, 2008).
The concept of SkM as an immunogenic producer/secretor
of cytokines, which exert an endocrine function, was proposed
by Pedersen (2013), who proposed that such cytokines and
other peptides should be classified as myokines (Pedersen, 2013).
The discovery of the role of SkM as an endocrine organ
expanded the knowledge of how the nervous, endocrine and
immune systems contribute synergistically to the maintenance
of body homeostasis (Febbraio and Pedersen, 2005; Karstoft and
Pedersen, 2016). Myokines are an important local agent, having
effects onmetabolism, angiogenesis andmuscle growth, as well as
being capable of systemically acting on other organs and systems
(Febbraio and Pedersen, 2005). A tissue of great metabolic
importance that has been the subject of studies on crosstalk with
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FIGURE 1 | Noncommunicable Diseases (NCDs) Risk Factors. NCDs have become a major global public health problem. Tobacco and alcohol (misuse) use,
unhealthy diet and physical inactivity represent important health risks. Physical inactivity is a leading cause of death worldwide. It increases the risk of major
noncommunicable diseases (NCDs) such as coronary heart disease, type 2 diabetes and breast, and colon cancers, responsible in 2008 for an estimated five million
deaths or about 9% of the total global premature mortality. According to the World Health Organization, poor life habits such as physical inactivity and unhealthy diets
are the main indications for the development of metabolic disorders that increase the risk factors for the development of NCDs. Data available at: http://www.who.int/
news-room/fact-sheets/detail/noncommunicable-diseases.
SkM is adipose tissue (AT). AT is widely known, not only for
its ability to store energy, but also for its important endocrine
component. AT in mammals consists of at least two different
functional types: white and brown (Rosen and Spiegelman, 2006).
White adipose tissue (WAT) is the main site of energy storage
and release of hormones and cytokines that modulate whole
body metabolism and insulin resistance, whereas brown adipose
tissue (BAT) is important both for energy expenditure and the
release of energy as heat. This thermogenic effect is mediated
by the expression of decoupling protein-1 (UCP1; Cypess et al.,
2009).
Both AT and SkM are significantly affected by exercise. One
of the adaptations of these tissues to exercise is the secretion of
molecules capable of modulating not only local metabolism but
also systemic metabolism (pleiotropic). These secreted molecules
can act in an endocrine manner to facilitate crosstalk between
these tissues (tissue-to-tissue) and thus work together to improve
overall metabolic health. In this review, we sought to produce an
update on the state of knowledge in relation to the potential of
physical exercise as inducer of myokines capable of modulating
AT, as well as the impact of this crosstalk on health maintenance
and promotion.
Physical Exercise as an Inducer of an
Anti-inflammatory Response
In recent years, several well-designed studies have demonstrated
that performing acute aerobic exercise is an important mediator
of systemic anti-inflammatory response (Petersen and Pedersen,
2005; Pedersen and Fischer, 2007; Pedersen et al., 2007). Muscle
contraction induced by physical exercise results in increased
gene expression and secretion of interleukin-6 (IL-6) by skeletal
myocyte. Consequently, depending on the exercise variables
(volume, intensity, density), there is an increase in IL-6 plasma
levels (Steensberg et al., 2003). Following acute aerobic exercise,
there is an increase in the cytokines interleukin-10 (IL-10),
interleukin-1 receptor antagonist (IL1-ra), and the soluble
receptors of the tumor necrosis factor I and II (TNF I and II). This
set of changes is characterized as an “anti-inflammatory effect”
(Petersen and Pedersen, 2005).
Given this condition, the hypothesis that has been proposed
is that the regular practice of physical exercise, organized in
a exercise training program (chronic effect), exerts an anti-
inflammatory effect induced by the sessions (acute effect), which
leads to improved protection against chronic inflammatory
situations, levels of proinflammatory cytokines and C-reactive
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protein (Petersen and Pedersen, 2005; Fischer, 2006; Lira et al.,
2009; Batista et al., 2010). However, the possible mechanisms
modulating this “beneficial” effect are not well established.
In general, this anti-inflammatory effect has been shown
to be more evident in some pathological conditions, such as
atherosclerosis, type II diabetes, obesity and heart failure (HF),
especially those presenting a two- to three-fold systemic increase
in the levels of proinflammatory cytokines and C-reactive protein
(Fischer et al., 2007). In addition, this cytokine production profile
that occurs during and immediately after physical exercise is
dependent on several factors, such as; population (sedentary,
presence of diseases, etc.), the intensity or duration of the physical
exercise, glucose availability and sample collection time (Flynn
et al., 2007).
In addition to this, several cross-sectional studies have
shown that there is a slight increase in the plasma levels of
proinflammatory molecules under various conditions, such as
physical inactivity (sedentary; Petersen and Pedersen, 2005;
Flynn et al., 2007; Pedersen, 2007; Pedersen et al., 2007) in
elderly people (Bruunsgaard et al., 2003), as well as in patients
with diseases such as intermittent claudication (Tisi et al., 1997),
T2DM (Boule et al., 2001), and atherosclerosis, among others.
Under these conditions, the term “chronic low-grade systemic
inflammation” has been used to characterize a 2- to 3-fold
increase in plasma levels of TNF-α, IL-1α, IL-6, IL-1ra, sTNFR1
and 2, and C-reactive protein (CRP), inflammatory markers
noted as important both in the development and the progression
of these inflammatory processes. Despite the evident correlation
between exercise and anti-inflammatory effects, little information
has been produced so far to explain the possible mechanisms
responsible for the relationship between physical training and
the reduction in these markers (Pedersen and Fischer, 2007). In
these disease conditions, the origin of this systemic alteration is
not well characterized, however, it has been proposed that WAT
and peripheral blood mononuclear cells (especially lymphocytes)
may be themain source of these cytokines (Steensberg et al., 2003;
Fischer, 2006; Pedersen and Fischer, 2007).
Chronic Effect of Exercise: Physical Training and
Neuroimmune-Metabolic Response
In general, exercise training programs are usually characterized
by repetitive phases of overload, overreaching, maintenance of
overtraining and recovery (Steinacker et al., 2004). The overload
phases are characterized by a difference between the total amount
of the overload (volume x intensity x density) and the recovery
time between the exercise training sessions. Recovery between
exercise sessions is necessary to allow recuperation, and over
time, an improvement in exercise performance, metabolism and
homeostasis.
On the other hand, if the recovery time is insufficient a chronic
state of changes (molecular, biochemical and regulatory) can be
produced that compromise well-being, increase the incidence of
illness and decrease physical performance. The balance between
exercise and recovery determines the positive or “beneficial”
outcomes or adaptations of a given period of exercise training
(Lehmann et al., 1993b; Steinacker et al., 2004).
Lehmann et al. proposed a biphasic model of response
to training overload (Lehmann et al., 1993a) involving
predominantly: 1-peripheral mechanisms in the early stages
of overload in the organism, and 2-central mechanisms in the
more pronounced and lasting phases of the overload period,
with the hypothalamus as a central integrator of all afferent
signaling to the brain and having an important role in regulating
central responses to stress and physical training (Steinacker et al.,
2004). These interactions involve afferent information from the
autonomic nervous system, direct metabolic effects, hormones,
cytokines and also information from superior brain centers,
demonstrating a complex interaction involving bi-directional
communication between the neuroendocrine and immune
systems (Spinedi and Gaillard, 1998).
Researchers have examined the interaction of various systems
in relation to the stimulus provided by physical exercise
(Pedersen et al., 2007; Ruiz-Casado et al., 2017; Ishiuchi et al.,
2018). Many researchers have sought to examine the role of
the SkM themselves, particularly peripheral factors probably
originating from successive muscle contractions during exercise
that mediate changes in the tissue itself as well as having a
systemic effect on other organs such as the liver and AT.
Adipose Tissue
Currently, AT is characterized as an important endocrine organ
present in the body, related both to the expression of various
cytokines and to the regulation and coordination of energy
homeostasis, blood pressure, immune function, angiogenesis,
mechanical shock protection, and thermogenic function (Prins,
2002; Trayhurn and Wood, 2004). The cytokines that are
produced in the AT are called adipokines, molecules which have
properties that allow them to generate autocrine and paracrine
effects, or even a systemic effect, thanks to their endocrine
characteristic, being able to reach distant tissues and have
metabolic consequences in the whole organism (Kershaw and
Flier, 2004).
Histologically, AT is characterized as connective tissue with
special properties (Sheehan et al., 2000). In anatomical terms,
two different specialized types of AT with different origins and
functions, known as WAT and BAT, are described (Tsoli et al.,
2012). WAT can be found in different regions in the body, being
responsible mainly for the storing excess energy inside its cells in
the form of triacylglycerol (TG). This stored energy is used when
there is a caloric deficit (Kajimura et al., 2015). The anatomic
location of AT determines its metabolic identity and central
functions. In humans, WAT is located in many different deposits,
such as the intra-abdominal visceral deposit, whose deregulation
is associated with greater risks for metabolic diseases; and the
subcutaneous deposit that can transmit protective effects on
energy homeostasis (Kusminski et al., 2016). On the other hand,
BAT has a more limited distribution. In mice, large BAT deposits,
including interscapular, axillary and cervical BAT, develop in
the prenatal period and provide a source of heat to protect
newborns against exposure to cold (Kajimura et al., 2015). In
adult men, the highest concentration of BAT occurs in the
interscapular region (Kajimura et al., 2015). Its cellular structure
presents a great concentration of mitochondria, having as one
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of its main function the thermogenic control of the organism
(Sidossis and Kajimura, 2015). This process occurs through a
mitochondrial protein called uncoupling protein 1 (UCP-1),
which has the property of dissipating energy in the form of heat, a
process described as non-shivering thermogenesis. Accordingly,
this process results in the maintenance of body temperature
when exposed to extreme situations (e.g., low temperatures;
Karamanlidis et al., 2007; Wu et al., 2013).
As regards cellularity, both WAT and BAT are composed of
several cell types, such as fibroblasts, endothelial cells, immune
cells, nerves, preadipocytes and adipocytes, where the latter
changes shape and function betweenWAT and BAT.WhileWAT
adipocytes are characterized by the presence of a single large
lipid (unilocular) droplet, BAT maintains multiple small droplets
(multilocular) within its adipocytes (Sidossis and Kajimura,
2015). Although WAT is morphologically and metabolically
different from BAT, about 30 years ago it was seen that there were
adipocytes in the WAT that had morphological similarities with
the BAT adipocytes, which until then were believed to be the only
ones that had the thermogenic property (Harms and Seale, 2013;
Wu et al., 2013). These adipocytes, as in the BAT adipocytes,
were multilocular, had a larger number of mitochondria and
when stimulated by low temperatures received β3-adrenergic
stimulation, expressed UCP-1, elevated cellular metabolism and
finally dissipated energy in the form of heat (Wu et al., 2013).
These white cells with characteristics of brown cells were named
as beige cells or “brite-brown in white,” and the name given to this
phenomenon of cellular differentiation was browning of WAT
(Wu et al., 2012, 2013).
Metabolic Diseases and Systemic Repercussions of
AT
As already mentioned, both physical inactivity and NCDs,
particularly those diseases characterized by metabolic diseases,
present a clear morpho-functional dysfunction of AT. Taken
together, these stressors, depending on their intensity and
duration, result in the remodeling of the AT. This process
is characterized by a set of changes, such as: modification
of the adipocyte area (hypertrophy, hyperplasia or atrophy;
Arner, 2000); disturbance in fatty acid turnover (lipolysis and
lipogenesis; Arner et al., 2010); rearrangement of extra-cellular
matrix components (Scherer, 2016); inflammation (Batista et al.,
2012); modulation of the browning phenotype related to the
thermogenic effect (Kir et al., 2014); among others. The end
results of this process are both local (i.e., in tissue) and systemic
(ectopic fat, insulin resistance, etc.) impairment of the normal
physiological functions of this tissue.
Physical inactivity contributes to being overweight or
obese and the development of chronic conditions, including
cardiovascular diseases, T2DM, gallbladder disease and
osteoarthritis (Greenwood et al., 2010). Obesity, the excessive
accumulation of body fat (mainly due to an imbalance between
energy intake and expenditure) is at the heart of all these
problems. Excessive fat accumulation in the adipocytes can
result in an imbalance in TG turnover, inflammation in the AT
and a consequent increase in the secretion of a large number of
proinflammatory factors, such as TNF-α, and others (Mraz and
Haluzik, 2014). Excess AT and consequent dysfunction plays
an important role in the pathophysiology of other metabolic
diseases such as metabolic syndrome (Grundy, 2015).
On the other hand, people with a deficiency of AT (for
example, lipodystrophy) can also be diagnosed with metabolic
syndrome. This happens because in this case redistribution of
fat is almost always directed to SkM which directly leads to
insulin resistance (Grundy, 2015). In cancer cachexia, AT is
affected early, prior to the establishment of the main signs
and symptoms of the syndrome (Fouladiun et al., 2005). The
breakdown in fatty acid turnover is the most well characterized
physiological event, evidenced by the increase of lipolysis and
changes in of lipogenesis (Henriques et al., 2017). Increases
of cellular infiltrate, in particular macrophages (Batista et al.,
2013), increased collagen and impairment of adipocyte turnover
(Franco et al., 2017), has also been described. As a result, AT loses
its TG storage capacity and, consequently, presents a reduction
in the mass of this tissue. This scenario (AT mass loss) presents
a negative correlation with cancer patient survival (Ebadi et al.,
2017).
Skeletal Muscle as an Immunogenic Organ
The Concept of Myokines
The SkM is a highly organized tissue at the micro and
macroscopic level and is the body’s main protein reserve
(Hornberger, 2011; Bentzinger et al., 2013). SkM tissue is an
important component related to quality of life, health, survival,
and metabolic balance (Rodriguez et al., 2014; Salanova et al.,
2014). It is a plastic tissue and continuously adaptable to
various situations such as mechanical stimulation or disuse,
leading to the condition of maintenance and/or muscular
hypertrophy (increase of muscle mass) and atrophy (reduction
of muscle mass), respectively. In addition, such tissue has
a high capacity to alter its phenotype, depending on the
mechanical load applied to it (Williamson et al., 2001). SkM
tissue is also identified as an organ that synthesizes and
secretes cytokines and other peptides, and these molecules
have been given the name myokines (Pedersen et al., 2007).
SkM is one of the largest organs of the human body, and
in addition to its important functions such as providing
locomotion, maintaining body temperature and metabolic
homeostasis (Henningsen et al., 2010), the discovery that muscle
contraction secretes proteins defined a new paradigm; SkM
is a secretory organ, synthesizing and secreting myokines in
response to muscle contraction. The products secreted by this
tissue can influence the metabolism and function of SkM,
in addition to other tissues and organs (Pedersen, 2013).
Studies on the humoral component of SkM date back to the
middle of the twentieth century, with a focus on the role
of physical exercise as a modulator of glucose metabolism,
with no conclusion about the mechanisms involved in this
regulatory process (Goldstein, 1961). The ability of SkM to
secrete myokines from muscle contraction was termed as “work
stimulus,” “work factor,” or “exercise factor” (Figure 2; Pedersen,
2011). The concept of “exercise factor” was based on the fact
that muscle contractions engage metabolic and physiological
responses in other organs, and that these are not mediated by
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FIGURE 2 | Myokines involved in induced-exercise muscle-adipose tissue
crosstalk. The secretion and action of different types of Myokines is exercise
type-dependent. Some Myokines like Irisin, Myostatin, IL-6 e IL-15 have been
the subject of a number of published studies about their mechanisms.
However, FGF21, Myonectin, ANGPTL4, and BAIBA need more studies about
their role as exercise factor. Solid lines represent already known mechanisms,
while broken lines represent the mechanisms that still have to be unraveled.
The red line represents factors released during endurance training practice
while the blue line represents factors released during resistance training
practice. The Myokines released by exercise and their effects on White
Adipose Tissue. Muscle contraction-induces a set of molecules that have an
endocrine function. Muscle-adipose tissue crosstalk exerts functions such as
reduction of adiposity, increase in thermogenesis due to increased adrenergic
activity, increased markers of the browning phenomenon and increased
lipolytic activity.
the nervous system (Pedersen et al., 2003). This concept was
established after a study with electrical stimulation in paralyzed
muscles, in which it was verified that the capacity of muscle
contractions in modulating other tissues occurs through an
independent pathway of activation of the nervous system (Kjaer
et al., 1996). Thus, myokines began to be understood as a
protective factor against disease and the effects of physical
inactivity.
Table 1 provides a list of original articles that investigated the
potential of exercise/physical training as an inducer of myokines
and evidence of mechanisms or outcomes relating to the muscle-
adipose tissue crosstalk.
Myokines That Act on Crosstalk Between
SkM and AT
As described above, myokines are released from SkM in response
to exercise. Thus, following the characterization of irisin as
a myokine capable of activating adipose tissue browning in
rodents in response to exercise (Bostrom et al., 2012) the concept
that factors secreted by SkM could signal to other organs has
grown and developed. More recently, Lee et al. (2014) shown
that irisin and FGF21, both induced by submaximal exercise,
have a function in promoting the browning of adipose tissue
to meet the increased demand for fat oxidation. Moreover,
the characterization of these two molecules opened an avenue
of possibilities in the search for new factors that will add to
our understanding of muscle-adipose tissues crosstalk and the
options for treatment (Figure 2). In this review article, the main
proteins identified in the literature that are expressed/secreted
by SkM and have a capacity to act on the crosstalk between
muscle-adipose tissues will be explored.
Myostatin
Transforming growth factor beta superfamily (TGF-β) and
related factors such as myokines are first candidate molecules
identified in SkM, and reported to induce biological signals
that regulate cell growth, regeneration, differentiation,
transformation and death of SkM (Iizuka et al., 2014). Among
them are: myostatin, activins or inhibins, follistatin and bone
morphogenic proteins (BMP). Myostatin is a protein related to
the control of muscle growth and body metabolism (Feng and
Derynck, 2005).
Among the different proteins of the TGF-β family, myostatin
(also known as GDF8) is a protein secreted during embryonic
development and its function is to limit muscle growth in
the physiological situation during development. However, it is
known today that myostatin is also expressed and secreted even
in adulthood (Argiles et al., 2012). Myostatin circulates in the
blood in a latent form and when cleaved, it presents itself actively.
Once activated, it has high affinity to ACTRIIB Activins receptors
(de Caestecker, 2004). Once attached to its receptor, it triggers the
activation of the Smad family transcription factors (Smad2 and
Smad3). This activation in turn culminates in muscle atrophy,
through the subsequent activation of the Forkhead Box family
transcription factors, FOXO (1, 2, and 3) together with inhibition
of the AKT/mTOR pathway (Braun and Gautel, 2011). The
importance ofmyostatin as an atrophic component is highlighted
in patients with HF and cancer, who present increased serum
levels of this protein, which can result in cachexia, which can
only be reversed by the deletion of the gene, as can be observed in
in vitro assays and transgenic animal models (George et al., 2010;
Heineke et al., 2010).
In addition to the ability to modulate the Smad, FOXO and
AKT pathways, the interaction between myostatin and physical
exercise also appears to occur through the transcription factor
peroxisome proliferator-activated receptor gamma co-activator
1-alpha (PGC-1α) in muscle, which in turn is stimulated by
exercise (Han et al., 2013). Studies have shown that inhibition of
myostatin results in up-regulation of PGC-1α activity in the SkM,
thus stimulating mitochondrial biogenesis. PGC-1α in turn binds
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TABLE 1 | List of original papers that investigate proteins expressed and/or secreted by skeletal muscle which act on muscle-adipose tissue crosstalk.
References Experimental model Training protocol Myokines
analyzed






Combined strength and endurance
training for 12 weeks, including two
endurance bicycle sessions (60
min−70% VO2máx) and two whole
body strength training sessions
(60min) per week.
FNDC5/Irisin ↑ FNDC5 mRNA expression in
skeletal muscle.
↑ Plasma concentration of irisin
after 45min ergometer cycling
(∼1.2-fold) and ↓ after 2 h rest.
There was little or no effect of
long-term training on selected
browning genes and no correlation
between circulating irisin with UCP1








Acute session of exercise on
cycloergometer following graded,
stepwise cold exposure to maximal
capacity (VO2max) and sub-maximal
exercise test at 40% VO2max for 1 h.
Irisin ↑ Irisin in maximal exercise group
compared to cold exposure.
In vitro experiments (BAT) provide
mechanistic insight into in vivo
observations. The results indicate that
shivering-stimulated irisin, in concert
with FGF21, phenotypically
transforms white adipocytes to








Cycling on a leg ergometer for
55min, 3 days/week, for 8 weeks.
Irisin ↑ Serum irisin level in the
middle-aged/older training group
↔Serum irisin level in the young
training group
In the middle-aged/older training
group, the endurance
training-induced reduction in visceral
adipose tissue area was negatively






Combined training performed 3 times
per week during 3 months. Intensity
was maintained at 70–85% of
maximal heart rate and strength
training Intensity was maintained at
70–85% of maximal heart rate.
FNDC5/Irisin Exercise did not affect
Fndc5/irisin
Was observed a down regulation of
Fndc5/irisin in adipose tissue and
circulation in T2D group.
Roca-Rivada
et al., 2013
Lean and obese rats
and obese men
Free access to the activity wheel for 1
or 3 weeks
FNDC5/Irisin ↑ FNDC5/irisin in muscle after 3
weeks of exercise
↑ FNDC5/irisin in adipose tissue
after 1 week of exercise and ↓
after 3 weeks exercise
75% of irisin expression by skeletal
muscle and 28% by AT. No correlation
between expression of UCP1 in





Acute low-intensity aerobic exercise
was performed with bicycle
ergometer for 1 h at a low intensity of
50% VO2max
Single resistance exercise of 5 sets of
10 repetitions in leg press until failure.
Heavy-intensity endurance exercise,
twice a week and combined EE and
RE training
FNDC5/irisin ↑ FNDC5 mRNA only in young
men post-RE
No change in plasma level of irisin on
adipose tissue.
Irisin and FNDC5were not associated
with glucose tolerance and being




Wistar rats 1.5 h/day, 45min at 9:00 AM and
45min at 05:00 h PM, for 4 weeks.
Myostatin ↔ In mRNA myostatin between
exercised and sedentary normal
diet and HFD rats
↑ In mRNA myostatin in BAT of
high-fat rats after swimming
↓ In mRNA myostatin in mesenteric
AT of high-fat trained rats versus
sedentary high fat diet rats
Hjorth et al.,
2016
Sedentary men 12 weeks of two interval bicycle
sessions (60min, 45-minbicycle test
at 70% of VO2max) and two full-body
strength training sessions (60min) per
week
Myostatin ↓mRNA myostatin in skeletal
muscle after acute and long-term
exercise




↑ Enhanced rate of glucose
oxidation and lactate production
in muscle cells incubated with
myostatin
The expression of myostatin was
correlated negatively
with insulin sensitivity
↑ Myostatin mRNA in AT after 12
weeks of training and correlated




C57BL/6 mice Mice ran for 120min at 15 m/min,
with an incline of 5%.
IL-6 ↑ Expression and secretion of
IL-6 and IL-10 in skeletal muscle
in exercise HFD group
↑ On infiltrates cells in AT of HFD
group
↓ F480 and CD11 in AT in exercise
HFD group
(Continued)
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TABLE 1 | Continued
References Experimental model Training protocol Myokines
analyzed




C57BL/6 mice Mice ran for 2 h at 15 m/min at a 5%
incline, during 4 weeks
IL-6 ↔ No differences in plasma IL-6
between sedentary and trained
mice
↑ In levels of il-6 mRNA epididymal AT
with no increase in IL-1β and TNF-α
↑ In protein and mRNA levels of IL-6
receptor in epididymal AT
BAT, Brown Adipose Tissue; AT, Adipose Tissue; EE, Endurance Exercise; RE, Resistance Exercise; T2D, Type 2 Diabetes; ↑, increase, ↓, decrease and ↔, no alterations.
to FOXO and inhibits its transcriptional activity (Lebrasseur
et al., 2009). Another effect is an increase in AMPK activity in
themuscle, which increases insulin sensitivity and responsiveness
(Zhang et al., 2011).
However, myostatin is not exclusively secreted by SkM tissue,
with studies indicating that AT also secretes this protein. Its
importance in this tissue is related to the maintenance of adipose
mass and greater sensitivity to insulin (Hamrick et al., 2006;
Guo et al., 2009). Myostatin mRNA levels increase substantially
in genetically-modified obese mice (leptin-deficient ob/ob mice)
and also in those receiving a high fat diet (HFD), so both
circulating and SkMmyostatin levels are present in obese subjects
when compared to non-obese subjects (Allen et al., 2008; Hittel
et al., 2009). Transgenic mice that expressed non-functional
myostatin (conditioned to SkM), presented not only increased
muscle mass but also resistance to weight gain (fat mass) and
insulin resistance even when receiving a high-fat diet (Zhao
et al., 2005). On the other hand, knockout animals for myostatin
presented not only an increase in muscle mass but also an
improvement in composition due to a reduction of fat mass,
which in turn was due to the presence of the browning phenotype
in the WAT, mainly because of an increase in the expression of
irisin (Shan et al., 2013).
However, there are few studies in the literature that investigate
the direct role of myostatin as an “exercise factor” and its ability
to modulate AT. Bueno et al. (2011), evaluated the expression of
myostatin and its ACTRIIb receptor in both SkM and AT from
obese and insulin resistant rats who practiced swimming training.
No change was found in myostatin expression in the SkM of
trained animals compared to the control group. However, in the
BAT the expression of myostatin and ACTRIIb was increased
in the trained obese animals compared to the sedentary obese,
while in the mesenteric adipose tissue (meAT) they were reduced
(Table 1). The authors suggest that these changes are due to the
ability of myostatin tomodulate energetic homeostasis in exercise
and obesity, since no change was observed in non-obese animals
(Bueno et al., 2011). A recent study investigated the relationship
between myostatin, physical activity and dysglycaemia in men
with or without dysglycaemia who underwent a 30–45min cycle
test before and after 12 weeks of combined training (Hjorth
et al., 2016). They found that myostatin mRNA expression was
reduced in SkM after acute exercise and was further reduced
over 12 weeks of training, while myostatin expression in AT
increased after 12 weeks of training and correlated positively with
insulin sensitivity markers (Table 1). Analysis at cellular levels
with recombinant myostatin showed increased glucose uptake
in human SkM cells, suggesting a complex regulatory role of
myostatin in SkM homeostasis.
However, these last two studies have not yet elucidated direct
evidence on muscle-adipose tissue crosstalk, since modulation in
myostatin levels from exercise was due to qPCR analysis from
AT. It is clear that myostatin is modulated by exercise, but more
work on the modulation of myostatin muscle levels and its direct
action in the exercise state are still necessary.
Interleukins
Interleukins (IL) are a group of cytokines bound to the
immune system that have the ability to develop several
different cellular responses when bound to surface receptors.
These molecules have around 30 different isoforms that act
in a paracrine and autocrine way, being strongly linked to
inflammatory pathologies (Brocker et al., 2010). They play an
important role in inflammatory processes and can exert a pro
or anti-inflammatory function (Batista et al., 2010). The main
proinflammatory cytokines are IL-6 and IL-1β, while the main
anti-inflammatory ones are IL-4, IL-10, and IL-13, which act to
inhibit the expression of other proinflammatory proteins (Lira
et al., 2009). Other ILs such as IL-4, IL-8, IL-7, and IL-15 are also
released by muscle tissue (Pedersen, 2011).
Interleukin-6 (IL-6)
Interleukin-6 (IL-6) is an important IL that is at high levels after
exercise and plays an important role in systemic inflammation
(Pratesi et al., 2013). High levels of IL-6 are observed in situations
where glycogen levels are low, as a response tometabolic demand,
since higher levels of IL-6 are related to a higher lipolytic rate by
activation of the AMPK pathway and/or PI3-kinase activating the
oxidation of the fatty acids which leads to greater availability of
energy supply from this energy source (Keller et al., 2001).
Some studies suggest that increased IL-6 during and after an
acute exercise session might be related to the type of exercise
performed. Higher plasma levels of IL-6 have been reported in
some studies that use running as a model of physical exercise
compared to those which use cycling (Nieman et al., 1998; Starkie
et al., 2001). According to these studies, the running model
leads to a greater release of IL-6 because of the greater muscle
damage which occurs due to its eccentric component being larger
compared to that of cycling. Other studies comparing the IL-6
response in these two exercise models did not show significant
differences (Starkie et al., 2001).
Increased levels of IL-6 after exercise are followed by increased
expression of the IL-1 receptor antagonist (IL-1ra) and IL-10,
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such adjustment chronically constitutes an anti-inflammatory
component and a response to the increase in circulating IL-
6 induced by exercise (Febbraio and Pedersen, 2002). Plasma
concentrations of IL-6 may increase up to 100-fold after exercise.
However, the increase in circulating IL-6 after exercise does not
appear linearly over time, with a study finding an exponential
acceleration in IL-6 secretion soon after exercise (Macdonald
et al., 2003). In a recent study, in which the effects of voluntary
running in tumor-bearing mice were evaluated, running animals
showed a 29-fold increase in IL-6 levels in SkM, increased
secretion of NK cells and a reduction in tumor volume, whereas
trained animals receiving an IL-6 antagonist did not exhibit the
same rate of tumor reduction as well as less infiltration of NK cells
into the tumor (Pedersen et al., 2016). Such a finding confirms
the importance of IL-6 as an “exercise factor” with the ability to
modulate the immune system during tumor progression.
However, studies have shown that IL-6 can induce an
anti-inflammatory environment, not only by inducing the
production of anti-inflammatory cytokines, but also, under
specific conditions, by inhibiting the production of TNF-α, as
demonstrated in an in vitro study (Beyaert and Fiers, 1999) and
in mice (Petersen and Pedersen, 2005). In humans, infusion of
rhIL-6, an experimental procedure that mimics the increase in
IL-6 levels induced by exercise, was able to inhibit the increase
in endotoxin-induced TNF-α plasma levels (Starkie et al., 2003).
In addition, evidence of an anti-inflammatory effect of IL-6 has
shown to be related to a direct relation between muscle tissue
and AT. This kind of relationship is characterized as crosstalk
(Macpherson et al., 2015).
This study was conducted in C57bl/6 mice that received a high
fat diet (HFD) and were exposed to running training (Table 1).
At the end of the study, it was possible to observe that even
without changes in adipose mass, higher levels of IL-6 expression
in the SkM were responsible for the increase in IL-10 expression,
together with a significant reduction in inflammatory infiltrates
in AT (Macpherson et al., 2015).
As described previously, IL-10 can act on different cell types
to induce suppression of the inflammatory response and it has
been postulated that it is the main molecule responsible for
the “orchestration” of inflammatory reactions, in particular
those involving the activation of monocyte/macrophage cells.
Therefore, in humans, when IL-10 is added to the culture
medium of mononuclear cells and circulating neutrophils
stimulated with lipopolysaccharide(LPS), the synthesis of
proinflammatory cytokines (TNF-α, IL-1β, IL-6) is inhibited
through post-transcriptional mechanisms, a direct consequence
of a higher mRNA degradation rate of the corresponding genes
(Christiansen et al., 2010).
Interleukin-15 (IL-15)
Another IL expressed by SkM with an important metabolic role
is IL-15. It has been suggested to be an important modulator
of body fat mass, which also actively participates in the innate
immune response, playing an important role in the development
and function of natural killer (NK) cells and lymphocytes (Quinn
et al., 2013).
In a study by Nielsen et al. which analyzed the rate of secretion
of IL-15 in SkM of individuals who practiced Resistance Training
(RT), it was possible to confirm that 24 h after the last RT session
a two-fold increase in IL-15 mRNA levels was observed, and that
this response was also dependent on the type of muscle fiber
(Nielsen et al., 2007). Studies indicate that this cytokine is the
main agent in crosstalk between SkM tissue and AT (Pedersen
et al., 2007). The relationship of IL-15 and AT can be observed
in a translational study (Nielsen et al., 2008), which verified
in humans an inverse relationship between IL-15 (mRNA) and
AT mass indexes. In mice transfected with IL-15 overexpressing
plasmid, they showed reductions in AT mass compared to the
control group.
The concentration of circulating IL-15 was shown to be
closely related to physical exercise, in addition to increasing
lipid oxidation and gene expression of peroxisome proliferator-
activated receptor delta (PPARδ) in rodents when they were
treated with the cytokine (Quinn et al., 2013). In addition, IL-
15 is directly related to muscle metabolism, or even diet-induced
obesity and insulin sensitivity (Quinn et al., 2011, 2013).
Because it has an anti-inflammatory function, IL-15 inhibits
the action of TNFα in the muscle during cachexia (Pajak
et al., 2008). In addition, any deregulation of this cytokine can
lead to several pathologies linked to autoimmune diseases such
as rheumatoid arthritis and leukemia (Fehniger and Caligiuri,
2001). However, further studies are required to establish its full
clinical importance.
Some previous studies demonstrated the link between IL-
15 release, SkM, and NCDs. In an in vitro study, cells treated
with IL-15 had increased expression of heavy chain myosin
and induced anabolism in SkM cells without stimulation of
precursor myogenic cells (Furmanczyk and Quinn, 2003). Also,
the ability of IL-15 to induce hypertrophy in SkM cells has
been demonstrated through the reduction of the rate of protein
degradation during cachexia and sarcopenia, highlighting the
therapeutic power of this cytokine (Quinn et al., 2002). The
ability of IL-15 to act on muscle- adipose tissue crosstalk was
investigated by the same group, showing IL-15 overexpression in
relation to reduced adiposity. To test the hypothesis, transgenic
animals that overexpress IL-15 (mRNA and protein) in SkMwere
used in two experimental conditions: overexpression of muscle-
free IL-15 in the circulation and overexpression of muscle IL-
15 without secretion into the circulation. Only the group that
had the increased levels of IL-15 from the muscle in circulation
had a reduction in adiposity due to the greater targeting of this
substrate for energy generation (Quinn et al., 2009). However, no
study has been able to provide evidence of the direct mechanism
of IL-15 as an “exercise factor” in muscle-adipose tissue crosstalk.
FGF-21
Fibroblast growth factor 21 (FGF21) is an endocrine-member of
the FGF family. The expression and circulating levels of FGF21
are dependent on factors such as nutritional status, diet, hormone
levels, and activities of various transcriptional factors. FGF21 acts
in the control of glucose and lipid homeostasis (Kharitonenkov
et al., 2005). In general, FGF21 stimulates the uptake of glucose
by adipocytes and inhibits the production of glucose in the
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liver. In addition, FGF21 appears to protect pancreatic β cells
from cell death induced by glycotoxicity (Kharitonenkov et al.,
2005, 2007). Hojman et al. found that FGF21 is expressed in
both plasma and SkM after insulin stimulation in humans, and
thus classified FGF21 as an insulin regulatory myokine (Hojman
et al., 2009). However, studies that aimed to correlate FGF21
and its importance as “exercise factor” are still inconclusive.
A study by Cuevas-Ramos et al. found an increase in serum
FGF21 levels in runners after 2 weeks of training, but found
no change in their gene expression in SkM (Cuevas-Ramos
et al., 2012). However, another study analyzed the expression
of FGF21 after an acute session of running exercise in both
an experimental mice model and in humans and showed an
increase in serum FGF21 levels (Kim et al., 2013b). However,
this increase was not in SkM or AT but in the liver (Kim
et al., 2013b). The authors, observed that this increase is in
turn accompanied by increased hepatic peroxisome proliferator-
activated receptor alpha (PPARα) expression, required for the
activation of lipolysis and also of ATF4 (Kim et al., 2013b),
a transcription factor identified in several stress response
situations, including autophagy, mitochondrial stress, and amino
acid deprivation (Kim et al., 2013a). In this respect, more studies
are needed to confirm the importance of FGF21 as “exercise
factor,” since studies on the systemic effects of this molecule focus
on quantifying their plasma levels (Cuevas-Ramos et al., 2012;
Lee et al., 2014), rather than on verifying their expression in the
SkM during contraction.
Irisin
Irisin is considered the most promising myokine in the context
of metabolism maintenance because it is secreted by SkM and
has been suggested to mediate the effect of exercise on WAT
metabolism (Aydin et al., 2014). Irisin, formerly called Iris, is a
recently identified myokine, released into the circulation by SkM
in an exercise-dependentmanner. It is reported to have the ability
to convert WAT to BAT, a phenomenon known as browning;
a phenotype set of adaptations that results in increasing total
energy expenditure (Bostrom et al., 2012).
Irisin was discovered and characterized by Bostrom et al.
(2012), in a study that sought to elucidate the relevance of
the transcriptional coactivator PGC-1αin the control of obesity
(Bostrom et al., 2012). First, an algorithm was used to predict
candidate proteins produced by SkM that may mediate the
browning process in AT, excluding mitochondrial target proteins
(Figure 3). Five candidate proteins were found to be mediated
by PGC-1α in the muscle: IL-15, Fndc5, VEGFβ, Lrg1, and
TIMP4. However, only the irisin precursor FNDC5 was able to
promote the differentiation of stromal vascular cells isolated from
WAT from beige mice (browning phenomenon; Bostrom et al.,
2012). Consequently, there was an emerging search for a deeper
understanding of the mechanisms of action of irisin, whether
they were local or systemic as well as its role as an “exercise
factor” (Huh et al., 2012, 2014, 2015; Hecksteden et al., 2013;
Moraes et al., 2013; Pekkala et al., 2013; Roca-Rivada et al., 2013;
Aydin et al., 2014; Daskalopoulou et al., 2014; Pardo et al., 2014;
Tsuchiya et al., 2014; Kim et al., 2015; Miyamoto-Mikami et al.,
2015; Fagundo et al., 2016; Duft et al., 2017). However, most
of the studies only analyzed plasma levels of FNDC5/irisin and
did not assess its expression by SkM. A study aimed to verify
the physiological variables effect of irisin in healthy groups of
swimmers of different ages and explore the direct effects on
muscle metabolism, and found: (1) higher irisin serum levels in
the younger group compared to the older group (age effect); (2)
serum irisin levels were elevated in the swimmer groups (training
effect); (3) rates of plasma irisin were related to the intensity
of exercise training, with the group that performed intermittent
high-intensity exercise having higher levels; (4) Higher rates of
irisin were related to the metabolism of glucose and lipids in SkM
through AMPK phosphorylation; despite the differences in basal
irisin levels, exercise-induced irisin secretion is independent of
age or fitness level. Increased irisin can directly modulate muscle
metabolism through 5’ AMP-activated protein kinase (AMPK)
activation (Huh et al., 2014).
Another study aimed to elucidate the association between
endurance exercise and the impact of irisin induction on body
fat in 25 healthy (± 21 years old) and elderly (± 68 years)
individuals who practiced 8 weeks of cycloergometer training
at 60–70% of VO2peak for 45min, 3x/week. The main results
indicated an increase in serum irisin levels in the elderly group
compared to the young group (age 21± 1 years) accompanied by
a reduction in visceral adiposity which was negatively correlated
with irisin levels (r = −0.54, P < 0.05; Miyamoto-Mikami et al.,
2015). However, the irisin modulation seemed to be dependent
on themodality and intensity of the exercise. In this respect, irisin
secretion was observed in volunteers of different ages submitted
to a protocol of aerobic exercise of moderate to maximum
intensity (70–75% VO2max until exhaustion; Huh et al., 2014).
In this study, it was possible to verify that intense exercise, until
exhaustion, promoted higher irisin serum levels after exercise in
the young group compared to the old group (age 67.9 ± 5.0).
The same study also analyzed the secretion of irisin in swimming
adolescents in groups that either practiced high or moderate
intensity swimming. It was observed that there was a significant
increase in serum irisin levels immediately and up to 1 h after
an exercise session in the group that practiced high-intensity
swimming compared to the moderate intensity group.
Norhein et al. argue that the regulatory effect of physical
training on the expression of muscular FNDC5 is not clear.
In this study, 26 physically inactive men (normoglycemic and
diabetic) were submitted to a 12-week physical training program
combining strength and endurance exercises (Table 1). Muscle
biopsies were performed before and after the intervention and
it was observed that muscle mRNA levels for both PGC-1α
and FNDC5 were increased after exercise. However, circulating
levels of irisin were only increased acutely and shortly after
the exercise session (1.2-fold; Table 1). As far as the analysis of
muscle-adipose tissue crosstalk was concerned, few effects were
seen in AT browning: AT UCP1 mRNA levels were not directly
correlated with FNDC5 levels in both AT and in SkM (Norheim
et al., 2014). Pekkala et al. analyzed the effects of different
short-term and long-term exercise protocols on the FNDC5 and
PGC-1α of healthy trained and untrained men, who either did
low intensity aerobic exercise, resistance training, high intensity
exercise or combined endurance training, and assessed levels of
muscle and irisin serum, as well as studying the associations
of irisin and FNDC5 with health parameters (Pekkala et al.,
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FIGURE 3 | Exercise-induced browning in WAT. Increased expression of PGC-1a in muscle as a result of exercise causes increased expression of FNDC5, a type I
membrane protein, which C-terminally cleaved and secreted as irisin into the circulation. Irisin binds to a receptor yet unknown in WAT adipocytes and leads to
phenotypic modification. WAT, white adipose tissue; FNDC5, Fibronectin Type III Domain Containing 5; UCP1, Uncoupling Protein Type 1.
2013). In this study, it was observed that muscle irisin levels
were only increased in the young group that performed a single
resistance training session, without any changes in irisin serum
levels regardless of training. No association was found between
levels of FNDC5 and health parameters (Table 1). The group
also concluded that data on exercise and irisin modulation are
questionable.
However, it is important to note that irisin is not a protein
exclusively secreted by muscle tissue. The study presented by
Arturo Roca-Rivada et al. was a pioneer in showing that WAT
also secretes FNDC5, the precursor of irisin, indicating that it is
not only a myokine but also an adipokine (Roca-Rivada et al.,
2013). The study was based on gene and protein expression
analyses by explant assay of subcutaneous and visceral AT from
rats. He also found that both tissues secreted FNDC5/irisin under
the stimulus of endurance training.
ANGPTL4
Angiopoietin-like protein (ANGPTL) is a group of proteins
that can be secreted by the AT, SkM, intestinal, and liver
cells and is responsible for several processes, among them
energy metabolism, and TG turnover modulation in AT and the
regulation of blood glucose levels (Ingerslev et al., 2017; Popova
et al., 2018). Despite the name, ANGPTLs are not specific ligands
for angiopoietin, but are named after the structural similarity
with this protein (Cinkajzlova et al., 2018).
ANGPTL is regulated through peroxisome proliferator-
activated receptor (PPAR) and has the ability to regulate serum
triglyceride levels. This ability is related to increased lipoprotein
lipase (LPL) activity, promoting lipolysis in AT, and improving
glucose tolerance (Ingerslev et al., 2017). Specifically, plasma
ANGPTL4 acts on myotubes, and is well-established as a
myokine derived from physical exercise (exercise factor; Raschke
and Eckel, 2013; Ingerslev et al., 2017).The performance of
this protein is related to several physiological processes, among
them are insulin sensitivity, lipid metabolism, adipogenesis
(Cinkajzlova et al., 2018), and the increase of circulating fatty
acids, which are generated mainly by chronic caloric restrictions,
fasting, and aerobic physical training (Raschke and Eckel, 2013).
It was seen that when muscle contraction was stimulated in
myocytes during exercise using electrical pulse stimulus, there
was an increase in the gene expression of ANGPTL4 after 4 h, and
an increase of the supernatant proteins after 8 h of stimulation,
corroborating the link between exercise and the expression of
ANGPTL4 (Scheler et al., 2013). However, there are contrary
findings, as in the study by Catoire et al. using acute endurance
exercise in a single leg, ANGPTL4 was shown to be more highly
expressed in unexercised legs than in exercised legs (Catoire et al.,
2014).
The practice of fasting combined with physical exercise is
indicated as an important inducer of ANGPTL4 expression
and may be beneficial to those with high serum levels of
long chain fatty acids (Ingerslev et al., 2017). In addition,
an increase in serum ANGPTL4 in obese patients (with or
without T2DM) was observed, and the same was observed in
patients who underwent bariatric surgery and in fasting patients,
while it was reduced in patients with anorexia (Cinkajzlova
et al., 2018). However, even with published data indicating
a role for ANGPTL4 in obesity, and glucose intolerance
(Morris, 2018), this protein is still poorly studied and there
is much about its therapeutic role that needs to be further
investigated.
BAIBA
β-aminoisobutyric acid (BAIBA) are natural metabolites of
thymine and valine secreted primarily by myocytes during
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the practice of physical exercise (Roberts et al., 2014). The
increase of PGC1α observed during physical exercise results in a
concomitant increase in BAIBA serum levels. In the same study,
in vitro, when BAIBA was cultivated with primary cells from
subcutaneous adipose tissue (scAT), there was an up regulation of
brown and beige adipocytes marker, such as UCP1 and CIDEA.
In this way, it was shown that BAIBA has a potential to induce
browning in white adipocytes, in addition to demonstrating that
physical exercise increases its production by the body. Moreover,
BAIBA has been proposed as a promising molecule capable
of inducing the thermogenic framework by an independent
pathway of adrenergic activation (Jeremic et al., 2017).
BAIBA also has an important therapeutic role against obesity
(Ginter and Simko, 2014), mainly by stimulating the oxidation
of fatty acids, reducing the process of lipogenesis in WAT, and
attenuating inflammation and insulin resistance (Jung et al.,
2018). The regulation of BAIBA is mediated through AMPK
signaling, and plays an important role in several pathologies.
In addition to obesity, BAIBA is reported to attenuate
hepatic apoptosis by reducing ER stress on hyperlipidemia and
improving renal fibrosis (Jung et al., 2018). Furthermore, it has
been shown that circulating levels of BAIBA have an important
role against cardiometabolic risks (Kammoun and Febbraio,
2014). Thus, with these data, it is possible to determine that the
crosstalk between SkM, cardiac muscle, liver and WAT and BAT
has a strong correlation with the practice of physical exercise
(Kammoun and Febbraio, 2014).
Myonectin
Myonectin, also known as C1q/TNF-related protein 15
(CTRP15), is a new myokine recently found as a protein
typical of fatty acid metabolism in response to exercise (Seldin
et al., 2012; Toloza et al., 2018), although in other studies the
relationship between the expression of myonectin and physical
exercise is contradictory (Peterson et al., 2014).
The study by Seldin et al., which made a general
characterization of this myokine, showed that it is widely
expressed in SkM, more precisely in myotubes (Seldin et al.,
2012). In addition, it is described as a potent inducer of cell
differentiation in C2C12 cells, which, according to the authors,
indicates that this protein is produced in muscle fibers, not
in satellite cells (Seldin et al., 2012). A test performed in vivo
using the soleus and plantaris muscles showed increased gene
expression and circulating levels of myonectin in animals that
had been fed (compared to animals that had not). It was also
shown that in the presence of carbohydrates or lipids in the
gastrointestinal tract there was potent stimulation of myonectin
expression in the assessedmuscles (Seldin et al., 2012), suggesting
a strong correlation between myonectin and nutrient uptake
(Toloza et al., 2018).
High levels of myonectin were observed in individuals with
T2DM, glucose intolerance, and obesity (Li et al., 2018). Other
members of the CTRP family are expressed by AT, and they
are described as adiponectin paralogue genes (Wong et al.,
2008).This gene family is up-regulated in ob/ob mice and are
highly expressed when stimulated with peroxisome proliferator-
activated receptor gamma (PPARγ) agonists (Wong et al., 2008),
however, because it is newly discovered, there is as yet little in the
literature regarding the direct crosstalk between myonectin and
AT.
In summary, myonectin, as well as irisin, promote glucose
and fatty acid uptake and oxidation in both the liver and AT,
acting more specifically on lipid metabolism mediated by CD36,
fatty acid transporter protein (FATP) and fatty acid binding
protein (FABP4), but not participating in lipolysis and glucose
homeostasis (Gamas et al., 2015). Myonectin, is, therefore,
a potent target for studies that focus on identifying future
therapies, mainly related to insulin resistance. It is fundamental
to characterize molecules that may present a function mimicking
the effects of physical exercise and consequently positively
modulating lipid homeostasis and lipogenesis in AT (Gamas
et al., 2015).
CONCLUSION
Over the last decades, exercise training has been suggested
as a preventive and therapeutic strategy for managing and
treating several NCDs, including T2DM, hypertension, heart
disease, obesity, and sarcopenia. Physical exercise is known to
improve metabolic health through adaptations to several tissues,
including SkM and AT. Although metabolic improvements
from exercise training in SkM and AT are important in
themselves, an important concept that has been evidenced in
exercise physiology is the concept of tissue communication, or
“crosstalk.” In addition, many studies have proposed that in
NCDs, mainly in those related to metabolic diseases such as
obesity, a low-grade chronic inflammatory profile is a well-
characterized scenario. Interestingly, several recent studies have
characterized and identified variousmyokines released from SkM
during and after a single bout of exercise. In particular, myokines
may act pleiotropically, mediating many aspects related to
AT metabolism. Myokines have also provided a new basis to
understand the molecular mechanisms underlying the beneficial
effects of exercise training on the reduction of morbidity
and mortality rates. Although the identified myokines share
a common role in regulating metabolism, how each myokine
works and how these myokines work together still remains
to be elucidated. In addition, given the role of myokines in
fine-tuning the metabolic process associated with exercise, the
development of specific exercise regimens or compounds derived
from myokines that mimic the effects of exercise are promising
areas to explore in the treatment of metabolic diseases through
exercise.
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Skeletal muscle possesses a high ability to regenerate after an insult or in pathological
conditions, relying on satellite cells, the skeletal muscle stem cells. Satellite cell behavior
is tightly regulated by the surrounding microenvironment, which provides multiple
signals derived from local cells and systemic factors. Among epigenetic mechanisms,
histone deacetylation has been proved to affect muscle regeneration. Indeed, pan-
histone deacetylase inhibitors were found to improve muscle regeneration, while
deletion of histone deacetylase 4 (HDAC4) in satellite cells inhibits their proliferation
and differentiation, leading to compromised muscle regeneration. In this study, we
delineated the HDAC4 function in adult skeletal muscle, following injury, by using a
tissue-specific null mouse line. We showed that HDAC4 is crucial for skeletal muscle
regeneration by mediating soluble factors that influence muscle-derived cell proliferation
and differentiation. These findings add new biological functions to HDAC4 in skeletal
muscle that need considering when administering histone deacetylase inhibitors.
Keywords: HDAC inhibitors, satellite cells, muscle regeneration, soluble factors, muscular dystrophies
INTRODUCTION
Skeletal muscle possesses a high capacity to regenerate and muscle regeneration has been
extensively studied since the 50′s. In addition to physiological demand, such as during muscle
growth or upon exercise, new muscle fibers are generated in response to muscle damage following
injury or in degenerative diseases. Although several types of cells, including muscle-derived cells
(MDCs), contribute to skeletal muscle regeneration, a crucial role of adult muscle stem cells, i.e.,
satellite cells (SCs), in this process is now well established (Torrente et al., 2001; Jankowski et al.,
2002).
Usually quiescent, upon proper stimulation SCs become activated, proliferate, differentiate,
and fuse to repair damaged myofibers or to create newly formed ones (Dumont et al., 2015).
SC expansion, commitment, differentiation and fusion are sequential phases, strictly controlled
by numerous transcription factors, also considered as specific stage-markers of SCs. Quiescent
and activated SCs do express Pax7, a paired box transcription factor (Le Grand and Rudnicki,
2007; Wang and Rudnicki, 2012). Upon activation, SCs proliferate and can either generate self-
renewing stem cells or differentiated ones, depending on symmetric or asymmetric division (Kuang
et al., 2007). Once SCs are committed to myogenesis, they start expressing other transcription
factors, such as Myf5 or MyoD (Dumont et al., 2015). The transition from myoblast to myotube
is mainly regulated by MyoD, which directly regulates the transcription of the other myogenic
regulatory factor (MRF) family members, myogenin and MRF4. In addition, myocyte enhancer
factor-2 (Mef2) proteins co-operate with MRFs to activate the expression of skeletal muscle
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terminal differentiation genes, such as myosin heavy chains
(MHCs) or creatine kinase (Lilly et al., 1994; Black and Olson,
1998) Myocytes fusion requires the expression of specific genes,
including myomaker and myomerger (Millay et al., 2013; Quinn
et al., 2017).
In adult skeletal myofibers, SCs reside between the basal
lamina and the sarcolemma, in a surrounding microenvironment
referred to as “niche.” SC niche consists of the basement
membrane, extracellular matrix, vascular and neural networks,
several types of surrounding and interstitial cells and several
diffusible molecules (Yin et al., 2013; Furuichi and Fujii, 2017).
Structural and biochemical cues from the niche act on SC
behavior to regulate cell quiescence, self-renewal, proliferation
or differentiation, through cell-cell interactions or paracrine
signals. Soluble factors play a critical role in the maintenance
of muscle homeostasis in physiological conditions and may
be involved in the progression of skeletal muscle diseases (De
Pasquale et al., 2012; De Paepe and De Bleecker, 2013; Furuichi
and Fujii, 2017). An increasing number of diffusible molecules
secreted by skeletal muscle have been discovered playing a role
in SC behavior. Among them, fibroblast growth factor (FGF),
transforming growth factor-beta (TGF-β), tumor necrosis factor-
alpha (TNF-α) or obestatin modulate different phases of muscle
regeneration, in both physiological and pathological conditions
(Floss et al., 1997; Coletti et al., 2005; Gurriarán-Rodríguez
et al., 2015; Delaney et al., 2017; Pawlikowski et al., 2017).
Also, circulating hormones regulate SC pool and skeletal muscle
regeneration (Moresi et al., 2009; Costa et al., 2014; Kim et al.,
2016).
Several epigenetic mechanisms are active at multiple steps of
muscle regeneration, fine-tuning SC gene expression (Giordani
and Puri, 2013; Moresi et al., 2015). Proper chromatin
remodeling accompanies SC activation and differentiation.
A permissive chromatin state that characterizes and distinguishes
the pluripotency of stem cells is established by the general lack
of repressive mark trimethylation of lysine 27 on histone H3
(H3K27me3) and the concomitant presence of the permissive
mark trimethylation of lysine 4 on histone H3 (H3K4me3) at the
transcription start sites (Dilworth and Blais, 2011; Moresi et al.,
2015). For instance, Pax7 expression is progressively silenced
during SC differentiation, changing its chromatin status from
a transcriptionally permissive state, characterized by elevated
levels of H3K4me3, to a repressive one, enriched in H3K27me3.
In addition to histone methylation, histone acetyltransferases
(HATs) and histone deacetylases (HDACs) modify the acetylation
status of histones or transcription factors, thereby acting as
transcriptional activators or repressors, respectively (Peserico
and Simone, 2011). Among HDAC family members, class I
HDACs inhibit MyoD gene transcription and activity. During
SC differentiation, the sequential interaction of class I HDACs
with MyoD and the hypo-phosphorylated pRb complex allows
the transcriptional activation of the differentiation genes, such as
myogenin or muscle creatine kinase (Puri et al., 2001). Instead,
the class II HDAC member HDAC4 promotes SC proliferation,
by repressing the transcription of the cell cycle inhibitor Cdkn1a,
and differentiation, by inhibiting the expression of Sharp1
gene (Marroncelli et al., 2018). Moreover, the class II HDACs
translocate from the nucleus into the cytoplasm, thereby releasing
the inhibition on Mef2 and their target genes (Lu et al.,
2000).
Muscle regeneration: (i) relies on SCs, which are influenced by
their “niche”; (ii) takes place in sequential stages, each one strictly
regulated by cell-autonomous and non-autonomous cues; (iii)
HDAC4 function in SCs has been partially elucidated. Therefore,
in this study, we aimed to define the HDAC4 functions in adult
skeletal muscle, by analyzing muscle regeneration in vivo in mice
carrying a tissue-specific deletion of HDAC4.
With this purpose, we studied muscle regeneration in
a mouse model in which HDAC4 was deleted specifically
in skeletal muscle (HDAC4fl/fl myogenin;Cre mice, thereafter
named HDAC4 mKO mice). Here we report that HDAC4 in
skeletal muscle is required for proper timing and efficiency of
muscle regeneration, besides HDAC4 functions in SCs. Indeed,
deletion of HDAC4 compromises muscle regeneration process
in vivo. MDCs from HDAC4mKO mice efficiently proliferate and
differentiate in vitro, suggesting that HDAC4 mediates muscle
regeneration in vivo, via soluble factors. Indeed, sera from injured
HDAC4 mKO mice inhibit proliferation and differentiation of




Mice were treated in strict accordance with the guidelines of the
Institutional Animal Care and Use Committee, and to relevant
national and European legislation, throughout the experiments.
Animal protocols were approved by the Italian Ministry of
Health (authorization # 244/2013-B). HDAC4fl/fl myogenin-Cre
(HDAC4 mKO) mice were generated by crossing HDAC4fl/fl with
a mouse line expressing the Cre recombinase under the control
of myogenin promoter, i.e., myogenin-Cre mice. HDAC4fl/fl mice
were used as controls.
Freeze Injury
Freeze injury was performed in 8-week-old HDAC4fl/fl and
HDAC4 mKO male mice. Mice were anesthetized with
intraperitoneal (IP) injections of 50 mg/kg Zoletyl, 10 mg/kg
Xylazine solution. To induce freeze injury, the tip of a steel probe
precooled in dry ice was applied, for 10 seconds, to posterior
muscles of anesthetized mice. This procedure induces a focal,
reproducible, injury (Moresi et al., 2008; Marroncelli et al., 2018).
Serum Collection
The sera were collected by cardiac puncture in the right atrium of
anesthetized male mice, 4 days after injury. About 1 ml of blood
was transferred to an Eppendorf tube and allowed to stand at
room temperature for 30 min. Blood was centrifuged at 3000 rpm
for 10 min and the supernatant serum was recovered. Samples
were stored at 4◦C for up to 6 months.
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Histological Analyses
Tibialis anterior muscles were dissected and embedded in Jung
tissue freezing medium (Leica, Wetzlar, Germany) and frozen
in liquid nitrogen precooled isopentane. Cryosections of 8 µm
were obtained by using a Leica cryostat. Muscles were sectioned
throughout the entire length, and the injury/regeneration site was
identified by extemporary toluidine blue staining. Histological
sections were collected at the level of the injury/regeneration site.
The section containing the maximal area of injury/regeneration
was identified and further analyzed. For histological analyses,
cryosections were fixed in 4% paraformaldehyde (PFA) buffered
solution and stained with hematoxylin/eosin using standard
method. The sections were examined with an Axioskop 2 plus
system (Zeiss) microscope with relative camera AxioCamHRc
and software.
Morphometric Analyses
Photomicrographs of regenerating muscles were taken at
standard resolution (1300×1030 pixel) and the cross-sectional
area of regenerating fibers, identified by morphological criteria
(presence of centrally located nuclei) was measured by using
Image J, Scion Image software. Due to the well-known wide
distribution of CSAs of fibers in a regenerating muscle, we
used the median of the CSA measurements to characterize
our population. In addition, regenerating fiber distribution was
generated by clustering the regenerating fibers into classes and
expressing the value as percentage, over the regenerating fiber
number.
Muscle Derived Cell Isolation
Muscle-derived cells were isolated from hind-limb muscles
of 3-week-old male mice by sequential enzymatic digestions:
firstly, for 30 min at 37◦C, with freshly prepared 1 mg/ml
collagenase/dispase (Roche Diagnostics, Mannheim, Germany)
in phosphate-buffered saline (PBS), followed by a second one,
for 15 min at 37◦C, with 0.1 mg/ml type II collagenase
(Sigma-Aldrich) in PBS. The enzymatic reaction was blocked
by adding cell growth medium, then the cell suspension was
filtered through 40-micron cell strainer filter (Falcon) and
mildly centrifuged. Cells were re-suspended in growth medium
and, after two preplatings of 1 h each to deplete fibroblasts,
MDCs were plated on 0.01% collagen (Sigma-Aldrich)-coated
dishes.
Culture Conditions and Treatments
Cells were cultured with Dulbecco’s modified Eagle medium
supplemented with 20% horse serum (Sigma-Aldrich), 100 U/ml
penicillin (Sigma-Aldrich), 100 µg/ml streptomycin (Sigma-
Aldrich), 50 µg/ml gentamicin (Sigma-Aldrich), 3% of chicken
embryo extract as growing medium (GM). After 3 days, or
when cells reached 50% of confluence, GM was replaced with
a differentiation medium (DM), consisting of a 1:10 dilution of
GM. For conditioned cultures, horse serum was replaced with
murine serum, derived from HDAC4 mKO or HDAC4fl/fl injured
mice, 4 days after the surgical procedure.
Immunostaining Analyses
For MHC immunofluorescence, differentiated cells were fixed in
4% PFA buffered solution for 10 min and then blocked in 10%
goat serum in PBS for 1 h. Cells were incubated overnight with
sarcomeric MHC antibody (clone MF 20, Developmental Studies
Hybridoma Bank), diluted 1:10 in 1% BSA PBS. Fluorescent
conjugated secondary anti-mouse IgG1 antibody (Alexa488,
Invitrogen) diluted 1:500 in 1% BSA PBS was used to detect
the primary antibody. For Ki-67 immunofluorescence, growing
cells at 24 h were fixed in 4% PFA buffered solution for
10 min, permeabilized in 0.2% Triton in PBS for 30 min,
then blocked in 3% BSA in PBS for 20 min. Cells were
incubated overnight with 1:100 Ki-67 antibody (Santa Cruz
Biotechnology) in 0.5% BSA in PBS. Fluorescent conjugated
secondary anti-goat antibody (Alexa 555, Invitrogen) diluted
1:200 in 0.5% BSA in PBS was used to detect the primary
antibody. Nuclei were counterstained with [0.5 µg/ml] Hoechst
and samples were mounted with 60% glycerol in Tris HCl 0.2M
pH 9.3.
RT-PCR and Real-Time PCR
Total RNA from Tibialis Anterior muscle was isolated using
TRIzoL reagent (Thermo Fisher), according to manufacturer’s
instructions, 4 days following injury. cDNA synthesis was
performed from 0.5 to 1 µg of RNA using Reverse Transcription
Kit (Takara), following the manufacturer’s instructions.
Quantitative PCR was performed using the ABI PRISM 700
SDS (Applied Biosystems) with SYBR Green reagent (Applied
Biosystems) and primer listed in Table 1.
Statistics
Statistical significance was determined using two-tailed Student’s
t-test with a significance level < 0.05, or by using one-way
analysis of variance (ANOVA), followed by Tukey’s HSD as a
post hoc test, when more than two conditions needed to be
compared. All values are expressed as mean ± standard error of
the mean (SEM). VassarStats, a statistical computation website
TABLE 1 | Primers used for real-time PCR.
Gene Reference number Forward primer Reverse primer
HDAC4 NM_207225.2 GTCTTGGGAATGTACGACGC GTTGCCAGAGCTGCTATTTG
Pax7 NM_011039.2 TCCCCCTGGAAGTGTCCA TGGGAAACACGGAGCTGA
MyoD M84918.1 ACCCAGGAACTGGGTGGA AAGTCGTCTGCTGTCTCAAA
Myogenin NM_031189.2 GCACTGGAGTTCGGTCCCAA TATCCTCCACCGTGATGCTG
e-MHC M11154.1 TGGTCGTAATCAGCAGCA TCGTCTCGCTTTGGCAA
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available at http://vassarstats.net/, was used for the statistical
analyses.
RESULTS
HDAC4 Expression Is Modulated in
Skeletal Muscle Upon Injury
Aiming to investigate the role of HDAC4 in skeletal muscle
regeneration, we evaluated its expression levels in regenerating
skeletal muscle over time. The tibialis anterior muscle of adult
HDAC4fl/fl male mice was subjected to a localized, reproducible,
freeze injury to induce regeneration, (Moresi et al., 2008) and
HDAC4 expression was evaluated over time, by real-time PCR
(Figure 1). HDAC4 expression in skeletal muscle is significantly
induced upon injury, compared to un-injured muscles, and
reached a peak of expression at day 4, suggesting a role for this
epigenetic factor in the early phases of muscle regeneration.
Deletion of HDAC4 in Skeletal Muscle
Compromised Muscle Regeneration
The expression of HDAC4 is significantly up-regulated in
skeletal muscle in response to injury. Therefore, to define
HDAC4 functions in adult skeletal muscle, we analyzed muscle
regeneration in a mouse line in which HDAC4 deletion is
mediated by a Cre-recombinase under the control of the
myogenin promoter, i.e., since the embryonic stage E8.5
(HDAC4 mKO mice) (Cheng et al., 1992). This mouse line
does not show overt abnormalities in skeletal muscle under
physiological conditions (Moresi et al., 2010; Pigna et al.,
2018). However, 1 week after injury, HDAC4 mKO mice
showed smaller regenerating fibers than HDAC4fl/fl mice, used
as controls, by histological analyses (Figure 2A). Morphometric
analyses of regenerating myofiber cross-sectional area (CSA)
FIGURE 1 | HDAC4 expression is up-regulated in regenerating HDAC4fl/fl
muscles. Real-time PCR for HDAC4 in regenerating muscles, at the indicated
time points following injury, over un-injured muscles. Data are presented as
mean +/– SEM. n = 6 mice for each condition. One-way ANOVA showed a
significant effect of the treatment between groups (F = 5.16; df = 3; p = 0.01)
and a significant interaction between un-injured HDAC4fl/fl mice and 2.5 days
(∗p < 0.05) or 4 days (∗∗p < 0.01) after injury by Tukey’s HSD test.
confirmed that HDAC4 mKO mice exhibited smaller, centrally
nucleated myofibers with respect to HDAC4fl/fl mice (Figure 2B).
Regenerating fiber distribution confirmed that HDAC4 KO
mice displayed a significantly higher number of smaller
regenerating myofibers (400–599 µm2) than HDAC4fl/fl mice, at
the expenses of the larger ones (1000–1199 µm2) (Figure 2C).
Molecular analyses performed at the time of maximal expression
of HDAC4 in regenerating muscles, i.e., 4 days following
injury, corroborated a significant reduction of the expression
of myogenic markers of early, intermediate and terminal
differentiation, i.e., Pax7, MyoD, myogenin and embryonic
MHC, in HDAC4 mKO mice, compared to HDAC4fl/fl mice
(Figure 2D).
To discriminate whether the HDAC4 deletion in skeletal
muscle resulted in delayed or compromised muscle regeneration,
we analyzed regenerating muscles at later time points, 2 weeks
and 1 month after injury. Differences in muscle regeneration
ability persisted between genotypes after 2 weeks and after
1 month following injury, as shown by histological and
morphometrical analyses of regenerating fiber CSA (Figure 3),
indicating that deletion of HDAC4 in skeletal muscle is sufficient
to hamper muscle regeneration.
HDAC4 mKO Muscle Derived Cells
Efficiently Proliferate and Differentiate
in vitro
Because HDAC4 is crucial for muscle stem cell proliferation
and differentiation (Marroncelli et al., 2018), we wondered
whether MDC proliferation and/or differentiation was affected in
HDAC4 mKO mice. MDCs were isolated, and cell proliferation
was assessed by immunofluorescence for Ki-67, a protein
associated with cellular proliferation, after 24 h in growing
condition. HDAC4 mKO MDCs showed a similar amount of
Ki-67 positive cells, and of total MDCs, respect to HDAC4fl/fl
mice (Figures 4A–C). Terminal differentiation was induced and
assessed by immunofluorescence for MHC (Figure 4D). No
significant differences in terminal differentiation were detected
between HDAC4 mKO and HDAC4fl/fl MDCs, as also quantified
by the differentiation (i.e., the number MHC positive cells, over
total nuclei) or the fusion (the number of myonuclei in myotubes,
over total nuclei) indexes (Figure 4E).
These data indicate that deletion of HDAC4, upon myogenin
expression, does not affect MDC proliferation or differentiation,
implying that HDAC4 controls muscle regeneration in vivo via
soluble factors.
HDAC4 mKO Serum Negatively Affects
MDC Proliferation and Differentiation
To prove that HDAC4 affects MDC biology in a cell non-
autonomous manner, HDAC4 mKO and HDAC4fl/fl sera were
withdrawn 4 days following injury, at the time of the HDAC4
maximal expression in skeletal muscle. Control MDCs were
cultured with conditioned media by using HDAC4 mKO or
HDAC4fl/fl sera, and MDC proliferation was evaluated after
24 h in growing condition, by Ki-67 immunofluorescence
(Figure 5A). Quantification of Ki-67-positive cells revealed that
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FIGURE 2 | HDAC4 mKO mice exhibit delayed muscle regeneration. (A) Representative images of HDAC4 mKO and HDAC4fl/fl tibialis anterior regenerating
muscles, 1 week after injury. Scale bar = 50 micron. (B) Regenerating fiber CSA of HDAC4 mKO and HDAC4fl/fl mice, 1 week after injury. Data are presented as
median +/− SEM. n = 8 mice for genotype. ∗p < 0.05 by Student’s t-test. (C) Morphometric analysis of the distribution of regenerating fiber cross-sectional area, 1
week after injury. n = 8 mice for genotype. Data are presented as average +/- SEM. ∗p < 0.05 by Student’s t-test. (D) Gene expression of indicated myogenic
markers in HDAC4 mKO and HDAC4fl/fl mice, by real-time PCR, 4 days following injury. Data are presented as mean +/− SEM. n = 8 mice for genotype. ∗p < 0.05;
∗∗p < 0.005 by Student’s t-test.
HDAC4 mKO sera reduced the MDC proliferating cell number,
compared to HDAC4fl/fl sera (Figure 5B), data also confirmed by
the quantification of the MDCs (Figure 5C).
To investigate if the reduction in MDC proliferation
influences their terminal differentiation, control MDC were
induced to differentiate, by mean of conditioned media
with HDAC4 mKO or HDAC4fl/fl mouse sera, as control.
HDAC4 mKO sera significantly reduced also MDC terminal
differentiation and fusion, as assessed by immunofluorescence
for MHC and quantification of the differentiation and fusion
indexes (Figures 5D,E). Quantification of MDCs, after 3 days
of differentiation, confirmed a significant reduction in the MDC
number upon HDAC4 mKO serum treatment with respect to
controls (Figure 5F). These data demonstrate that HDAC4
mediates the production and release of circulating factors able to
negatively affect MDC proliferation and differentiation.
DISCUSSION
Numerous studies clarified that MDC biology is controlled
by cell-autonomous and non-autonomous cues, as well as by
epigenetic mechanisms (Boonen and Post, 2008; Moresi et al.,
2015). In this study, we investigated which functions HDAC4
plays during muscle regeneration. HDAC4 is a stress-responsive
epigenetic factor known to regulate multiple responses in
skeletal muscle, including satellite cells biology upon injury
(Moresi et al., 2010; Choi et al., 2014; Marroncelli et al.,
2018). We found HDAC4 to be induced to a significant
extent in skeletal muscle upon injury, in line with previous
findings (Choi et al., 2014), with the expression peaking
in the early phases of regeneration, suggesting that HDAC4
mediates skeletal muscle response to injury. To dissect the
HDAC4 biological functions in skeletal muscle, excluding SCs
in the early phases of differentiation, we generated HDAC4
mKO mice, in which HDAC4 deletion occurs upon myogenin
expression. HDAC4 mKO mice do not show skeletal muscle
abnormalities at baseline (Moresi et al., 2010; Pigna et al., 2018).
However, following injury, deletion of HDAC4 in skeletal muscle
significantly hampered muscle regeneration. When HDAC4
deletion occurs in myogenin-positive cells, MDCs efficiently
proliferate and differentiate in vitro, differently from HDAC4
KO SCs, having compromised expansion and differentiation
in a cell-autonomous manner (Choi et al., 2014; Marroncelli
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FIGURE 3 | HDAC4 mKO mice show impaired muscle regeneration. (A) Representative images of HDAC4 mKO and HDAC4fl/fl tibialis anterior regenerating
muscles, 2 weeks after injury. Scale bar = 50 micron. (B) Regenerating fiber CSA of HDAC4 mKO and HDAC4fl/fl mice, 2 weeks after injury. Data are presented as
median +/− SEM. n = 8 mice for genotype. ∗∗p < 0.02 by Student’s t-test. (C) Morphometric analysis of the distribution of regenerating fiber cross-sectional area, 2
weeks after injury. n = 8 mice for genotype. Data are presented as average +/- SEM. ∗p < 0.05 by Student’s t-test. (D) Representative images of HDAC4 mKO and
HDAC4fl/fl tibialis anterior regenerating muscles, 1 month after injury. Scale bar = 50 micron. (E) Regenerating fiber CSA of HDAC4 mKO and HDAC4fl/fl mice, 1
month after injury. n = 8 mice for genotype. Data are presented as median +/− SEM. ∗p < 0.05 by Student’s t-test. (F) Morphometric analysis of the distribution of
regenerating fiber cross-sectional area, 1 month after injury. n = 5 mice for genotype. Data are presented as average +/- SEM. ∗p < 0.05 by Student’s t-test.
et al., 2018). Despite MDC ability to differentiate in vitro,
compromised muscle regeneration in HDAC4 mKO mice
indicates that, in the injured muscle, HDAC4 influences MDCs
behavior, evidencing novel HDAC4 cellular functions depending
on the timing and/or the cell sub-type where this enzyme is
expressed.
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FIGURE 4 | HDAC4 mKO MDCs efficiently proliferate and differentiate in vitro. (A) Representative pictures of immunofluorescence for Ki-67 in HDAC4 mKO and
HDAC4fl/fl MDCs, after 24 h in growth media. Scale bar = 50 µm. (B) Quantification of the proliferating Ki-67+ cells, over the total cell number. Data are presented as
mean +/– SEM. n = 3 mice for genotype. (C) Quantification of HDAC4 mKO and HDAC4fl/fl MDC number, after 24 h in growth media. Data are presented as mean
+/– SEM. n = 3 mice for genotype. (D) Representative pictures of immunofluorescence for MHC in HDAC4 mKO and HDAC4fl/fl MDCs, after 3 days in differentiation
medium. Scale bar = 50 µm. (E) Quantification of the differentiation and fusion indexes of HDAC4 mKO and HDAC4fl/fl MDCs. Data are presented as mean +/–
SEM. n = 3 mice for genotype.
Interestingly, the decrease of the expression level of the
SCs marker Pax7 4 days after injury indicates a deficit
in either SC number or proliferation. The paired box
transcription factor Pax7 is the master regulator of SC
(Seale et al., 2000), required for SC function in adult
skeletal muscle. Indeed, upon Pax7 deletion, SCs exhibit
cell-cycle arrest and dysregulation of MRFs, muscles resulted
smaller and muscle regeneration was severely impaired
(Oustanina et al., 2004; Kuang et al., 2006; Relaix et al.,
2006). Since HDAC4 mKO MDCs were able to proliferate or
differentiate efficiently in vitro, soluble factors likely mediate
the reduction of Pax7 expression in regenerating HDAC4 mKO
muscles.
By using culture media conditioned with sera from injured
HDAC4 mKO or HDAC4fl/fl mice, we proved that HDAC4 does
mediate the secretion of circulating factors able to influence MDC
proliferation and differentiation. Numerous environmental
factors regulate adult myogenesis during regeneration. Growth
factors released from injured myofibers strictly regulate the
activation of quiescent SC (Furuichi and Fujii, 2017). SC
proliferation is supported by mitogens such as FGF and insulin-
like growth factor (IGF), which get up-regulated in skeletal
muscle after injury (Guthridge et al., 1992; Bischoff and Heintz,
1994). Furthermore, activated SCs secrete miRNAs - containing
exosomes, which in turn modulate SC proliferation and
differentiation (Harding and Velleman, 2016). SC differentiation
is strictly influenced by secreted factors as well. For instance,
insulin-like growth factor 1 (IGF1) and interleukin 15 (IL-15)
secretion is induced after membrane damage or during exercise,
these myokines promote SC differentiation and contributes to
muscle hypertrophy by enhancing protein synthesis (DeVol
et al., 1990; Adams, 2002; Quinn et al., 2002; Furmanczyk
and Quinn, 2003). Among soluble factors acting on SC
differentiation, several inflammatory cytokines are known to
inhibit this process. TNF-α and interleukin 1 (IL-1) are
inflammatory mediators of muscle wasting and interfere with
the expression of myogenic factors in differentiating myoblasts,
by activating the nuclear factor – kappa beta (NFkβ) and
caspases (Langen et al., 2001; Moresi et al., 2008, 2009). In
addition to inhibit SC activation and self-renewal, numerous
secreted factors negatively affect also SC differentiation and
fusion, among them myostatin and growth differentiation factor-
11 (GDF11) (TGFβ superfamily’s members) are known to hamper
muscle regeneration by inhibiting SC activity on distinct phases
during myogenesis (Reisz-Porszasz et al., 2003; Egerman et al.,
2015).
HDACs have been shown to regulate soluble factors in
different cell types. In neuronal and glial cells, the release
of brain-derived neurotrophic factor (BDNF) and fibroblast
growth factor 1 (FGF1) is mediated by HDACs (Hossain
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FIGURE 5 | HDAC4 mKO serum negatively affects control MDC proliferation and differentiation. (A) Representative pictures of immunofluorescence for Ki-67 in
control MDCs, after 24 h in conditioned media with sera from either injured HDAC4 mKO or HDAC4fl/fl mice. Scale bar = 50 µm. (B) Quantification of the proliferating
Ki-67+ cells, over the total cell number. Data are presented as mean +/– SEM. n = 6 mice for genotype. ∗p < 0.05 by Student’s t-test. (C) Quantification of MDC
number cultured with sera from either injured HDAC4 mKO or HDAC4fl/fl mice. Data are presented as mean +/– SEM. n = 6 mice for genotype. ∗p < 0.05 by
Student’s t-test. (D) Representative pictures of immunofluorescence for MHC in control MDCs cultured with conditioned media with sera from either HDAC4 mKO or
HDAC4fl/fl injured mice, after 3 days in differentiation medium. Scale bar = 100 µm. (E) Quantification of the differentiation and fusion indexes of control MDCs
cultured with sera from either injured HDAC4 mKO or HDAC4fl/fl mice, after 3 days in differentiation medium. Data are presented as mean +/– SEM. n = 6 mice for
genotype. ∗∗p < 0.005 by Student’s t-test. (F) Number of control MDCs cultured with sera from either injured HDAC4 mKO or HDAC4fl/fl mice, after 3 days in
differentiation medium. Data are presented as mean +/– SEM. n = 6 mice for genotype. ∗∗p < 0.005 by Student’s t-test.
et al., 2018), as well as in fibroblasts the production of
several proinflammatory cytokines/chemokines (Li et al., 2011),
thus contributing to chronic inflammatory processes. Moreover,
HDACs modulate IL-4 expression and secretion in mast cells
and monocyte-derived DCs (moDCs) (López-Bravo et al.,
2013; Nakamaru et al., 2015). In addition to its classical
roles, new evidence links HDACs and soluble factors. For
instance, cytoplasmic protein acetylation/deacetylation balance
has been involved in extracellular vesicles content and release
in colon cancer cells (Li et al., 2016; Chao et al., 2017).
In skeletal muscle, the expression of several soluble factors,
such as TGF-β and follistatin, are modulated by HDAC4
during myogenesis (Sun et al., 2010; Winbanks et al., 2011).
Moreover, HDAC4 promotes skeletal muscle reinnervation
via the release of FGF binding protein 1 (Williams et al.,
2009).
A preclinical study in a murine Duchenne Muscular
Dystrophy model demonstrated that Givinostat, a class I and
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II HDAC inhibitor, improves skeletal muscle regeneration by
reducing fibrotic and adipose tissues (Mozzetta et al., 2013).
Similarly, trichostatin A (TSA), another class I-II HDAC
inhibitor, promotes skeletal muscle regeneration by targeting
fibro-adipogenic cells and inducing the expression and the release
of follistatin, a pro-myogenic soluble factor identified as a central
mediator in myoblast recruitment and fusion (Iezzi et al., 2004;
Mozzetta et al., 2013). Our results are in apparent contrast
with the findings of previous studies obtained by administering
HDAC inhibitors during muscle regeneration. However, different
experimental conditions could reconcile such discrepancy. In
those studies, muscle regeneration was improved by daily
systemic administration of class I and II HDAC inhibitors after
injury, which is different from our study exploiting HDAC4
mKO mice, a tissue-specific KO mouse bringing the genetic
deletion at embryonic stage E8.5 of one member of the class IIa
HDACs.
CONCLUSION
The present study sheds further light on multiple HDAC4
functions in skeletal muscle following injury stress. HDAC4
not only promotes SC replenishment and differentiation in
a cell-autonomous manner via the epigenetic regulation of
gene transcription but also influences MDC proliferation and
differentiation via muscle derived-soluble factors. These findings
should be considered when administering class I-II HDAC
inhibitors to treat muscular diseases.
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Blood flow restriction (BFR) combined with low-intensity strength training has been
shown to increase skeletal muscle mass and strength in a variety of populations. BFR
results in a robust metabolic stress which is hypothesized to induce muscle growth
via increased recruitment of fast-twitch muscle fibers, a greater endocrine response,
and/or enhancing the cellular swelling contribution to the hypertrophic process. Following
exercise, neutrophils are the first immune cells to initiate the tissue remodeling process
via several mechanisms including an increased production of cytokines and recruitment
of monocytes/macrophages, which facilitate the phagocytosis of foreign particles, the
differentiation of myoblasts, and the formation of new myotubes. Thus, the purpose of
this review was to discuss the mechanisms through which metabolic stress and immune
cell recruitment may induce skeletal muscle remodeling following BFR strength training.
Keywords: immune cell, occlusion, hypertrophy, resistance exercise, KAATSU training
INTRODUCTION
Strength training has been the classically employed exercise program to increase skeletal muscle
hypertrophy and strength. TheAmerican College of Sports Medicine (Evetovich, 2009) recommends
strength training with intensities over 70% of the one repetition maximum (1RM) to increase
muscle mass, and several studies have shown that intensities in excess of 70% 1RM greater stimulate
muscle protein synthesis, satellite cell activity, and decrease proteolysis when compared to low-
intensity resistance exercise (Harridge, 2007; Louis et al., 2007). There is a growing body of
evidence, however, that lower-intensity strength training induces similar degrees of muscle protein
synthesis acutely (Burd et al., 2010, 2012) and muscle hypertrophy chronically (Schoenfeld et al.,
2016) when sets are carried out to muscular failure. Although heavier loading seems necessary to
maximize muscular strength development (Peterson et al., 2005), high-intensity loads performed
in traditional strength training programs may not be a viable option for sarcopenic populations,
older individuals with chronic health problems, or individuals with injuries who may be unable to
tolerate heavy loading.
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Blood flow restriction (BFR), also known as occlusion or
KAATSU training (Abe et al., 2005), combined with low-intensity
strength training (20–30% 1RM) has been shown to increase
muscle size and strength in the elderly (Libardi et al., 2015),
athletes (Takarada et al., 2002), untrained (Clark et al., 2011), and
people with injuries (Loenneke et al., 2013). This training model
requires the use of inflatable cuffs that are placed at the proximal
ends of the upper arms or thighs to restrict blood flow, whereby
the external pressure applied is sufficient to maintain arterial
inflow whilst occluding venous outflow distal to the occlusion
site (Kaijser et al., 1990), thus resulting in an ischemic/hypoxic
environment that enhances the training effect in exercising
muscle (Takada et al., 2012).
Several studies have compared low-intensity strength training
with BFR and high-intensity strength training without BFR
and demonstrated similar increases in muscle cross-section area
between exercise protocols (Ellefsen et al., 2015; Farup et al.,
2015; Libardi et al., 2015), however, the mechanisms responsible
for such effects are still poorly understood. Mechanical tension
and metabolic stress are suggested to be the factors primarily
responsible for hypertrophic adaptations following BFR training
(Pearson and Hussain, 2015).
Themechanisms by whichmechanical tension inducesmuscle
hypertrophy include mechanotransduction, where sarcolemmal-
bound mechanosensors (i.e., integrins) stimulate intracellular
anabolic and catabolic pathways which convert mechanical
energy into chemical signals promoting protein synthesis instead
of degradation (Zou et al., 2011). Exercise-induced muscle
damage can be influenced by an increase in the volume, velocity,
initial muscle length, or the intensity of the exercise. These
stimuli can result in an overstretching of the sarcomere to
such an extent that it becomes disrupted, resulting in z-disk
damage and eventually a disruption of the cytoskeletal matrix
(Proske and Morgan, 2001). This may promote activation of
the stretch-activated calcium channels or transient receptor
potential channels (Allen et al., 2005). Consequently, cytokines
are released and there is an immune system activation, directing
the local satellite cells to the site of muscle damage and initiating
the phagocytosis of debris and tissue remodeling (Tidball and
Villalta, 2010).
In contrast to the muscle damage that occurs as a result of
traditional strength training, a review conducted by Loenneke
et al. (2014a) does not support the hypothesis that BFR training
increases the incidence of muscle damage. Sudo et al. (2015)
verified muscle fiber damage following high-intensity eccentric
contractions and BFR plus eccentric contractions in male Wistar
rats with different levels of occlusion pressure (140, 160, and
200 Torr). Despite BFR increased Ribosomal S6 kinase 1 (S6K1)
phosphorylation, a downstream target of rapamycin (mTOR)-
phosphorylation kinase, there was nomeasurable muscle damage
for any of the three different pressures (2.6± 1.2%), (3.0± 0.5%),
(0.2 ± 0.1%), respectively, compared to high-intensity (26.4
± 4.0%) when verified the histochemical muscle fiber damage
(area of damaged fibers/total fiber area analyzed). In humans,
Neto et al. (2018) compared low-load resistance exercise (20%
1RM) plus continuous or intermittent BFR and high-intensity
resistance exercise (80% 1RM) and observed higher creatine
kinase and lactate dehydrogenase after high-intensity compared
with both continuous or intermittent exercise with BFR 24 and
48 h post-exercise. In addition, Wilson et al. (2013) demonstrated
significantly increases muscle activation and muscle thickness,
but no changes in muscle soreness, power, and muscle swelling
after 4 sets of leg press (30-15-15-15-repetition at 30% 1 RM)
in trained men. Collectively, this research refutes the muscle
damage hypothesis post-BFR training.
In this sense, the metabolic stress during BFR as a result of
the ischemic/hypoxic environment seems to be the prevailing
mechanism whereyby BFR could potentiate hypertrophy during
low-intensity strength training. Metabolic stress and/or hypoxia
may leads to an increased recruitment of fast-twitch muscle
fibers (Suga et al., 2009), increased inflammatory and endocrine
response (Fujita et al., 2007), cellular swelling (Loenneke et al.,
2013), and elevated intramuscular inorganic phosphates (Takada
et al., 2012), all of which have been shownmediatemuscle protein
signaling and satellite cell proliferation (Figure 1).
Hypoxia-inducible factor-1 alpha (HIF-1α) activation
contributes to an increased expression of angiogenic factors,
vascular endothelial growth factor (VEGF), endothelial nitric
oxide synthase (eNOS) (Larkin et al., 2012), and monocyte
chemotactic protein-1 (MCP-1). Warren et al. (2004) used a
freeze injury model to evaluate muscle repair and inflammation
in mice and observed a significant importance for MCP-1,
macrophage inflammatory protein (MIP)-1alpha, MIP-1beta,
and monocyte chemoattractant protein during muscle repair.
Mice that were null mutants for MCP-1 were found to have
a slowed recovery from muscle injury compared to wild-type
animals as assessed by muscle force production. Shill et al.
(2017) observed that BFR using unilateral isometric wrist
exercise increased concentrations of fibroblast growth factor,
FIGURE 1 | The role of metabolic stress (H+, Pi, Lactate) leading to anabolic
signaling (hormonal release, hypoxia, cell swelling, ROS production) and
inflammatory response induced by blood flow restriction training for enhancing
muscle adaptations.
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IL-6, IL-10, TNFα, and VEGF during exercise and reduced
the percentage of oxygen saturation, demonstrating that the
hypoxic environment generated during BFR was associated with
a heightened inflammatory cytokine production.
Thus, as hypothesized by Pearson and Hussain (2015), both
mechanical tension and metabolic stress would synergistically
contribute to the hypertrophic adaptations of BFR strength
training, with metabolic stress playing the dominant role.
Although the efficacy of BFR strength training to induce
skeletal muscle hypertrophy has been well demonstrated in the
literature (Loenneke and Pujol, 2009; Patterson and Ferguson,
2011; Takada et al., 2012; Loenneke et al., 2013; Pope et al.,
2013), the mechanism by which BFR results in an inflammatory
response and immune cell recruitment is still poorly understood.
Therefore, the purpose of this review is to discuss the relationship
between metabolic stress and immune cell recruitment in skeletal
muscle remodeling following BFR strength training.
THE INFLAMMATORY RESPONSE DURING
BLOOD FLOW RESTRICTION TRAINING:
POTENTIAL MECHANISMS
The stress induced by exercise results in an inflammatory
response mediated by an increase in myokine production, which
are one of several hundred cytokines and proteoglycan peptides
that are produced and released by muscle cells (myocytes) in
response to muscular contractions (Giudice and Taylor, 2017).
Myokines, specifically IL-6, play a role in skeletal muscle tissue
regeneration after damaging exercise, in part by participating
in the recruitment of neutrophil, monocytes, and lymphocytes,
which phagocytize debris materials (Vannella and Wynn, 2017).
In addition, IL-6 also contributes to the activation, differentiation
and proliferation of satellite cells, which migrate and fuse to
the spaces where muscle fiber damage occurred and contribute
new myonuclei (Serrano et al., 2008). Recently, Gao et al. (2017)
investigated the influence of IL-6 on mTORC1 signaling and
protein synthesis in cultured myotubes. It was observed that
IL-6 can increase protein synthesis by activating the gp130-Akt
and mTORC1 pathway in a dose-sensitive manner, suggesting
that the IL-6 response to resistance exercise potentiates muscle
hypertrophy.
Regarding the influence of BFR on the inflammatory response,
Patterson and Ferguson (2011) compared the effects of BFR (five
sets of unilateral knee extensions with 20% 1-RM and 30-s rest
between each set) with low-load resistance exercise without BFR
older men. The authors observed that both conditions increased
serum IL-6 at 60 and 120min post-exercise, but GH and VEGF
only increased following the BFR condition. Takarada et al.
(2000) also compared the IL-6 response after BFR using five
sets of 14 repetitions at 20% of 1-RM vs. the same exercise
protocol without occlusion (control). The results showed that
plasma IL-6, lactate, GH and norepinephrine was greater in BFR
than the control condition without any increase in CK activity
24 h post-exercise in either condition, suggesting that BFR may
induce a higher metabolic stress (accumulation of lactate) and
hormonal response without apparent markers of muscle damage.
Supporting this, Nielsen et al. (2017) showed that short-term
BFR (unilateral knee extensor exercise to failure at 20% 1-
RM) generated modest increases in the inflammatory responses
(MCP-1, IL-6, and TNF-α) with lower muscle damage.
According to these findings it appears that the early increase in
IL-6 in response to BFR may be in part due to a greater metabolic
stress more so than muscle damage. Studies consistently
demonstrate that BFR generates a high concentration of lactate
accumulation, H+, and a significant decrease in intramuscular
pH, suggesting that BFR is highly reliant on rapid glycolytic
metabolism (Takarada et al., 2000; Suga et al., 2009, 2012).
Previous studies also reported an association between anaerobic
metabolism and an increase in the production of inflammatory
cytokines (Pedersen and Febbraio, 2005). Additionally, the
reduction of muscle glycogen during exercise seems to potentiate
the IL-6 response (Pedersen and Febbraio, 2005), and acute
ischemic exercise induced by BFR results in a higher degree of
glycogen depletion of type II fibers compared with non-ischaemic
exercise (Sundberg, 1994). In this context, the increased IL-6
response by BFR may be explained by the predominance of
anaerobic glycolytic metabolism and glycogen depletion.
Another possible driver of the IL-6 response during BFR could
be attributed to intramuscular hypoxia. It has been reported
that BFR decreases muscle oxygenation, generating a hypoxic
environment (Karabulut et al., 2011; Ganesan et al., 2015)
leading to a robust activation of HIF-1α. Several studies have
demonstrated that HIF-1α has the potential to increase pro-
inflammatory gene expression, such as IL-6 and TNF-α, via
increasing nuclear factor kappa B (NF-kB) translocation to the
cell nucleus (Van Uden et al., 2008; Oliver et al., 2009; Szade
et al., 2015). An increased expression of HIF-1α has also been
associated with a high production of inflammatory cytokines (IL-
6 and TNF-α). Leire et al. (2013) reported that when cell cultures
were treated with AKB-4924, an activator of HIF-1α, IL-6 levels
significantly increased, demonstrating the influence of HIF-1α
on IL-6 production. In support of this hypothesis, Drummond
et al. (2008) found that bilateral knee extension exercise with
BFR (4 sets of 30, 15, 15, 15 repetition at 20% of 1RM, with
30 s rest period) increased HIF-1α gene expression. Shill et al.
(2017) observed that BFR using unilateral isometric wrist exercise
increased concentrations of fibroblast growth factor, IL-6, IL-
10, TNFα, and VEGF and reduced the percentage of oxygen
saturation, demonstrating a link between the BFR induced
hypoxic environment and cytokine production (Figure 2).
In summary, studies have demonstrated that BFR increases
the IL-6 concentrations absent of significant muscle damage,
suggesting that other mechanisms likely regulates the IL-6
response to BFR. It seems that the metabolic stress associated
with glycogen depletion and hypoxia could be a potential
mechanism bywhich BFRmodulates the acute immune response.
NEUTROPHIL AND MACROPHAGE
RESPONSE TO RESISTANCE EXERCISE
Multiple immune cell types play a critical role in muscle repair,
regeneration and remodeling following exercise. Neutrophils,
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FIGURE 2 | The inflammatory response during blood flow restriction plus
low-intensity strength training.
macrophages and T cells seem to be the first immune cells to
initiate the recovery process following exercise-induced muscle
damage. Neutrophils constitute 60% of the circulating leukocytes
and are the most abundant cellular component of the human
immune system, with a total number of approximately 5 × 1011
cells in a 70 kg individual (Pyne, 1994). It has been suggested
(Pyne, 1994) that neutrophil recruitment is an essential role in
the initial stages of muscle repair and regeneration after exercise,
as neutrophils act to clear cellular debris via the release of
proteolytic enzymes for several hours after exercise.
Neutrophils accumulation in skeletal muscle likely starts
immediately after exercise, as Frenette et al. (2000) showed a
60% increase in neutrophil invasion 2 h after muscle injury.
Previous studies demonstrated neutrophil accumulation in the
blood vessels of skeletal muscle occurs after 1 and 24 h after
eccentric exercise (Raastad et al., 2003; Paulsen et al., 2010),
and histological studies have demonstrated that after 24–48 h
of exercise, there is an increase of leukocytes infiltratation in
the extracellular space within the muscle (Hellsten et al., 1997;
Paulsen et al., 2010). Animal studies have also demonstrated
a clear influence of neutrophils on muscle regeneration after
exercise, as depletion of neutrophils in mice before muscle
injury impairs skeletal muscle regeneration, likely as a result of
a reduced capacity to remove tissue debris by phagocytes that
slowed regenerative process (Teixeira et al., 2003).
After the acute neutrophil accumulation, macrophages, a
subpopulation of leukocytes, infiltrate the muscle and play
an important role in the later stages of muscle repair and
regeneration. The monocytes/macrophages are attracted in
skeletal muscle tissue by chemotactic factors such as fractalkine
(CX3CL1) and monocyte chemotactic protein-1 (MCP-1),
contributing to skeletal muscle repair by phagocytosis of foreign
particles, secreting pro-inflammatory cytokines (e.g., TNFα and
IL-6) and stimulating satellite cell proliferation (Peake and
Neubauer, 2017). Previous studies report that the increase in
macrophages in human skeletal muscle occurred at later time
points in recovery, around at 48 h to 7 days after exercise (Jones
et al., 1986; Marklund et al., 2013). It has been demonstrated
that macrophages play a critical role for muscle regeneration,
as inhibiting the recruitment of monocytes to injured muscles
impairs muscle regeneration (Lu et al., 1998). Warren et al.
(2004) used a freeze injury model to evaluate muscle repair and
inflammation in mice and observed a significant importance
for MCP-1 and macrophage recruitment to potentiate skeletal
muscle regeneration. Mice that were null mutants for Chemokine
Receptor 5 (CCR5) and MCP-1 were found to have slowed
recovery from muscle injury compared to wild-type animals as
assessed by muscle force production as an index of recovery.
Additionally, both macrophages and neutrophils appear
to mediate muscle hypertrophy by the secretion of pro-
inflammatory cytokines (IL-6 and TNFα), leading to anabolic
signaling through a pathway that phosphorylates mTORC1
(Schoenfeld et al., 2016). It has been demonstrated that the
production of ROS may stimulate anabolic signaling, as ROS
can act with a signaling molecule to activate mTORC1 signaling
via the IGF-1 and MAPK pathways (Kefaloyianni et al., 2006;
Handayaningsih et al., 2011). In addition, neutrophils and
macrophages can release growth factors such as insulin-like
growth factor (IGF-1), basic Fibroblast Growth Factor (bFGF),
Transforming Growth Factor (TGF), and Mechano Growth
Factor (MGF), and these factors contribute to the muscle
regeneration and hypertrophic response by activating satellite
cells and mTORC1 signaling (Jiang et al., 1992; Cantini et al.,
2002; Koh and Pizza, 2009; Zanou and Gailly, 2013; Figure 3).
NEUTROPHIL AND MACROPHAGE
RESPONSE TO BLOOD FLOW
RESTRICTION EXERCISE
After traditional resistance exercise there is an increase in
neutrophils (Macintyre et al., 2000; Simonson and Jackson, 2004)
and macrophages (Malm et al., 1999); however, the influence
of BFR on the immune cell response is less discussed in the
literature. Nielsen et al. (2017) investigated the effect of 3 weeks
of BFR training (20%-1RM to concentric failure) compared to
work-matched traditional resistance training performed at low
(20%-1RM) or high-intensities (HI; 70%-1RM) and observed
that proinflammatory macrophages (M1) increased 108% with
BFR training and 165% with low intensity strength training
3 days after training cessation. Additionally, anti-inflammatory
phenotype (M2) increased 163% only with BFR training.
Membrane and intracellular HSP27 expression increased 60-
132% at 8 days into the intervention with BFR. The authors
concluded that signs of myocellular stress were observed in
the early phase of the training intervention with inflammation
occurring after the training program. Thus, this research furthers
the hypothesis that the macrophage response to BFR training
occurs due to a heightened inflammation response but is likely
not related to muscle damage.
Regarding neutrophils, Behringer et al. (2017) investigated
the effects of moderate-intensity (four sets at 75% of 1RM until
volitional failure) eccentric knee extensions with BFR (20mmHg)
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FIGURE 3 | Relationship between inflammatory, neutrophil, and macrophage in the remodeling of skeletal muscle mass induced by blood flow restriction plus
strength training.
TABLE 1 | Effect of blood flow restriction plus low-intensity strength training on the inflammatory response.
Author (year) Aim Results
Takarada et al., 2000 Compared the IL-6 response after BFR using five sets of 14 repetitions at 20% of
1-RM vs. the same exercise protocol without occlusion (control)
↑ IL-6, lactate, GH, and norepinephrine in BFR condition
↔ Creatine kinase in both conditions
Patterson and
Ferguson, 2011
Compared the effects of BFR (five sets of unilateral knee extensions with 20%
1-RM and 30-s rest between each set) with low-load resistance exercise without
BFR on the inflammatory response
↑ IL-6 in both conditions
↑ GH and VEGF only in BFR condition
Nielsen et al., 2017 Investigated the effect of 3 weeks of BFR training (20%-1RM to concentric
failure) compared to two groups that performed a matched amount of work at
low (20%-1RM) or high-intensities (HI; 70%-1RM)
↑ macrophages (M1) in BFR and low intensity training
conditions
↑ macrophage (M2) only in BFR condition
↑ HSP27 expression only in BFR condition
↔ L-6, TNF-α, and MCP-1 in BFR condition
↑ CK only in HI condition
Behringer et al., 2017 Investigated the effects of moderate-intensity (four sets at 75% of 1RM until
volitional failure) eccentric knee extensions with BFR (20 mmHg) and without
(control) on blood lactate, hormonal response, muscle swelling, biomarkers of
muscle damage and neutrophil counts
↓ volume in BFR compared with control condition
↑ neutrophil counts, lactate muscle swelling, GH, and
CK in both conditions
↑, significant increased; ↓, significant decreased; ↔ , no changed.
and without on blood lactate, endocrine response, muscle
swelling, biomarkers of muscle damage, and neutrophil counts.
The results showed that the total number of repetitions was lower
in BFR compared with the control condition, however, despite a
lower volume, BFR induced a similar increase in metabolic stress
(lactate), muscle swelling, plasma GH, creatine kinase (CK), and
neutrophil counts. The authors suggested that the lower oxygen
supply during BFR may have led to a greater metabolic stress and
membrane damage due reactive oxygen species (ROS) from an
ischemia–reperfusion sequence or by invading neutrophils. The
higher intensity (75% 1RM vs. 20-30% 1RM) and lower occlusion
pressure may explain the discrepancies in markers of muscle
damage found in this study compared to other BFR studies.
The mechanism by which macrophages and neutrophils are
recruited to skeletal muscle after BFR is not fully understood,
but can be partially attributed to transcription factors such
as HIF-1α that respond to decreases in available oxygen at
the cellular level (Drummond et al., 2008). Leire et al. (2013)
investigated the role of AKB-4924, an activator of HIF-1α, on
neutrophil recruitment in mice. The results showed that AKB-
4924 increased the recruitment of neutrophils to the site of
inflammation induced by lipopolysaccharide (LPS) injection.
When a high dose (5 µg) of LPS was injected in HIF-1α knockout
mice, neutrophil recruitment to the injury site was reduced
compared with control mice. HIF-1α activation via hypoxia
contributes to increased expression of MCP-1 (also known as
CCL2) (Larkin et al., 2012), which is a chemokine with potent
macrophage recruitment and activating functions (Lu et al., 1998;
Chazaud et al., 2003). Roseguini et al. (2010) demonstrated that
intermittent pneumatic compressions, a method conceptually
similar to BFR, increases skeletal muscle MCP-1 expression in
rats. It is likely the myocellular macrophage infiltration after BFR
as demonstrated by Nielsen et al. (2017) may be explained by
increased MCP-1 in skeletal muscle via HIF-1 activation. Thus,
activation of HIF-1α may be one potential mechanism that BFR
increases neutrophil and macrophage response.
BFR training increases the IL-6 production, which may
also induce the recruitment of immune cells (Takarada
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et al., 2000; Patterson and Ferguson, 2011; Nielsen et al.,
2017), and in particular, neutrophils. Fielding et al. (2008)
showed that mice with alterations in IL-6/gp130 signaling
by the knockout of IL-6 receptor (gp130) decreased the
rate of neutrophil trafficking during acute inflammation. In
addition, the researchers demonstrated that IL-6 can regulate
neutrophil trafficking in a STAT3 dependent-manner. Therefore,
increasing IL-6 levels via BFR training could increase neutrophil
recruitment for skeletal muscle remodeling.
Another mechanism whereby BFR may increase the
recruitment of neutrophils without inducing muscle damage
may be attributed to catecholamine release, specifically
norepinephrine. Takarada et al. (2000) demonstrated that a
BFR protocol using five sets at 20% of 1-RM and 14 repetitions
induced greater norepinephrine production compared with
the same exercise protocol without occlusion. Shimizu et al.
(2016) compared the influence of BFR (3 sets at 20% of
1RM with 30 s of rest interval) vs. resistance exercise without
occlusion (control) on the endocrine response in healthy
elderly people. It was observed that BFR generated a higher
production of norepinephrine as well as lactate, VEGF and
GH compared with the control condition. Previous studies
showed that noradrenaline may act as “danger signals” during
fatiguing exercise, thereby increasing neutrophil activation
and function. Hinchado et al. (2012) found that after exercise
when neutrophils were incubated with norepinephrine there
was an increase of chemotaxis, phagocytosis and microbicide
capacity, demonstrating an improved neutrophil function. These
findings may explain in part the increase of neutrophils counts
induced by BRF (Behringer et al., 2017), as norepinephrine
seems to play a significant role in neutrophil function and
activation.
The immune system appears to act in a straightforward
manner to contribute to the plasticity of skeletal muscle tissue via
the phagocytosis of foreign particles and increasing inflammation
by releasing cytokines that stimulate further infiltration of
immune cells in an attempt to repair and regenerate damaged
tissues. We believe that hypoxia, metabolic mediators, and
IL-6 mediated by BFR during low-intensity strength training
could be important factors to potentiate the macrophage and
neutrophil recruitment contributing to improvement skeletal
muscle remodeling; however, there are few studies in the
literature investigating the effects of BFR training on immune
cells response according showed at Table 1. Therefore, future
studies should be conducted to better understand the immune
system response during acute and chronic BFR training, and to
further investigate how BFR may be employed as an appropriate
treatment in muscle wasting disorders characterized by chronic
low-grade inflammation.
FUTURE PERSPECTIVE
The immune system is virtually involved in every repair and
regeneration response in skeletal muscle cells. However, the
immune system is not activated only in response to conditions
of muscle damage, but also in response to muscle contractions,
with muscle metabolites and substrates utilization being major
drivers of such response. At the moment, several studies that
demonstrate minimal to no muscle damage following BFR
contractions refute the muscle damage hypothesis (Wilson et al.,
2013; Loenneke et al., 2014b; Sudo et al., 2015). However, a
certain degree of caution should be taken when interpreting
this data since signs of muscle damage may occur in the
absence of either soreness, reduced force production, and/or
increased plasma CK. Nevertheless, infiltration of immune
cells in the muscle is seen after a BFR exercisewhich poses
the question of, mechanistically, who is directing immune
cells to the muscle and what tasks they are performing,
since there does not appear to be any measurable muscle
damage. In regards to “who” is recruiting immune cells to the
skeletal muscle, a multitude of mechanisms may exist, from
cytokines secreted by the contracting muscle to activation of
transcription factors activating chemotactic proteins (Giudice
and Taylor, 2017; Vannella and Wynn, 2017), both of which
are reinforced by muscle hypoxia. The question of “what
task” they are performing may be more related to muscle
remodeling, since BFR is a potent method to induce muscle
hypertrophy, and, in fact, the studies which show a robust
infiltration of immune cells to the muscle are the studies
reporting robust muscle hypertrophy in short periods of
time (i.e., 19 days) (Nielsen et al., 2012). Although classical
hypertrophic pathways, such as mTOR, have been shown to
be activated by BFR, non-canonical activations via growth
factors secreted by the immune cells may reinforce the intrinsic
muscle contraction effects on signaling pathways. Such cell
signaling activation can lead to increased protein synthesis
and muscle hypertrophy. In this case, multiple pathways and
modus operandis may be coordinately working to produce
muscle hypertrophy and immune system activation. The
question remains: If there is no muscle damage, then what is
triggering the immune system to work so hard in the BFR
paradigm?
CONCLUSION
Skeletal muscle hypertrophy is an important goal for individuals
pursuing both athletic or rehabilitative gains. With this goal in
mind, new strategies have been employed to investigate varying
cell signaling pathways, cellular types, and hormonal triggers, and
which seem to be activated via tension or metabolic overload.
Traditionally, exercises involving muscle damage are well known
activators of muscle satellite cells, pro-inflammatory cytokines,
and immune cells. However, the recent literature has pointed
out that metabolic stimuli (induced by resistance training plus
BFR) such as hypoxia and metabolic overload (H+, Pi, lactate
accumulation) are also potential activators of IL-6, macrophages
and neutrophils. Taken collectively, these anabolic stimuli could
help to explain the effectiveness of suchmethods in the absence of
high mechanical forces and muscle damage. Mechanistic studies
will help to dissect the importance of each variable in the role
of the metabolic response, thus strengthening the concept that
BFR exercises, although characterized as low force exercises, are
effective not only to increase the MPS response, but also the
multitude of immune cell responses that accompanies muscle
hypertrophy.
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Vasopressin (arg8-vasopressin) and oxytocin are closely related nonapeptide
hormones, synthesized as pre-hormones in the magnocellular neurons of the paraventricular
and supraoptic nuclei of the hypothalamus. Vasopressin and oxytocin are secreted in response to a
variety of physiological stimuli, serving such different functions as controlling water balance, milk
ejection, uterine contraction, mood, and parental behavior (Lechan and Toni, 2000; Costa et al.,
2014a).
MUSCLE AS A TARGET OF NEUROHYPOPHYSEAL HORMONES
Skeletal muscle or myogenic precursors have never been considered, until recently, as targets
of neurohypophyseal hormones. However, very early evidence was provided by Wakelam and
collaborators, who showed some mild effects of vasopressin on carbohydrate metabolism in
myoblasts (Wakelam and Pette, 1982; Wakelam et al., 1987). These initial observations were
corroborated by later studies showing that stimulation of primary chick embryo myoblasts or
murine L6 and L5 myogenic cell lines with vasopressin, oxytocin, their analogs and antagonists
resulted in the structure- and concentration-dependent activation of phospholipase C (PLC)
signaling, the stimulation ofmyogenic differentiation, and the hypertrophy of newly formedmuscle
fibers (Teti et al., 1993; Nervi et al., 1995). Worth noting, PLC activates Protein Kinase C family
members, among which the theta isoform plays an important role in both muscle differentiation
and disease (Marrocco et al., 2014, 2017; Lozanoska-Ochser et al., 2018). The potent pro-myogenic
effect of vasopressin was further characterized in myogenic cells cultured in a serum-free medium,
a “clean” experimental model that allowed us to establish that L6 myogenic cells express the
vasopressin V1a receptor (V1a-R) and that vasopressin elicits a complex signal transduction
response in these cells (Minotti et al., 1998; Scicchitano, 2002, 2005; Naro et al., 2003; Toschi et al.,
2011; Costa et al., 2014b). Moreover, it was found that V1a-R expression is modulated during the
differentiation of L6 cells, probably in a post-translational manner (Alvisi et al., 2008).
Studies from other laboratories highlighted the presence of functional oxytocin receptors
(OT-R) in humanmyoblasts derived from postnatal satellite cells (Breton et al., 2002), and in C2C12
myogenic cells which respond to oxytocin by activating the calcium–CaMKK–AMPK pathway (Lee
et al., 2008). A recent in vitro study showed that C2C12 myoblasts express not only OT-R but also
oxytocin and that the expression of both products increases upon myogenic differentiation of the
cells (Berio et al., 2017). Furthermore, myotubes treated with 17β-estradiol overexpress oxytocin
and OT-R genes by approximately 3- and 29-fold, respectively (Berio et al., 2017).
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While cell cultures provide useful models to define, under
controlled conditions, the effects of vasopressin or oxytocin
on myogenic differentiation at the molecular level, in vivo
data support the idea that both neurohypophyseal hormones
play physiological roles in skeletal muscle. Indeed, a role for
neurohypophyseal hormones in prenatal muscle development
was first suggested by the presence of immunoreactive
vasopressin in human fetal and neonatal skeletal muscle
(Smith et al., 1992). Moreover, a >120-fold increase in oxytocin
expression was observed in bovine muscle during early to
mid-fetal calf development, coincident with active myofiber
formation (De Jager et al., 2011), findings in keeping with the
above reported in vitro data.
In an in vivo murine experimental model, we reported that
V1a-R expression, measurable under basal conditions in muscle,
was strongly up-regulated in the early phase of regeneration
(9 h after injury) and gradually decreased in the following days,
along with the regeneration process. In this model, vasopressin
administration promoted muscle regeneration. Furthermore,
overexpression of V1a-R in muscle sufficed to dramatically
enhance post-injury muscle regeneration, without administering
exogenous vasopressin (Toschi et al., 2011). In an in vivo
mouse model of tumor necrosis factor (TNF)-inhibited muscle
regeneration, the administration of vasopressin rescued the
inhibitory effect of TNF, likely through a mechanism involving
themodulation of HSP70 levels (Moresi et al., 2009). Again, TNF-
mediated muscle atrophy was rescued by the overexpression of
the V1a-R in vivo (Costa et al., 2014b).
Altogether, the in vivo evidence supports the notion that both
vasopressin and oxytocin have potent effects, in the development,
regeneration and homeostasis of skeletal muscle.
Further insights came from studies conducted in aged mice
(Elabd et al., 2014). The authors focused on the reduced
muscle regeneration and muscle atrophy (sarcopenia) occurring
in aging. While it is known that aging is accompanied by
reduced physiological levels of sex steroids, the authors found
that circulating oxytocin level is also reduced. Interestingly,
satellite cells from aged animals exhibited a significantly lower
OT-R expression than those from young animals. Moreover,
comparing young and aged mice treated with an oxytocin
selective antagonist or with exogenous oxytocin, respectively,
the authors demonstrated that oxytocin is required for efficient
muscle regeneration (Elabd et al., 2014). The impaired muscle
regeneration of aged mice was shown to depend primarily
upon reduced proliferation of satellite cells, a phenomenon
rescued by exogenous oxytocin administration. The oxytocin
effect on satellite cell proliferation was reported to be mediated
by the MAPK/ERK pathway (Elabd et al., 2014). In line
with the above findings, muscle regeneration in oxytocin
KO mice was severely compromised. Young oxytocin KO
mice displayed a premature decline in muscle regeneration,
as well as muscle fibrosis and fat infiltration, showing a
muscle phenotype characteristic of sarcopenia (Elabd et al.,
2014).
Therefore, both neurohypophyseal hormones appear to
regulate positively muscle homeostasis in different models:
oxytocin, in the aging and KOmouse models (Elabd et al., 2014);
and vasopressin, in injured muscle or TNF-induced muscle
wasting (Moresi et al., 2009; Toschi et al., 2011; Costa et al.,
2014b).
The apparent overlapping between the observed effects of the
two neurohypophyseal hormones in the regulation of muscle
differentiation and trophism may depend on the fact that both
V1a-R and OT-R cross-bind their ligands, albeit with different
affinities (Barberis et al., 1998; Gupta et al., 2008). Furthermore,
the results obtained in the myogenic L6 cell line used as
an experimental tool to show the effect of neurohypophyseal
hormones probably depend on a peculiar expression of the
receptors for these hormones, in comparison to other myogenic
cell types.
MUSCLE TISSUE AS A SOURCE OF
VASOPRESSIN AND OXYTOCIN
Interestingly, the possibility that myogenic cells express one of
the neurohypophyseal hormones, as suggested by the pioneering
results of Smith in prenatal human muscle for vasopressin
(Smith et al., 1992), was recently proposed again (Berio
et al., 2017), with regard to oxytocin and OT-R. Based on
these observations, muscle can thus be added to the list of
previously unrecognized sites of oxytocin expression, such
as testes, ovaries, heart and lungs (Assinder et al., 2000;
Jankowski et al., 2004; Kiss and Mikkelsen, 2005; Gutkowska
and Jankowski, 2012). Further results supporting this hypothesis,
were obtained in studies aimed to investigate the mechanisms
triggered by the administration of steroids used to increase
muscle mass in livestock farming. Cattle regularly treated with
anabolizing agents displayed dramatically enhanced oxytocin
mRNA expression in skeletal muscle, accompanied by a ∼50-
fold higher level of circulating oxytocin (De Jager et al.,
2011). Intriguingly, the authors provided evidence that the
hypertrophying effect of anabolic steroids is prevalently mediated
by OT-R signaling. Furthermore, in a more recent study, Divari
reported that serum levels of oxytocin increased dramatically
in cattle regularly treated with 17β-estradiol, but not with
either dexamethasone or placebo. This administration of 17β-
estradiol also resulted in increased (33-fold) skeletal muscle
expression of the oxytocin-precursor mRNA (Divari et al.,
2013). Increased expression of the oxytocin-precursor mRNA
was also found in the muscle of sheep subjected to chronical
treatment with a combination of 17β-estradiol and the synthetic
androgen trenbolone acetate (TBA). Also the circulating oxytocin
level increased in steroid-treated sheep compared to placebo-
treated controls (Kongsuwan et al., 2012). Together, the above
studies indicate a correlation between the steroid-inducedmuscle
hypertrophy and the increased expression of both oxytocin and
OT-R in skeletal muscle.
The mechanisms underlying regulation by steroids of
oxytocin expression remain to be fully elucidated. The oxytocin
promoter does not possess a classical Estrogen Response
Element, whereas it has a high affinity binding-site for nuclear
orphan receptors/estrogen related receptor alpha (ERRα). Koohi
reported that the estrogen dependent control of the oxytocin
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promoter is independent of classical Estrogen Receptor (ER)
binding, but requires a functional ERRα (Koohi et al.,
2005). These authors further demonstrated that the estrogenic
stimulation of the OT-R occurs through the ERK/MAPK-
mediated stimulation of the transcriptional activity of ERRα.
The up-regulation of oxytocin expression by this non-classical
mechanism may, in turn, sustain an autocrine feed-forward
oxytocin/OT-R loop which amplifies the response to oxytocin, as
shown in bone (Colaianni et al., 2012; Berio et al., 2017).
Worth noting, exercise (i.e., muscle contraction) represents
a physiological stimulus increasing the levels of circulating
neurohypophyseal hormones, as well as their expression (or the
expression of their receptors) in several tissues beside skeletal
muscle (Martins et al., 2005). Based on several studies in man
and other mammals, it is clear that exercise induces a five-
fold increase in the circulating levels of vasopressin (Melin
et al., 1980; Convertino et al., 1981; Alexander et al., 1991).
This increase, associated to the beneficial effects of exercise on
muscle homeostasis, suggests a model whereby physical activity
stimulates muscle secretion of the neurohypophyseal hormones
and induces a generalized sensitization to these factors through
the up-regulation of their receptors in various districts. An
exercise-mediated increase in vasopressin and/or oxytocin could
ultimately contribute to maintaining muscle homeostasis and
add to the additional benefits of exercise, including an increased
life span and general well-being.
FINAL REMARKS
The in vitro and in vivo studies discussed above suggest that
skeletal muscle is a target of neurohypophyseal hormones, which
regulate muscle homeostasis and function in both physiological
and pathological conditions. On the other hand, skeletal muscle
has been recognized as the source of a wide range of circulating
factors, namely myokines, which regulate a number of different
functions with paracrine or endocrine mechanisms (Pedersen
and Febbraio, 2008; Hoffmann and Weigert, 2017). In the light
of its abundance in the organism, skeletal muscle may thus be
regarded as the largest endocrine gland in the body. In this article,
we discuss in vitro and in vivo studies showing that oxytocin
is synthesized by muscle and that its secretion significantly
contributes to the level of circulating hormones. This activity
appears to be central to the mechanisms which regulate muscle
homeostasis, to contribute to muscle hypertrophic responses
and to be altered in atrophic conditions. As a whole, this
evidence suggests that OT and AVP be considered as potential
myokines. In addition, these considerations suggest a potential
therapeutic use of these molecules, along with more selective
and potent analogs, in atrophic and muscle wasting conditions,
such as sarcopenia and cachexia, and as a tool in adjuvant
therapies against muscular dystrophies and neuromuscular
diseases.
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Skeletal Muscle Atrophy in Simulated
Microgravity Might Be Triggered by
Immune-Related microRNAs
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Exposure to microgravity induces skeletal muscle disorders including atrophy, muscle
force decrease, fiber-type shift. Microgravity also contributes to immune-function
alterations and modifies microRNAs (miRs) expression. To understand the link between
microgravity-induced skeletal muscle atrophy and immune function deregulation, a
bioinformatics study was performed. The web platform MiRNet was used for miRs-
targets interaction analysis from previous proteomic studies on human soleus (SOL) and
vastus lateralis (VL) muscles. We predicted miRs targeting deregulated gene expression
following bed rest as a model of microgravity exposure; namely, let-7a-5p, miR-125b-5p
for over-expressed genes in SOL and VL; miR-1-3p, miR-125b-5p and miR-1-3p, miR-
95-5p for down-expressed genes in VL and SOL. The predicted miRs have important
immune functions, exhibiting a significant role on both inflammation and atrophy.
Let-7a down-expression leads to proliferation pathways promotion and differentiation
pathway inhibition, whereas miR-1-3p over-expression yields anti-proliferative effect,
promoting early differentiation. Such conflicting signals could lead to impairment
between proliferation and differentiation in skeletal muscles. Moreover, promotion
of an M2-like macrophage phenotype (IL-13, IL-10) by let-7a down-regulation and
simultaneous promotion of an M1-like macrophage (IL-6, TNF-α) phenotype through
the over-expression of EEF2 lead to a deregulation between M1/M2 tuning, that
is responsible for a first pro-inflammatory/proliferative phase followed by an anti-
inflammatory pro-myogenic phase during skeletal muscle regeneration after injury. These
observations are important to understand the mechanism by which inflammation may
play a significant role in skeletal muscle dysfunction in spaceflights, providing new links
between immune response and skeletal muscle deregulation, which may be useful to
further investigate possible therapeutic intervention.
Keywords: space flight, bioinformatics, miRs prediction, web-based platform, immune function deregulation,
skeletal muscle atrophy
INTRODUCTION
Microgravity poses one of the greatest risks to astronauts during prolonged missions (Williams
et al., 2009). Exposure to microgravity results in decreased muscle strength and endurance,
raising concerns that muscle atrophy could increase long-term spaceflight risk unless adequate
countermeasures were undertaken. Indeed, the employed physical exercise countermeasures are
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still incapable of preventing muscle atrophy, thus increasing
needs for development of more focused program. Immune
deregulation is also a major issue during spaceflights and was
first observed in astronauts following missions, making them
most exposed to infections (Johnston et al., 1975). Muscle
atrophy is a feature of many diseases affecting skeletal muscle
and it also responsible for muscle disease exacerbation (Kovanda
et al., 2018). Exposure to microgravity during spaceflights might
modify miRs expression as compared to normal gravity. MiRs
are short non-coding RNAs able to regulate gene expression.
Muscle specific miRs (myomiRs) regulate several processes in
skeletal muscle, such as myogenesis, muscle homeostasis and
response to external stimuli. Muscle-specific miRs (myomiRs)
control various processes in skeletal muscles, from myogenesis
and muscle homeostasis to responses to environmental stimuli,
such as exercise. MiRs are critical regulators of both adult
skeletal muscle differentiation/maintenance and inflammatory
cytokine signaling (Bartel, 2004; Baltimore et al., 2008; Sonkoly
et al., 2008). We hypothesized that links might exist between
skeletal muscle atrophy and inflammation deregulation
triggered by microgravity. The aim of the present work is
to explore the mechanism by which the immune response
to simulated microgravity may play a role in skeletal muscle
dysfunction in spaceflights, providing a new mechanism
linking the action of inflammatory cytokines to skeletal
muscle deregulation. Deregulated proteins associated to
bed rest as a microgravity model from a previous study
(Moriggi et al., 2010) were employed to build a network
identifying new putative miRs involved. MiRNet, an easy-
to-use web-based tool1, helped us to identify new regulatory
mechanisms associated to immune microgravity muscle
atrophy.
MATERIALS AND METHODS
The proteome profile previously performed on muscle
biopsies (from VL to SOL) from 12 healthy subjects before
and after 55 days of bed rest (Moriggi et al., 2010) has
been used for this study. The proteins that showed a
differential expression in the two conditions in VL and
SOL muscles have been divided into 2 different groups:
over- and down-expressed. The Swiss-Prot accession number
of the deregulated proteins (genes) was used in PubMed2
to look for the associated official gene symbol. This latter
has been used in miRNet to build a network identifying
new putative miRs-targets interactions. The network shows
the interactions existing between a miRNA and the genes
modulated1. We used the mRNA area and we uploaded
4 different lists of gene symbols: VL over-expressed; VL
down-expressed; SOL over-expressed; SOL down-expressed.
We first performed the analysis inserting H. sapiens as
organism and the official gene symbol as ID type. We also
repeated a second analysis choosing “muscle” as tissue
1http://www.mirnet.ca
2https://www.ncbi.nlm.nih.gov/pubmed
(human only) option. In this way, a network with nodes
and connections between our genes and miRs has been
built.
RESULTS
We used the proteome profile from Moriggi et al. (2010)
where 55 days bed rest modulated different muscle genes.
A list of modulated SOL and VL miRs was used for miRNet
analysis to look for miRs-targets connections. We found putative
miRs associated to up- and down-regulated genes (Table 1).
Furthermore, when the analysis was performed choosing mRNAs
from human muscle, different miRs emerged.
We performed a bibliographic analysis of the muscle miRs
and their putative targets emerged from the miRNet analysis.
We found that let-7a-5p and miR-1 are evidently involved in a
proliferation/differentiation conflicting signaling (Figure 1) and
their down- and up-regulation (respectively) play a fundamental
role in tissue adaptation under simulated microgravity, resulting
TABLE 1 | Results obtained by miRNet analysis.









let-7a-5p (EEF2; ID: 1938; eukaryotic translation
elongation factor 2) (VCL; ID: 7414; vinculin)
miR-125b-5p (VDAC1; ID: 7416; voltage






miR-1-3p (SUCLA2; ID: 8803; succinate-CoA
ligase ADP-forming beta subunit) (PRDX2; ID:
7001; peroxiredoxin 2)







let-7a-5p (VCL; ID: 7414; vinculin) miR-125b-5p






miR-1-3p (SUCLA2; ID: 8803; succinate-CoA
ligase ADP-forming beta subunit) (ACTC1; ID:
70; actin, alpha, cardiac muscle 1) miR-95-5p
(ACTC1; ID: 70; actin, alpha, cardiac muscle 1)
We reported the putative microRNAs that are associated to the over- and down-
expressed VL/SOL proteins (genes). The genes associated to muscle tissue are
also reported in parenthesis (bold). VL, vastus lateralis human muscle; SOL, human
soleus.
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FIGURE 1 | Hypothesis of the conflicting signals responsible for atrophy observed during reduced gravity environment. Down-expressed genes, microRNAs and
inhibited signals (arrows) are indicated in red, while over-expressed genes, microRNAs and activated signals (arrows) are indicated in green. Black lines indicate the
possible interactions between mRNA and microRNAs evidenced by the miRNet analysis.
in skeletal muscle atrophy, strictly associated to immune-
function dysregulation.
DISCUSSION
The results of our bioinformatic analysis predicted some
miRs dysregulation in healthy subjects undergoing bed rest as
microgravity model. Our results evidenced that let-7 down-
regulation and simultaneous miR-1 up-regulation might play
a fundamental role in tissue adaptation under microgravity
resulting in skeletal muscle atrophy. Let-7 promotes cell
differentiation and cellular proliferation inhibition in several
cellular systems (Roush and Slack, 2008). The let-7miRs family
plays a key role in modulating inflammatory responses as
well (Song and Lee, 2015). Let-7a is involved in inflammation
processes by participating to NF-κB and angiogenesis signaling
(Song et al., 2016). When miRs of let-7 family are downregulated,
the levels of IL-6 and IL-10 cytokines are downregulated too
(Liu et al., 2011; Schulte et al., 2011). Moreover decreased levels
of let-7 following microbial infection enhance the expression of
TLR4 (Androulidaki et al., 2009; Hu et al., 2009). Let-t is also
related to adaptive immune response since it has been show a
regulation by let-7 of the production of IL-13 by T lymphocyte
during the inflammatory process due to airway allergic response.
Indeed, let-7 can inhibit the anti-inflammatory cytokine IL-
13 secretion (Fan et al., 2016); on the other hand let-7 miRs
expression is dynamically regulated in response to TNF-α (and
other factors as serum glucose). Thus let-7 down-expression,
as in simulated microgravity, exacerbates inflammation. Finally,
our bioinformatics (in silico) analysis of the interactions between
miRs and the pathways involved in the inflammatory process,
and in skeletal muscle wasting, such as TNF-alpha and NF-kB
pathways identified let-7 family as one of the main predicted
regulators of the aforementioned pathways. Noteworthy, many
transmembrane receptors involved in these pathways (TNFR1,
TNFR2, and IL1R) are targets of let-7 miRNA (Brennan et al.,
2017).
Our in silico analysis showed that let-7 targets vinculin (VC),
a protein connecting integrins to actin filaments, and that is
recruited to focal adhesions (FAs) in response to force. VCL
is suggested to be linked to FA mechanosensitivity and it is
essential for FA stabilization under force (King et al., 2018).
Migration of satellite cells (SC), necessary for skeletal muscle
development and regeneration, is strictly dependant on the
formation of mature FA connecting the cell to the extracellular
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matrix (Goetsch et al., 2014). In particular VCL is critical during
the remodeling of the junction, due to the force exerted by the
cytoskeleton, to avoid junction opening (Huveneers et al., 2012).
TNF-α induces substantial reorganization of actin cytoskeleton
and FA (Koukouritaki et al., 1999). In 55 days bed rest, VCL
might fail to ensure proper migration and alignment for the cell to
differentiate. Cells expressing VCL by 20% over endogenous level
had altered locomotory properties. VCL is a key control protein
for FA modeling and it is regulated by tension (Spanjaard and
de Rooij, 2013). VCL expression at FA is negatively regulated by
TNF-alpha that also indices cytoskeletal actin depolymerization
(Scott and Panitch, 2014). Let-7 also targets EEF2 and, in turn,
EEF2 suppresses let-7 expression (Ding et al., 2008). EEF2
activation activates subsequent TNF-α elongation (via MKK3/6-
p38γ/δ pathway).
The restoration of let-7 levels might represent an interesting
strategy for therapeutic approaches to prevent up-regulation of
key proteins implicated in microgravity-driven inflammation and
other key pathological hallmarks of atrophy processes.
Our in silico research also predicted miR-1-3p deregulation.
MiR-1 family (belonging to myomiRs) controls myosin content,
fiber type and muscle performance and directly targets HDAC4
(histone deacetylase 4) (Zuo et al., 2015). HDAC4 is directly
inhibited by miR-1. This inhibition is responsible for cell-cycle
arrest in G1 and G2, an anti-proliferative effect typical of HDAC
inhibitors (Sun et al., 2015). HDAC4 has an inhibitory effects
upon MEF2 (myocyte enhancer factor) transcription factor,
responsible for the activation of early myogenic differentiation
(Sun et al., 2015). A mutual regulation also exists between mir-1
and YY1, an inhibitor of myogenic differentiation; in fact miR-1
binds the 3′-UTR of YY1 and YY1 targets miR-1 (Sun et al., 2015).
Expression of miR-1 is regulated by nNOS signaling through
HDCA2. HDAC may regulate the expression of iNos and NF-
kB dependent genes, which can further induce the expression
of cytokines (Kharitonov and Ito, 2009). MiR-1 also controls
G6PD, a relevant enzyme in oxidative stress response (Sun et al.,
2015).
Glucocorticoids induce skeletal muscle atrophy with miR-
1 expression through glucocorticoid receptor and myostatin.
The results suggest that miR-1 is a catabolic miR and might
have a central role in microgravity-induced skeletal muscle
atrophy. MiR-1 also blocks Pax7 which has been suggested
to have a role in the maintenance of the proliferative phase
through the prevention of early differentiation, thus miR-
1 up-regulation results in a block of proliferation and early
differentiation induction. Pax7 is also a regulator of MyoD and
may be involved in MyoD up-regulation observed during SC
activation. Pax7 has also been demonstrated to be sufficient for
the activation of the myogenic program in CD45+/Sca1+ cells
isolated from adult skeletal muscle tissue (Zammit et al., 2006).
Hosoyama et al. (2017) hypothesize that human skeletal muscle
stem/progenitor cells pool may be reduced during microgravity
when Pax7 is down-regulated through TRAF6/ERK signaling
pathway.
Our results also showed that miR-125b-5p is associated either
to over- and down-expressed muscle VL genes and associated
to over-expressed muscle SOL VCL gene. MiR-125b-5p targets
mitochondrial apoptotic pathways and regulates the phenotype
of macrophages targeting B7-H4 (Diao et al., 2017). MiR-
125b-5p over-expression down-regulates B7-H4 expression in
macrophage. B7-H4, an immunoglobulin superfamily molecule
that has been shown to inhibit T cell responses through cell
cycle arrest and inhibition of T cell proliferation and cytokine
release. B7-H4 has been also identified in skeletal muscle. MiR-
125b plays a role in innate immune response. MiR-125-b induces
fibrosis by targeting apelin (Chen et al., 2017). MiR-125a and
miR-125b indirectly activate NK-kB pathway via suppression
of TNF-alpha-induced protein 3 (TNFAIP3, A20) (Chen et al.,
2017). Down-regulation of miR-125b-5p increases inflammation
(Chen et al., 2017).
Our results also predicted that miR-95-5p is associated
with ACTC1 down-expressed SOL gene muscle. MiR-95-5p
has been proposed as a new miR biomarker candidate in
muscular dystrophy (dystromir). MiR-95 promotes myogenic
differentiation by down-regulating the AIMP2 translation.
ACTC1 is an AIMP2 interacting protein and both have been
found to be implicated in FA.
The results also demonstrated an over-expression of miR-222-
3p and miR-320a in both VL and SL. SLC2A4 gene (GLUT4
protein) (Xu et al., 2015) is a direct target of miR-222-3p. Limb
immobilization halved muscle GLUT4 protein concentration
in animal models. GLUT4 decrease is also associated with
insulin resistance and high levels of inflammatory markers.
The oxidative stress-responsive microR-320a is a skeletal muscle
mitochondrial metabolism and migration regulator. It regulates
glycolysis by directly downregulating phosphofructokinase,
in diverse biological systems (Tang et al., 2012). Increased
levels of miR-320a may account for an impairment of the
glycolytic system by suppressing a key enzyme in the glycolysis
process.
Several are the miRs associated to skeletal muscle proliferation
and differentiation (myomiRs) e.g., miR-1, 133a/b, 206, 208a/b,
499a/b and others are more and more coming to limelight,
but except for miR-1, these were not associated to the over-
and down-expressed VL/SOL proteins (genes) experimentally
detected by Moriggi et al. (2010). Moreover, we find some miRs
that were not described by others. For examples, in murine
gastrocnemius in spaceflight environment the ratio of miR-1/
miR-133a was significantly increased (Allen et al., 2009) but
none of ours were found. These differences might be accounted
for different models (animals vs. human), different environment
(spaceflight vs. bed rest), different target (gastrocnemius vs. VL
and SOL).
CONCLUSION
In conclusion, our bioinformatics analysis revealed that
conflicting signals are taking place simultaneously in reduced
gravity environment, resulting in impairment between
proliferation and differentiation signaling pathways which
might be responsible for the observed atrophy (Figure 1). The
same predicted dysregulated miRs are, at the same time, also
responsible for an inflammation response, which might be
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the reason of atrophy outcome thus suggesting that immune
dysregulation is one of the molecular pathways ensuing
microgravity-generated muscle atrophy. In this report we
highlighted the roles played by the pathways controlled mainly
by let-7a and miR-1, miR-125b-5p, miR-95-5p, miR-222-3p.
The miRs here discussed are, of course, not exhaustive of
the mechanisms involved in skeletal muscle response to
microgravity, however, they highlight the important role played
by inflammation in muscle atrophy as already demonstrated in
other forms of skeletal muscle pathologies.
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Increased physical activity is an optimal way to maintain a good health. During exercise,
triacylglycerols, an energy reservoir in adipose tissue, are hydrolyzed to free fatty
acids (FAs) which are then released to the circulation, providing a fuel for working
muscles. Thus, regular physical activity leads to a reduction of adipose tissue mass
and improves metabolism. However, the reduction of lipid reservoir is also associated
with many other interesting changes in adipose tissue FA metabolism. For example, a
prolonged exercise contributes to a decrease in lipoprotein lipase activity and resultant
reduction of FA uptake. This results in the improvement of mitochondrial function and
upregulation of enzymes involved in the metabolism of polyunsaturated fatty acids. The
exercise-induced changes in adipocyte metabolism are associated with modifications
of FA composition. The modifications are adipose tissue depot-specific and follow
different patterns in visceral and subcutaneous adipose tissue. Moreover, exercise
affects adipokine release from adipose tissue, and thus, may mitigate inflammation and
improve insulin sensitivity. Another consequence of exercise is the recently described
phenomenon of adipose tissue “beiging,” i.e., a switch from energy-storing white
adipocyte phenotype to thermogenic FA oxidizing beige adipocytes. This process is
regulated by myokines released during the exercise. In this review, we summarize
published evidence for the exercise-related changes in FA metabolism and adipokine
release in adipose tissue, and their potential contribution to beneficial cardiovascular
and metabolic effects of physical activity.
Keywords: exercise, adipose tissue, fatty acid, adipokine, myokine, adipose tissue beiging
INTRODUCTION
In the 21st century, when obesity is recognized as a civilization-related, economic and social burden
and the numbers of obese and overweight individuals still increase, we need new strategies to
prevent and treat those conditions. Since excess body weight results from an imbalance between
energy intake and energy expenditure (Jakicic and Otto, 2005), one way to maintain a correct
body weight is to stimulate lipid catabolism through increased physical activity. Appropriately
designed training simulates lipolysis, i.e., the hydrolysis of triacylglycerols stored in adipose tissue
(AT), which results in the release of free fatty acids (FFAs) to circulation and their oxidation in
muscles and other tissues. Elevated blood concentration of FFAs, observed in obesity and metabolic
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syndrome, is an adverse condition that may lead to lipotoxicity
and ectopic deposition of lipids in other tissues (Mika and
Sledzinski, 2017). Thus, efficient uptake and oxidation of FFAs
in working muscles are critical for maintaining their normal
blood levels. Moreover, exercise contributes to an increase in
the number of mitochondria in white AT (WAT) and stimulates
the expression of brown adipocyte-specific genes, which leads
to “beiging” of WAT and amelioration of glucose intolerance
induced by a high-fat diet (Sutherland et al., 2009; Xu et al.,
2011; Roberts et al., 2014) (Figure 1). These effects of exercise
on AT are associated with significant changes in metabolism
and composition of fatty acids (FAs), the main components of
adipocytes. Aside from the storage of triacylglycerols, AT acts
also as an endocrine organ, releasing many biologically active
substances referred to as adipokines. Exercise may also modulate
the endocrine function of AT. There are three types of AT: WAT,
located subcutaneously and viscerally, brown adipose tissue
(BAT), and beige AT formed as a consequence of white adipocyte
“beiging,” i.e., their phenotypic and metabolic transition to cells
similar to brown adipocytes. WAT, abundant in both humans and
rodents, is primarily responsible for triacylglycerols storage and
release of various adipokines into the blood. While in rodents
BAT forms a large interscapular depot, as well as smaller depots
in other locations, its existence in humans, around the neck,
spine and major blood vessels, has been demonstrated quite
recently. BAT, rich in mitochondria, is primarily responsible for
thermogenesis (Lehnig and Stanford, 2018). Recent studies in
humans and in rodents have identified controversial results in
BAT activity in response to regular physical exercise. In trained
humans, Vosselman et al. (2015) and Motiani et al. (2017) have
observed a decrease in BAT activity (mitochondrial activity,
glucose uptake, and thermogenesis, Figure 1). In this review,
we discuss the exercise-induced changes in the composition and
metabolism of FAs in AT, with particular emphasis on AT depot-
specific differences.
EFFECT OF EXERCISE ON FA
COMPOSITION IN AT
The release of FAs from adipocytes to deliver them to working
muscles contributes to changes in the amount and composition
of AT lipids. However, these effects were shown to depend on
the exercise intensity (Nikolaidis and Mougios, 2004). Some
studies demonstrated that low-intensity endurance training leads
to maximal lipid oxidation, but available evidence in this matter
is inconclusive (Romain et al., 2012). Triacylglycerols are the
major class of lipids, representing up to 90–99% of all AT
lipids (Nikolaidis and Mougios, 2004). WAT in mammalian body
forms a few depots and can generally be classified into visceral
and subcutaneous AT differing in terms of the composition of
triacylglycerols-forming FA (Garaulet et al., 2006). Published
data about the effects of exercise on FA composition in human
AT are limited. An early studies revealed a decrease in oleic
acid (18:1) and increase in linoleic acid (18:2 n−6) content
in subcutaneous AT after chronic training (Allard et al., 1973;
Sutherland et al., 1981). The decrease in the level of 18:1, the
main monounsaturated FA (MUFA), which was observed in
both studies mentioned above, might be associated with reduced
activity of stearoyl-CoA desaturase (SCD1) in AT (Nikolaidis
and Mougios, 2004). Since metabolic disorders were shown to be
associated with enhanced synthesis of 18:1 and other MUFA by
SCD1 (Mika et al., 2015), a post-exercise decrease in AT content
of 18:1 may be considered a favorable change. Published evidence
suggests that physical training may contribute to a preferential
mobilization of some FAs from AT. Already after 2 weeks of the
training in senior oarsmen, the authors observed a significant
decrease in total serum triacylglycerols and cholesterol, along
with changes in the FA profile of AT: a decrease in palmitoleic acid
(16:1) and an increase in stearic acid (18:0) content, comparing
to previously untrained controls (Danner et al., 1984). A more
recent study demonstrated that 6 months of increased physical
activity contributed to a significant increase in 18:2 n−6 in
overweight elderly subjects, while no such effect was observed
in untrained controls (Sjögren et al., 2012). Taken altogether,
this sparse evidence from human suggests that chronic exercise
may contribute to a decrease in 18:1 content, with concomitant
increase in 18:2 n−6 and 18:0. Since 18:1 is the main FA
found in triacylglycerols (Ntambi and Miyazaki, 2003; Liu et al.,
2011), the decrease in its content may contribute to a relative
increase in other FAs. 18:2 n−6 is an essential FA, a substrate
for synthesis of other n−6 PUFA, that in turn may be than
converted into proinflammatory oxylipins, including eicosanoids
(Mika and Sledzinski, 2017). However, regular exercise training
seems to reduce systemic inflammation (Görgens et al., 2015).
More data in this matter originate from rodent models, and based
on this evidence we may compare the effect of exercise on FA
composition in various WAT depots, as well as in BAT (May et al.,
2017). Most of the animal studies demonstrated that chronic
exercise contributed to a decrease in MUFA content, which is
consistent with the observations made in humans (Nikolaidis and
Mougios, 2004). Regarding polyunsaturated FAs (PUFAs), most
animal studies showed an increase in their content, especially
n−6 PUFAs; however, in some studies, the post-exercise levels
of PUFAs were lower than prior to the exercise or remained
unchanged. The chronic exercise-induced changes in PUFA
content in AT are depot-specific (Bailey et al., 1993; Nikolaidis
and Mougios, 2004). Petridou et al. (2005) reported decrease
in MUFA levels after chronic exercise and an increase in n−6
PUFA content in visceral WAT but not in subcutaneous WAT.
Among the MUFAs of visceral fat, chronic exercise contributed
to a decrease in 16:1, but not in 18:1 (Petridou et al., 2005); the
same phenomenon was also observed by Rocha-Rodrigues et al.
(2017b) in a rat model. In recent study conducted by May et al.
(2017) the authors performed a comprehensive analysis of FA
content in phospholipids and triacylglycerols from subcutaneous
WAT and BAT of mice subjected to a 3-week exercise training.
The study demonstrated that while the exercise contributed to a
significant increase in MUFA level and a significant decrease in
PUFA content in WAT phospholipids, an inverse phenomenon,
i.e., a decrease in MUFAs and an increase in PUFAs was
observed in BAT phospholipids. Moreover, a significant decrease
in triacylglycerol content of SFAs, MUFAs and PUFAs in BAT
and triacylglycerol content of PUFAs in WAT was observed
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FIGURE 1 | Exercise-induced adaptations to white adipose tissue (WAT), brown adipose tissue (BAT) and beige adipocytes. Histological sections of WAT and BAT
are stained with haematoxylin and eosin.
(May et al., 2017). However, it should be stressed that in that
study, FA content was expressed in nmol per mg of protein, rather
than as a percentage of total FAs as in previously mentioned
experiments. These findings suggest that post-exercise changes in
FA composition of AT are not only depot- but also lipid molecule-
specific. In both WAT and BAT, physical exercise contributed
to a significant decrease in the total content of triacylglycerols,
but with a concomitant increase in the level of triacylglycerols
containing long-chain FAs (58–60 total carbons) (May et al.,
2017). The effects of exercise on FA composition in AT and other
AT parameters in human and animal studies is summarized in
Table 1.
EFFECT OF EXERCISE ON FA
METABOLISM IN AT
The post-exercise decrease in triacylglycerols content in AT
is with no doubt a consequence of enhanced lipolysis. The
process, initiated by adipose triglyceride lipase (ATGL), is
then continued by hormone-sensitive lipase (HSL), upon
phosphorylation thereof; eventually, the last FA chain is
hydrolyzed by monoacylglycerol lipase (MAGL) (Chen et al.,
2015). While the rate of lipolysis is decreased by obesity and high-
fat diet, chronic exercise was shown to normalize the markers of
this process, phosphorylated HSL and ATGL, in mice that have
been previously maintained on a high-fat diet (Chen et al., 2015).
Surprisingly, however, Holland et al. (2016) demonstrated that
voluntary wheel running for 42 days contributed to a decrease
in phosphorylated HSL level in rats. In contrast, chronic exercise
was shown to stimulate the activity of lipolytic enzymes in the
adipocytes of obese mice (Woo and Kang, 2016), and a recent
study demonstrated that endurance exercise contributed to an
increase in triacylglycerol lipase activity in human AT, especially
during the first 10 min of the training (Petridou et al., 2017). An
upregulation of HSL after chronic exercise was also mentioned in
a review paper published by Steinberg (2009). Moreover, irisin,
an adipokine released by working muscles, was shown to induce
the expression of ATGL and HSL in 3T3L1 adipocytes (Gao et al.,
2016). Thus, the results of most published studies suggest that
physical exercise may stimulate lipolytic activity within AT, that
may contribute to more efficient reduction of AT mass and/or
prevent accumulation thereof.
Physical activity may also modulate FA synthesis, desaturation
and elongation. The reduction of MUFA content after chronic
exercise reported by many authors might be a consequence of a
decrease in FA desaturation by SCD1 (Nikolaidis and Mougios,
2004). However, this conclusion is based on the desaturation
indices calculated from SFA and MUFA contents in AT. Thus,
it cannot be excluded that those parameters were also influenced
by preferential uptake and release of certain FAs in AT during
exercise (Halliwell et al., 1996). One study demonstrated that
chronic exercise did not affect the expression of SCD1 in mice
subcutaneous WAT, but contributed to lesser activity of this
enzyme in BAT (May et al., 2017). Also in human subcutaneous
AT, the expression of SCD1 gene remained unchanged after
the chronic exercise (Sjögren et al., 2012). Published data about
the exercise-induced changes in the activity of other lipogenic
enzymes are inconclusive. According to May et al. (2017), 3-week
exercise contributed to an increase in acetyl-CoA carboxylase
(ACC) mRNA level in mice subcutaneous WAT, but not in BAT
whereby mRNA level for this enzyme was reduced. Similarly,
a 6-week exercise resulted in an increase in ACC protein level
in visceral WAT of rats (Holland et al., 2016). In contrast,
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TABLE 1 | The summary of effects of exercise on adipose tissue metabolism and adipokine secretion.
The effect of exercise on: Subcutaneous WAT Visceral WAT BAT Reference
Fatty acid profile 18:0 ↑h DNF DNF Danner et al., 1984
16:1 ↓h ↓r DNF Danner et al., 1984; Petridou et al., 2005;
Rocha-Rodrigues et al., 2017b
18:1 ↓h NCr DNF Allard et al., 1973; Sutherland et al., 1981; Petridou
et al., 2005; Rocha-Rodrigues et al., 2017b
MUFA ↓h, NC or ↓r ↓r DNF Bailey et al., 1993; Nikolaidis and Mougios, 2004;
Petridou et al., 2005; Rocha-Rodrigues et al., 2017b
MUFA in TG NCm DNF ↓m May et al., 2017
MUFA in PL ↑m DNF ↓m May et al., 2017
18:2 n−6 ↑h, ↑r NCr DNF Sutherland et al., 1981; Bailey et al., 1993; Sjögren
et al., 2012
n−6 PUFA ↑h, ↑r DNF DNF Nikolaidis and Mougios, 2004
PUFA in TG ↓m DNF ↓m May et al., 2017
PUFA in PL ↓m DNF ↑m May et al., 2017
Expression/activity
of enzymes of lipid
metabolism
HSL NCm ↑m, ↓r DNF Chen et al., 2015; Holland et al., 2016; Woo and Kang,
2016
ATGL NCm ↑m DNF Chen et al., 2015; Woo and Kang, 2016
SCD1 NCh, NCm DNF ↓m Sjögren et al., 2012; May et al., 2017
ACC ↑m ↑m, ↓r ↓m May et al., 2017; Holland et al., 2016;
Rocha-Rodrigues et al., 2017a
FADS1 DNF ↑r DNF Rocha-Rodrigues et al., 2017a




Adiponectin NCr, ↑ or NCh ↑r, ↑h DNF Görgens et al., 2015; Kato et al., 2018
Leptin NCh DNF DNF Görgens et al., 2015
IL-6 ↓ or NCh DNF DNF Bruun et al., 2006; Klimcakova et al., 2006
Apelin DNF ↑r DNF Kazemi and Zahediasl, 2018
Adipose tissue beiging ↑r, ↑m DNF – Lehnig and Stanford, 2018
WAT, white adipose tissue; BAT, brown adipose tissue; ↑, increased; ↓, decreased; NC, not changed significantly; h, in human; r, in rat; m, in mouse; DNF, data not
found; TG, triacylglycerols; PL phospholipids; HSL, hormone-sensitive lipase; ATGL, adipose triglyceride lipase; SCD1, stearoyl-CoA desaturase 1; ACC, acetyl-CoA
carboxylase; FADS1, fatty acid desaturase 1; ELOVL5, fatty acid elongase 1; Il6, interleukin 6.
Rocha-Rodrigues et al. (2017a) found reduced activity of ACC in
visceral AT of rats subjected to an 8-week endurance training.
The same study demonstrated a post-exercise increase in the
expressions of enzymes involved in PUFA metabolism, FA
desaturase 1 and elongase 5 (Rocha-Rodrigues et al., 2017a);
these findings are consistent with the results published by other
authors who observed a chronic exercise-induced increase in
PUFA content and elongase indices (Nikolaidis and Mougios,
2004). In line with those findings, May et al. (2017) found elevated
levels of mRNA for elongase 3 and 4 in AT from chronically
exercised mice. Taken altogether, the abovementioned findings
suggest that the effect of exercise on the expression of enzymes
involved in lipid metabolism may vary depending on FA group
and AT depot.
IMPACT OF EXERCISE ON ADIPOKINE
SECRETION IN AT
Muscle work during the exercise may activate a signaling cascade;
specifically, myokines released from the muscle cells may trigger a
release of adipokines, signaling molecules synthesized in the AT.
Aside from the production of adipokines, AT can also synthesize
many myokines, among others IL-6, MCP1, TNFα, visfatin and
myostatin, which are collectively referred to as adipomyokines
(Görgens et al., 2015). Thus, plasma level of adipomyokines
does not necessarily reflect solely the pool which is synthesized
in the AT and acts on the muscles, and the origin of each
molecule should be identified at a cellular level. Adiponectin is
an insulin-sensitizing hormone that enhances FA oxidation in the
muscles and downregulates the synthesis of lipids and glucose
in the liver (Swierczynski and Sledzinski, 2012). The evidence
from both human and animal studies analyzing the effects of
exercise on serum adiponectin level is inconclusive; chronic
exercise was either shown to increase the serum concentration
or expression in AT of this adipokine or did not affect it at
all (Kato et al., 2018; Lehnig and Stanford, 2018). Available
data imply that the release of adiponectin from human AT may
depend on exercise intensity (Görgens et al., 2015). Another
adipokine, leptin, is synthesized primarily in the AT, regulates
appetite and boosts peripheral metabolism (Swierczynski and
Sledzinski, 2012). Chronic exercise was shown to contribute to
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a decrease in serum leptin concentration, but this effect was
associated with the reduction of AT mass (Lehnig and Stanford,
2018). However, previous studies demonstrated that excess
body weight was associated with leptin resistance (Swierczynski
and Sledzinski, 2012), and chronic exercise might improve
leptin sensitivity (Kang et al., 2013). Thus, the simultaneous
reduction of serum leptin level and AT mass does not necessarily
correspond to a decrease in the activity of this adipokine.
Serum concentration of IL-6, acting as an anti-inflammatory
myokine, was shown to increase substantially after acute exercise,
and this effect was demonstrated to result from local synthesis
of IL-6 by the working muscles. However, the level of IL-6
after chronic exercise was decreased or remained unchanged
(Görgens et al., 2015). Also, the expression of IL-6 in the AT
did not change or was reduced, depending on the type of
chronic exercise (Bruun et al., 2006; Klimcakova et al., 2006).
Generally, moderate chronic exercise seems to be associated with
a decrease in the release of pro-inflammatory cytokines, such as
TNF-α, leptin and MCP-1, from the AT and working muscles;
this may contribute to attenuation of systemic inflammation
(Görgens et al., 2015). A recent study demonstrated that
chronically exercised rats showed enhanced expression of apelin,
an adipomyokine that decreases insulin resistance (Kazemi and
Zahediasl, 2018). Apelin induced glucose uptake by AT, but at
the same time decreases triglyceride amounts in mouse AT and
lipid storage in 3T3-L1 preadipocytes (Indrakusuma et al., 2015).
Also, serum concentration of resistin, an adipokine promoting
insulin resistance, was shown to decrease in rats subjected to
an chronic exercise (Shirvani and Arabzadeh, 2018). Altogether,
these findings suggest that chronic exercise may improve the
profile of adipokines released from the AT, and thus, may be
beneficial for health.
EXERCISE LEADS TO AT “BEIGING” — A
PROCESS MEDIATED BY MYOKINES
Aside from the metabolic processes discussed above (lipolysis, FA
uptake, FA synthesis), FAs are also oxidized in mitochondria, in a
process referred to as β-oxidation. A number of previous studies
demonstrated that chronic exercise enhanced mitochondrial
activity in visceral and subcutaneous AT, in both rodents
(Stallknecht et al., 1991; Sutherland et al., 2009; Vernochet
et al., 2012; Wu et al., 2012; Stanford et al., 2015a,b) and
humans (Ruschke et al., 2010; Rönn et al., 2014). The process
of mitochondrial β-oxidation in the AT is not as intensive as
in the muscles but still can provide an extra pool of energy
for adipocytes after the exercise. Furthermore, there is one AT
depot that shows greater mitochondrial activity than visceral
and subcutaneous WAT; this is BAT which contains numerous
mitochondria whereby FAs undergo oxidization, becoming a
source of energy for thermogenesis. The main protein involved
in thermogenesis is uncoupling protein 1 (UCP1), mediating
proton leakage across the inner mitochondrial membrane into
the mitochondrial matrix, and thus, playing a role in heat
production (Lehnig and Stanford, 2018). Recent research showed
that chronic exercise may contribute to “beiging” of subcutaneous
WAT, a process which is also referred to as the “browning” of AT.
During the process of “beiging,” a phenotype and metabolism of
white adipocytes in the AT change and resemble the respective
characteristics of brown adipocytes in the BAT (Lehnig and
Stanford, 2018). This phenotypic and functional switch includes
an increase in mitochondrial respiration and enhancement of
UCP1 protein expression, as well as the upregulation of other
genes characteristic for BAT (Wu et al., 2012). In one study,
ablation of beige adipocytes resulted in the development of
obesity and insulin resistance in mice; this implies that these cells
may play a role in the regulation of systemic energy metabolism
(Stanford and Goodyear, 2016). While the exercise-induced
adipocyte “beiging” has been well documented in rodents, still
little is known about this phenomenon in humans (Lehnig and
Stanford, 2018). However, it needs to be stressed that BAT in
adult humans resembles murine beige AT, rather than the BAT
(Wu et al., 2012). A number of potential mechanisms responsible
for AT “beiging” have been proposed thus far. According to one
hypothesis, the process may be mediated by myokines and small
molecules released from working muscles (Lehnig and Stanford,
2018), specifically by irisin (Boström et al., 2012), myostatin
(Feldman et al., 2006), meteorin-like 1 (Metrnl) (Rao et al.,
2014), lactate (Carriere et al., 2014) and/or β-aminoisobutyric
acid (BAIBA) (Roberts et al., 2014).
CONCLUSION
Physical exercise stimulates lipolysis, decreases FA uptake by
the adipocytes, exerts an effect on FA composition within
the AT and modulates the expression of enzymes involved in
FA synthesis, elongation and desaturation. Moreover, exercise
promotes “beiging” of AT and contributes to an increase in
mitochondrial activity, which leads to enhanced FA oxidation in
the AT. As a result of all those metabolic processes, physically
active persons can maintain adequate volume of AT. Chronic
exercise influences the release of adipokines, which may attenuate
systemic inflammation and prevent insulin resistance. Moreover,
transplantation of AT from trained to untrained mice was
shown to improve glucose tolerance (Stanford et al., 2015b).
Taken altogether, these findings imply that the exercise-induced
changes in AT metabolism may exert a beneficial effect on global
metabolic health.
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(grant no. ST40), National Science Centre of Poland (grant no.
NCN 2016/21/D/NZ5/00219), and by the Italian Ministry of
University and Research (grant prot. 2012N8YJC3—Caporossi
Daniela PRIN2012).
Frontiers in Physiology | www.frontiersin.org 5 January 2019 | Volume 10 | Article 2697
fphys-10-00026 January 24, 2019 Time: 16:14 # 6
Mika et al. Effect of Exercise on Adipose Tissue Metabolism
REFERENCES
Allard, C., Alteresco, M., Ferguson, R. J., Chaniotis, L., Choquette, G., and
Skinner, J. (1973). Changes in adipose tissue and increased serum cholesterol
of coronary patients following training. Can. Med. Assoc. J. 109, 194–197.
Bailey, J. W., Walker, E., and Beauchene, R. E. (1993). Fatty acid composition
of adipose tissue in aged rats: effects of dietary restriction and exercise. Exp.
Gerontol. 28, 233–247. doi: 10.1016/0531-5565(93)90031-8
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., et al.
(2012). A PGC1-α-dependent myokine that drives brown-fat-like development
of white fat and thermogenesis. Nature 481, 463–468. doi: 10.1038/nature10777
Bruun, J. M., Helge, J. W., Richelsen, B., and Stallknecht, B. (2006). Diet and
exercise reduce low-grade inflammation and macrophage infiltration in adipose
tissue but not in skeletal muscle in severely obese subjects.Am. J. Physiol. Metab.
290, E961–E967. doi: 10.1152/ajpendo.00506.2005
Carriere, A., Jeanson, Y., Berger-Muller, S., Andre, M., Chenouard, V., Arnaud, E.,
et al. (2014). Browning of white adipose cells by intermediate metabolites:
an adaptive mechanism to alleviate redox pressure. Diabetes 63, 3253–3265.
doi: 10.2337/db13-1885
Chen, N., Cheng, J., Zhou, L., Lei, T., Chen, L., Shen, Q., et al. (2015). Effects of
treadmill running and rutin on lipolytic signaling pathways and TRPV4 protein
expression in the adipose tissue of diet-induced obese mice. J. Physiol. Biochem.
71, 733–742. doi: 10.1007/s13105-015-0437-5
Danner, S. A., Wieling, W., Havekes, L., Leuven, J. G., Smit, E. M., and Dunning,
A. J. (1984). Effect of physical exercise on blood lipids and adipose tissue
composition in young healthy men. Atherosclerosis 53, 83–90. doi: 10.1016/
0021-9150(84)90108-4
Feldman, B. J., Streeper, R. S., Farese, R. V., and Yamamoto, K. R. (2006). Myostatin
modulates adipogenesis to generate adipocytes with favorable metabolic effects.
Proc. Natl. Acad. Sci. U.S.A. 103, 15675–15680. doi: 10.1073/pnas.0607501103
Gao, S., Li, F., Li, H., Huang, Y., Liu, Y., and Chen, Y. (2016). Effects and
molecular mechanism of GST-Irisin on lipolysis and autocrine function in
3T3-L1 adipocytes. PLoS One 11:e0147480. doi: 10.1371/journal.pone.0147480
Garaulet, M., Hernandez-Morante, J. J., Lujan, J., Tebar, F. J., and Zamora, S.
(2006). Relationship between fat cell size and number and fatty acid
composition in adipose tissue from different fat depots in overweight/obese
humans. Int. J. Obes. 30, 899–905. doi: 10.1038/sj.ijo.0803219
Görgens, S. W., Eckardt, K., Jensen, J., Drevon, C. A., and Eckel, J. (2015). Exercise
and regulation of adipokine and myokine production. Prog. Mol. Biol. Transl.
Sci. 135, 313–336. doi: 10.1016/bs.pmbts.2015.07.002
Halliwell, K. J., Fielding, B. A., Samra, J. S., Humphreys, S. M., and Frayn, K. N.
(1996). Release of individual fatty acids from human adipose tissue in vivo after
an overnight fast. J. Lipid Res. 37, 1842–1848.
Holland, A. M., Kephart, W. C., Mumford, P. W., Mobley, C. B., Lowery, R. P.,
Shake, J. J., et al. (2016). Effects of a ketogenic diet on adipose tissue, liver, and
serum biomarkers in sedentary rats and rats that exercised via resisted voluntary
wheel running. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311, R337–R351.
doi: 10.1152/ajpregu.00156.2016
Indrakusuma, I., Sell, H., and Eckel, J. (2015). Novel mediators of adipose tissue and
muscle crosstalk. Curr. Obes. Rep. 4, 411–417. doi: 10.1007/s13679-015-0174-7
Jakicic, J. M., and Otto, A. D. (2005). Physical activity considerations for the
treatment and prevention of obesity. Am. J. Clin. Nutr. 82, 226S–229S. doi:
10.1093/ajcn/82.1.226S
Kang, S., Kim, K. B., and Shin, K. O. (2013). Exercise training improve leptin
sensitivity in peripheral tissue of obese rats. Biochem. Biophys. Res. Commun.
435, 454–459. doi: 10.1016/j.bbrc.2013.05.007
Kato, H., Shibahara, T., Rahman, N., Takakura, H., Ohira, Y., and Izawa, T. (2018).
Effect of a 9-week exercise training regimen on expression of developmental
genes related to growth-dependent fat expansion in juvenile rats. Physiol. Rep.
6:e13880. doi: 10.14814/phy2.13880
Kazemi, F., and Zahediasl, S. (2018). Effects of exercise training on adipose tissue
apelin expression in streptozotocin-nicotinamide induced diabetic rats. Gene
662, 97–102. doi: 10.1016/j.gene.2018.04.003
Klimcakova, E., Polak, J., Moro, C., Hejnova, J., Majercik, M., Viguerie, N., et al.
(2006). Dynamic strength training improves insulin sensitivity without altering
plasma levels and gene expression of adipokines in subcutaneous adipose tissue
in obese men. J. Clin. Endocrinol. Metab. 91, 5107–5112. doi: 10.1210/jc.2006-
0382
Lehnig, A. C., and Stanford, K. I. (2018). Exercise-induced adaptations to white and
brown adipose tissue. J. Exp. Biol. 221(Pt Suppl. 1):jeb161570. doi: 10.1242/jeb.
161570
Liu, X., Strable, M. S., and Ntambi, J. M. (2011). Stearoyl CoA desaturase 1: role
in cellular inflammation and stress. Adv. Nutr. 2, 15–22. doi: 10.3945/an.110.
000125
May, F. J., Baer, L. A., Lehnig, A. C., So, K., Chen, E. Y., Gao, F., et al. (2017).
Lipidomic adaptations in white and brown adipose tissue in response to exercise
demonstrate molecular species-specific remodeling. Cell Rep. 18, 1558–1572.
doi: 10.1016/j.celrep.2017.01.038
Mika, A., Kaska, L., Korczynska, J., Mirowska, A., Stepnowski, P., Proczko, M.,
et al. (2015). Visceral and subcutaneous adipose tissue stearoyl-CoA desaturase-
1 mRNA levels and fatty acid desaturation index positively correlate with BMI
in morbidly obese women. Eur. J. Lipid Sci. Technol. 117, 926–932. doi: 10.1002/
ejlt.201400372
Mika, A., and Sledzinski, T. (2017). Alterations of specific lipid groups in serum of
obese humans: a review. Obes. Rev. 18, 247–272. doi: 10.1111/obr.12475
Motiani, P., Virtanen, K. A., Motiani, K. K., Eskelinen, J. J., Middelbeek, R. J.,
and Goodyear, L. J. (2017). Decreased insulin-stimulated brown adipose tissue
glucose uptake after short-term exercise training in healthy middle-aged men.
Diabetes Obes. Metab. 19, 1379–1388. doi: 10.1111/dom.12947
Nikolaidis, M. G., and Mougios, V. (2004). Effects of exercise on the fatty-acid
composition of blood and tissue lipids. Sports Med. 34, 1051–1076. doi: 10.2165/
00007256-200434150-00004
Ntambi, J. M., and Miyazaki, M. (2003). Recent insights into stearoyl-
CoA desaturase-1. Curr. Opin. Lipidol. 14, 255–261. doi: 10.1097/01.mol.
0000073502.41685.c7
Petridou, A., Chatzinikolaou, A., Avloniti, A., Jamurtas, A., Loules, G.,
Papassotiriou, I., et al. (2017). Increased triacylglycerol lipase activity in adipose
tissue of lean and obese men during endurance exercise. J. Clin. Endocrinol.
Metab. 102, 3945–3952. doi: 10.1210/jc.2017-00168
Petridou, A., Nikolaidis, M. G., Matsakas, A., Schulz, T., Michna, H., and
Mougios, V. (2005). Effect of exercise training on the fatty acid composition of
lipid classes in rat liver, skeletal muscle, and adipose tissue. Eur. J. Appl. Physiol.
94, 84–92. doi: 10.1007/s00421-004-1294-z
Rao, R. R., Long, J. Z., White, J. P., Svensson, K. J., Lou, J., Lokurkar, I., et al.
(2014). Meteorin-like is a hormone that regulates immune-adipose interactions
to increase beige fat thermogenesis. Cell 157, 1279–1291. doi: 10.1016/j.cell.
2014.03.065
Roberts, L. D., Boström, P., O’Sullivan, J. F., Schinzel, R. T., Lewis, G. D., Dejam, A.,
et al. (2014). β-Aminoisobutyric acid induces browning of white fat and hepatic
β-oxidation and is inversely correlated with cardiometabolic risk factors. Cell
Metab. 19, 96–108. doi: 10.1016/j.cmet.2013.12.003
Rocha-Rodrigues, S., Rodríguez, A., Becerril, S., Ramírez, B., Gonçalves, I. O.,
Beleza, J., et al. (2017a). Physical exercise remodels visceral adipose tissue and
mitochondrial lipid metabolism in rats fed a high-fat diet. Clin. Exp. Pharmacol.
Physiol. 44, 386–394. doi: 10.1111/1440-1681.12706
Rocha-Rodrigues, S., Rodríguez, A., Gonçalves, I. O., Moreira, A., Maciel, E.,
Santos, S., et al. (2017b). Impact of physical exercise on visceral adipose tissue
fatty acid profile and inflammation in response to a high-fat diet regimen. Int.
J. Biochem. Cell Biol. 87, 114–124. doi: 10.1016/j.biocel.2017.04.008
Romain, A. J., Carayol, M., Desplan, M., Fedou, C., Ninot, G., Mercier, J., et al.
(2012). Physical activity targeted at maximal lipid oxidation: a meta-analysis.
J. Nutr. Metab. 2012:285395. doi: 10.1155/2012/285395
Rönn, T., Volkov, P., Tornberg, Å., Elgzyri, T., Hansson, O., Eriksson, K.-
F., et al. (2014). Extensive changes in the transcriptional profile of human
adipose tissue including genes involved in oxidative phosphorylation after a
6-month exercise intervention. Acta Physiol. 211, 188–200.doi:10.1111/apha.
12247
Ruschke, K., Fishbein, L., Dietrich, A., Klöting, N., Tönjes, A., Oberbach, A., et al.
(2010). Gene expression of PPARgamma and PGC-1alpha in human omental
and subcutaneous adipose tissues is related to insulin resistance markers and
mediates beneficial effects of physical training. Eur. J. Endocrinol. 162, 515–523.
doi: 10.1530/EJE-09-0767
Shirvani, H., and Arabzadeh, E. (2018). Metabolic cross-talk between skeletal
muscle and adipose tissue in high-intensity interval training vs. moderate-
intensity continuous training by regulation of PGC-1α. Eat. Weight Disord.
doi: 10.1007/s40519-018-0491-4 [Epub ahead of print].
Frontiers in Physiology | www.frontiersin.org 6 January 2019 | Volume 10 | Article 2698
fphys-10-00026 January 24, 2019 Time: 16:14 # 7
Mika et al. Effect of Exercise on Adipose Tissue Metabolism
Sjögren, P., Sierra-Johnson, J., Kallings, L. V., Cederholm, T., Kolak, M.,
Halldin, M., et al. (2012). Functional changes in adipose tissue in a randomised
controlled trial of physical activity. Lipids Health Dis. 11:80. doi: 10.1186/1476-
511X-11-80
Stallknecht, B., Vinten, J., Ploug, T., and Galbo, H. (1991). Increased activities of
mitochondrial enzymes in white adipose tissue in trained rats. Am. J. Physiol.
261, E410–E414. doi: 10.1152/ajpendo.1991.261.3.E410
Stanford, K. I., and Goodyear, L. J. (2016). Exercise regulation of adipose tissue.
Adipocyte 5, 153–162. doi: 10.1080/21623945.2016.1191307
Stanford, K. I., Middelbeek, R. J., and Goodyear, L. J. (2015a). Exercise effects on
white adipose tissue: beiging and metabolic adaptations. Diabetes 64, 2361–
2368. doi: 10.2337/db15-0227
Stanford, K. I., Middelbeek, R. J., Townsend, K. L., Lee, M.-Y., Takahashi, H.,
So, K., et al. (2015b). A novel role for subcutaneous adipose tissue in exercise-
induced improvements in glucose homeostasis. Diabetes 64, 2002–2014. doi:
10.2337/db14-0704
Steinberg, G. R. (2009). Role of the AMP-activated protein kinase in regulating
fatty acid metabolism during exercise. Appl. Physiol. Nutr. Metab. 34, 315–322.
doi: 10.1139/H09-009
Sutherland, L. N., Bomhof, M. R., Capozzi, L. C., Basaraba, S. A. U., and Wright,
D. C. (2009). Exercise and adrenaline increase PGC-1{alpha} mRNA expression
in rat adipose tissue. J. Physiol. 587, 1607–1617. doi: 10.1113/jphysiol.2008.
165464
Sutherland, W. H., Woodhouse, S. P., and Heyworth, M. R. (1981). Physical
training and adipose tissue fatty acid composition in men. Metabolism 30,
839–844. doi: 10.1016/0026-0495(81)90061-5
Swierczynski, J., and Sledzinski, T. (2012). “The role of adipokines and
gastrointestinal tract hormones in obesity,” in Principles of Metabolic
Surgery, eds W. K. Karcz and O. Thomusch (Berlin: Springer),
53–79.
Vernochet, C., Mourier, A., Bezy, O., Macotela, Y., Boucher, J., Rardin, M. J., et al.
(2012). Adipose-specific deletion of TFAM increases mitochondrial oxidation
and protects mice against obesity and insulin resistance. Cell Metab. 16, 765–
776. doi: 10.1016/j.cmet.2012.10.016
Vosselman, M. J., Hoeks, J., Brans, B., Pallubinsky, H., Nascimento, E. B., van
der Lans, A. A., et al. (2015). Low brown adipose tissue activity in endurance-
trained compared with lean sedentary men. Int. J. Obes. 39, 1696–1702. doi:
10.1038/ijo.2015.130
Woo, J., and Kang, S. (2016). Diet change and exercise enhance protein expression
of CREB, CRTC 2 and lipolitic enzymes in adipocytes of obese mice. Lipids
Health Dis. 15:147. doi: 10.1186/s12944-016-0316-2
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., et al. (2012).
Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human.
Cell 150, 366–376. doi: 10.1016/j.cell.2012.05.016
Xu, X., Ying, Z., Cai, M., Xu, Z., Li, Y., Jiang, S. Y., et al. (2011). Exercise
ameliorates high-fat diet-induced metabolic and vascular dysfunction, and
increases adipocyte progenitor cell population in brown adipose tissue. Am. J.
Physiol. Integr. Comp. Physiol. 300, R1115–R1125. doi: 10.1152/ajpregu.00806.
2010
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The handling Editor is currently co-organizing a Research Topic with one of the
authors VD, and confirms the absence of any other collaboration.
Copyright © 2019 Mika, Macaluso, Barone, Di Felice and Sledzinski. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Physiology | www.frontiersin.org 7 January 2019 | Volume 10 | Article 2699
fphys-10-00042 January 28, 2019 Time: 18:42 # 1
MINI REVIEW




University of São Paulo, Brazil
Reviewed by:
Kunihiro Sakuma,
Tokyo Institute of Technology, Japan
Nicolas J. Pillon,







This article was submitted to
Striated Muscle Physiology,
a section of the journal
Frontiers in Physiology
Received: 05 November 2018
Accepted: 14 January 2019
Published: 30 January 2019
Citation:
Lee JH and Jun H-S (2019) Role
of Myokines in Regulating Skeletal
Muscle Mass and Function.
Front. Physiol. 10:42.
doi: 10.3389/fphys.2019.00042
Role of Myokines in Regulating
Skeletal Muscle Mass and Function
Jong Han Lee1,2* and Hee-Sook Jun1,2,3*
1 College of Pharmacy, Gachon University, Incheon, South Korea, 2 Lee Gil Ya Cancer and Diabetes Institute, Gachon
University, Incheon, South Korea, 3 Gachon University Gil Medical Center, Gachon Medical and Convergence Institute,
Incheon, South Korea
Loss of skeletal muscle mass and strength has recently become a hot research topic
with the extension of life span and an increasingly sedentary lifestyle in modern society.
Maintenance of skeletal muscle mass is considered an essential determinant of muscle
strength and function. Myokines are cytokines synthesized and released by myocytes
during muscular contractions. They are implicated in autocrine regulation of metabolism
in the muscle as well as in the paracrine/endocrine regulation of other tissues and
organs including adipose tissue, the liver, and the brain through their receptors. Till
date, secretome analysis of human myocyte culture medium has revealed over 600
myokines. In this review article, we summarize our current knowledge of major identified
and characterized myokines focusing on their biological activity and function, particularly
in muscle mass and function.
Keywords: muscular contraction, myocytes, myokines, skeletal muscle mass, muscle strength
INTRODUCTION
The muscle is a tissue composed of cells or fibers that produce force and movement of the body.
They are primarily responsible for maintaining and changing body position, locomotion as well as
the movement of internal organs. Different types of muscles perform different functions according
to their location and type. Skeletal muscles are one of the most dynamic tissues involved in
voluntary contraction according to command (Frontera and Ochala, 2015; Noto and Edens, 2018).
They comprise approximately 40% of the total body weight (Frontera and Ochala, 2015; Noto and
Edens, 2018). In contrast, cardiac and smooth muscles are associated with involuntary contraction
without awareness (Frontera and Ochala, 2015; Hafen and Burns, 2018; Noto and Edens, 2018).
Smooth muscles are found throughout the body and tightly regulate many of the body subsystems
implicated in maintaining survival (Hafen and Burns, 2018).
Myokines are cytokines or peptides synthesized and released by myocytes in muscle tissue in
response to muscular contractions (Pedersen et al., 2007). The term “myokine” was first introduced
by a Swedish scientist, Bengt Saltin, in 2003 (Pedersen et al., 2003). Myokines are implicated in
the autocrine regulation of metabolism in muscles as well as in the para/endocrine regulation
of other tissues and organs including the adipose tissue, liver, and brain (Carson, 2017) through
their receptors. Since myostatin was first identified as a myokine in 1997, secretome-based analysis
of human myocyte culture medium has revealed over 600 myokines till date (Gorgens et al.,
2015). However, the majority of these myokines are still not sufficiently characterized. Only few
of them have been studied for their biological activity and function and have provided some
clear evidence as being released directly from muscle contraction. Moreover, studies potentially
associated with muscle atrophy barely exist. Understanding the biological and physiological roles
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of these myokines in skeletal muscle atrophy or weakness is
important and valuable to find novel targets for therapeutic
intervention.
In this review, we summarize our current knowledge focusing
on myokines released directly by muscle contraction and their
potential roles associated with skeletal muscle mass and function.
MYOSTATIN
Myostatin, growth differentiation factor 8, was the first identified
myokine in 1997 by Se-Jin Lee and his colleagues (McPherron
et al., 1997). It is encoded by the myostatin gene and is known
as a highly conserved member of the TGF beta protein family
(McPherron et al., 1997). It is abundantly expressed in skeletal
muscles, but is also expressed to a lesser extent in cardiac muscles
and fat tissues (McPherron et al., 1997; Sharma et al., 1999).
Myostatin levels in the plasma of healthy young men has been
shown to significantly decrease within 24 h post-exercise when
compared to pre-exercise and has also been shown to positively
correlate with plasma IL-6 (Kazemi, 2016). In contrast, serum
myostatin has been shown to increase in patients with spinal cord
injury after aerobic exercise (Han et al., 2016). Although heavily
contradicting reports exist on both sides, circulating myostatin
shows an obvious increase in females rather than males during
sarcopenia (Bergen et al., 2015), and a decrease in cancer-cachexia
(Loumaye and Thissen, 2017) and generic neuromuscular disease
patients (Awano et al., 2008; Anaya-Segura et al., 2015; Burch
et al., 2017).
The effects of myostatin are mediated through the activin type
IIB receptor (ActRIIB), which is expressed ubiquitously (Pistilli
et al., 2011; Amthor and Hoogaars, 2012). The downstream
mediators of myostatin, Smad2 and Smad3, are phosphorylated
and form a complex with Smad4. This complex in turn stimulates
FoxO-dependent transcription and regulates the transcription
of genes associated with the proliferation and differentiation in
skeletal muscle precursor cells as well as protein degradation
pathways (such as the ubiquitin-proteasome processes, and
autophagy) in mature myofibers (Burks and Cohn, 2011; Han
et al., 2013). In addition, myostatin-mediated Smad signaling
activation inhibits protein synthesis in muscle tissues by
suppressing the Akt-mediated mTOR signaling pathway (Han
et al., 2013). Functionally, myostatin is a negative regulator
of muscle growth thereby leading to inhibition of myogenesis
through muscle cell differentiation and growth (McPherron
et al., 1997). Animals blocking myostatin activity with substance
show significantly increased muscle mass (myofiber hypertrophy
rather than hyperplasia) (Morvan et al., 2017). In myostatin-
knockout mice, the muscle mass is approximately twice increased
compared to that in normal mice (McPherron et al., 1997).
In humans, individuals with mutations in both copies of the
myostatin gene showed significantly increased muscle mass
and muscle strength compared to that observed in normal
individuals (Schuelke et al., 2004). Growing evidence indicates
that increasing myostatin and its analog activin A contribute to
the incidence of muscle atrophy (Morvan et al., 2017). Thus,
myostatin is considered a promising target molecule for the
treatment of muscle wasting. In the past two decades, several
agents, such as follistatin (myostatin antagonist), and selective
antibody-based approaches targeting ActR-IIB, myostatin, and
activin A were developed to antagonize/suppress myostatin
signaling. These molecules were evaluated under various
pathological conditions such as muscular wasting or atrophy.
For example, a myostatin antibody, MYO-029/stamulumab, was
tested in broad muscle dystrophic models, including Becker’s
muscular dystrophy (BMD) and facioscapulohumeral dystrophy,
but failed to show clinical efficacy in elevating muscle strength
(Leung et al., 2015). Overexpression of the follistatin isoform,
FS344, using an AVV vector showed improved ambulation in
patients with BMD and inclusion body myositis (Al-Zaidy et al.,
2015; Mendell et al., 2015; Mendell et al., 2017). However, so far
none of these treatments have proven to be clinically sufficient as
shown in Table 1 (Cohen et al., 2015; Mariot et al., 2017). There
are still obstacles (such as lack of target specificity and potential
clinical toxicities) to overcome for their use in human patients.
In addition, a recent study showed that activin A prominently
regulates muscle mass in primates than does myostatin in rodents
(Busquets et al., 2012; Cohen et al., 2015), suggesting that
targeting myostatin alone may not be sufficient to treat muscle
atrophy in humans.
IRISIN
Irisin is a cleaved form of Fibronectin type III domain-containing
protein 5 (FNDC5), which was simultaneously discovered by
two independent groups in 2002 (Teufel et al., 2002; Colaianni
et al., 2014) It was first reported as a potential mediator of the
beneficial effect of exercise (Raschke et al., 2013b). Initially, the
expression of PGC1α in muscle stimulates FNDC5 expression,
which drives brown fat-like development of white fat cells named
beige cells and increases thermogenesis (Bostrom et al., 2012).
Although exercise-induced increase in the level of irisin in the
blood is heavily debated (Pekkala et al., 2013), many reports have
continuously shown an increase in FNDC5 mRNA expression
upon exercise in rodent models (Dun et al., 2013; Roberts
et al., 2013) and humans (Huh et al., 2012; Lecker et al., 2012),
thus triggering renewed interest in exercise-induced myokines.
In line with these observations, expression of mitochondrial-
specific transcription factors, such as PGC-1α and mitochondrial
transcription factor A, increases in C2C12 myotubes exposure
to recombinant irisin for 24 h. They are all involved in elevated
mitochondrial content and oxygen consumption (Vaughan et al.,
2015). Moreover, irisin and myostatin are inversely secreted
from skeletal muscles after physical exercise (MacKenzie et al.,
2013), thereby suggesting its potential myogenic role. Reza
et al. reported that irisin induced skeletal muscle hypertrophy
and attenuated denervation-induced atrophy by activating IL-6
signaling in rodents (Reza et al., 2017). The effects of irisin on
hypertrophy were shown to be established by the activation of
muscle satellite cells and elevation of protein synthesis (Reza
et al., 2017). This study substantially opened up potential research
avenues on irisin with respect to muscle atrophy. Moreover,
a latest study showed that circulating irisin levels were lower
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TABLE 1 | Summary of current trials of myostatin-activin pathway inhibitors.













Myostatin peptide AMG-745/PINTA-745 Chronic kidney disease Dropped
Activin A antibody REGN-2477 Healthy subjects Ongoing
ActRllb-FC (myostatin decoy
receptor)
ACE-031 Duchenne muscular dystrophy Dropped
Anti-myostatin adnectin BMS-986089 Ambulatory boys with DMD Ongoing
ActRIIB antibody BYM-338/Bimagrumab Cancer cachexia Sarcopenia
Type 2 diabetes
Ongoing
Myostatin antagonist Follistatin isoform FS344 Becker muscular dystrophy Ongoing
ACE-031, Ramatercept; REGN, Trevogrumab; BMD, Becker’s muscular dystrophy; FSHD, Facioscapulohumeral dystrophy; LGMD, limb-girdle muscular dystrophy.
in women with postmenopausal sarcopenia when compared to
those with pre-sarcopenia and that they negatively correlated
with the quadricep cross-sectional area (Park et al., 2018),
suggesting that irisin may also function as a potential pro-
myogenic factor in human pathological conditions. Further
studies are needed to reveal the biological effects of human irisin
and the underlying mechanism in human skeletal muscles.
IL-6
Interleukin 6 (IL-6) was identified in 2000 and is the most studied
myokine (Steensberg et al., 2000; Pedersen and Febbraio, 2008).
It is secreted from muscles into the blood vessel in response to
muscle contractions (Pedersen and Febbraio, 2008), by which
skeletal muscles communicate with central and peripheral organs
(Pedersen et al., 2003). The circulatory level of IL-6 is affected by
both the duration and intensity of muscle contraction in humans
(Steensberg et al., 2000; Helge et al., 2003). Interestingly, IL-6
is highly produced and released after post-exercise while insulin
action is enhanced. However, IL-6 is also associated with obesity
and insulin resistance (Pedersen and Febbraio, 2008). IL-6 has an
insulin-like effect on glucose metabolism. IL-6 increases insulin-
stimulated glucose disposal in humans as well as glucose uptake
and fatty acid oxidation in vitro through AMP-activated protein
kinase and PI3K-Akt signaling pathways (Al-Khalili et al., 2006;
Carey et al., 2006). Individuals with spinal cord injury (SCI) are
prone to develop metabolic diseases due to the lack of exercise-
related IL-6 response, suggesting that IL-6 plays a pivotal role in
regulating glucose homeostasis (Kouda et al., 2012).
On the other hand, the role of IL-6 on muscle atrophy seems
to be a negative effect rather than a beneficial effect. Increased
circulating angiotensin II (AngII) reduces lean body mass in
chronic kidney disease. In mice, AngII infusion resulted in
increased circulating IL-6 and its hepatic production, suggesting
that AngII-induced inflammation might be a trigger for muscle
loss (Zhang et al., 2009). In contrast, AngII-induced muscle
atrophy was suppressed in IL-6-deficient mice (Zhang et al.,
2009). IL-6 is overproduced in patients with Duchenne muscular
dystrophy and in muscles of the mdx animal model. Inhibition
of IL-6 activity with an interleukin-6 receptor (Il-6r) neutralizing
antibody attenuates the dystrophic phenotype, severe muscle
degeneration, inflammation, as well as accumulation of non-
functional fat and fibrotic tissues (Wada et al., 2017). In
addition, pharmacological inhibition of IL-6 activity in mdx male
mice inhibits anti-inflammatory responses and improvement in
muscle repair (Pelosi et al., 2015). Therefore, inhibition of IL-6
might be beneficial for preventing muscle loss.
BRAIN-DERIVED NEUROTROPHIC
FACTOR
Brain-derived neurotrophic factor (BDNF) is the second
member of the neurotrophin family of growth factors, which
regulates neuronal survival, plasticity, growth, and death through
tropomyosin-related kinase receptor B (TrkB). It was for the
first time purified from pig brain in 1982 (Barde et al.,
1982). After 11 years, the BDNF gene was identified by two
independent groups (Metsis et al., 1993; Binder and Scharfman,
2004). Initially, BDNF has been studied mostly in relation with
nervous system development and function (Clow and Jasmin,
2010). However, the expression of several neurotrophin receptors
is identified in skeletal muscles, thus implicating the certain
role of BDNF. Indeed, Chevrel et al. (2006) reported that
BDNF is differentially expressed in skeletal muscles according
to physiological or pathological conditions. In adult skeletal
muscles, BDNF is also expressed in muscle satellite cells (Mousavi
et al., 2004) and is upregulated in muscle injury followed by
the activation and proliferation of satellite cells, suggesting that
BDNF might play an important role in mediating the satellite
cell response to muscle injury (Omura et al., 2005). Jasmin
et al. showed that BDNF substantially regulates satellite cell
differentiation and skeletal muscle regeneration, by using BDNF
null and muscle-specific BDNF KO mice (Clow and Jasmin,
2010). These results indicate that BDNF might be involved in the
regulation of damaged muscles. Although there are many studies
associated with the role of BDNF in muscle development and
function, there is no clear evidence indicating that it is a myokine.
In fact, the effect of muscle contraction on circulating BDNF
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FIGURE 1 | The function of muscle contraction-induced myokines. The figure shows the selected the functions for each myokines released from muscle contraction
(exercise) in muscle. BDNF, brain-derived neurotrophic factor; FGF21, fibroblast growth factor 21; SPARC, secreted protein acidic and rich in cysteine; IL, interleukin.
levels is controversial. Some studies have reported no change
in serum BDNF right after either acute or chronic exercise.
On the other hand, several studies have shown that circulating
BDNF increases with physical exercise (Ferris et al., 2007; Yarrow
et al., 2010; Pereira et al., 2018). In skeletal muscle cells, BDNF
mRNA expression is increased by contraction and increased fat
oxidation through activation of AMP-activated protein kinase
(Matthews et al., 2009). Overall, these studies suggest that muscle-
derived BDNF is important for regulating muscle regeneration
right after muscle injury. However, many key questions on
the biological functions of BDNF in skeletal muscles remain
unresolved. A major issue would be to elucidate the mechanism
by which BDNF regulates satellite cell differentiation and skeletal
muscle regeneration, and in which BDNF substantially recover
muscle strength and function. Manipulating BDNF may thus
represent an important therapeutic tool for alleviating dystrophic
muscle atrophy.
IL-15
Interleukin-15 (IL-15) is a cytokine with a structure similar to
interleukin-2 (IL-2). It was discovered by two different research
groups in 1994 and was characterized as a T cell growth factor
(Steel et al., 2012). Later on, several studies showed that IL-
15 is accumulated in the muscles as a result of regular exercise
training, indicating that it is a myokine (Pedersen, 2011; Tamura
et al., 2011; Brunelli et al., 2015). Moreover, IL-15 mRNA
expression is upregulated along with myoblast differentiation
(Pedersen and Febbraio, 2008). Supportively, several studies
showed that exogenously treated IL-15 or IL-15 overexpression
promotes myoblast differentiation and increases muscle mass in
the mouse C2 skeletal myogenic cell line (Quinn et al., 1995,
2002). In rats with cancer cachexia, IL-15 treatment attenuates
skeletal muscle wasting by suppressing protein degradation
through inhibition of the ATP-dependent ubiquitin proteolytic
pathway (Carbo et al., 2000). IL-15 administration was found
to improve diaphragm strength with increased muscle fiber
cross-sectional area and decreased collagen accumulation in
dystrophic mdx mice (Harcourt et al., 2005). In contrast, systemic
infusion of IL-15 induces muscle atrophy in skeletal muscles
of rodents (Pistilli and Alway, 2008). IL-15 treatment increased
the glucose uptake in skeletal muscle cells via activation of
the Jak3/STAT3 signaling pathway (Krolopp et al., 2016) or
the AMPK signaling pathway (Gray and Kamolrat, 2011). In
addition, Quinn L et al. and coworkers reported that IL-
15 transgenic mice exhibited increased fat oxidation, energy
expenditure and running endurance even with lower muscle
mass compared to that in wild type mice. Interestingly, these
mice also expressed troponin I and myosin heavy chain
mRNA isoform indicating the conversion of muscles to a more
oxidative phenotype (Quinn et al., 2013; Chalkiadaki et al.,
2014). Collectively, the above controversial reports indicate that
IL-15 acts differently according to the normal and pathological
conditions. Thus, further studies should be focused on clarifying
the different factors influencing the varying roles of IL-15
between different physiological conditions.
MYONECTIN (CTRP15)
Myonectin is a myokine belonging to the C1q/TNF-related
protein (CTRP) family, and was discovered by Seldin et al. (2012).
It is a novel nutrient-responsive myokine secreted from skeletal
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FIGURE 2 | Signaling pathways of muscle contraction-induced myokines. The myokine-mediated signaling pathways lead to its target genes expression, which in
turn regulate muscle cell proliferation, differentiation, and growth. It ultimately increases/decreases muscle mass. ALK, activin receptor-like kinase; ActRIIB, activin
type IIB receptor; BDNF, brain-derived neurotrophic factor; TrKB, tropomyosin-related kinase receptor B; FGF21, fibroblast growth factor 21; SPARC, secreted
protein acidic and rich in cysteine.
muscles (Seldin et al., 2012; Peterson et al., 2014). Myonectin is
released into the blood stream by muscular contraction, and is
functionally similar to insulin as it promotes fatty acid uptake into
cells by increased expression of fatty acid transport genes (CD36,
FATP1, Fabp1, and Fabp4) (Seldin and Wong, 2012; Seldin et al.,
2012). In the mouse liver and cultured hepatocytes, recombinant
myonectin treatment suppresses starvation-induced autophagy
by inhibiting LC3-dependent autophagosome formation, p62
degradation, and other autophagy-related genes expression.
Furthermore, the ability of myonectin to suppress autophagy
is abolished by inhibition of the PI3K/Akt/mTOR signaling
pathway (Seldin et al., 2013). Autophagy is considered to be a
mechanism that induces muscle atrophy (Bonaldo and Sandri,
2013). In addition, the PI3K/Akt signaling pathway is involved
in anabolic responses in the body. Therefore, these observations
indicate that myonectin may play an important role in increasing
muscle mass by elevating protein synthesis and inhibiting
protein degradation. On a related note, mitochondrial content
in muscles is an important determinant for muscle type and
function. Myonectin is remarkably increased following depletion
of mtDNA and increases glucose uptake and fatty acid oxidation
through activation of the AMPK signaling pathway in rat skeletal
myocytes (Park et al., 2009; Lim et al., 2012). Interestingly,
oxidative, slow-twitch muscle fiber types express a higher level
of myonectin than does glycolytic, fast-twitch muscle fiber types,
suggesting that it may be involved in mitochondrial biogenesis
and sensing cellular energy state (Seldin and Wong, 2012).
However, there is no study associated with its biological function
and mechanism on muscle mass and muscle mitochondrial
biogenesis in normal physiology and in the diseased state.
DECORIN
Decorin is small leucine-rich proteoglycan identified as a
myokine by Kanzleiter et al. (2014). It is secreted in skeletal
muscles during muscular contraction and plays an important
role in muscle growth. Decorin directly binds to and inactivates
myostatin (a potent inhibitor of muscle growth) in a zinc-
dependent manner, and inhibits its anti-myogenic effects (El
Shafey et al., 2016). In vivo over-expression of Decorin in murine
skeletal muscles promotes expression of the pro-myogenic factor
Mighty (Marshall et al., 2008). Mighty is ubiquitously expressed
but appears to be negatively regulated by myostatin in skeletal
muscles. Decorin overexpression increases the expression of
Myod1 and follistatin, whereas it reduces the muscle-specific
ubiquitin ligases atrogin1 and MuRF1 (Marshall et al., 2008).
Thus, Decorin might act as a myogenic factor and might be a
possible therapeutic target for the treatment of muscle wasting.
FIBROBLAST GROWTH FACTOR
(FGF) 21
Fibroblast growth factors (FGFs) are signaling proteins with
diverse biological functions in development and metabolism.
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FGFs are classified as para, intra, and endocrine according
to their action manners. Paracrine FGFs mostly function as
local signaling molecules in developmental processes whereas
intracrine FGFs mainly serve as intracellular molecules in
neuronal processes (Itoh and Ornitz, 2011). FGF21 functions
as endocrinal hormone-like or local signaling molecules in
metabolism. FGF21 does not have proliferative activity as
other paracrine and endocrine FGFs family and is only
associated with metabolism (Itoh, 2014). FGFs activate several
intracellular signaling pathways including phosphatidylinositol
3-kinase (PI3K)/serine-threonine protein kinase AKT, signaling
transducer and activator of transcription (STAT), mitogen
activation protein kinase (MAPK), and phosphoinositide
phospholipase C (PLC) γ (Itoh, 2014). Specifically, FGF21 acts
through FGF receptor 1c with β-Klotho as a cofactor. Skeletal
muscle-specific Akt1 transgenic mice showed skeletal muscle
fiber hypertrophy with increasing Fgf21 expression in the muscle
and in serum indicating that FGF21 plays an important role in
regulating muscle mass (Izumiya et al., 2008). In addition, FGF21
expression is coupled to mitochondrial dysfunction and insults
of various stresses in skeletal muscles. Autophagy deficiency
and subsequent mitochondrial dysfunction elevates the level of
FGF21 as a myokine, thereby protecting against diet-induced
obesity and insulin resistance (Kim et al., 2013; Keipert et al.,
2014). In cultured myoblasts, mitochondrial complex inhibitor
treatment increased expression by promoting the binding of
activating transcription factor 2 (ATF2) for the promoter region
of the Fgf21 gene (Ribas et al., 2014). Moreover, in human brain
vascular smooth muscle cells, FGF21 protects against angiotensin
II-induced cerebrovascular aging by elevating mitochondrial
biogenesis (Wang et al., 2016). All the above studies suggest
that FGF21 may be potentially involved in switching muscle
type and regulating mitophagy, thereby regulating muscle mass
and function. Thus, targeting FGF21 might be an attractive
approach to treat mitochondrial-based myopathy and muscle
dysfunction.
SECRETED PROTEIN ACIDIC AND RICH
IN CYSTEINE (SPARC)
Aoi et al. (2013) reported SPARC/osteonectin as a novel myokine,
which is released from the skeletal muscles of both humans and
mice after exercise, even though it was identified earlier (Aoi
et al., 2013). Exercise-stimulated SPARC secretion was shown
to inhibit colon tumorigenesis by enhancing apoptosis in colon
cancer cells (Aoi et al., 2013). SPARC was also shown to be
upregulated in inherited and idiopathic muscle wasting diseases
such as Duchenne muscular dystrophy and congenital muscular
dystrophy (Jorgensen et al., 2009). SPARC overexpression almost
completely abolished myogenic differentiation in the muscle
progenitor cell line, C2C12 (Petersson et al., 2013). Thus, SPARC
may play a certain functional role in the repair of muscle damage
in muscle satellite cells. However, very limited studies associated
with the role of myokines are currently available. Further studies
need to first determine and address the expression profile and
role of SPARC in muscle development and regeneration. The
underlying signaling pathways also need to be studied in detail.
CONCLUSION
Skeletal muscle atrophy is an emerging medical problem
worldwide owing to increasing elderly populations and various
classical reasons including genetic mutation, disease-derived
cachexia, and accidents. However, although our understanding
of molecular mechanisms regulating muscle atrophy/muscle
weakness has substantially progressed, there is no specific
treatment for muscle atrophy. Recently, a number of myokines
have been identified through secretome analysis and some
have proven to be very informative while searching for novel
myokines (Raschke et al., 2013a; Hartwig et al., 2014; Grube
et al., 2018). However, the majority of myokines are not
still sufficiently characterized with regard to their biological
activity and function. Only few myokines have been restrictively
characterized (Figure 1) and their potential signaling pathways,
implicated in muscle cell proliferation, differentiation, and
growth in order to maintain muscle mass, muscle strength, and
function, been identified (Figure 2). Therefore, it is important
to better understand their precise role and function on skeletal
muscles under normal physiological and pathophysiological
conditions. Targeting novel myokines for either increasing or
suppressing their functional activity in certain pathological states
could be an attractive novel therapeutic tool for combating
skeletal muscle atrophy.
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The purpose of this study was to investigate if exertional rhabdomyolysis induced
by an acute bout of plyometric exercise in untrained individuals was associated with
histological characteristics of skeletal muscle, creatine kinase (CK) polymorphism or
secondary damage. Twenty-six healthy male untrained individuals completed a bout
of plyometric exercise (10 sets of 10 maximal squat jumps, with each standardized
to achieve at least 95% of individual maximal jump height). Blood samples were
taken, and perceived pain was scored immediately before the exercise intervention
and 6 h, 1, 2, and 3 days post-intervention. Muscle biopsies were collected 9 or
4 days before (baseline) and 3 days after plyometric jumps. Subjects were divided into
two groups, high (n = 10) and low responders (n = 16), based on a cut-off limit for
exertional rhabdomyolysis of peak CK activity ≥ 1000 U/L in any post-exercise blood
sample. Perceived pain was more severe assessed in squat than standing position. Low
responders perceived more pain at 6 h and 1 day, while high responders perceived more
pain than low responders on days three and four after exercise; structural (dystrophin
staining) and ultra-structural (transmission electron microscopy) analysis of muscle fibers
revealed no baseline pathology; damage was evident in all individuals in both groups,
with no difference between high and low responders in either damage or fiber type
proportion. High responders had significantly higher total white blood cell and neutrophil
counts 6 h and significantly higher C-reactive protein (CRP) 6 h and days one and
two after exercise compared to low responders. High responders had significantly
greater muscle myeloperoxidase (MPO) levels in baseline and 3 day post-exercise
biopsies compared to baseline of low responders. MLCK C49T single polymorphism
was present in 26% of volunteers, whose CK responses were not higher than those
with MLCK CC or CT genotype. In conclusion, perceived pain is more effectively
assessed with potentially affected muscle under eccentric strain, even if static. High
CK responders also have pronounced CRP responses to unaccustomed plyometric
exercise intervention. Exertional rhabdomyolysis after unaccustomed eccentric exercise
may be related to underlying inability to resolve intramuscular MPO.
Keywords: eccentric exercise and muscle damage, creatine kinase, myoglobin, single nucleotide polymorphism,
myeloperoxidase
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INTRODUCTION
Elevated circulating creatine kinase (CK) is a hallmark of muscle
damage caused by intense and unaccustomed exercise including
muscle-group targeted eccentric resistance exercise, downhill
running and plyometric jumping (Nosaka et al., 2001; Macaluso
et al., 2012b, 2013; van de Vyver and Myburgh, 2012). Literature
reports that certain individuals, despite apparently similar
characteristics to other study participants, may experience greater
increases in CK activity following unaccustomed eccentric
exercise (Clarkson et al., 2005; Devaney et al., 2007; Yamin
et al., 2008). This biological phenomenon remains unexplained
(Sayers and Clarkson, 2002).
Individuals who experience severe muscle damage may
present with exertional rhabdomyolysis which is characterized
by the continued release of myoglobin (Mb) into the circulation
(Sayers and Clarkson, 2002; Scalco et al., 2016). Typically,
elevations in CK and Mb go hand and in hand after extreme
bouts of unaccustomed eccentric exercise (Clarkson et al., 2005),
but CK activity is most commonly measured (Damas et al.,
2016). The laboratory diagnostic cut-off limit for exertional
rhabdomyolysis varies across studies and study populations
(Sayers and Clarkson, 2002; Warren et al., 2002; Lauritzen et al.,
2009), however, a lower limit for exertional rhabdomyolysis has
been suggested to be CK ≥ 1000 U/L (Lee and Clarkson, 2003;
Thoenes, 2010). Although this phenomenon is well described,
including the potential for clinical sequelae (Hill et al., 2017), the
potential mechanisms pre-disposing certain individuals remains
to be elucidated fully.
Potential role players could include background genetic
polymorphisms, the pre-exercise condition of skeletal muscle
itself or pre-exercise systemic profile – such as relative
leukocyte distribution or inflammatory processes. Several genetic
polymorphisms of skeletal muscle proteins have been associated
with exertional muscle damage variability. A few studies have
indicated that genes involved in muscle structure (ACTN3)
(Clarkson et al., 2005), growth (IGF2) (Devaney et al., 2007)
or regulation of force production (MYLK) (Clarkson et al.,
2005), can present polymorphisms that affect baseline CK
activity and exacerbate the muscle damage response to eccentric
exercise. Similarly, inflammation-related polymorphisms (TNFA
and IL6) have been associated with elevated CK activity following
unaccustomed eccentric exercise (Yamin et al., 2008). For a recent
review, see Baumert et al. (2016).
Muscle damage results in the activation and mobilization of
circulating leukocytes to the damaged area, where they release
reactive oxygen species (ROS) and proteolytic enzymes (Smith
et al., 2008). Oxidative stress has been shown to play an important
role in muscle damage (Lee and Clarkson, 2003; Yamin et al.,
2008) and redox individuality has been implicated in damage
variability observed after eccentric exercise (Margaritelis et al.,
2014). More specifically, neutrophils are early inflammatory
responders and known to be a source of oxidative stress (Vollaard
et al., 2005; Smith et al., 2008). In addition, myeloperoxidase
(MPO), which is also highly expressed in neutrophils and released
during the respiratory burst (Childs et al., 2001), is not an oxygen
radical per se, but at elevated concentrations is also known to
cause tissue damage. Schneider and Tiidus (2007) suggested
inclusion of intramuscular MPO assessment in investigations
aimed at elucidating the extent of neutrophil activity in muscle
(Schneider and Tiidus, 2007). Chronologically, in response to
mechanical damage and neutrophil-induced secondary damage,
C-reactive protein (CRP) dependent complement activation
facilitates removal of cellular debris (Pereira Panza et al., 2015).
CRP elevation after an acute bout of eccentric biceps exercise has
been shown to be sensitive to a nutritional intervention in the
form of a supplement containing antioxidants and docohexanoic
acid (Phillips et al., 2003). The supplement had no effect on
CK levels. This suggests that CRP should be investigated in
more detail as a biomarker of secondary damage following
unaccustomed exercise that may induce muscle damage.
Unaccustomed eccentric exercise damages type II muscle
fibers in greater proportion than type I fibers (Macaluso et al.,
2012b). Therefore, sedentary individuals with a larger percentage
of type II muscle fibers may present with higher values of the
indirect markers used to describe exertional muscle damage.
However, whether participants with higher proportions of Type
II fibers also present with higher CK activity responses, within the
range of exertional rhabdomyolysis, is currently not known.
The aim of this study was to probe in untrained individuals
different mechanisms which may predispose to exertional
rhabdomyolysis, induced by an acute bout of plyometric exercise
that results in varying levels of post-exercise circulating CK.
Variables assessed were selected from different categories of
potential contributors namely genetic background (MYLCK
genotype), skeletal muscle phenotype (fiber type; MPO content)
and inflammatory profile (circulating leukocytes; CRP).
MATERIALS AND METHODS
Study Design
The study was granted ethical clearance (reference no.
N09/05/164) by Sub-committee C of the Research Committee of
University of Stellenbosch. On the day of the plyometric exercise
intervention, blood samples and perceived pain scores were
collected both immediately before (day 0) and 6 h 1, 2, 3 and
4 days after exercise intervention; whilst muscle biopsies were
obtained 4 or 9 days before and 3 days after the acute bout of
plyometric exercise.
Subjects
Twenty-six healthy male untrained individuals
(age = 21.5 ± 1.6 years; height = 175.9 ± 8.9 cm;
weight = 73.0 ± 14.1 kg) were recruited. Participants were
informed of the criteria for inclusion and exclusion and all the
experimental procedures and associated risk before providing
written informed consent. All participants completed a habitual
and recent physical activity and health history questionnaire,
and they were healthy and had no medical contraindications
or any muscle or lower limb injury in the previous 6 months.
No participants were currently or chronically treated by any
corticosteroid-containing medication (including inhaled forms).
Exercise criteria for inclusion were: habitually physically active
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0–2 times per week without any systematic training of the
lower body; no plyometric exercise of the lower body other
than typical daily activities. All participants refrained from
unaccustomed exercise or vigorous physical activity during
the study. Volunteers were informed to maintain their normal
dietary habits, and not to take any anti-inflammatory drugs
(e.g., non-steroidal anti-inflammatory drugs) or nutritional
supplements (e.g., vitamins, protein/amino acids) during the
experimental period. The habitual exercise and healthy history
questionnaire confirmed that none of the participants practiced
plyometric exercise before the study.
Plyometric Exercise Intervention
Volunteer subjects first completed 5 min of backward and
forward running together with light stretching as a warm-up
before performing three maximal squat jumps. The maximal
height reached by the head was recorded and 95% of this height
served as a target height which subjects had to maintain during
the exercise intervention. The plyometric exercise intervention
consisted of 10 sets of 10 maximal squat jumps, separated by
1 min recovery time between sets. This protocol has previously
been used to induce transient muscle damage in the knee extensor
muscles (Vissing et al., 2008; Macaluso et al., 2012b). Subjects
were allowed to swing their arms which assisted with balance
and generating momentum with each jump. However, by not
adopting a 90◦ knee joint angle on landing and not maintaining
an upright trunk position and the minimum jump height all
constituted incorrect jumps. The jump technique was observed
by the researcher and when incorrect jumps were observed, the
subjects were instructed to stop and given a 1 min rest period
before completing that set, thereby completing 100 proper squat
jumps (Macaluso et al., 2012b). Static stretching for less than 60 s
was permitted since data in literature reported that this would not
affect maximal muscle performance (Kay and Blazevich, 2012).
Blood Sampling and Analysis
After an equilibration time of 5 min in a supine position,
blood samples were drawn from the antecubital vein and
collected in SST and EDTA vacutainer tubes (Becton Dickinson
and Company). Tubes were inverted 5–6 times, and then
centrifuged at 3500 rpm for 10 min at 4◦C. Blood samples were
then analyzed by commercial laboratory PathCare pathology
laboratory (Stellenbosch Medi Clinic, South Africa) for CK
activity (Access one-step sandwich assay CK-MB assay), Mb (Mb-
chemiluminescence), CRP (CRP-immunoturbidimetric method
Beckman Coulter, Inc.,), total and differential white blood cell
count (WBC) using a CellDyne 3700CS Hematology Analyzer
(Abbott Diagnostics, Fullerton, CA, United States).
High and Low Responders Groups
Subjects were categorized as high (n = 10) or low (n = 16)
responders based on CK activity: individuals for whom CK
activity at all time points assessed was lower than 1000 U/L, were
considered low responders, whereas individuals exhibiting CK
activity in access of 1000 U/L at any time point, were categorized
as high responders. In literature CK ≥ 1000 U/L has been
suggested to be lower limit for exertional rhabdomyolysis (Lee
and Clarkson, 2003; Thoenes, 2010).
From this point forth the groups will be defined as high
(height = 180 ± 0.05 cm; weight = 71.1 ± 10.05 kg;
95% jump height 211 ± 0.06 cm) and low responders
(height = 180 ± 0.11 cm; weight = 74.2 ± 16.37 kg; 95% jump
height 211 ± 0.14 cm).
Perceived Pain
Perceived pain was measured using a visual pain scale.
Participants indicated soreness of the knee-extensors ranging
from 0, None; 2, Discomfort; 4, Annoying; 6, Horrible; 8,
Dreadful; 10, Agonizing. This was done in two different
positions (standing and squatting position) as described by
Macaluso et al. (2012b).
Muscle Sampling
Muscle biopsies of vastus lateralis muscle were obtained 9 or
4 days prior and 3 days after the plyometric exercise intervention
using the suction-assisted technique (Macaluso et al., 2012a).
Biopsies were taken by a medical doctor experienced in the
technique and experienced in obtaining follow-up biopsies from
the same depth. The second biopsy was taken from the opposite
leg. Each biopsy was split into three parts: one was snap frozen
in liquid nitrogen, the second was embedded in tissue freezing
medium and frozen in isopentane (cooled in liquid nitrogen) for
subsequent cryosectioning and immunofluorescent microscopy,
and the third (1 × 3 mm) was fixed in 2.5% glutaraldehyde.
Immunofluorescence Staining
Cross sections of the muscle tissue were cut using a cryostat
microtome (Leica CM1100, Leica Microsystem Nussloch GmbH,
Germany) at −22◦C, mounted on slides and stored at −20◦C.
The next day the slides were brought to room temperature, rinsed
in 0.01 M phosphate buffered saline (PBS) containing 0.25%
Triton X-100 (15 min) and washed with PBS (3 × 5 min). The
following primary antibodies were used: MHC II (1:250; A4.74,
mouse monoclonal antibody, Developmental Studies Hybridoma
Bank, Iowa City, IA, United States) to identify fast twitch
muscle fibers and dystrophin (1:250, rabbit polyclonal, Santa
Cruz Biotechnology, Santa Cruz, CA, United States) to identify
the sarcolemma. The first primary antibody was left to incubate
for 1 h at room temperature, after which sections were revealed
with Alexa fluor 488 conjugated secondary antibody (1:250, goat
anti-mouse, Invitrogen, Eugene, OR, United States) and Alexa
fluor 594 (1:250, goat anti-rabbit, Invitrogen, Eugene) conjugated
secondary antibody for 1 h at room temperature. bisBenzimide H
33342 trihydrochloride (Hoechst, 1:200; Sigma Aldrich, B2261)
was added to all sections to visualize nuclei. Samples were
then washed in PBS (3× 5 min), mounted with fluorescent
mounting medium (DAKO; GLostrup, Denmark) and analyzed
with a direct fluorescent microscope (model DM 5000 CTR; Leica
Microsystem Nussloch GmbH) with 10× and 20× objectives.
Images obtained were assessed for fiber positivity to MHC II
antibody for fiber type determination (MHC-IIa fibers are highly
positive; MHC IIx fibers are positive with lower intensity; MHC-I
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fibers are negative) and loss of dystrophin staining to determine
which were damaged (Macaluso et al., 2012b, 2014).
Transmission Electron Microscopy
Analysis
Muscle specimens from each volunteer for both time points were
cut in a longitudinal orientation, fixed in 2.5% glutaraldehyde
and post-fixed in 1% osmium tetroxide for 1 h. Next the samples
were dehydrated with graded ethanol 30, 50, 70, 95, and 100% v\v
and tissue pieces were placed in propylene oxide for 30 min and
infiltrated with resin (EPON 812, Electron Microscopy Sciences,
Hatfield, PA, United States) at passages of 1:3, 2:2 and 3:1
resin to propylene oxide) 1 day before polymerization at 50◦C
for 48 h. Ultrathin (50–70 nm) longitudinal skeletal muscle
sections were cut with an ultramicrotome (model RM2125
RT; Leica Microsytem Nussloch GmbH, Germany). Images of
ultrathin sections of resin-embedded muscle were obtained
using a transmission electron microscope (Jeol-Jem 1011 TEM,
Leica Microsystem Nussloch GmbH, Germany). The longitudinal
sections were assessed for the presence of damaged sarcomeres
(Z-disk streaming) or necrotic and hypercontracted areas as
described by Lauritzen et al. (2009).
MPO Enzyme-Linked Immunosorbent
Assay
The concentration of secreted MPO in muscle tissue was
determined using the Abcam MPO Human ELISA kit
(ab119605), as recommended by the manufacturer. Briefly, 2 mm
frozen muscle tissue was washed 2× in Phosphate-buffered
saline (PBS) and homogenized in RIPA (pH 7.4, Tris–HCL
2.5 mM, EDTA 1 mM, NaF 50 mM, dithiothreitol 1 mM,
phenylmethylsulfonyl fluoride (PMSF) 0.1 mM, benzamidine
1 mM, 4 mg/ml SBTI, 10 mg/ml leupeptin, 1% NP40, 0.1%
SDS and 0.5% Na deoxycholate) using a tissue homogenizer
(Ultra-Turrax, Germany). The homogenate was then centrifuged
at 5000 × g for 5 min and immediately assayed. The sample
readings were performed using the ELx800 universal microplate
reader (Biotek Instruments, Inc., VT, United States).
Genotyping Analysis
Snap frozen muscle tissue (baseline muscle biopsy) was sent
to the Central Analytical Facility (CAF, Stellenbosch University,
South Africa) to test possible single nucleotide polymorphism
(SNP) MYLCK C49T. DNA extraction was performed as
follows: Tissue was placed in 1.7 ml tube and homogenized
with the TissueLyzer (Qiagen). Next 400 µl of Buffer PL2
(NucleoSpin Plant II Kit, Separations) with 2 µl of proteinase K
(10mg/ml; Sigma-Aldrich) was added. The sample was incubated
overnight in a waterbath at 60◦C, following the protocol of the
manufacturer. Extraction was performed on the Tecan TMP 2000
Liquid Handling Platform. The DNA extract was then analyzed
for selected SNPs within the genes of selected muscle structure
proteins. TaqMan primer sets for SNPs were: TTC AGA GCA
ACT TCA GGA GCTT (forward primer); GCC AGT GGG
ACA GGA AAGG (Reverse Primer). The PCR was performed
in a cycler (Verity, Applied Biosystems, Life Technologies, CA,
United States) with the following cycling conditions: 95◦C for
10 min followed by 44 cycles at 92◦C for 15 s and a final extension
of 60◦C for 1 min. Post-PCR purification was done using
the NucleoFast purification system (NucleoFast, Separations,
Germany). Sequencing was performed with BigDye Terminator
(V1.3, Applied Biosystems, Life Technologies, CA, United States)
followed by electrophoresis on the DNA Analyser (3730xl,
Applied Biosystems, Life Technologies, CA, United States).
Sequences were analyzed and trimmed using Sequencing
Analysis (V5.3.1, Applied Biosystems, Life Technologies, CA,
United States). Alignments were done using the ClustalW
module, BioEdit version 7.0.4.1 with the downloaded SND-ID
as reference. Possible polymorphism variants included MYLCK
C49T genotype CC, CT, and TT (Clarkson et al., 2005).
Statistical Analysis
Data were assessed for normality by inspecting normal
probability plots. A logarithmic transformation (Log10) was
applied to non-normally distributed data (CK, Mb, CRP, and
perceived pain) before analysis. Changes in perceived pain (in
squat and in standing position), blood parameters (CK, Mb,
and CRP), total and differential WBC in high responders vs.
low responders over time were analyzed by two-way mixed
model repeated-measures analysis of variance. If a significant
difference was detected, this was further evaluated by the post hoc
Fisher’s LSD test. Statistical analyses were performed using PASW
(version 18; SPSS Inc., Chicago, IL, United States). Significance
was accepted at P ≤ 0.05.
RESULTS
Muscle Damage
In the standing position, perceived pain scores for both low and
high CK responders were fairly low and followed a similar time
course, with significant elevations reported at 6 h and days 1
and 2 following plyometric exercise (Table 1). In contrast, in the
squat position, both groups reported moderate to severe soreness,
with highest scores on days 1 and 2 post-exercise, although on
days 3 and 4, soreness scores were still significantly elevated
from baseline in both groups. Time-dependent group differences
were evident: while perceived soreness scores were higher in low
responders at 6 h post-plyometric exercise, high responders rated
their soreness at days 3 and 4 higher than low responders, but
only in the squat position. At these later time points, the high
responders’ perceived pain scores were still at least 4-fold higher
than the 6 h time point, whilst that of low responders was only
≈1.5-fold higher than 6 h.
Electron micrographs of muscle biopsies performed on the 3rd
day after the acute bout of plyometric exercise revealed muscle
damage in the form of Z-disk streaming in all subjects (refer to
Figures 1A,B for representative images of pre- and post-exercise
sections in the longitudinal plane of vastus lateralis muscle).
Necrotic and hyper-contracted areas were not evident in any
of the muscle samples. Qualitative assessment of ultrastructural
muscle damage did not reveal any overt differences between high
and low responders.
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TABLE 1 | Perceived muscle soreness over time before and after a single bout of
plyometric exercise.









−4 day 0.0 ± 0.0 1.4 ± 1,6 0.0 ± 0.0 0.9 ± 1.1
0 day 0.0 ± 0.0 1.0 ± 1.2 0.0 ± 0.0 1.1 ± 1.2
6 h 1.3 ± 1.4∗ 2.0 ± 1.0∗ 0.9 ± 1.0∗ψ 1.0 ± 1.0ψ
1 day 1.5 ± 1.6∗ 5.8 ± 1.7∗ 1.4 ± 1.0∗‡ 6.6 ± 1.2∗#
2 days 1.5 ± 2.4∗ 6.3 ± 2.5∗ 0.9 ± 0.9∗ 7.5 ± 1.7∗#
3 days 0.60 ± 1.0 3.8 ± 1.7∗ 0.6 ± 1.0 5.0 ± 1.0∗ψ
4 days 0.5 ± 1.2 2.8 ± 1.5∗ 0.2 ± 0.4 4.4 ± 1.2∗ψ
Soreness in the squat position and in the standing position for the low (n = 16)
and high (n = 10) responders, respectively. ∗Significantly different from time
points −4 and 0 day, (P < 0.0001), #significantly different from time point 6 h
(P < 0.001), ‡significantly different from time point 3 and 4 days (P < 0.05),
ψsignificantly different response between high and low responders (P < 0.05). Data
are expressed as mean ± SD.
FIGURE 1 | Analysis of skeletal muscle sections. Electron micrographs of
longitudinal sections. Illustration of undamaged sarcomeres (A). Arrangement
of one sarcomere: Z, Z-line; and m, mitochondria. Damaged sarcomeres (B)
on day 3 following eccentric exercise in human skeletal muscle: Zs, z-line
streaming. No difference in ultrastructural damage was observed between low
and high responder groups. Immunofluorescence of muscle cross-sections
also on day 3 after the plyometric exercise intervention, using double
immunostaining with anti-dystrophin (C) and anti-myosin heavy chain II (D).
Arrows show examples of the loss in dystrophin staining; IIa and IIx indicate
examples of MHC-II positive fibers; I, MHC-I fibers.
In line with the qualitative assessments of EM images,
qualitative assessment of sarcolemmal damage, as assessed by
loss of dystrophin continuity in membranes (Figure 1C) in the
red channel of the double-stained sections, revealed breaks in
dystrophin in both groups. Fiber type distribution did not differ
between low and high responders (Table 2). Quantitative data of
sarcolemmal damage for specific fiber types generated by direct
comparisons of the red and green channels (Figures 1C,D),
revealed no differences between high and low responders in
terms of the proportion of each fiber type exhibiting sarcolemmal
damage (Table 2).
In terms of indirect indicators of muscle damage, serum CK
activity was significantly elevated from baseline and pre-exercise
values at both 6 h (P < 0.00001) and day 1 (P < 0.00001)
after plyometric exercise intervention in the low responders,
after which it returned toward baseline. In the high responders,
a greater magnitude of increase (ANOVA effect of group,
P < 0.0001) was observed for CK activity in response to the
exercise intervention. In this group, CK activity remained at
significantly higher levels when compared to pre-exercise values
for all time points assessed (Figure 2A). A similar pattern to CK
was observed for serum Mb, with greater and more sustained
response in the high responders (Figure 2B). The only exception
was that for Mb, the values in low responders returned to baseline
levels already at day 1.
Inflammation
Total WBC and neutrophil counts for both high and low
responders were significantly but transiently increased 6 h after
exercise, following which it returned to baseline values (Table 2).
Both WBC and neutrophil counts peaked at significantly higher
levels in high responders than low responders at 6 h (P < 0.5).
Serum CRP levels increased (P < 0.05) transiently on day 1
after exercise in the low responders (Figure 3A). High responders
had a more robust response, with significantly higher CRP levels,
which were sustained at levels significantly higher than pre-
exercise levels for all post-exercise time points. A significant
group difference was evident from the 6 h time point to day 2.
Pre-exercise intramuscular MPO levels were significantly higher
(P < 0.05) in high responders when compared to low responders
at baseline (Figure 3B). Neither group showed a significant
MPO response to plyometric exercise at 3 days after plyometric
exercise, which was the only time point after the intervention that
a biopsy was taken.
(A) Serum C-reactive-protein (CRP) and
(B) Myeloperoxidase (MPO) levels in skeletal muscle before
and on day 3 after exercise intervention. The triangle and
circle dot in the lines indicate high (n = 10) and low (n = 16)
responders, respectively.
Profile of MLCK Single Nucleotide
Polymorphisms
All three alleles for MLCK C49T were observed among our
participants: Twelve participants presented with the homozygous
wild type CC allele, 6 with the CT allele and 7 with the TT
allele. Participants with the CC allele had circulating CK and Mb
activities of 7806 ± 5827 U/L and 299 ± 132 ng/ml, respectively,
3 days after plyometric jumping, versus somewhat lower values
for those with the heterozygote allele (CT: 4485 ± 2912 U/L;
Mb 227 ± 58 ng/ml) or the mutant homozygous allele (TT: CK
2442 ± 1779 U/L; Mb 146 ± 37 ng/ml).
DISCUSSION
To date, it remains unclear why, within a group of individuals
exercising in a similar environment and at similar intensity,
the development of exertional rhabdomyolysis is only observed
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TABLE 2 | Percentage fiber type and the proportion within each fiber type category that were damaged fibers (loss of dystrophin continuity) comparing low responders
and high responders.
Type I muscle fiber Type II muscle fiber Type IIa muscle fiber Type IIx muscle fiber
Responders (%) Damaged (%) (%) Damaged (%) (%) Damaged (%) (%) Damaged (%)
Low 35.2 ± 10.5 9.9 ± 8.3 64.8 ± 10.5 12.9 ± 5.7 59.8 ± 16.6 12.2 ± 5.4 8.8 ± 7.2 22.5 ± 18.2
High 37.6 ± 9.5 10.4 ± 6.1 62.4 ± 9.5 13.2 ± 7 52.2 ± 12.4 13.6 ± 8.2 10.2 ± 10 16.2 ± 10.7
Data are presented as mean ± SD. No significant differences were observed between high and low responders in the percentage of muscle fiber type and in percentage
of damaged muscle fibers at day 3 after the plyometric exercise intervention. The muscle biopsy was performed in the vastus lateralis.
FIGURE 2 | (A) Serum creatine kinase (CK) and (B) myoglobin (Mb) over time
before and after a single bout of plyometric exercise. The square and circle
dot indicate high (n = 10) and low responder (n = 16) groups, respectively. The
dashed line indicates the exertional rhabdomyolysis cut-off used in this study.
The arrow indicates the plyometric exercise intervention. ∗Significantly
different from time points –4 and 0 day, (P < 0.001), #significantly different
from time point 6 h, (P < 0.05), ‡significantly different from time point 1 day,
(P < 0.01), †significantly different response between high and low responders,
(P < 0.0001). Data are expressed as mean ± SD.
within a small percentage of these individuals (Clarkson et al.,
2005; Devaney et al., 2007; Yamin et al., 2008). The strength
of the current study is that the unexplained dilemma of low
and high responders to eccentric exercise was assessed from
multiple points of view with the same volunteers within the
same study. These viewpoints ranged from perceived pain, which
was not similar at all time points between the two groups,
to blood biomarkers of damage and inflammation, to genetic
polymorphism testing (variants of MLCK gene) and muscular
FIGURE 3 | (A) Serum C-reactive-protein (CRP) and (B) skeletal muscle
myeloperoxidase (MPO) levels before and on day 3 after exercise intervention.
The square and circle dot in the lines indicate high (n = 10) and low (n = 16)
responders, respectively. ∗Significantly different from time points –4 and 0 day,
(P < 0.001), #significantly different from time point 6 h, (P < 0.05),
‡significantly different from time point 1 day, (P < 0.01), †significantly different
response between high and low responders, (P < 0.0001). Data are
expressed as mean ± SD.
parameters. The results provide evidence suggesting that pre-
existing elevated skeletal muscle MPO pre-disposes to higher
CK responsiveness following unaccustomed plyometric exercise
and that the inflammatory response, assessed here by subsequent
CRP elevations in the days after muscle damaging exercise,
is exacerbated in high CK responders. While other factors,
such as muscle and genetic characteristics, are suggested to be
contributing factors to muscle damage, these are not clearly
evident unless a larger number of individuals are assessed and are
therefore unlikely to be predictive in the individual setting.
In the literature, reports have found a poor correlation
between perceived pain reporting and the degree of change in
other indirect markers of muscle damage. For example, pain
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was found to be elevated 1 day post-marathon and while pain
resolved, CK levels remained elevated 2 days after (Clifford et al.,
2017). Furthermore, CK activity does not correlate well with
the amount of structural damage or the reduction of muscle
function and thus is an unreliable marker (Sorichter et al.,
1997; Chimera et al., 2004). Nosaka et al. (2002) who used
an eccentric elbow flexor model of muscle damage, reported
that delayed onset muscle soreness (DOMS) correlated poorly
not only with eccentric exercise-induced muscle damage and
loss of maximal isometric force, but also smaller elbow joint
angles, larger upper arm circumference and plasma CK activity.
In the current study, despite all participants completing the
required number of jumps between 95 and 100% of maximal
jump height, the low CK responders reported significantly more
perceived pain at the early time point of 6 h after plyometric
jumping than the high responder group. The high responder
group reported significantly higher delayed perceived soreness
scores compared to the low responder group on days 3 and 4
following the exercise intervention, in particular when soreness
was assessed in the squat position. This suggests that soreness
should be assessed when the affected muscle groups are under
eccentric strain, even if this is static. Coaches and athletic
trainers should be aware that delayed soreness scores should be
assessed for at least 4 days or more following intensive plyometric
training in order to distinguish individuals possibly at risk of
exertional rhabdomyolysis.
Muscle ultrastructural (Z-disk streaming) and structural
damage (loss of dystrophin stain) was evident using electron and
fluorescent microscopy, respectively, 3 days after the plyometric
intervention. Nosaka et al. (2001) have reported that the repeated
bout effect may last up to 6 months following an initial
heavy eccentric exercise bout. However, some volunteers with
a moderate to extreme response to unaccustomed eccentric
exercise, who performed a second bout of eccentric exercise
3 weeks after the first bout, exhibited deformed fibers after the
second bout (Paulsen et al., 2013). Given the qualitative evidence
of muscle damage after the acute eccentric exercise intervention
in all participants in the current study, it is unlikely that any of the
participants did not fulfill the inclusion criterion of no habitual
or recent training or plyometric exercise of the lower body. In
previous studies, we observed acute bouts of plyometric jumping
resulted in preferential fast twitch fiber damage (Macaluso
et al., 2012b, 2014). McEwen and Hulland (1986) also observed
preferential degeneration, but not exclusively to type II fibers,
in horses affected by exertional rhabdomyolysis. Together, these
findings could suggest that individuals with a greater percentage
of fast twitch fibers may present more fiber damage, resulting in
higher CK levels. However, no significant difference was observed
between high and low responders in the proportions of fast and
slow muscle fibers in the current study. The fiber type distribution
was variable in both groups, which may explain this finding.
A limitation is that with the size of the current study, there were
no subjects with a very high proportion of fast twitch fibers.
Therefore, it cannot be excluded that an even higher proportion
of fast twitch fibers than that observed in the participants of the
current study may be predictive of exertional rhabdomyolysis risk
in other individuals.
Exertional rhabdomyolysis is common amongst military
recruits (Hill et al., 2017), especially in the early phases after
entry into service and if unaccustomed, excessive training is
undertaken. The volume of such training is typically higher
than that in laboratory research studies and the cut-off point
for rhabdomyolysis may be as high as 5 times the upper limit
of the normal, typically in the range of 1300 U/L (Warren
et al., 2002). However, since signs such as dark colored urine
are part of the diagnostic criteria for definitive clinical diagnosis
of rhabdomyolysis (Hill et al., 2017), it has been found that
exertional rhabdomyolysis may be underreported in some
settings (Sauers et al., 2016). Therefore, in the current study
a slightly lower cut-off limit of 1000 U/L was used, which is
similar to other laboratory studies (Lee and Clarkson, 2003;
Thoenes, 2010).
Recent reports suggest that SNPs may be responsible for
inter-subject damage variability and CK response after eccentric
exercise (Scalco et al., 2016). These studies have already
established the genotypes of the different SNPs using larger
study populations. Clarkson et al. (2005) demonstrated that
individuals homozygous for the rare MLCK 49T allele (4% of
152 participants) had significantly greater increases in CK and
Mb compared to the heterozygotes. The current data was not in
line with this previous publication. Five of the seven individuals
with this genotype were low responders for CK release and
all of them were low responders for Mb. A major difference
between the current cohort and that of Clarkson et al. (2005)
is that 28% of the small cohort actually presented with the TT-
homozygous allele. Therefore, this allele cannot be considered
rare in our population. Although it might be considered a
limitation for genotype assessment that the number of subjects in
the current study was relatively low, taking the previous results
and the current results together, they indicate the necessity of
conducting genotype-phenotype studies in multiple populations
around the world.
The two most interesting results of this study were the
differences between the groups in the CRP profile and the
baseline intramuscular MPO activity. High responders presented
with significantly higher CRP levels following eccentric exercise
when compared to their low responder counterparts, despite
similar levels at baseline. Indeed, CRP was higher in high CK
responders already at 6 h post-exercise and continued to be
higher on days 1 and 2 when compared to the low responders,
indicating prolonged cross-talk between damaged muscle and the
liver. No group differences were evident at days 3 and 4, although
high responders were still elevated from their own baseline at
these two later time points. Although circulating neutrophil levels
were significantly greater in the high responder group at 6 h post-
exercise compared to the low responder group post-exercise, they
did not remain elevated in the days following the intervention.
Within 2 h after mechanical damage, neutrophils accumulate in
the injured area (Hertel, 1997) and phagocytose cellular debris
via the production of oxygen free radicals (Hertel, 1997; Toumi
and Best, 2003; Pizza et al., 2005). Neutrophil activation may
cause damage to cell membranes and surrounding non-injured
tissue by rapidly releasing high concentrations of ROS and
oxygen free radicals through a respiratory burst (Hertel, 1997;
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Brickson et al., 2001). In the context of unaccustomed eccentric
exercise, this would be considered as secondary damage. By using
a single stretch injury model in rabbit tibialis anterior muscle,
Brickson et al. (2003) demonstrated that muscle fiber damage
could be reduced by inhibiting neutrophil respiratory burst with
a monoclonal antibody (M1/70). Furthermore, this model also
showed the preservation of muscle structural proteins desmin
and dystrophin (Brickson et al., 2003).
Myeloperoxidase is primarily expressed by neutrophils and
plays an important role in microbicidal activity and cell debris
destruction within the phagosome via oxidizing reactions (Hurst,
2012). Circulating monocytes also elevate intracellular MPO
in response to eccentrically biased exercise such as downhill
running (van de Vyver et al., 2016). Previous reports indicate
that muscle loading during exhaustive exercise results in
increased MPO activity per neutrophil (Suzuki et al., 1996) and
downhill running increases intramuscular MPO (van de Vyver
and Myburgh, 2014). Notably, the current data demonstrated
higher MPO at baseline within the tissue targeted by the
exercise in the high responders even before the plyometric
intervention, which remained high at 3d after. This suggests
that an inability to resolve MPO in muscle may contribute
to a relatively exacerbated CRP response independent of the
magnitude of the acute neutrophil response. It is unclear if the
intramuscular MPO observed was of neutrophilic or monocytic
origin. Given that there was no evidence of overt muscle
pathology in the baseline biopsy samples, it is possible that
pro-inflammatory macrophages may have been basally active
in the high responder group’s muscle. However, MPO has
also been shown to delay neutrophil apoptosis in an ex vivo
model and to delay resolution of acute lung injury in mice
(El Kebir et al., 2008). Neutrophil quantification in the muscle
samples for future studies will be important. Not only in
muscle fibers, but in the interstitial spaces between fibers; in
the perivascular areas and beneath the epimysium in order to
explain the difference in baseline MPO levels between high
and low responders (Malm et al., 2004). In the current age
of exercise prescription for rehabilitation and in groups with
underlying disease, knowledge of baseline intramuscular MPO
status may be valuable for decisions regarding the type of training
prescribed. Merritt et al. (2013) showed that aged populations
are particularly susceptible to muscle inflammation. This study
also provided evidence that the skeletal muscle regenerative
response is impaired with age following unaccustomed eccentric
exercise, due to either high pro-inflammatory signaling at rest
or a greater inflammatory response to damage and subsequent
myoblast impairment.
In conclusion, in relatively healthy individuals, CRP responses
to training are recommended for monitoring purposes and
may indicate that a more conservative approach to training
prescription should be followed where exercise interventions
may be used as therapy for an individual’s recovery and in
aged populations. In aged individuals and other individuals
with conditions that may already put them at risk for
compromised intramuscular inflammation, response to eccentric
contraction and perceived pain should be assessed under static
eccentric conditions.
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The management of cancer patients is frequently complicated by the occurrence of
cachexia. This is a complex syndrome that markedly impacts on quality of life as well as
on tolerance and response to anticancer treatments. Loss of body weight, wasting of both
adipose tissue and skeletal muscle and reduced survival rates are among the main features
of cachexia. Skeletal muscle wasting has been shown to depend, mainly at least, on the
induction of protein degradation rates above physiological levels. Such hypercatabolic
pattern is driven by overactivation of different intracellular proteolytic systems, among
which those dependent on ubiquitin-proteasome and autophagy. Selective rather than
bulk degradation of altered proteins and organelles was also proposed to occur. Within
the picture described above, the muscle is frequently considered a sort of by-stander
tissue where external stimuli, directly or indirectly, can poise protein metabolism toward
a catabolic setting. By contrast, several observations suggest that the muscle reacts
to the wasting drive imposed by cancer growth by activating different compensatory
strategies that include anabolic capacity, the activation of autophagy and myogenesis.
Even if muscle response is eventually ill-fated, its occurrence supports the idea that in the
presence of appropriate treatments the development of cancer-induced wasting might
not be an ineluctable event in tumor hosts.
Keywords: muscle wasting, protein turnover, energy metabolism, myogenesis, adaptive response, oxidative
stress
INTRODUCTION
Cachexia is a complex multiorgan syndrome that affects 50–80% of cancer patients and accounts
for about 20% of cancer deaths (Argilés et al., 2014). Characteristic features of this syndrome
are body weight loss, muscle wasting, adipose tissue depletion and metabolic abnormalities. The
main symptoms include anorexia, anemia, asthenia and fatigue, that eventually result in severely
impaired patient quality of life.
The pathogenesis of cancer cachexia is a complex phenomenon that includes nutritional
changes, hypoanabolism, the onset of an overall hypercatabolic response that mainly affects
proteins and lipids, chronic inflammation and altered energy metabolism. Last, but not least,
the standard of care of neoplastic disease generally includes chemotherapy, further complicating
the scenario. Indeed, cachectic patients very frequently cannot cope with anti-cancer treatment
schedule and often require dosage limitation and/or therapy interruption, reducing both drug
effectiveness and patient survival (Pin et al., 2018).
Several potential anti-cachexia drugs are currently being tested in clinical trials, but none of them
has proved effective enough to be routinely applied in the clinical practice (Morley et al., 2014). In
this regard, the small number of clinical trials and the poor knowledge about the pathogenesis of
cancer cachexia likely account for the lack of effective treatments (Penna et al., 2016b).
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The present review will discuss the mechanisms underlying
cancer-induced wasting and will focus on the adaptive response
set up by the skeletal muscle to the challenge posed by alterations
at the systemic level. In this regard, most of the existent studies
and reviews consider the skeletal muscle as a passive target
of stimuli that eventually lead to reduced anabolism and/or
increased catabolism. By contrast, muscle tissue attempts to strike
back by modulating metabolism in order to set up a sort of
defensive strategy against a hostile external environment. This
is particularly relevant since understanding and potentiating
such reactive behavior could improve the effectiveness of anti-
cachexia treatments.
MALNUTRITION
Cancer-associated malnutrition reflects into involuntary body
weight loss that results from the combination of several factors
such as reduced food intake, malabsorption, altered substrate
utilization and increased substrate demand. The occurrence of
malnutrition is highly unfavorable, since both recovery and
tolerance to antineoplastic treatments are definitely improved
in well-nourished than in malnourished subjects (e.g., with
unintentional body weight loss >5%). Being malnutrition a
potent predictor of bad outcome, the achievement of a good
nutritional state in cancer patients should become a goal to be
pursued in the clinical practice (Aversa et al., 2017). In this
regard, helpful guidelines for the management of malnutrition in
cancer patients have been set up by both the European Society of
Parenteral and Enteral Nutrition (ESPEN; Arends et al., 2017a)
and the Academy of Nutrition and Dietetics (AND; Thompson
et al., 2017). These documents include the need of an early
nutritional assessment, the relevance of nutritional counseling
during the course of the disease, the definition of an appropriate
and personalized nutritional support, the identification of the
right moment for the adoption of such support.
Nutritional habits in cancer patients can be affected very early,
resulting in latent malnutrition that becomes frankly evident
while the disease progresses, accompanying the appearance of
cachexia. Multiple mechanisms contribute to malnutrition, such
as tumor localization at the gastrointestinal tract, pain, anxiety,
malabsorption, and anorexia. While this latter is very often
recognized in cancer patients, in the early phases of disease it
happens to be underestimated and for this reason it might not be
promptly addressed. To circumvent this possibility, nutritional
behavior should be accurately assessed in all cancer patients at
first diagnosis (Arends et al., 2017b), in order to pick up and
evaluate even small changes from usual habits.
Humoral factors produced by the host as well as by the tumor
have been proposed to work in concert to modulate patient
nutritional behavior, affecting, directly or indirectly, the central
regulation of appetite. In this regard, several pro-inflammatory
cytokines have been shown to contribute to anorexia in cancer,
per se, but also enhancing the availability of neuropeptides
acting at the central nervous system level such as melanocortin,
neuropeptide Y, or leptin (Ezeoke and Morley, 2015). Particularly
relevant in this regard is ghrelin, an orexigenic hormone mainly
produced in the stomach, whose levels are usually increased in
cancer patients. Such increase could result from both an attempt
to counteract anorexia and the onset of ghrelin resistance (Argilés
et al., 2017). The resulting picture is the induction of signaling
pathways involved in causing anorexia at the expense of those
able to stimulate food intake, eventually leading to loss of appetite
and/or increased satiety (Argilés et al., 2014).
Despite reduced food intake is an important component
of body weight loss, nutrient availability being lower than
normal, cancer-associated malnutrition is quite different from
that occurring in subjects exposed to fasting or to caloric
restriction. Indeed, cancer patients very often are no more
able to appropriately modulate their metabolism to meet the
lack of nutrients. As an example, caloric restriction in healthy
subjects results in increased glucose and lipid mobilization,
sparing proteins as much as possible. By contrast, reduced food
intake in cancer patients is associated with random mobilization
of substrates, setting protein metabolism toward a persistently
negative nitrogen balance.
MUSCLE PROTEIN TURNOVER
The loss of muscle mass and function, one of the main features
of cancer cachexia, markedly impairs patient quality of life and
survival. In addition, muscle mass depletion has been associated
with reduced tolerance to anticancer treatments (Figure 1).
In addition, recent observations show that immunotherapy by
checkpoint inhibitors lose effectiveness in cachectic patients,
likely due to the establishment of primary resistance (Coss
et al., 2018). For these reasons, an accurate estimate of muscle
mass and quality should be pursued during the management of
cancer patients. By contrast, still nowadays the first evaluation
of a patient mainly takes into account parameters such as
body weight or body mass index (BMI), that do not provide
any information about body composition. Indeed, normal body
weight and/or BMI could result from increased adiposity or
tissue water content, de facto masking the occurrence of muscle
mass depletion.
Protein content, the most relevant component of muscle
mass, depends on the balance between rates of protein synthesis
and breakdown. Physiologically speaking, disruptions of
such equilibrium activate an adaptive response aimed at
reaching a new homeostasis that can alternatively result in
muscle hypertrophy or hypotrophy, respectively depending
on the prevalence of protein synthesis or degradation
(Argilés et al., 2014).
Protein Breakdown
Intracellular protein degradation in the skeletal muscle relies
on the activity of four main proteolytic pathways that depend
on calpains, caspases, lysosomes, and proteasome. Results
obtained in both experimental and clinical studies have clearly
demonstrated that muscle wasting in cancer hosts is associated
with supra-physiological activation of these proteolytic pathways
(Penna et al., 2014), with particular reference to those depending
on proteasome and lysosomes. These systems are involved in
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FIGURE 1 | Relevance of muscle wasting to cancer patient management. The occurrence of metabolic changes that result in muscle protein hypercatabolism and
impaired regeneration capacity negatively impinges on both patient quality of life and survival. ks = fractional rate of protein synthesis; kd = fractional rate of protein
degradation.
different aspects of intracellular protein degradation, the former
breaking down short-lived and regulatory proteins, the latter
being in charge of the disposal of altered organelles and structural
proteins (Penna et al., 2014).
The activity of the proteasome-dependent proteolytic
system depends on the availability of both ubiquitin and
enzymes involved in protein substrate ubiquitylation, namely
E1 (ubiquitin activating enzymes), E2 (ubiquitin conjugating
enzymes) and E3 (ubiquitin ligases). As for the E3 family, some
members are defined as muscle-specific. The most widely studied
are MAFbx/atrogin-1 and MuRF1/TRIM63. The former is in
charge of targeting proteins involved in cell cycle control, cell
differentiation and cell death, while the latter mainly marks for
degradation structural proteins (Argilés et al., 2014). The most
recently discovered member of the muscle-specific E3 family
is SMART (Milan et al., 2015). The expression levels of these
muscle-specific ubiquitin ligases have been accepted as molecular
markers of proteasome-dependent proteolysis and have been
demonstrated to increase in different experimental models of
cancer cachexia (Argilés et al., 2014). As for human studies,
several reports show that in cancer patients this proteolytic
system is activated above physiological levels. Of particular
relevance, such enhanced activity has been observed also in
non-weight losing gastric cancer patients (Bossola et al., 2003),
recalling the need of early assessment of cachexia. On the
other side, studies reporting unchanged levels of molecular and
biochemical markers pertaining to the ubiquitin-proteasome
proteolytic system in cancer patients do exist (Op den Kamp
et al., 2012; Tardif et al., 2013).
The involvement of lysosomal proteolysis in muscle wasting
is mainly referred to the overactivation of autophagy. This is a
physiological process in charge of degrading cellular components,
whose rate is increased by lack of nutrients or by the presence
of damaged organelles, such as mitochondria or peroxisomes.
Some years ago the discovery of autophagy-related (ATG) genes
has refreshed the field, providing useful tools to investigate the
process. Indeed, at least some of the proteins encoded by these
genes, such as beclin 1 and LC3B are now accepted markers of
autophagy. The physiological protein homeostasis in the muscle
is maintained by basal autophagy, in view of its role in the
routine clearance of wasting products such as altered proteins
and organelles. Disruption of autophagy has been shown to
be associated with progressive muscle derangements, such as
those occurring in mice lacking the Atg7 or the OPA1 genes
(Masiero et al., 2009; Tezze et al., 2017) or carrying the BCL2
AAA mutation (He et al., 2012). On the other side, markers
of autophagy are overexpressed in several muscle wasting-
associated states such as denervation and fasting, suggesting that
stress-induced autophagy is activated above physiological levels
in these diseases. Consistently, the induction of autophagy in
the skeletal muscle of both tumor-bearing animals and cancer
patients is demonstrated by several reports (Penna et al., 2013;
Tardif et al., 2013; Aversa et al., 2016; Pigna et al., 2016).
However, despite autophagic flux is increased, the process does
not reach its final step with complete cargo degradation, as
indicated by the observation that autophagosomes accumulate in
the muscle of cancer hosts, likely due to lysosomal engulfment
(Penna et al., 2013; Aversa et al., 2016; Pigna et al., 2016). On
the whole, these observations demonstrate that the relevance
of autophagy, enhanced or inhibited, to muscle wasting can
be significantly different, according to the specific situation.
In other words, both excessive and defective autophagy are
unwanted scenarios, and treatments impinging on these modality
of protein degradation should be aimed at maintaining/restoring
a physiologic autophagic flux.
Myofibrillar protein degradation depends on the preliminary
disruption of myofilaments. Such preventive cleavage cannot
be performed either by proteasome or lysosomes and has been
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proposed to involve other proteases, such as caspases and calpains
(Penna et al., 2014). Consistently, these latter are upregulated and
overactivated in the skeletal muscle of tumor-bearing animals
(Llovera et al., 1995; Costelli et al., 2002; Pin et al., 2017) and of
cancer patients (Smith et al., 2011).
Unfolded protein response (UPR) is important for the
maintenance of skeletal muscle mass in adults. Because PERK
regulates protein folding and calcium homeostasis, it is important
to investigate how these functions of PERK are affected in skeletal
muscle of smPERK-KO mice. How the activation of PERK
is regulated in conditions of muscle growth and atrophy and
whether modulation of its activity can improve skeletal muscle
mass in various catabolic states is also an important area of
future research.
Protein Synthesis
While the enhancement of muscle protein breakdown rates in
cancer cachexia is clearly demonstrated, the same does not apply
to protein synthesis, reduced, normal, or increased rates being
reported (Argilés et al., 2014). As for experimental cachexia,
the generally short time frame from tumor implantation and
animal death frequently results in impaired anabolic capacity, at
least in the skeletal muscle, although contrasting observations
have been reported. As an example, results obtained in mice
bearing the C26 or the LLC tumors show a reduction of muscle
protein synthesis rates, that cannot be restored by treatments able
to improve muscle mass (Toledo et al., 2016a; Nissinen et al.,
2018). On the other side, protein synthesis rates close to those of
controls have been observed in rats implanted with the Yoshida
AH-130 hepatoma (Costelli et al., 1993). Further variability can
be observed when tissues different from muscle are taken into
consideration. As an example, enhanced pro-synthetic capacity
has been measured in the liver of tumor-bearing animals, likely
due to the increased demand of acute phase proteins. These
observations put in evidence the limitations of the experimental
models, where cachexia frequently develops markedly faster than
in cancer patients.
The modulation of protein synthesis rates in cancer patients is
less clear. Some old studies, but also a recent one, have reported
that muscle protein synthesis is reduced in human pathology
(Emery et al., 1984; Hanson et al., 2017). By contrast, another
research group shows that pancreatic cancer patients are able
to improve baseline protein synthesis rates, that result poised
at values higher than those measured in healthy subjects (van
Dijk et al., 2015). Between these opposites, several studies report
muscle protein synthesis rates comparable to those of controls or
of non-weight losing cancer patients (Engelen et al., 2016).
Stimulation of muscle protein synthesis has been proposed
as a mean to improve muscle phenotype in cancer cachexia.
Most of the attempts, mainly unsuccessful, have involved
nutritional interventions or molecular tools aimed at improving
the muscle anabolic capacity. Indeed, advanced cancer patients
treated with both parenteral and enteral nutrition, including
or not the supplementation with amino acids, do not show
any improvement in muscle protein synthesis (Engelen et al.,
2016). Similar results have been obtained in studies attempting
to activate muscle protein anabolism by means of both drugs or
genetic tools (Costelli et al., 2006; Penna et al., 2010a). Recent
observations, however, show that there is the possibility to exploit
a sort of anabolic window in cancer patients (see below).
ENERGY METABOLISM
The vast majority of cancer patients are hypermetabolic,
presenting with resting energy expenditure (REE) higher than
normal (Vazeille et al., 2017). The underlying tumor-driven
mechanisms are still unclear, however released mediators and/or
pro-inflammatory stimuli rather than tumor burden, that is
usually quite low with respect to patient body weight (Purcell
et al., 2016), are likely involved. A recent study describes the
occurrence of hypermetabolism associated with body weight loss,
inflammation, altered energy balance and low performance status
in about 50% out of 390 cancer patients at first diagnosis, e.g., in
the absence of any anticancer treatment (Vazeille et al., 2017). As
stated above, metabolic alterations are an early feature in cancer
patients. Indeed, the study by Vazeille et al. (2017) shows that
about half of the hypermetabolic patients are non weight-losing
and present with good performance status. Consistently, normal
metabolism is rapidly restored in bladder cancer patients after
surgery, while body weight recovery is markedly delayed (Tobert
et al., 2017). These observations, coupled to those reported
above on skeletal muscle protein depletion, stress the need of
tools allowing an early detection of metabolic modulations in
cancer hosts.
Additional mechanisms leading to increased REE in cancer
patients may depend on alterations in thermogenesis. The tissues
mainly in charge of this process are the brown adipose tissue
(BAT) and the skeletal muscle. Both of them express high
amounts of uncoupling proteins (UCPs), whose levels have been
shown to further increase in tumor-bearing animals and cancer
patients (Collins et al., 2002; Bing, 2011). In the last few years,
white adipocytes have been proposed to convert into brown
adipocyte-like (beige) cells. This process, known as ‘browning,’
relies on increased UCP1 expression, resulting in a shift of
mitochondrial activity from ATP to heat production, increasing
both lipolysis and energy expenditure (Argilés et al., 2014).
In addition to increased expenditure, also reduced energy
production, due to undernutrition, decreased fat free mass
and low physical activity, participates to generate the negative
energy balance that frequently occurs in cancer patients. In
this regard, in the last few years particular emphasis has
been given to mitochondrial alterations occurring in the
skeletal muscle, these organelles being the main source of
energy production.
Muscle mitochondria in tumor-bearing animals show
ultrastructural alterations (Shum et al., 2012; Fontes-Oliveira
et al., 2013; Pin et al., 2015; Shum et al., 2018) associated
with uncoupling, leading to reduced oxidative capacity
(Julienne et al., 2012; Tzika et al., 2013). Such impairment
can be associated with the systemic inflammatory response
occurring in cachexia, as suggested by observations showing that
activation of the transcription factor NF-κB decreases muscle
oxidative capacity and down-regulates mitochondrial biogenesis
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(Julienne et al., 2012). In addition, altered mitochondrial
dynamics (fusion and fission) and biogenesis have been reported
in the ApcMin/+ mice, characterized by high circulating levels
of IL-6 (White et al., 2012). Moreover, mitochondria alterations,
in addition to impinge on energy production, also favor the onset
of oxidative stress, both working as catabolism-inducing stimuli.
OXIDATIVE STRESS
The intracellular sources of oxidative species such as reactive
oxygen and nitrogen species (ROS/RNS) are organelles such
as mitochondria and sarcoplasmic reticulum, and enzymes,
in particular the nicotinamide adenine dinucleotide phosphate
oxidase and the xanthine oxidase. The occurrence of oxidative
stress depends on an altered balance between the production
of ROS/RNS and the activity of the intracellular antioxidant
systems. An altered redox homeostasis may exert important
effects on the integrity of biological macromolecules, with
potential consequences on both cell survival and metabolism
(Gomez-Cabrera et al., 2009). In this regard, muscle wasting
in cancer hosts has been associated with increased ROS/RNS
levels and with enhanced oxidative damage to lipids and proteins
(Mastrocola et al., 2008; Sullivan-Gunn et al., 2011; Salazar-
Degracia et al., 2018). At the muscle level, these feature have
also been correlated with increased protein breakdown rates
as well as with the activation of the inflammatory response
(Gomes-Marcondes and Tisdale, 2002; Mastrocola et al., 2008;
Puig-Vilanova et al., 2015).
The increase of oxidative species in cachectic subjects may
rely on several mechanisms among which pro-inflammatory
cytokines, antineoplastic treatments and the loss of coupling
between phosphorylation and oxidation in mitochondria. As
reported above, several intracellular signaling pathways are
regulated, partially at least, by ROS/RNS. Particularly relevant are
those leading to activation of the redox-sensitive transcription
factors NF-κB and AP-1. The former, in particular, has been
shown to contribute to impaired myogenesis (see below) and
to enhance the expression of molecules pertaining to the
intracellular proteolytic machinery. In this regard, oxidative
stress has been proposed to impinge on the activation of
Ca2+-dependent proteolysis in the presence of Ca2+ overload,
on caspase-3 dependent induction of proteasome activity and
on up-regulation of muscle-specific ubiquitin ligases (Ábrigo
et al., 2018). Moreover, a lot of evidence suggests that also
autophagic degradation can be regulated by oxidative species,
mainly acting on signaling pathways dependent on p38 or
PI3K/Akt (Ábrigo et al., 2018).
Finally, redox homeostasis in the cell largely depends
on mitochondria ‘well-being.’ Indeed, altered or damaged
mitochondria fail to produce energy and may become both an
uncontrolled source of ROS and a target for such oxidant species.
The presence of altered mitochondria is an additional pro-
catabolic stimulus, resulting in activation of mitophagy. While
the goal of such activation is to get rid of useless organelles, the
result is a reduction of muscle mitochondria abundance, that
frequently in cachectic subjects is not associated with enhanced
mitochondrial biogenesis, also in view of the reduced energy
availability (Ábrigo et al., 2018).
CYTOKINES AND HORMONES
More than 150 years ago, Rudolf Virchow proposed that
carcinogenesis requires a pro-inflammatory milieu, mainly on the
basis that morphological analysis repeatedly reports infiltration
of the tumor stroma by inflammatory cells (Liu et al., 2017).
About one century later, the discovery of cytokines and of
the role that these mediators play in tumor progression has
provided an additional support to the relevance of inflammation
to carcinogenesis. In addition, the same mediators have been
shown to significantly contribute to the pathogenesis of cancer
cachexia (Argilés et al., 2014).
In the last two decades, cancer cachexia has been mainly
explained as the result of systemic inflammation (acute phase
response) due to the host response to tumor growth (Figure 2).
Several observations support such hypothesis. Indeed, in cancer
patients plasma levels of acute phase reactants, C reactive protein
in particular, are positively correlated with increased REE and
predict reduced survival rates. Along this line, circulating C
reactive protein levels contribute to build up the Glasgow
prognostic score (Fearon et al., 2006). To obtain the amino
acids necessary to synthesize the acute phase proteins, the liver
markedly impinges on muscle metabolism, leading to increased
protein degradation and, depending on the tumor, to reduced
protein synthesis rates. Finally, also the skeletal muscle of tumor-
bearing mice has been shown to express mRNAs coding for
several acute phase reactants (Bonetto et al., 2011), although the
real meaning of this expression pattern is still unknown.
The hypercatabolic setting that characterizes cancer cachexia
results, partially at least, from the complex interplay among
humoral mediators, including proinflammatory cytokines,
hormones and growth factors. Reciprocal regulations occur in
cancer hosts, cytokines being able to impinge on the hormonal
homeostasis and vice versa. High plasma levels of IL-6, TNFα,
and γ-INF have been observed in both tumor-bearing animals
and cachectic cancer patients (Tisdale, 2010). Several cytokines,
among which TNFα, have been shown to modulate peripheral
insulin sensitivity, with a mechanism that affects the activation
of the insulin receptor and of down-stream signaling molecules.
In addition, TNFα also down-regulates the signaling pathways
dependent on the insulin-like growth factor (IGF)-1, reducing
muscle anabolic capacity and enhancing the pro-catabolic
stimuli (Tisdale, 2010). Few years ago, TGFβ deriving from
bone resorption due to metastatic disease has been shown
to significantly contribute to cancer-induced muscle wasting
(Waning et al., 2015). Quite recently, TGF-β and TNFα have
been shown to mediate the expression of the zinc transporter
ZIP14, that is overexpressed in the skeletal muscle of both
cachectic tumor-bearing animals and patients affected by
metastatic cancer and that plays a causative role in muscle
wasting (Wang et al., 2018).
The relevance of cytokines to cachexia has been demonstrated
by studies showing that their administration to healthy animals
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FIGURE 2 | Humoral mediators of cancer cachexia. Humoral mediators differentially involved in the inflammatory response play a crucial, but probably not exclusive,
role in the pathogenesis of cancer cachexia.
results in skeletal muscle atrophy (Tisdale, 2010) as well as in
alterations of lipid metabolism associated with down-regulation
of lipoprotein lipase activity, induction of the hormone-sensitive
lipase and stimulation of hepatic lipogenesis (Tisdale, 2009). Most
of these effects also occur in tumor-bearing animals, and can
be prevented treating the animals with specific anti-cytokine
antibodies (Tisdale, 2009). Despite these observations, however,
there is still no clear-cut evidence that anti-cytokine strategies can
be useful to manage cachexia in cancer patients.
In addition to acute phase reactants, hormones and cytokines,
other mediators have been proposed to contribute to the onset
and progression of cancer cachexia. As an example, fat-derived
leptin has been shown to inhibit both food intake and adipose
tissue mass in healthy animals, although its circulating levels do
not increase in both cancer patients and tumor-bearing animals,
suggesting that its role in cachexia is not a causative one (Argilés
et al., 2014). Among the mediators possibly involved in causing
adipose tissue depletion in cachexia, the lipid mobilizing factor,
increased in the circulation of cachectic cancer patients (Bing,
2011), has been shown to induce triglyceride disassembly by
stimulating the activity of both the adipose triglyceride lipase
and the hormone sensitive lipase, and to upregulate UCP2
expression in liver and muscle (Bing, 2011). Several reports have
shown that the expression of myostatin, a molecule belonging
to the TGFβ family and endowed with inhibitory activity on
muscle enlargement, is enhanced in the muscle of tumor-bearing
animals, although its relevance to muscle wasting in cancer
hosts has not been completely defined. In this regard, recent
observations show that myostatin can be secreted by the BAT,
leading to impaired mTOR signaling in fast myofibers. As a
result, the expression levels of several proteins, among which
components of the mitochondrial electron transport chain, are
reduced, affecting the energy balance (Kong et al., 2018). Several
observations report the causal involvement of other TGFβ family
members such as activins, and on the basis of these findings,
drugs able to interfere with the activin receptor, which is
also shared by myostatin, are currently under investigation as
potential tools to manage cancer cachexia (Hatakeyama et al.,
2016; Nissinen et al., 2018).
Recent reports suggest that receptors of the Toll-like family
(TLRs) can be involved in mediating muscle wasting in
cancer cachexia. In particular, TLR4 appears to directly activate
muscle protein breakdown in mice hosting the Lewis lung
carcinoma. Consistently, TLR4 inhibition exerts a protective
effect against muscle wasting, likely by reducing the production
of pro-inflammatory cytokines such as TNFα and IL-6 (Zhang
et al., 2017a). In addition, the activation of TLR4 has also
been shown to depend on Hsp70 and Hsp90 that reach
the muscle through exosomes released by the tumor (Zhang
et al., 2017b). Similarly, the activation of TLR7 by miR-21
contained into tumor-derived extracellular vesicles has been
proposed to trigger apoptosis in cultured myoblasts, potentially
contributing to the defective myogenesis reported in cancer
cachexia (He et al., 2014).
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MYOGENESIS
Myogenesis is a physiological process induced during embryonal
development and susceptible of activation in the adult after
skeletal muscle injury, where it is more properly defined
as regeneration. Irrespective of the trigger, muscle fiber
degeneration following damage implies the recruitment and
activation of satellite cells, stem cells resident in the muscle
underneath myofiber basal lamina, that proliferate and fuse
with existing fibers to restore the original muscle mass. When
regeneration is triggered by chronic pathologies such as muscle
dystrophies, satellite cell pool can be exhausted, leading to
substitution of muscle with connective tissue.
The amount of satellite cells is not the same in every
muscle type. As an example, it is higher in oxidative than
in glycolytic muscles, respectively characterized by slow and
fast contraction (Yin et al., 2013). In addition, satellite cell
population is heterogeneous in terms of both myogenic potential
and ability to perform the asymmetric division, the hallmark of
stemness. In addition to satellite cells, several other cell types
have been recognized as endowed with myogenic potential, such
as mesoangioblasts and PW1+ cells. Finally, an important role
during myogenesis/regeneration is played by fibroadipogenic
progenitors (FAPs), cells that are unable to differentiate to muscle,
but that are crucial to sustain myogenic precursors during
proliferation and differentiation (Costamagna et al., 2015).
The activation of myogenesis in the adult strictly relies
on modulations of the muscle microenvironment, that are
different depending on the regenerative stimulus, e.g., acute
damage or chronic diseases. Particularly relevant, in this regard,
are the interactions occurring among immune cells, humoral
mediators and myogenic precursors. Indeed, the recruitment
of pro-inflammatory (M1) macrophages in the injured muscle
is concomitant with satellite cell activation. However, the
subsequent step of myogenic differentiation (satellite cell fusion
with existing myofibers) strictly requires the induction of M1
cell apoptosis and their replacement with anti-inflammatory
(M2) macrophages (St Pierre and Tidball, 1994). This transition
must take place with an accurate timing (M1: 1–2 days post-
injury; M2: 4 days post-injury) in order to ensure damage
repair and the down-regulation of injury-induced inflammatory
response. A crucial role in such process is played by cytokines,
produced by macrophages but also deriving from other cellular
sources. The production of TNFα and IL-10 allows the shift
from pro-inflammatory to anti-inflammatory milieu, killing FAPs
and M1 macrophages and allowing the recruitment of M2 cells
(Perdiguero et al., 2011; Fiore et al., 2016). In addition, IL-
10 also promotes the differentiation of myogenic precursors
different from satellite cells (Bosurgi et al., 2012). If cytokine
production does not conform to the correct regeneration
schedule, however, the process can be markedly impaired. As an
example, if TNFα is produced earlier than days 3–4 post-injury,
regeneration is impaired due to persistently cycling satellite cells
(Guttridge et al., 2000; Bakkar et al., 2008). The other way
round, if TNFα is not produced at the right moment, FAPs will
not die and, taking advantage of anti-inflammatory cytokines
such as IL-10 and TGFβ, will result in the overproduction
of extracellular matrix, eventually leading to muscle fibrosis
(Fiore et al., 2016).
Alterations in the regenerative process have been proposed
to contribute to muscle wasting occurring in several chronic
diseases such as dystrophies, myopathies, autoimmune diseases,
and cancer. Focusing on this latter, experimental studies
performed in mice hosting the C26 tumor have shown in the
muscle increased expression of Pax7, a marker of satellite cell
activation, and reduced levels of myogenin, an indicator of
ongoing differentiation. Similar observations have been reported
in cancer patients (Ramamoorthy et al., 2009; Penna et al.,
2010b; He et al., 2013). Consistently, in vivo regeneration is
delayed in the muscle of tumor-bearing mice, with a mechanism
that has been proposed to involve a persistent activation of the
transcription factor NF-κB (He et al., 2013), and the increased
phosphorylation of the stress kinase ERK (Penna et al., 2010b).
Recent observations have shown that overexpression of
Twist1, a transcription factor associated with the malignant
progression of several tumors, in myogenic precursors leads
to skeletal muscle hypotrophy. Such a pattern is associated
with increased myostatin expression in Twist1+ satellite cells.
The authors hypothesize that in satellite cells Twist1 drives
both myostatin synthesis and secretion. The released myostatin
targets myofibers that respond by increasing Twist1 expression,
resulting in muscle wasting (Parajuli et al., 2018). Of interest,
Twist1 levels higher than in healthy mice have been observed
in the skeletal muscle of animals bearing different experimental
tumors. Not only, if Twist1 expression is abrogated in satellite
cells of tumor hosts, cancer-induced muscle wasting appears
prevented (Parajuli et al., 2018). Finally, the zinc transporter
ZIP14, recently shown to contribute to muscle wasting in cancer
hosts, has also been proposed to interfere with regeneration, since
it is induced in satellite cells isolated from cachectic muscles.
Consistently, differentiation is impaired in ZIP14 overexpressing
C2C12 myoblasts in the presence of zinc (Wang et al., 2018).
THE SKELETAL MUSCLE STRIKES
BACK: ADAPTIVE MECHANISMS TO
FACE THE WASTING DRIVE
Looking at the history of skeletal muscle biology, it is quite
evident that while the relevance of this tissue to the organism
life has been understood very early, for quite a long time the
muscle has been considered as a sort of protein-containing black
box, that receives nutrients, oxygen and signals from outside and
returns the contractile activity necessary for breathing, moving,
heart beating, etc. Only in the last few decades the idea that
the skeletal muscle is indeed a metabolically active tissue able
to release mediators and to influence, directly or indirectly,
other body compartments has been gaining a growing consensus.
However, still nowadays, when pathological muscle wasting is
addressed, the general approach is to take into consideration,
mainly at least, only alterations that take place in the extra-muscle
body compartments and that target the muscle. This occurs, for
example, when cancer-induced systemic inflammation and/or
malnutrition are evoked to explain muscle wasting in cachexia.
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For sure, the role played by these features is overall recognized;
what is lacking to this picture, however, is the response set up
by the muscle to the systemic alterations. The general view,
in this regard, is that the muscle passively suffers this sort of
‘aggression’ coming from the extra-muscle environment, being
unable to face the external catabolic stimuli that eventually
lead to the loss of muscle mass and function. However, several
evidence suggest that the skeletal muscle is indeed able to set
up compensatory, although eventually unsuccessful, strategies
attempting to counteract cancer-induced hypercatabolism and
hypoanabolism. Along this line, understanding these strategies
will be highly valuable in order to design protocols aimed to
support the muscle in the struggle against the wasting drive.
Muscle Anabolic Response
The above reported concept that slimming in cachexia is
different from that due to caloric restriction is based on the
observation that the latter is adopted in a physiological metabolic
environment, while the former occurs in the presence of marked
abnormalities, such as inflammation and hypermetabolism. In
particular, cancer hosts might not properly activate protein
synthesis following an increased nutrient loading, a condition
that has been defined as ‘anabolic resistance.’ Its occurrence
seriously questions the usefulness of anabolism-promoting
strategies: if the patient cannot activate protein synthesis, no
nutritional or pro-anabolic intervention will ever be successful.
In the last few years, however, the idea that cancer hosts
still maintain the ability to activate anabolism, at least until
cachexia does not reach the refractory stage, has gained a
growing consensus (Prado et al., 2013; Engelen et al., 2016;
Antoun and Raynard, 2018).
Several observations derived from both experimental and
clinical studies support this hypothesis. Muscle wasting in tumor-
bearing animals is unexpectedly associated with unchanged or
increased levels of molecules involved in the protein synthetic
machinery. As an example, the PI3K-Akt-mTOR signaling is
poised toward activation in mice implanted with the C26
tumor (Penna et al., 2010a), while protein synthesis rates are
unchanged with respect to controls in rats hosting the Yoshida
AH-130 hepatoma or the MCA sarcoma (Tessitore et al.,
1987; Stallion et al., 1995). As for human pathology, habitual
myofibrillar protein synthesis rates in gastric cancer patients,
either weight stable or weight losing, have been reported to
be comparable to control subjects (MacDonald et al., 2015).
Consistently, in the muscle of cancer patients, the pAkt/Akt
ratio and the levels of pGSK3β, both molecular markers of
an intracellular pro-anabolic setting, are comparable to control
levels or even increased (Aversa et al., 2012; Stephens et al.,
2015). A study performed on patients affected by non-small
cell lung cancer has shown the activation of a normal anabolic
response after an euglycemic, hyperinsulinemic clamp associated
with amino acid supplementation (Winter et al., 2012). Similarly,
a significantly high anabolic response independent from body
weight loss, muscle mass depletion and the occurrence of
inflammation, has been obtained feeding lung cancer patients
with an essential amino acid integration (Engelen et al., 2015).
Finally, the association of conventional nutritional support with
high leucine, fish oil and carbohydrate supplementation has
enhanced the muscle anabolic response in advanced cancer
patients (Deutz et al., 2011). On the whole, these observations
support the idea that, if adequately supported, cancer patients
might benefit from timely adopted nutritional, better if protein
enriched, interventions.
In addition to the supply of amino acids, mainly mere
‘bricks’ to build up new proteins, nutritional supplements can
also be useful in order to modulate both muscle and extra-
muscle environments. This applies, for example, when molecules
able to reduce inflammation are included in the nutritional
formula. Polyunsaturated fatty acids (PUFAs) belonging to the
ω-3 series have revealed promising in this regard: a recent
meta-analysis based on the screening of a huge number of
clinical trials involving chemotherapy-treated cancer patients has
shown that oral nutritional supplementation exerts beneficial
effects only when ω-3 PUFAs are included in the formulation
(de van der Schueren et al., 2018). It is still debated if ω-
3 PUFA supplementation also results in improved patient
outcome. While several studies support such possibility (reviewed
in Laviano et al., 2018), contrasting evidence do exist. In
this regard, no improvement of overall survival has been
reported in a study investigating the effects of ω-3 PUFA
supplementation in cachectic gastrointestinal cancer patients
treated with chemotherapy (Shirai et al., 2017).
Strategies aimed at counteracting members of the TGFβ
family such as myostatin and activin have been tested.
Particularly interesting appear the studies involving soluble
activin receptor type IIB and antibodies directed against the
activin II receptor (Bimargumab). In tumor-bearing mice the
former has been reported to increase survival and muscle wasting
as well as to improve the anabolic and anti-catabolic effect of
formoterol (Toledo et al., 2016b; Nissinen et al., 2018). Similarly,
Bimagrumab has proved effective in preventing muscle atrophy
induced by glucocorticoids or cancer (Lach-Trifilieff et al., 2014;
Hatakeyama et al., 2016). Clinical studies have been performed
or are currently ongoing in order to test humanized antibodies
targeting the activin IIB receptor. At present, the results available
demonstrate that lean mass and muscle strength are increased in
antibody-receiving volunteers (Becker et al., 2015).
Another exploitable strategy to improve anabolism is the
administration of ghrelin. In this regard, increased circulating
ghrelin markedly modulates protein and energy metabolism
(Ezquerro et al., 2017). Consistently, tumor-bearing animals
treated with ghrelin show increased food intake, improved body
composition and increased tolerance to anti-cancer drugs (Graf
and Garcia, 2017). Since ghrelin administration might also exert
undesirable effects, ghrelin analogs have been produced and are
currently studied in clinical trials. Among the most promising,
anamorelin has been shown to improve body composition and
muscle function in non-small cell lung cancer patients (Takayama
et al., 2016). By contrast, other studies have clearly shown that
anamorelin fails to improve motor function in cancer patients
(Temel et al., 2016), likely suggesting that muscle function cannot
be rescued by adopting single agent pharmacological strategies.
Subsequent investigations have shown that, in selected groups
of patients, anamorelin also leads to improved performance
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status (Katakami et al., 2018). Other appetite stimulants such as
macimorelin and a synthetic human ghrelin are actually under
investigation (Argilés et al., 2017).
Enhanced Intracellular Protein
Breakdown as a Salvage Pathway
An adequate protein homeostasis, e.g., a balance between protein
synthesis and degradation rates, is required to properly maintain
cell functions and to prevent the onset and progression of
diseases. In this regard, the observation that protein catabolism is
generally increased in several conditions associated with muscle
mass depletion, including cancer cachexia, has characterized
this arm of protein metabolism with a negative connotation.
However, normal cell function cannot disregard the presence
of an adequate rate of protein turnover, meaning that the
production of new proteins must be paralleled by the disassembly
of pre-existing damaged or misfolded proteins. This is true in
the whole organism and in the muscle in particular, where
several myopathies arise due to the absence of physiological
levels of protein catabolism (Bell et al., 2016). Indeed, the
physiological rate of protein degradation in the skeletal muscle is
considerably high, provided that this tissue is constantly exposed
to damaging events such as mechanical stretch, force generation,
and oxidative stress.
The observation that muscle intracellular proteolytic systems
are activated above physiological levels in cancer cachexia
(see above) has provided the basis for different experimental
approaches aimed at contrasting the onset and progression of
muscle mass depletion. As an example, genetic inhibition of
muscle-specific ubiquitin ligases has been shown to effectively
counteract the loss of muscle proteins (Rom and Reznick, 2016).
Such an approach, however, has not yet been validated for
the clinical use. Another tool has come from the discovery of
rather specific proteasome inhibitors such as bortezomib. While
this drug is widely used to treat hematologic malignancies,
studies performed on experimental models of cancer cachexia
have demonstrated that specific proteasome inhibition does
not improve muscle phenotype (Penna et al., 2016a). The lack
of effectiveness of the pharmacological approaches aimed at
counteracting proteasome-dependent proteolysis likely depend
on the compensatory activity set up by the other intracellular
proteolytic systems, further supporting the idea that if muscle
protein breakdown is overactivated in cancer cachexia, this does
not happen by chance. In other words, such activation above
physiological levels is likely part of an adaptive response due to
the steadily increased abundance of damaged/unwanted proteins,
ultimately aimed at maintaining vital functions. In this regard,
targeting the mechanisms leading to protein alteration rather
than protein degradation systems should be pursued.
Particularly relevant in terms of protein homeostasis
maintenance is the proteolytic system that relies on autophagy.
Enhancement of the autophagic-lysosomal protein degradation
has been demonstrated in several conditions characterized by
muscle wasting, including myopathies and cancer cachexia
(Penna et al., 2014), suggesting that limiting the activation of
this proteolytic system could be the goal to achieve in order to
prevent or at least delay the loss of muscle mass and function.
Such interpretation, however, does not take into account the
physiological relevance of autophagy. In this regard, observations
performed on experimental animals genetically manipulated
in order to obtain a muscle-specific autophagy-defective
phenotype have clearly shown that autophagy is required to
maintain a correct muscle morphology, a healthy mitochondrial
compartment and a proper force-generating capacity (Masiero
et al., 2009). Consistently with these observations, gene strategies
aimed at silencing Beclin-1, a key player of autophagosome
formation, have proved ineffective in preventing the reduction of
myofiber atrophy in mice hosting the C26 tumor (Penna et al.,
unpublished). In addition, frankly cachectic C26-bearing mice
treated with pharmacological inhibitors of the autophagic flux
do not survive (Penna et al., 2013). This observation suggests
that autophagy in the muscle of the C26 hosts is activated above
physiological levels also in order to provide substrates that are
no more available from the usual sources. In this regard, at a
certain point at least, such overactivation becomes an adaptive
response that is crucial to maintain the body homeostasis or to
support a new homeostatic level in stressful conditions. Partially
consistent with these observations are the results reported by
a study showing that stimulation of stress-induced autophagy
obtained through mTOR inhibition improves muscle phenotype
in tumor hosts (Pigna et al., 2016). However, long term treatment
with mTOR inhibitors in patients has been shown to result in
muscle wasting (Gyawali et al., 2016). Finally, overactivation
of autophagy obtained through TP53INP2/Dor overexpression
was shown to exacerbate the loss of muscle mass observed in
experimental diabetes, confirming that both direct inhibition and
stimulation of autophagy are detrimental in wasting conditions
(Sala et al., 2014).
On the whole, these observations support the idea that
modulations of autophagy can be good treatment options to
manage muscle wasting in cancer cachexia only if they succeed
in maintaining the physiological flux. In other words, too less
autophagy is as detrimental as too much autophagy. Finally, the
observation reported above clearly define that the prevention
or delay of the onset and progression of muscle wasting in
cancer cachexia cannot be obtained by targeting one specific
proteolytic system. By contrast, acting on the mechanisms that
activate the hypercatabolic drive appears a more promising
strategy. Just as an example, β2-adrenergic agonists have been
demonstrated to effectively improve muscle phenotype in tumor-
bearing animals as well as in cancer patients (Busquets et al.,
2004); such protection is associated with down-regulation of both
proteasome activity and autophagy (Penna et al., unpublished).
The regulation of protein hypercatabolism in muscle wasting
has also been associated with the activation of the UPR due to
endoplasmic reticulum (ER) stress (Afroze and Kumar, 2017; Ma
et al., 2017). Indeed, increased expression of ER stress markers
has been reported in denervated muscles (Yu et al., 2011) as well
as in the muscle of tumor-bearing animals (Bohnert et al., 2016).
Such a response has been proposed to reflect a compensatory
mechanism, since inhibition of both ER stress and UPR results
in the induction of muscle wasting, the more so when the muscle
is already depleted (Afroze and Kumar, 2017). More recently,
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FIGURE 3 | Muscle compensatory mechanisms activated in response to tumor growth. The skeletal muscle is a plastic tissue able to autonomously respond to the
wasting stimuli in order to maintain the homeostasis. Muscle loss occurs as a consequence of the failure to adapt to the alterations induced by the tumor.
Anti-cachexia drugs targeting specific cellular and molecular processes will boost the muscle adaptation potential, counteracting the wasting process.
evidence suggesting the relevance of the PERK arm of the
unfolded protein response to the maintenance of muscle mass
and function has been reported (Gallot et al., 2018).
Oxidative Stress Management
Oxidative species such as ROS and RNS have been involved in
the pathogenesis of cancer-induced muscle wasting (see above).
Along this line, antioxidant compounds such as vitamins C and
E, α-lipoic acid, N-acetylcysteine, and polyphenols have been
proposed as useful therapeutic tools. Polyphenols, in particular,
have been shown to protect against the onset of cachexia in
different types of tumors (Oelkrug et al., 2014; Gil da Costa
et al., 2017), likely due to their inhibitory effect on NF-κB (Gil
da Costa et al., 2017). On the other side, several pre-clinical
and clinical studies have demonstrated that the anti-cachectic
effects exerted by anti-oxidant drugs are poor, if not frankly
detrimental (Busquets et al., 2007; Assi et al., 2016). In this regard,
depending on the body compartment, tumor included, a pro-
oxidant environment can be either detrimental or beneficial and
anti-oxidant treatments can be helpful and exert unwanted effects
at the same time.
Both systemic mediators and intramyofiber events, such
as proinflammatory cytokines and mitochondrial alterations,
respectively, can generate a pro-oxidant environment in the
skeletal muscle of cancer hosts. However, even when muscle mass
and function are significantly reduced with respect to control
values, the tissue is able to activate an effective antioxidant
response. Indeed, increased mRNA expression of both Cu/Zn
SOD and catalase, associated with unchanged levels of protein
carbonylation and malondialdehyde, can be observed in the
muscle of C26-bearing mice (Assi et al., 2016; Ballarò et al.,
unpublished). Such antioxidant response is further enhanced
when tumor-bearing animals are exposed to a moderate exercise
protocol, that also results in improved muscle mass and function
(Ballarò et al., unpublished).
These results suggest that, despite profound metabolic
alterations occur in the muscle of cancer hosts, this tissue is still
able to activate and maintain an efficient anti-oxidant response,
suggesting that tissue-specific interventions able to improve
such adaptation would be beneficial to prevent or delay the
progression of cachexia toward the refractory phase.
Activation of the Myogenic Response
Physiologically, the skeletal muscle activates the regeneration
program to face myofiber injury. Previous observations have
reported that this process is activated in the skeletal muscle of
cancer hosts (see above), however, what is actually triggering
regeneration in this situation is still debated. In this regard, few
studies suggest that alterations of the dystrophin glycoprotein
complex leading to sarcolemma leakage play a crucial role
(Acharyya et al., 2005; He et al., 2013). However, the observation
that an inflammatory infiltrate is lacking in the muscle of tumor-
bearing animals (Berardi et al., 2008) does not support this
hypothesis. Another possibility is that the activation of the
regenerative response is another face of the residual anabolic
capacity reported in the muscle of cancer hosts. According to
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this possibility, but with unknown mechanisms, the muscle could
react to the hypercatabolic state by recruiting and activating
myogenic precursors, attempting to counteract the loss of muscle
proteins. Such a strategy is however ineffective, since for unclear
reasons committed Pax7+ myogenic precursors do not reach the
complete differentiation and accumulate in the muscle without
proceeding to fuse with existing myofibers. Consistently with
this hypothesis, treatments able to release the impairment of
myogenesis, such as MEK inhibitors or Pax7 silencing, also result
in improved muscle mass and function (Penna et al., 2010b;
Prado et al., 2012; He et al., 2013; Talbert et al., 2017).
Very little is known about the mechanisms that impair
complete myogenic differentiation in the muscle of cancer
hosts. The first possibility is that something has changed in
muscle stem cells, leading to altered differentiation capacity.
However, myogenic precursors isolated from the muscle of
C26-bearing mice have been shown to perfectly differentiate
in vitro (He et al., 2013; Inaba et al., 2018; Costamagna
et al., unpublished data), demonstrating that the impaired
regeneration does not depend on a cell autonomous defect.
Taking into consideration these results, a possible alternative
is that the presence of the tumor results in the generation
of a muscle microenvironment that is not permissive for
complete regeneration. Along this line, the persistently
increased activation of both ERK and NF-κB (see above)
are likely part of the mechanism that modulates muscle
microenvironment. An additional mechanism can rely on the
reduced recruitment to the muscle of neutrophils, macrophages,
and mesenchymal progenitors occurring in tumor-bearing
animals (Inaba et al., 2018).
Basal autophagy is also required to ensure both the
maintenance of satellite cell homeostasis and a proper
muscle regenerative response. Indeed, autophagy is steadily
activated in quiescent satellite cells in order to get rid of
potentially dangerous wasting products, preserving cell ‘well-
being.’ Defective autophagy results in satellite cell senescence,
mainly due to the accumulation of altered mitochondria
that leads to oxidative stress, eventually reducing both the
stem cell pool and function. Senescent muscle stem cells are
unable to be recruited and activated in response to damaging
stimuli (Sousa-Victor et al., 2018). Such pattern can be
reversed by restoring basal flux of autophagic degradation
or by pharmacological inhibition of ROS release above
physiological levels (García-Prat et al., 2016). In addition,
in the regenerating muscle autophagy has been proposed to
impinge on myoblast differentiation (Fiacco et al., 2016; Fortini
et al., 2016). Last but not least, autophagy is responsible for
providing activated satellite cells with nutrients required to
sustain the increased demand to exit quiescence and entering
the cell cycle (Tang and Rando, 2014). Consistently with this
hypothesis, the reduced expression of TP53INP2/DOR in the
skeletal muscle of tumor-bearing mice and cancer hosts (Penna
et al., unpublished) suggest that indeed basal autophagy is
reduced in these conditions, potentially impinging also on
Pax7+ cells.
The activation of satellite cells is characterized also by
modulations in the oxidative pattern. Quite recent studies show
that genetic manipulation of Pitx2 and Pitx3 transcription factors,
known to regulate the redox homeostasis during embryonal
myogenesis also affects the differentiation of adult satellite cells.
In particular, muscle regeneration fails in animals depleted of
both factors, that are characterized by markedly increased ROS
levels (L’honoré et al., 2018). The same study reports that,
while ROS increase is required by satellite cell to exit from
quiescence and to proceed toward differentiation, excess ROS
is detrimental (L’honoré et al., 2018). Along this line, reduced
oxidative potential has been reported in satellite cells isolated
from muscle biopsies of cancer patients, that are also endowed
with reduced ability to differentiate (Brzeszczyńska et al., 2016).
There is the possibility that the same alteration of redox state
applies to myogenic precursors isolated from tumor-bearing
animals, partially explaining the impaired regenerative response
(Penna et al., 2010b; He et al., 2013). On the other side, the
oxidative stress reported in the muscle of cancer hosts could also
reflect the attempt to generate an environment permissive for
satellite cell activation and differentiation.
CONCLUSION
Cancer cachexia arises from a complex milieu in which several
factors such as metabolic alterations, malnutrition and systemic
inflammation play a crucial role. Since this multiorgan syndrome
is an important challenge in patient management, the definition
of markers suitable to allow its early identification is actively
pursued for therapeutic purposes.
Several reviews analyzed the therapeutic strategies actually
available to counteract cancer cachexia (Advani et al., 2018;
Di Girolamo et al., 2018; Solheim et al., 2018); while quite
different approaches are adopted, all the studies agree in
stating that they are far from being effective, likely because
the mechanisms underlying this syndrome are only partially
elucidated. Particularly relevant in this regard, is the observation
that target tissues such as the skeletal muscle are able to
react to the wasting stimuli activating compensatory responses
(Figure 3). These counteractive strategies, however, are not
potent enough and do not succeed in preventing the progression
of cachexia. Along this line, the multimodal therapeutic protocol
to treat cachexia could take advantage also of new approaches
that, relying on understanding tissue-specific compensatory
responses, contribute to support the organism effort in defeating
the wasting drive.
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Recently, many studies showing the regeneration potential of both cardiac and hematopoietic 
stem cells in adult heart following injury were definitively retracted by the literature. Therefore, 
stimulating myocardial angiogenesis becomes to be important for preventing cardiovascular 
diseases. Regular endurance exercise has been reported to induce capillary growth in 
healthy and diseased myocardium resulting in cardioprotective phenotype. Previously, 
we demonstrated a significantly increased capillary proliferation in mouse hearts following 
30 and 45 days of endurance training. In the present study, we examined the localization 
and expression pattern of vascular endothelial growth factor receptors (VEGFR-1/Flt-1 
and VEGFR-2/Flk-1), hypoxia-inducible factor-1α (HIF-1α), and inducible nitric oxide 
synthase (iNOS) in heart neocapillarization in response to a mild, moderate, and high 
intensity of endurance training. Sixty-three Swiss male mice were divided into four untrained 
control groups and three groups trained for 15 (T15), 30 (T30), and 45 (T45) days with a 
gradually increasing intensity on a treadmill. We observed the localization of studied proteins 
with immunostaining and their expression level with Western blot analyses. We found that 
VEGFR-2/Flk-1 expression progressively increased in trained groups compared with 
controls, while VEGFR-1/Flt-1 and HIF-1α were higher in T15 than in controls, T30, and 
T45 animals. Differently, iNOS levels enhanced after 15 and 30 days of exercise. The 
localization of these factors was not altered by exercise. The results showed that the 
expression of VEGFR-1/Flt-1, VEGFR-2/Flk-1, HIF-1α, and iNOS is differently regulated 
in cardiac angiogenesis according to the exercise intensity. VEGFR-1/Flt-1 and HIF-1α 
are upregulated by a mild intensity exercise, while VEGFR-2/Flk-1 progressively enhances 
with increasing workload. Differently, iNOS protein is modulated by a moderate intensity 
exercise. VEGF pathway appears to be involved in exercise-related angiogenesis in heart 
and VEGF might act in a paracrine and endocrine manner. Understanding this relationship 
is important for developing exercise strategies to protect the heart by insults.
Keywords: heart, skeletal muscle, endurance training, angiogenesis, physical exercise, capillary growth, hypoxia, 
exercise intensity
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INTRODUCTION
Regular physical exercise is well known to reduce cardiovascular 
diseases, the main cause of death worldwide, increasing cardiac 
function and protecting against myocardial damage (Schuler 
et  al., 2013; Tao et  al., 2015). Heart adaptations can vary 
according to type, intensity, and duration of exercise and are 
commonly defined as the athlete’s heart (Pluim et  al., 2000; 
Fulghum and Hill, 2018). For instance, endurance exercises 
such as running or swimming performed for prolonged periods 
are a significant physiological stimulus for an enhanced demand 
of oxygen and nutrient leading to the formation of new capillary 
in myocardium (Brown, 2003; Bellafiore et  al., 2007; Fulghum 
and Hill, 2018). In detail, modifications in the blood flow, 
muscle contraction, and oxygen levels associated with 
hemodynamic mechanical events have been shown to be  key 
signals for triggering vessel wall remodeling and activation of 
growth factors involved in the proliferation, migration, and 
tube formation of endothelial cells in both heart and skeletal 
muscle (Brown, 2003; Prior et  al., 2004). This implies a cross 
talk between skeletal and cardiac muscle in order to respond 
synergistically to various stimuli derived by physical exercise. 
Indeed, several studies recently reported that exercise stimulates 
the release of circulating cytokines and growth factors, called 
myokines, by skeletal muscle that acts with endocrine functions 
mediating exercise-induced cardiovascular adaptations (Giudice 
and Taylor, 2017; Hoffmann and Weigert, 2017).
Among the molecules involved in the angiogenesis induced 
by physical exercise, vascular endothelial growth factor (VEGF) 
plays a crucial role in the induction of endothelial cell mitosis 
and promotion of capillary sprouting (Hudlicka et  al., 1995; 
Shibuya, 2006). The angiogenic action of VEGF is mediated by 
two primary receptors, such as VEGFR-1/Flt-1 and VEGFR-2/
Flk-1, both predominantly expressed on the endothelial cells 
but with different roles (Hudlicka et  al., 1995; Iemitsu et  al., 
2006; Shibuya, 2006). VEGFR-1/Flt-1 has higher affinity for 
VEGF than VEGFR-2/Flk-1, and it was found to mediate 
chemotaxis, mitogenesis, and cytoskeletal reorganizations. In 
contrast, VEGFR-2/Flk-1 has a ligand-induced autophosphorylation 
activity much stronger than VEGFR-1/Flt-1 and is the major 
regulator of vasculogenesis and angiogenesis (Shibuya, 2006). 
Iemitsu et  al. (2006) found an increase in mRNA and protein 
expression of VEGFR-1/Flt-1 and VEGFR-2/Flk-1 associated with 
an enhanced capillary density in aged rat hearts after 8  weeks 
of swim training. Furthermore, Milkiewicz et  al. (2003) showed 
that these receptors were regulated by chronic ischemia/hypoxia 
and intermittent electrical stimulation in rat skeletal muscle. 
The role of hypoxia as a candidate for the initiation of angiogenesis 
in exercising muscle was reinforced by data indicating that 
hypoxia-inducible factor-1 α (HIF-1α) expression induced by 
hypoxia determined the upregulation of VEGF in trained rat 
muscles (Shweiki et al., 1992). Moreover, HIF-1α has been found 
to be  significantly overexpressed in rat left ventricle 48  h after 
the last training session of a 10-week mild intensity aerobic 
exercise protocol and to participate in cardioprotection (Giusti 
et al., 2009). This effect might be due to “ischemic preconditioning” 
induced by physical exercise and detected in both humans and 
animals (Marongiu and Crisafulli, 2014). This phenomenon 
consists of ischemia short episodes that render the myocardium 
more resistant to subsequent more prolonged ischemic events. 
In addition, HIF-1α has been discovered to activate the downstream 
genes of VEGF such as inducible nitric oxide synthase (iNOS) 
in cardiomyocytes and endothelial cells, resulting in an increase 
in angiogenesis and cardioprotection (Jung et  al., 2000;  
Tekin et  al., 2010).
In the past two decades, Anversa et  al. discovered that 
c-kit–positive cardiac stem cells and hematopoietic stem cells 
derived from the bone marrow can regenerate the heart muscle 
following a myocardial infarction (Beltrami et al., 2001; Anversa 
et  al., 2013). According to these studies, by injecting these 
stem cells into the heart, they could differentiate into 
cardiomyocytes and coronary vessels, leading to tissue repair. 
This result, whether it had been true, would have had a decisive 
relief for a very large number of patients all over the world. 
However, several of these studies were recently retracted from 
prestigious journals, and Harvard Medical School and Brigham 
and Women’s Hospital have recommended the retraction of 
other 31 papers of Anversa’s group (Drazen, 2018; Dyer, 2018). 
Therefore, the research of physical exercise-related stimuli 
inducing a cardioprotective phenotype results to be  really 
important for preventing cardiovascular diseases and improving 
heart function following injury. To this regard, little is known 
about the signaling molecules that regulate capillary growth 
in healthy myocardium according to the exercise intensity. This 
limitation might be  due to controversial evidence about the 
stimulation of new capillaries in healthy hearts by physical 
exercise and might depend on the intensity and length of 
exercise training selected for analyzing cardiac microvasculature 
(Brown, 2003). It has been indeed reported that exercise-induced 
formation of new capillaries is transient as capillaries transform 
into arterioles (Brown, 2003). In previous studies, we  showed 
a significantly increased capillary proliferation in mouse hearts 
following 30 and 45  days of an endurance training protocol 
(Bellafiore et al., 2007, 2013). Therefore, the aim of the present 
study was to investigate the localization and expression pattern 
of VEGFR-1/Flt-1, VEGFR-2/Flk-1, HIF-1α, and iNOS in the 
angiogenesis of mouse hearts in response to mild, moderate, 
and high intensity of endurance training. We speculated response 
patterns that differ among examined molecules and depend 
on the training workload.
MATERIALS AND METHODS
Experimental Design
Sixty-three male 10-week-old Swiss mice were randomly divided 
into seven groups. Four groups were selected as sedentary 
controls (C) (0, 15, 30, and 45  days) and three groups were 
trained through an endurance protocol for 15 (T15), 30 (T30), 
and 45  days (T45). Mice were trained for 5  days/week on a 
rotating treadmill progressively increasing both workload intensity 
and training time (Di Felice et  al., 2007). The exercise training 
intensity performed by T15, T30, and T45 mice corresponded 
to a mild, moderate, and high intensity, respectively. The study 
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conforms to the Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 85-23, revised 1996) and was 
approved by the local Ethical Committee of Palermo University 
(Comitato Etico Palermo 1). We  carried out this study using 
the same samples of heart prepared in our previous studies, 
in which we detected left ventricle hypertrophy associated with 
a significant increase in the capillary proliferation after 30 and 
45  days of endurance training (Bellafiore et  al., 2007, 2013).
Immunostaining Analyses
In order to examine the localization and expression of VEGFR-1/
Flt-1, VEGFR-2/Flk-1, HIF-1α, and iNOS, immunohistochemical 
analyses were performed. Hearts were fixed with formalin, 
embedded with paraffin, and cut to obtain 5  μm sections. 
After incubation of sections for 10  min with 0.3% H2O2, a 
serum-free protein block (DAKO, Carpinteria, USA) was added 
for 10  min. Sections were then incubated with the primary 
antibodies against VEGFR-1/Flt-1 (1:200; Chemicon® 
International, Serological Company, EU), VEGFR-2/Flk-1 (1:100; 
Chemicon® International, Serological Company, EU), HIF-1α 
(1:100; Chemicon® International, Serological Company, EU), 
and iNOS (1:50; Calbiochem®, San Diego, CA, USA) for 1  h 
at room temperature (RT). Non-immune mouse serum was 
substituted for negative controls. Before adding the primary 
antibodies for HIF-1α, the slides were treated with monohydrated 
citrate buffer (pH  6.0, 0.01  M) in a water bath for 40 and 
10  min, respectively, at 100°C for the antigen retrieval. After 
incubation for 10  min with a biotinylated secondary antibody, 
AEC chromogen (DAKO, Carpinteria, CA, USA) was used to 
develop the horseradish peroxidase (HRP)-streptavidin complex.
Western Blotting
The expression levels of VEGFR-1/FLT-1, VEGFR-2/FLK-1, 
HIF-1α, and iNOS were measured in the left ventricle (LV) 
from each single mouse of the control and trained groups by 
immunoblot analyses. Frozen LV fragments were homogenized 
in a lysis buffer, containing protease inhibitors, and centrifuged 
at 13,000  rpm for 10  min at 4°C. Total cellular lysate fraction 
was collected, and protein concentration was determined using 
a colorimetric assay (Bio-4 Rad, Philadelphia, USA). About 
20  μg of protein samples for each lane and a protein marker 
(Bio-Rad, Philadelphia, USA) were separated by 8% SDS-PAGE 
and transferred to a nitrocellulose membrane. After 1  h at 
RT with a blocking buffer, each membrane was incubated with 
primary antibodies against VEGFR-1/Flt-1 (1:1000; Chemicon® 
International, Serological Company, EU), VEGFR-2/Flk-1 (1:500; 
Chemicon® International, Serological Company, EU), HIF-1α 
(1:500; Chemicon® International, Serological Company, EU), 
and iNOS (1:500; Calbiochem®, San Diego, CA, USA) overnight 
at 4°C. After washing, each membrane was incubated with 
HRP-conjugated secondary antibody for 1  h at RT, and signals 
were detected using an enhanced chemiluminescence (ECL, 
Amersham Bioscience, UK) for autoradiography. After stripping, 
the same membranes were incubated with β-actin antibody 
(1:1000; Sigma-Aldrich, USA), and the ratio of proteins of 
interest and β-actin was determined. The intensity of bands 
was quantified by computer-assisted image analysis (ImageJ, 
Media Cybernetics, Silver Spring, MD, USA) calculating pixel 
number per cm2.
Statistical Analysis
Data are expressed as means ± standard deviations. One-way 
ANOVA test with Bonferroni’s multiple comparison test was 
used to analyze significant differences. Values were considered 
significantly different at p  <  0.05.
RESULTS
Cardiac Expression of VEGFR-1/Flt-1  
and VEGFR-2/Flk-1 in Response to 
Physical Exercise
Both receptors, VEGFR-1/Flt-1 and VEGFR-2/Flk-1, were 
expressed in subepicardial and subendocardial regions and 
specifically localized in the vascular endothelial cells as shown 
in Figure 1. We  observed the same localization in the hearts 
from both control and trained mice (data not shown). From 
immunoblotting analyses, we  obtained a band with molecular 
weight of about 180  kDa corresponding to VEGFR-1/Flt-1 
protein (Figure 2A) as reported in the literature. Because samples 
from C, T15, T30, and T45 groups did not significantly differ 
within the same group, a representative sample from each group 
has shown (Figures 2A,B). The expression of VEGFR-1/Flt-1 
was higher in T15 mice than in C, T30, and T45 groups (T15: 
1.17  ±  0.005 vs. C: 1.02  ±  0.01, T30: 1.03  ±  0.01, and T45: 
0.94  ±  0.01; p  <  0.05; Figure 2B). T30 animals did not show 
any significant difference compared with C groups. Moreover, 
in T45 animals, VEGFR-1/Flt-1 expression was lower than C 
and T30 mice (T45: 0.94  ±  0.01 vs. C: 1.02  ±  0.01 and T30: 
1.03  ±  0.01; p  <  0.05; Figure 2B).
As regards to VEGFR-2/Flk-1 expression, we  found a band 
with molecular weight of about 200 kDa that gradually increased 
in trained mice (T15, T30, T45) compared to controls (C) 
(T15: 0.97  ±  0.01, T30: 1.07  ±  0.007, and T45: 1.21  ±  0.01 
vs. C: 0.93  ±  0.01; p  <  0.05). In particular, VEGFR-2/Flk-1 
expression was higher in groups T30 and T45 than in T15 
(T30: 1.07  ±  0.007 and T45: 1.21  ±  0.01 vs. T15: 0.97  ±  0.01; 
p  <  0.05) and in T45 rather than T30 mice (T45: 1.21  ±  0.01 
vs. T30: 1.07  ±  0.007; p  <  0.05; Figure 2).
Regulation of HIF-1α Expression by the 
Endurance Training in the Myocardium
Immunostaining analyses showed that HIF-1α protein was 
specifically localized in the nucleus of vascular endothelial and 
myocardial cells of control and trained animals (Figure 1). 
The expression of HIF-1α was confirmed by immunoblotting 
analyses (Figure 3A), which showed a band with molecular 
weight of about 120  kDa. As samples from C, T15, T30, and 
T45 did not significantly differ within the same group, a 
representative sample from each group is shown (Figure 3). 
As shown in Figure 3B, it is evident that HIF-1α expression 
was significantly higher in T15 animals than in T30 and T45 
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control mice (T15: 1.40  ±  0.11 vs. C: 1.24  ±  0.05, T30: 
1.24 ± 0.12, and T45: 1.26 ± 0.10; p < 0.05). Moreover, control 
groups, T30, and T45 showed the same expression (Figure 3B).
Analysis of iNOS Cardiac Expression 
Related to Physical Exercise
In Figure 1, we  observe that iNOS protein was expressed in the 
cells of interstitial connective tissue and smooth muscle of the 
hearts from T30 mice. The same localization was found in hearts 
from T15, T45, and control animals (data not shown). Evaluation 
of iNOS expression (Figures 4A,B) showed a significantly higher 
level in T15 and T30 groups than in C and T45 animals (T15: 
0.48  ±  0.01 and T30: 0.92  ±  0.02 vs. C: 0.23  ±  0.009 and T45: 
0.36  ±  0.01). Furthermore, no significant difference was detected 
between T45 and C animals. As samples from C, T15, T30, and 
T45 did not significantly differ within the same group, a 
representative sample from each group is shown (Figure 4).
DISCUSSION
In this study, we  examined the relationship between VEGFR-1/
Flt-1, VEGFR-2/Flk-1, HIF-1α, iNOS expression and angiogenesis 
in heart in response to low, moderate, and high exercise intensity. 
FIGURE 1 | Representative microphotographs show the localization of VEGFR-1/Flt-1, VEGFR-2/Flk-1, HIF-1α, and iNOS performed by immunohistochemical 
analyses in the myocardium of T15 mice. Non-immune mouse serum was substituted for the negative controls. The specificity of the antibodies used was confirmed 
by the absence of staining in the negative controls.
A B
FIGURE 2 | Western blotting (A) and quantitative analysis (B) to measure VEGFR-1/Flt-1 and VEGFR-2/Flk-1 expression in hearts from trained and control mice. 
(B) VEGFR-1/Flt-1 protein levels resulted significantly higher in T15 than in groups C, T30, and T45. Conversely, T45 animals showed a lower VEGFR-1/Flt-1 
expression than C and T30 mice ($p < 0.05 T15 vs. T30 and T45; £p < 0.05 T45 vs. C and T30). VEGFR-2/Flk-1 expression gradually increased in trained mice 
(T15, T30, and T45) than control ones. Moreover, VEGFR-2/Flk-1 expression was higher in groups T30 and T45 than T15 ones and in T45 mice than T30 ones 
(*p < 0.05, T15, T30 and T45 vs. C; #p < 0.05, T30 and T45 vs. T15; §p < 0.05,T45 vs. T30).
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To this end, we  carried out the analyses in myocardial tissue 
samples in which we  previously found a relevant increase in 
the capillary proliferation following 30 and 45  days of moderate 
and high intensity endurance training, respectively (Bellafiore 
et  al., 2007, 2013). The main findings in the present study were 
that the expression levels of the examined molecules were dissimilar 
according to the neocapillarization extent and physical exercise 
intensity. Human epidemiological and animal studies have shown 
that a moderate to high intensity exercise is the best quantity 
that results in a reduction in the cardiovascular risk (Alleman 
et al., 2015). A recent paper reported that high intensity treadmill 
exercise training for up to 4  weeks produced greater increases 
in new capillary formation than low intensity exercise training 
in rat hearts (Waring et  al., 2014). However, results concerning 
the regulation of VEGFR-1/Flt-1, VEGFR-2/Flk-1, HIF-1α, and 
iNOS expression by exercise different intensities in healthy heart 
angiogenesis are limited.
Several studies reported an increase in VEGFR-1/Flt-1 and 
VEGFR-2/Flk-1 expression after 8  weeks of swim training or 
10  weeks of treadmill running in rat heart angiogenesis 
(Iemitsu et  al., 2006; Marini et  al., 2008). In our study, 
VEGFR-1/Flt-1 and VEGFR-2/Flk-1 proteins were specifically 
expressed in the vascular endothelial cells of myocardium 
and differently regulated by intensity and length of the 
endurance training. In particular, VEGFR-1/Flt-1 expression 
increased in T15 mice and reduced in T30 and T45 animals 
exhibiting the same level as the controls. On the other hand, 
VEGFR-2/Flk-1 expression gradually increased in mice trained 
for 15, 30, and 45  days. This dissimilar pattern of expression 
suggests different roles of these receptors in the angiogenesis 
process such as also reported by Shibuya (2006). According 
to this author, VEGFR-1/Flt-1 is a negative regulator for 
angiogenesis during embryogenesis, while it stimulates 
inflammation, tumor growth, and metastasis in adulthood. 
By contrast, VEGFR-2/Flk-1 transduces the major signals for 
angiogenesis. In effect, in old age myocardium, this receptor 
promotes an angiogenic cascade through phosphorylation of 
Akt and activation of endothelial nitric oxide (eNOS) pathway 
in response to exercise training (Iemitsu et  al., 2006). 
Furthermore, Milkiewicz et  al. (2003) showed a good spatial 
and temporal correlation between VEGFR2/Flk-1 protein levels 
and capillary growth induced by muscle activity. These findings 
are in agreement with our data that showed a similar pattern 
between VEGFR-2/Flk-1 expression and capillary proliferation 
in hearts of trained mice suggesting receptor’s involvement 
in the proliferation of vascular endothelial cells in response 
to endurance exercise (Bellafiore et  al., 2007, 2013).
The upregulation of VEGFR-1/Flt-1 after 15  days of exercise 
training might be  explained by the request of this factor in the 
early steps of angiogenic sprouting when endothelial cell migration 
rather than cell proliferation is necessary. This hypothesis is 
supported by the same expression pattern between VEGFR-1/
Flt-1 and MMP-9 pro-enzyme in exercise-related cardiac 
angiogenesis (Bellafiore et  al., 2013). Moreover, Waltenberger 
et al. (1994) showed that the activation of VEGFR-2/Flk-1 receptor 
by VEGF in cells devoid of VEGFR-1/Flt-1 resulted in a mitogenic 
response, while the activation of VEGFR-1/Flt-1 by VEGF did 
not induce cell proliferation in cells lacking VEGFR-2/Flk-1.
Hypoxia has been demonstrated to be  a potent stimulus 
for the activation of HIF-1α protein generating capillary growth 
in heart tissue (Shweiki et  al., 1992; Brown, 2003; Prior et  al., 
A
B
FIGURE 3 | HIF-1α expression was evaluated by Western blotting analysis 
(A) in hearts from trained and control mice and its intensity measured with an 
image software (B). HIF-1α levels resulted significantly higher in T15 than in 
C, T30, and T45 groups (*p < 0.05, T15 vs. C, T30, and T45).
A
B
FIGURE 4 | Western blotting (A) and quantitative analyses (B) were 
performed to measure iNOS expression in hearts from trained and control mice. 
iNOS protein levels were significantly higher in T15 and in T30 than in control 
and T45 mice (*p < 0.05,T15 vs. C and T45; #p < 0.05,T30 vs. C and T45).
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2004) through the activation of VEGF pathway genes, including 
VEGFR-1/Flt-1 but not VEGFR-2/Flk-1 (Gerber et  al., 1997). 
In our study, we detected that HIF-1α was specifically expressed 
in the nucleus of vascular endothelial cells and myocardiocytes 
from both sedentary and trained mouse hearts. The expression 
of this protein under normoxic conditions was confirmed in 
the myocardium also by other authors (Stroka et  al., 2001; 
Giusti et  al., 2009). This finding might be  due to a basal 
induction of genes that are necessary to providing cellular 
energy requirements. We  found that HIF-1α expression 
significantly increased in mice trained for 15 days and reduced 
in animals trained for 30 and 45  days reaching the same level 
as the controls. The reduced expression in T30 and T45 animals 
might be  explained by an increase in the supply of blood 
flow and O2 in the heart as a consequence of an increase in 
the capillary area, as shown in our previous study (Bellafiore 
et  al., 2007). On the contrary, in the hearts of T15 mice that 
did not show a significantly increased capillary area, brief and 
transient episodes of hypoxia might occur during the cardiac 
cycle in response to exercise and determine the upregulation 
of HIF-1α as shown in other studies (Stroka et al., 2001; Brown, 
2003; Marini et  al., 2008; Giusti et  al., 2009). The increased 
HIF-1α expression is indicative for an involvement of hypoxia 
signaling in the exercise-induced upregulation of VEGF receptors. 
Comparing the expression of HIF-1α and VEGFR-1/Flt-1, 
we  noted that their patterns are similar postulating an 
upregulation of VEGFR-1 by HIF-1α after 15 days of endurance 
training in agreement with Gerber et  al. (1997).
Nitric oxide (NO) as well as hypoxia has been reported 
to upregulate VEGF gene by enhancing HIF-1α activity and 
significantly contributing to the prosurvival/proangiogenic 
program of capillary endothelium (Ziche and Morbidelli, 
2000). Indeed, intermittent hypoxia has been described to 
induce protective effects against myocardial infarction in 
rodents via a signaling mechanism that depends upon iNOS 
(Tekin et  al., 2010). Furthermore, Akita et  al. (2007) showed 
that an increased expression of iNOS by eNOS upregulation 
was associated with late cardioprotection against ischemia-
reperfusion injury in mouse hearts after 7  days of treadmill 
exercise at a 60–70% maximal oxygen uptake. In our study, 
iNOS cardiac expression was higher than corresponding 
controls in response to mild and moderate exercise intensity, 
and in our best knowledge, this is the first study that reports 
the involvement of iNOS in healthy heart neocapillarization 
according to the exercise intensity.
In the light of the increased expression of iNOS and HIF-1α 
in T15 hearts, we propose iNOS upregulation by HIF-1α protein 
in the angiogenic process in agreement with the study of Jung 
et al. (2000). In fact, these authors exhibited that HIF-1α-binding 
site was required for transcriptional activation of iNOS gene 
in rat cardiomyocytes under hypoxic conditions. In our study, 
the localization of HIF1α and iNOS in different cell types 
suggests a cross talk among myocardium, vasculature, and 
connective tissue to promote capillary growth related to exercise 
in a paracrine fashion.
NO also participates in the regulation of VEGFR-1/flt-1 
gene in response to exercise as shown by NOS inhibition 
that reduced the exercise-induced increase in VEGFR-1/flt-1 
mRNA in rat skeletal muscle (Gavin and Wagner, 2002). 
Therefore, in our experimental model, the upregulation of 
iNOS, HIF-1α, and VEGFR-1/flt-1  in T15 mouse hearts 
suggests the involvement of iNOS in the angiogenesis process 
related to endurance training.
A limitation of this study is the lack of data coming from 
the expression of circulating angiogenic factors produced by 
other organs that could be associated with the exercise-related 
adaptive effects of cardiac muscle. The release of circulating 
factors by the exercising skeletal muscle might have a role 
in supporting angiogenesis of healthy or pathological hearts 
for prevention and rehabilitation of heart failure (Di Raimondo 
et  al., 2017). Recently, it has been reported that skeletal 
muscle cells communicate with heart cells in response to 
contraction or exercise training through the endocrine secretion 
of myokines (Giudice and Taylor, 2017). In particular, plasma 
levels of follistatin-like 1 (FSTL-1) glycoprotein increased 
after strength training (Norheim et  al., 2011). Moreover, the 
administration of this myokine caused an increase in the 
number of dividing cardiomyocytes and angiogenesis in 
the peri-infarct region of  mouse and swine heart (Wei et al., 
2015). On the contrary, systemic levels of VEGF were frequently 
unaltered in response to exercise, pointing toward mainly 
local effects (Landers-Ramos et  al., 2014).
Although the promising results of Anversa’s studies on the 
application of stem cells for the repair of the infarcted heart 
region have been retracted, the activation of resident or circulating 
stem/precursor cells by physical exercise might induce a 
cardioprotective phenotype against insults (Bellafiore et  al., 
2006). Indeed, recently, an increase in number and activity 
state of these cells was discovered in exercised hearts, resulting 
in an amplified expression of transcription factors involved in 
the differentiation toward either the cardiomyocyte or capillary 
lineages. Moreover, these adaptations have been observed to 
be dependent on exercise duration and intensity (Waring et al., 
2014). In skeletal muscle, the number of satellite cells is positively 
correlated to the capillarization of the myofiber, and angiogenesis 
results to be  essential for muscle repair (Mounier et  al., 2011). 
Therefore, increasing knowledge about molecular effectors of 
cardiac capillary growth related to exercise can be relevant in 
pre-clinical and clinical studies to generate native and synthetic 
biomaterials or three-dimensional structures able to induce 
stem cell differentiation and which might be used in pre-clinical 
and clinical studies (Di Felice et  al., 2015).
In conclusion, the present study shows that VEGFR-1/
Flt-1, VEGFR-2/Flk-1, HIF-1α, and iNOS are involved in 
the cardiac angiogenesis, and their expression is regulated 
by the intensity of endurance training. In detail, the expression 
of VEGFR-1/Flt-1 and HIF-1α is upregulated by an exercise 
mild intensity, while VEGFR-2/Flk-1 level progressively 
enhances with increasing workload. Differently, iNOS protein 
is modulated by a moderate intensity exercise. In the light 
of our results, we  retain HIF-1α as a central regulator of 
exercise-induced angiogenesis pathway in the myocardium. 
HIF-1α might act as an upstream regulator of VEGFR-1 
and iNOS in modulating cell proliferation and vascular 
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relaxation. VEGF pathway appears to be  involved in this 
regulation mechanism, and VEGF might act on heart 
endothelial cells in a paracrine and endocrine manner. Our 
endurance protocol was formulated for training human subjects 
and adapted to mice according to their body weight; therefore, 
understanding the molecular basis for exercise-induced 
angiogenesis is important in developing exercise strategies 
to protect the heart by insults.
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Skeletal muscle is a highly vascularized tissue that can secrete proteins called myokines.
These muscle-secreted factors exert biological functions in muscle itself (autocrine
effect) or on short- or long-distant organs (paracrine/endocrine effects) and control
processes such as metabolism, angiogenesis, or inflammation. Widely differing diseases
ranging from genetic myopathies to cancers are emerging as causing dysregulated
secretion of myokines from skeletal muscles. Myokines are also involved in the control
of muscle size and may be important to be restored to normal levels to alleviate muscle
wasting in various conditions, such as cancer, untreated diabetes, chronic obstructive
pulmonary disease, aging, or heart failure. Interestingly, many myokines are induced by
exercise (muscle-derived exerkines) and some even by specific types of physical activity,
but more studies are needed on this issue. Most exercise-induced myokines travel
throughout the body by means of extracellular vesicles. Restoring myokines by physical
activity may be added to the list of mechanisms by which exercise exerts preventative
or curative effects against a large number of diseases, including the deleterious muscle
wasting they may cause. Extending our understanding about which myokines could be
usefully restored in certain diseases might help in prescribing more tailored exercise or
myokine-based drugs.
Keywords: myokines, exercise, exerkines, skeletal muscles, atrophy
INTRODUCTION
Skeletal muscle is the largest tissue in the human body, accounting for about 30% of body mass in
women and 40% in men. Although, it can suffer in many incurable diseases, it is unexpectedly the
most “undrugged” tissue. Skeletal muscle is very plastic because it can be enlarged with adaptation
to specific exercise and/or high-protein content diet or reduced in catabolic conditions like fasting,
cancer, untreated diabetes, heart failure, AIDS, chronic obstructive pulmonary disease (COPD), or
aging (Piccirillo et al., 2014; Furrer and Handschin, 2018). This tissue is the main body’s protein
reservoir, able to break down its own proteins and release aminoacids into the bloodstream during
stress or fasting or disease. This process goes under the name of muscle wasting or cachexia, and
ultimately aggravates the disease state, even leading individuals to death (Kalantar-Zadeh et al.,
2013). Losing more than about 40% of normal body mass was incompatible with life in starved,
lager-confined Jews (Winick, 1979) and in HIV-infected patients before the successful advent of
antiretroviral therapy (Kotler et al., 1989; Roubenoff and Kehayias, 1991).
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Reduction in muscle size mainly consists of a decrease in
cell size caused by loss of organelles, cytosol and proteins.
This deleterious process is mainly driven by increased protein
breakdown through enhanced proteasomal and lysosomal
activities (coordinatively activated by FoxO3-dependent
transcription) (Sandri et al., 2004; Zhao et al., 2007) and reduced
protein synthesis (mainly regulated by the IGF-1/PI3K/AKT
pathway). During muscle atrophy, the removal of ATP-producing
organelles, such as mitochondria, through enhanced autophagy
(i.e., mitophagy) explains the increased propensity to fatigue of
muscle-losing patients (VanderVeen et al., 2017).
Physical exercise is among the ways by which muscles may
be protected against disease-induced muscle wasting. Physical
activity can be grossly divided into two types: aerobic (or
endurance) and anaerobic (or strength) exercise. The former
shifts muscle fiber types toward those with increased capacity
for aerobic metabolism and better ability to resist fatigue,
due to a larger number of mitochondria and vessels (types
I and IIA fibers), this is typical in runners, long-distance
cross-country skiers, bicyclists, swimmers. These fibers contract
slowly with a low peak force and generate ATP through
oxidative phosphorylation of glucose and non-esterified fatty
acids. The second type of exercise causes hypertrophy, especially
of myofibers IIX (and IIB in rodents), due to enhanced
synthesis of contractile proteins, resulting in increased strength
with no change in the number of mitochondria (typically
occurring in weight-lifters and body-builders). These fibers
generate fast contractions with a high peak force, and metabolize
phosphocreatine and glucose anaerobically to make ATP (Flück
and Hoppeler, 2003; Hawley et al., 2014).
Aerobic exercise induces in humans (Pilegaard et al., 2003)
and in rodents (Terada et al., 2002) the peroxisome proliferator-
activated receptor γ coactivator 1-α (PGC1-α). PGC1-α not only
promotes mitochondrial biogenesis, contrasting the propensity
to fatigue of cachectic muscles, but also directly antagonizes
protein catabolism by blocking FoxO3 (Sandri et al., 2006), the
master transcription factor coordinating both proteasomal and
lysosomal protein degradation (Sandri et al., 2004; Mammucari
et al., 2007; Zhao et al., 2007). As a result, oxidative fibers
are more resistant to cancer-induced atrophy than glycolytic
ones, typically enlarged upon muscle adaptation to anaerobic
exercise (Ciciliot et al., 2013). Conversely, anaerobic exercise,
by stimulating mainly myofibrillar protein synthesis through
activation of the PI3K/AKT pathway and overproduction of IGF-
1 (McCall et al., 2003), may obviate muscle wasting by enhancing
protein synthesis and inactivating FoxO3 through AKT-mediated
phosphorylation (Sandri et al., 2004).
It is becoming clear that physical activity mediates the release
from muscles of factors with anti-atrophic effects in an autocrine
fashion but, surprisingly, these muscle-derived molecules can
even contrast the primary disease, as is the case of the recently
identified anti-tumoral molecules of muscle origin (Aoi et al.,
2013; Gannon et al., 2015). Some examples are oncostatin M, able
to restrain mammary cancer cell growth in vitro (Hojman et al.,
2011), fatigue substance (F-Substance) isolated from muscles of
trained rats and displaying inhibitory effect on the breast cancer
cell line MCF-7 (Munoz et al., 2013) and secreted protein acidic
and rich in cysteine (SPARC). The latter is induced in plasma
of trained individuals or mice and it is able to suppress colon
tumorigenesis via regular exercise in mice (Aoi et al., 2013).
Skeletal muscle is a highly vascularized tissue and has secretory
abilities (Pedersen and Febbraio, 2008). In fact, muscles release
not only aminoacids in response to increased energy demand
and fuel the liver to undergo gluconeogenesis, but also proteins
to mediate inter-tissue crosstalk. These molecules have been
named myokines to underline their muscle origin. The current
definition of myokines is “cytokines or peptides which are
secreted by skeletal muscle cells and subsequently released into
the circulation to exert endocrine or paracrine effects in other
cells, tissues or organs” (Pedersen and Febbraio, 2012). Not all
myokines are exclusively originating by skeletal muscles. Some
myokines are mainly muscle-restricted proteins, like myostatin,
while others can also be secreted by other tissues, as is the case
of the adipomyokines (for example, IL-8 and MCP-1) (Trayhurn
et al., 2011). However, skeletal muscle is probably the main source
of most myokines secreted also by other tissues in the circulation
because it is amply vascularized and makes up 30–40% of the
human body mass.
More than 3000 myokines have been reported (Whitham
and Febbraio, 2016) and, among them, it is worth mentioning
those identified in humans: angiopoietin-like 4 (ANGPTL4),
apelin, brain-derived neurotrophic factor (BDNF), CCL2 or
MCP-1, CX3CL1 of fractalkine (FKN), fibroblast growth factor 21
(FGF21), interleukin-6 (IL-6), IL-7, IL-8, IL-15, irisin, leukemia
inhibitory factor (LIF), meteorin-like protein (Metrnl), myostatin
and SPARC (for a review see Catoire and Kersten, 2015). Myokine
secretion is a process conserved among species: Drosophila
melanogaster (Zhao and Karpac, 2017), adult Danio rerio (i.e.,
Zebrafish) (Rovira et al., 2017), and mammals (Demontis et al.,
2013b), among others, all have muscles able to release such
factors. The first reported myokine, Interleukin-6 (IL-6), is
conserved in Drosophila melanogaster where three orthologs
exist, Unpaired (Upd) also called Outstretched, Upd2 and Upd3,
increases with exercise (Ostrowski et al., 2000) and has anti-
inflammatory properties, at least in mammals (Pedersen and
Febbraio, 2008). Another example is myostatin that is secreted
by skeletal muscles and can stimulate activin type II receptors
(ActRII), ultimately leading to muscle atrophy; it is conserved
in Drosophila melanogaster (myoglianin) and in Zebrafish
(myostatin b). Notably, myostatin inactivation by spontaneous
missense mutations or intentional genetic ablation results in
hypermuscularity in a large number of species (McPherron and
Lee, 1997; McPherron et al., 1997; Prontera et al., 2009).
Some myokines are preferentially secreted by glycolytic fibers
[e.g., musclin (Banzet et al., 2007; Subbotina et al., 2015),
osteoprotegerin and angiogenin (Rutti et al., 2018)], and others
by oxidative fibers [e.g., myonectin (Seldin et al., 2012)] but the
fiber-type preference, if it exists, is unknown for most of the
other myokines. Along the same line, FGF21 that is an hormone-
like molecule involved in metabolism has been described as an
AKT-regulated myokine (Izumiya et al., 2008a; He et al., 2018),
hence, more typically secreted by glycolytic fibers, while irisin
expression is induced by PGC1α, thus, more typically secreted by
oxidative ones (Boström et al., 2012). Some myokines have been
renamed muscle-derived exerkines (Safdar and Tarnopolsky,
2018) because they are induced by physical activity and – most
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interestingly – some of them show a preference for muscle
induction through specific types of physical exercise (Figure 1A)
(Kanzleiter et al., 2014; Bazgir et al., 2015; Shin et al., 2015;
Laker et al., 2017; Ishiuchi et al., 2018).
Lecker et al. (2004) found a subset of genes that were
differentially expressed in muscles undergoing wasting in
unrelated conditions (fasting, uremia, tumor, and diabetes) in
rodent models and named them “atrogenes.” Among them,
FIGURE 1 | Exercise-sensitive myokines with a preference for aerobic or anaerobic exercise are altered in different muscle wasting disorders. (A) Muscle
adaptation to anaerobic and aerobic exercise is grossly depicted. In green, myokines altered in anaerobic exercise are listed with the appropriate references. In blue,
those altered by endurance training are reported. (B) Myokine alterations in the five diseases indicated are listed. Myokines sensitive to anaerobic or aerobic exercise
are depicted in green and blue, respectively, and those that change in both kinds of exercise in black. Myokines whose alteration by exercise is not clear are
indicated in gray.
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a subset of potentially secreted proteins, called “extracellular
matrix proteins,” were all downregulated in all conditions of
muscle atrophy tested and included fibrillin 1, fibronectin 1,
galectin 1, osteoblast specific factor 2, secreted modular calcium-
binding protein 2, and insulin-like growth factor binding protein
5. It would be worth clarifying whether these include some
that could be useful to reverse to basal levels to contrast
atrophy, and whether they can be classified as myokines or
not (i.e., “atromyokines”).
Most exercise-induced myokines travel through the body
by means of exosomes measuring between 30 and 100 nm
in diameter, or micro- or nano-sized extracellular vesicles
(EVs), through analyses in Vesciclepedia and ExoCarta (Safdar
and Tarnopolsky, 2018). These muscle-derived EVs increase in
number in the bloodstream upon exercise, perhaps through
calcium-dependent secretion coupled with muscle contractions
(Whitham et al., 2018). In a very elegant work, Whitham et al.
(2018) showed that when EV liberated in the blood of healthy
individuals after 1 h bout of cycling exercise were labeled and
transferred to donor mice, they were able to target organs
like the liver, but not all organs have been scrutinized. The
search for exercise factors of muscle origin mediated by these
structures has just started and could help explain why myokines
are not rapidly degraded by the numerous proteases in the
extracellular environment. Their protective lipid bilayers could
facilitate them to target muscle-unrelated tissues, affecting overall
body homeostasis. This would further help explain how genetic
modifications restricted to muscles impact on other tissues
(Rai and Demontis, 2016) as the reduced adiposity reported
in animals with muscle deficiency of myostatin (McPherron
and Lee, 2002) or the increased resistance to diet-induced
obesity and steatosis of mice with muscles overexpressing AKT1
(Izumiya et al., 2008b).
The secretion of myokines is altered in a growing number
of diseases, including congenital myotonic dystrophy (Nakamori
et al., 2017), and modulable through physical activities (Benatti
and Pedersen, 2015). This minireview gives an overview of
such factors in health and muscle atrophy-causing diseases
(Figure 1B) and how physical exercise could correct some of
them toward healthier levels, to spare muscle mass.
MYOKINES ALTERED IN DIABETES
Tissue cross-talk is emerging as vital to coordinate the different
organs implicated in glucose homeostasis. Among the cross-
talking factors, muscle-secreted myokines can influence the
function and survival of pancreatic β-cells as is the case of
angiogenin (previously known as an angiogenesis-promoting
factor) (Gao and Xu, 2008) and osteoprotegerin (involved also
in bone density’s regulation) (Simonet et al., 1997) that protect
β cells from the deleterious effects of proinflammatory cytokines
(Rutti et al., 2018).
Diabetes accounts for about 15% of total diseases related to
selected myokines (apelin, BDNF, IL-15, irisin, SPARC) (Son
et al., 2018). In adult humans, an insulin-resistant state preceding
diabetes onset, already alters myokine secretion, as is the case
of increased release of myonectin, but not FGF21 or myostatin
(Toloza et al., 2018), but the biological effects of this increase are
not clear yet. In another study, FGF21 was found increased in
the plasma of diabetic individuals, but if this is a compensatory
mechanism to increase glucose uptake from muscles remains
to be explored (Mashili et al., 2011). This myokine was found
increased also in human and murine plasma after a single bout
of endurance exercise (Tanimura et al., 2016). In streptozotocin-
induced diabetic mice, myostatin is increased and causes muscle
wasting (Hulmi et al., 2012). Molecules able to neutralize this
myokine are under tests for the treatment of diabetic myopathy in
animal models, but with contradictory results so far (Wang et al.,
2015; Dong et al., 2016).
Puzzingly, both CX3CL1 (Shah et al., 2011) and Metrln
(Chung et al., 2018) were elevated in the blood of patients
afflicted by type II diabetes and also in plasma and/or muscles of
individuals after acute endurance exercise (Catoire et al., 2014)
or short-term interval training (Eaton et al., 2018), but so far
their possible contribution to muscle size control has not been
explored. Finally, increased plasma apelin has been found to
predict type II diabetes but only in men, for reasons we still do
not understand (Ma et al., 2014). While the role of apelin in
improving insulin resistance by enhancing glucose utilization by
muscle and fat is clear (Dray et al., 2008), its direct ability to
protect muscles from diabetes-induced atrophy deserves further
studies, but its elevated expression upon aerobic exercise is of
note (Besse-Patin et al., 2014). IL-8, a chemokine whose muscle
secretion is altered by exercise in humans, though mostly after
extreme conditions in response to an ultraendurance exercise
bout in experienced athletes (Marklund et al., 2013), was found
to be overproduced by myotubes from type II diabetes patients
and to disfavor muscle capillarization, reducing muscle exposure
to glucose, so possibly further impinging on muscle wasting and
the primary disease itself (Amir Levy et al., 2015).
Further studies are needed to see whether and which other
myokine(s) is/are altered in muscles undergoing diabetic atrophy
(for a further summary on this topic see Carson, 2017), and
whether it might be useful to target for the cure of this
kind of atrophy.
MYOKINES ALTERED IN CANCER
CACHEXIA
Muscle wasting occurs in 80% of patients with advanced cancer
and causes death in 30–40% of cases (Fearon et al., 2011). Various
myokines may be involved in this kind of atrophy (for a review
see Manole et al., 2018). Cancer accounts for only 3.3% of total
diseases related to selected myokines (apelin, BDNF, IL-15, irisin,
SPARC) (Son et al., 2018), but additional myokines have been
shown to be more clearly involved in cancer cachexia.
We found stromal derived factor 1 (SDF1), also referred
to as CXCL12, as specifically and strongly downregulated only
in skeletal muscles of tumor-bearing mice and not in those
undergoing wasting for other reasons (i.e., uremia, diabetes,
fasting, or disuse) (Martinelli et al., 2016). Overexpression of
SDF1 in muscle through in vivo electroporation of plasmid
spared not only the cross-sectional area of transfected fibers
but also that of adjacent untransfected ones, indicating that
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SDF1 also exerts its anti-atrophic effects in a paracrine fashion
(Martinelli et al., 2016). Interestingly, Puchert and coworkers
found it to be induced in muscles of mice trained by running
for 4 weeks (Puchert et al., 2016). This muscle-secreted factor
has a role in myogenesis, muscle regeneration (Bobadilla et al.,
2014) and angiogenesis, similarly to VEGF (Arany et al., 2008)
and could be involved in increased muscle capillarization upon
adaptation to aerobic exercise. Overall, elevated muscle secretion
of SDF1 could be ascribed to the mechanisms by which aerobic
exercise or some drugs (e.g., Sunitinib) alleviate cancer-associated
muscle wasting (Pretto et al., 2015).
Myostatin-based signaling was found increased in muscles
of Yoshida hepatoma-bearing rats (Costelli et al., 2008), in
C26-bearing mice (Zhou et al., 2010), and in patients with
various malignancies (for a review see Han et al., 2013), while
in pre-cachectic cancer patients circulating levels of myostatin
increased only with certain types of tumors (Aversa et al., 2012).
Importantly, while myostatin is the main factor limiting muscle
size in mice, it seems that in humans activin A and growth
differentiation factor 11 (GDF11) also play major roles and
could be targeted to spare muscles during human diseases (Lach-
Trifilieff et al., 2014). Anti-ActRII drugs have in fact been tested
in cancer patients but unfortunately, there were no improvements
in functional parameters (for a review see Furrer and Handschin,
2018). Myostatin is one of the few myokines whose secretion is
reduced with both anaerobic (Walker et al., 2004) and aerobic
exercise (Hittel et al., 2010), in concordance with its role as a
negative modulator of muscle size.
The type of exercise that seems most effective at sparing
muscles during cancer seems the aerobic and not the
anaerobic one. In fact, the AKT/mTOR signaling appears
even hyperactivated in muscles of tumor-bearing rodents (Penna
et al., 2010). So, future research should focus on understanding
which aerobic exercise-induced myokine(s), besides SDF1,
have anticatabolic or proanabolic action in muscles during
cancer cachexia.
MYOKINES ALTERED IN COPD
Chronic obstructive pulmonary disease is an inexorable lung
disease caused by excessive inflammation and subsequent
damage to the airways and lung tissue, mainly occurring after
long-term exposure to cigarette smoking (Passey et al., 2016).
Very few myokines have been studied in relation to
COPD-induced muscle wasting, even though COPD is the
most prevalent disease worldwide causing excessive myopenia
and death (Lozano et al., 2012). COPD accounts for about
5% of total diseases related to selected myokines (apelin,
BDNF, IL-15, irisin, SPARC) (Son et al., 2018). Consistent
with its role in reducing muscle mass, myostatin expression
is increased in the vastus lateralis (Plant et al., 2010)
and quadriceps (Man et al., 2010) from COPD patients.
Circulating myostatin protein is also elevated in serum
from COPD patients and correlates with reduced muscle
mass in males (Ju and Chen, 2012). Clinical trials to
test bimagrumab (anti-ActRII-based drug) in COPD patients
have recently showed increases in lean body mass and
muscle volume in treated patients but unfortunately, no
improvements in functional parameters (for a review see,
Furrer and Handschin, 2018).
Irisin, a prominent PGC1α-induced myokine, is the cleaved
product of the transmembrane protein fibronectin type III
domain-containing protein 5 (FNDC5) (Boström et al., 2012)
and is induced by resistance exercise in mice and humans (Kim
et al., 2015). Most importantly, circulating irisin was low in
COPD patients and its levels correlate with exercise capacity
(Ijiri et al., 2015). More studies are still needed to dissect
the mechanisms behind COPD-related muscle atrophy, because
efficacious therapies are lacking.
MYOKINES ALTERED IN AGING
Many alterations occur in skeletal muscle with aging (Demontis
et al., 2013a), including enhanced activity of the proteasomal
pathway causing muscle atrophy (i.e., sarcopenia) (Altun et al.,
2010), but the question whether muscle’s ability to secrete
myokines changes with aging has only recently started to
attract attention. The increased sarcolemmal permeability of aged
muscles may favor increased release of myokines during aging.
Nonetheless, the expression of bone morphogenetic factor 7
(BMP7) is low in muscles of aged rats but can be restored through
either uphill or gradual downhill running (Kim et al., 2016).
This myokine may act by stabilizing the neuromuscular junction
(NMJ) that is reduced in number and function with aging (for
a review see, Demontis et al., 2013b; Larsson et al., 2019).
Moreover, BMP7 has been found to cause muscle hypertrophy in
mice through Smad1/5-mediated activation of mTOR signaling
(Winbanks et al., 2013). Similar results have been obtained for
irisin, whose secretion decreases in aging mice and is restored
with resistance exercise training (Kim et al., 2015). While
myostatin was unchanged in the elderly (Welle et al., 2002),
another member of the same transforming growth factor β
(TGFβ) family, GDF11, increases in blood (and muscles) during
aging in rats and humans and, even more importantly, inhibits
muscle regeneration (Egerman et al., 2015). The secretion of
FGF21 also seems dysregulated in aged mice (Tezze et al., 2017).
Apelin is an exerkine that has been recently found to have a
major role in counteracting age-associated muscle wasting (Vinel
et al., 2018), also by promoting mitochondriogenesis, alleviating
muscle-related inflammation and stimulating its regenerative
capacity. Its possible role in disease-associated muscle atrophy
is still unclear. SPARC is induced in plasma of humans by a
single bout of steady-state cycling exercise at 70% of VO2max
for 30 min, or after 4 weeks of cycling, three times a week
for 30 min at 70% of VO2max, and similarly in exercising
mice (Aoi et al., 2013). This protein was low in aged muscle
because its internalization in skeletal muscle progenitors becomes
defective with age, so its anti-adipogenic effect could be limited
and may contribute to fat infiltration in muscle upon aging
(Nakamura et al., 2014).
Finally, IL-15 and the soluble form of its receptor also
decrease in serum of aged mice (Quinn et al., 2010).
These findings are in concordance with the single nucleotide
polymorphisms (SNP) found in the human gene for such
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receptor that affects the muscularity and exercise capacity
of individuals (Pistilli et al., 2008) and may influence inter-
individual propensity to sarcopenia.
MYOKINES ALTERED IN HEART
FAILURE
Muscle wasting in patients with chronic heart failure (HF)
identifies those at high risk of death (Anker et al., 1997). IGF-
1 decreases in the skeletal muscle of pre-cachectic HF patients
(Hambrecht et al., 2002) and in animal models. Treatment
with IGF-1 helped contrast the HF-induced muscle atrophy,
improving exercise capacity (Dalla Libera et al., 2004).
GDF15 (also known as macrophage-inhibiting factor-1 and
involved in appetite regulation) was found elevated in the acute
muscle wasting following cardiac surgery and, interestingly,
GDF15-treated myotubes undergo wasting, supporting a pro-
cachectic role of this factor (Bloch et al., 2013). A recent study
showed the effect on muscle expression of an IL-6-like cytokine,
LIF, in rats undergoing myocardial infarction. In this model the
myocardial infarction-associated muscle wasting was recovered
upon interval exercise and LIF was upregulated as well in
gastrocnemii (Jia et al., 2018). These results contrast with other
reports of a pro-cachectic role of (tumor-derived) LIF in cancer-
associated muscle wasting (Seto et al., 2015), so further studies
are needed to dissect the signaling pathway activated by LIF in
muscle fibers and verify whether endogenous expression of LIF
is altered in muscles atrophying because of various conditions.
The upregulated expression of LIF by exercise is confirmed by
other studies (Broholm et al., 2008) and further proven by the
existence in the human LIF promoter of two nuclear factor
of activated T cells (NFAT) binding sites (Bamberger et al.,
2004), a transcription factor well-known to be activated by
muscle contractions through the Ca2+ calmodulin-calcineurin
axis (Schiaffino and Serrano, 2002).
Searching for similar binding sites in the gene regulatory
regions of other putatively exercise-induced myokines should be
a topic for future research to expand our knowledge of myokine
regulation at the transcriptional level.
CONCLUSION
An “exercise pill” to reproduce the multiple beneficial effects
of exercise on various organs seems to be unpractical because
exercise affects too many interconnected pathways and its
holistic effects also depend on the host genetics. Nonetheless,
expanding our knowledge about which types of activity in
humans control beneficial myokine secretion could give valuable,
more personalized suggestions to patients about which kind of
exercise to practice. Selected myokine-based drugs could be given
to act on specific pathways and help patients who for various
reasons cannot exercise.
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Obesity and ensuing disorders are increasingly prevalent worldwide. High-fat diets (HFD) 
and diet-induced obesity have been shown to induce oxidative stress and inflammation 
while altering metabolic homeostasis in many organs, including the skeletal muscle. 
We previously observed that 14 days of HFD impairs contractile functions of the soleus 
(SOL) oxidative skeletal muscle. However, the mechanisms underlying these effects are 
not clarified. In order to determine the effects of a short-term HFD on skeletal muscle 
glutathione metabolism, young male Wistar rats (100–125 g) were fed HFD or a regular 
chow diet (RCD) for 14 days. Reduced (GSH) and disulfide (GSSG) glutathione levels 
were measured in the SOL. The expression of genes involved in the regulation of glutathione 
metabolism, oxidative stress, antioxidant defense and inflammation were measured by 
RNA-Seq. We observed a significant 25% decrease of GSH levels in the SOL muscle. 
Levels of GSSG and the GSH:GSSG ratio were similar in both groups. Further, we observed 
a 4.5 fold increase in the expression of pro-inflammatory cytokine interleukin 6 (IL-6) but 
not of other cytokines or markers of inflammation and oxidative stress. We hereby 
demonstrate that a short-term HFD significantly lowers SOL muscle GSH levels. This 
effect could be mediated through the increased expression of IL-6. Further, the skeletal 
muscle antioxidant defense could be impaired under cellular stress. We surmise that these 
early alterations could contribute to HFD-induced insulin resistance observed in 
longer protocols.
Keywords: high-fat diet, young rats, muscle glutathione, oxidative stress, inflammation, gene expression
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INTRODUCTION
Obesity has become a major health, social, and economic burden 
worldwide (Hruby and Hu, 2015). This is particularly concerning 
among children, since the prevalence of obesity and overweightness 
in this age group has risen by nearly 10% in the last 4 decades 
(Rao et  al., 2016). Indeed, the risk of carrying excess weight 
into adulthood and of developing morbid obesity is much greater 
among obese children and adolescents (The et  al., 2010). 
Overweight children are also more at risk of developing obesity 
related diseases like type 2 diabetes and the metabolic syndrome 
in later stages of life (Biro and Wien, 2010).
A sedentary lifestyle and poor diet quality are known as 
two main contributors to obesity, as calorie-rich diets promote 
a positive energy balance leading to weight gain. Obesity 
increases the risk of developing a large number of metabolic 
disorders (Head, 2015). For instance, we have recently reported 
that only 2  weeks of high fat diet (HFD) significantly altered 
contractile functions of the oxidative skeletal muscle soleus in 
young rats, although the same result could not be  observed 
in the glycolytic extensor digitorum longus (EDL) muscle (Andrich 
et  al., 2018b). Hence, long known to cause excess lipid 
accumulation (Peckham et  al., 1962), HFDs have also been 
shown to stimulate the production of reactive oxygen species 
(ROS), thus leading to oxidative stress (Auberval et  al., 2014). 
Strong evidence shows that sub-clinical inflammation and 
oxidative stress are two of the main contributors for the 
pathogenesis of metabolic dysfunctions in the obese state 
(Galassetti, 2012). It appears as though HFD-stimulated excess 
ROS production (Vial et  al., 2011) can precede observable 
weight gain and insulin resistance (Matsuzawa-Nagata et  al., 
2008), indicating that oxidative stress might be  a result of the 
diet itself and not a consequence of excess lipid accumulation. 
Further, HFD induces inflammation and oxidative stress in 
the skeletal muscle of rodents (Yokota et  al., 2009; Gortan 
Cappellari et  al., 2016). Beyond its role in  locomotion and 
posture maintenance, skeletal muscle is a key player in the 
regulation of metabolic homeostasis (Frontera and Ochala, 
2015). In fact, skeletal muscle insulin resistance is considered 
as the primary cause of type 2 diabetes (DeFronzo and Tripathy, 
2009). Skeletal muscle dysfunctions can be induced by oxidative 
stress in type 2 diabetes patients (Tsutsui et  al., 2011; Diaz-
Morales et  al., 2016; Wang et  al., 2016), highlighting its role 
in the pathogenesis of the disease (Giacco and Brownlee, 2010). 
Further, 6  weeks of HFD has been shown to decrease reduced 
glutathione (GSH) levels, an important antioxidant, in the 
gastrocnemius of 8-week-old Sprague–Dawley rats (Anderson 
et al., 2009). After a similar exposure to HFD, higher glutathione 
disulfide (GSSG) levels and a lower GSH:GSSG ratio were also 
observed in the gastrocnemius muscle of 18-week old rats 
(Fisher-Wellman et  al., 2013). However, the early mechanisms 
underlying such alterations remain to be  elucidated. Further, 
it was previously shown that glutathione levels are more prone 
to undergo HFD-induced alterations in oxidative muscle (Pinho 
et  al., 2017). Therefore, this study aimed to investigate the 
effects of a short-term (14 days) HFD on glutathione metabolism 
in the soleus muscle of young rats. To do so, we  measured 
glutathione levels as well as gene expression of known factors 
regulating glutathione metabolism, oxidative stress, and 
inflammation. Thus, we hypothesized that a short-term exposure 
to an obesogenic diet alters glutathione production and redox 




This study was carried out in strict accordance with 
recommendations of the National Institutes of Health guide for 
the care and use of Laboratory animals. Before undergoing the 
experimental work, the protocol was approved by the Comité 
Institutionnel de Protection des Animaux (CIPA) of UQAM 
(Permit Number: 0515-R3–759-0516). After a 3-day acclimatization 
period at UQAM’s animal facility, young (100–125 g; approximately 
4  weeks old) male Wistar rats (Charles River, St-Constant, QC, 
Canada) were randomly fed with a regular chow diet (RCD; 
n  =  13) or HFD (n  =  12) for 14  days and submitted to a 
12-h light/dark cycle starting at 06:00. Animals were given ad 
libitum access to the diets and water throughout the experimental 
protocol. Sacrifice was achieved under anesthesia (3% isoflurane 
at 0.5  L/min of O2) after a 4  h fast to standardize the feeding 
status of each animal. The soleus (SOL) muscle of both legs 
was collected for glutathione determination and RNA extraction.
Diets
Physiological fuel values were calculated from modified 
Atwater factors (3.5  kcal/g carbohydrate; 3.5  kcal/g protein; 
8.5  kcal/g fat). The high fat diet was prepared from purified 
food-grade reagents according to a commercial formulation 
(D12492 diet, Research Diets Inc., New Brunswick, NJ, USA). 
It had a macronutrient weight content of 26.3% carbohydrate 
(19.2% kcal), 26.2% protein (19% kcal), and 34.9% fat (61.8% kcal) 
and a physiological fuel value of 4.80  kcal/g. Carbohydrate 
sources were maltodextrin and sucrose (64.5 and 35.5%, 
respectively), protein sources were casein and L-cystine (98.5 
and 1.5%, respectively), while lipid sources were lard and 
soybean oil (90.7 and 9.3%, respectively). The diet also contained 
cellulose (64.6  g/kg), calcium carbonate (7.1  g/kg), dicalcium 
phosphate (16.8 g/kg), potassium citrate (21.3 g/kg), and choline 
bitartrate (2.6 g/kg), as well as mineral (12.9 g/kg) and vitamin 
(12.9 g/kg) mixes. The regular chow diet (Charles River Rodent 
Diet # 5075, Cargill Animal Nutrition, MN, USA) had a 
macronutrient weight content of 55.2% carbohydrate 
(65.6% kcal), 18% protein (21.4% kcal), and 4.5% fat (13% kcal) 
and a physiological fuel value of 2.89  kcal/g.
Glutathione Measurements
Immediately after collection, 0.25 g of SOL muscle was homogenized 
(2  ×  10  s with Polytron Teador; Biospec Products Inc, Dremel-
Racine, WI) in 1.25  ml of iced and freshly prepared 5% (w/v) 
metaphosphoric acid (Fisher A280–100) and centrifuged for 
3  min at 7200  g. Pellets and supernatants were kept at −80°C 
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until protein and glutathione determinations, respectively. Reduced 
glutathione (GSH) and glutathione disulfide (GSSG) were quantified 
by capillary (75-μm × 50-cm silica) electrophoresis (75 mM boric 
acid and 25  mM Bis-Tris, pH  8.4, 28°C, 18  kV) as described 
previously (Lavoie et  al., 2008). The redox potential was defined 
as the half-cell reduction potential of the GSSG (2H+/2GSH 
couple) and calculated by using the Nernst equation (25°C, 
pH  7.0) (Turcot et  al., 2009).
RNA Extraction
Collected tissue samples were stored in RNAlater stabilization 
solution (Ambion) and stored at −20°C for later use. About 
15 to 60  mg of tissue per sample was homogenized in 1  ml 
of TRIzol Reagent (Ambion) with a TissueLyserII homogenizer 
(Qiagen) and extracted according to the manufacturer’s 
instructions. Samples were further processed using the PureLink 
RNA Mini Kit (Ambion), and contaminating DNA was removed 
via DNase on-column digestion. A BioDrop spectrophotometer 
was used to determine RNA concentrations, and the ratio of 
absorbance at 260 and 280  nm is used to assess purity. RNA 
integrity was evaluated by visualization of intact 18S and 28S 
RNA bands following agarose gel electrophoresis. SuperScript 
VILO Master Mix (Invitrogen) was used to synthesize cDNA 
with 1  μg of RNA per 20  μl reaction.
RNA Sequencing
RNA sequencing methodology was adapted from Pai et  al. 
(2016). Briefly, libraries were prepared using the Illumina TruSeq 
protocol. Once prepared, indexed cDNA libraries were pooled 
(six libraries per pool) in equimolar amounts, and the majority 
was sequenced with single-end 101  bp reads on the Illumina 
HiSeq4000. Low quality score bases and adaptor sequences 
were first trimmed using Trim Galore (version 0.2.7). The 
resulting reads were then mapped to a genome reference 
sequence (Ensembl Rnor_6.0 release 81) with STAR (version 
2.4.2) using the 1-pass protocol. The number of mismatches 
allowed for the pairs was of 5, and a soft-clipping step that 
optimizes alignment scores was automatically applied by the 
STAR software. Read counting on each gene was done with 
HTseq (version 0.6.1p1), which was launched separately on 
each alignment file with the intersection-nonempty option, 
supported by SAMtools (version 0.1.19) using the same gene 
reference file as for the alignments.
Statistical Analyses
Sample sizes were calculated as recommended (Charan and 
Kantharia, 2013) using data from previously published studies, 
as well as our own pilot studies using power set at 0.8 (80%) 
and significance set at p  <  0.05. All values are presented as 
means ± SD, except where noted. Normality was assessed using 
the Shapiro–Wilk test. Unpaired Student’s t tests were used to 
compare values between the two groups. Statistical analyses 
were performed using the SPSS 16.0 (IBM Corporation, Armonk, 
NY) software. For RNA-Seq analyses, the DESeq2 (version 
1.18.1) software was used to identify genes with a significantly 
different expression in the HF group. A FDR-adjusted p < 0.10, 
corresponding to the treatment variable, and an absolute fold 
change of mean expression level greater than 1.5 was required 
to qualify a gene as significantly differently expressed (Love 
et  al., 2014). Significance for all other statistical analyses was 
set at p  <  0.05.
RESULTS
As previously reported (Andrich et  al., 2018a,b), we  found no 
significant difference in body weight between both groups (data 
not shown). We  observed significantly lower total glutathione 
levels in the soleus muscle of the HFD group (p  =  0.046; 
Figure 1A), which was largely due to the significant 25% 
decrease of GSH levels (p = 0.042; Figure 1B). However, we did 
not find any difference in GSSG levels (p  =  0.722; Figure  1C), 
GSH:GSSG ratio (p  =  0.693; Figure 2A), or glutathione redox 
potential (p  =  0.534; Figure 2B).
When looking at gene expression levels, we  did not find 
any significant differences in glutathione metabolism (Pizzorno, 
2014) enzymes glutamate cysteine ligase catalytic subunit 
(GCLC; adjusted p = 0.865), glutamate cysteine ligase modifier 
subunit (GCLM; adjusted p  =  0.800), glutathione synthase 
(GSS; adjusted p = 0.984), methionine synthase (MTR; adjusted 
p  =  0.917), glutathione reductase (GSR; adjusted p  =  0.978), 
γ-glutamyltransferase-7 (GGT7; adjusted p  =  0.248), or the 
Nrf2 transcription factor (NFE2L2; adjusted p  =  0.990; 
Figure  3A). Further, we  did not find any differences in 
major antioxidant enzymes glutathione peroxidase (GPX; 
adjusted p  =  0.912), catalase (CAT; adjusted p  =  0.399), or 
mitochondrial superoxide dismutase (SOD2; adjusted 
p  =  0.600; Figure 3B).
A B C
FIGURE 1 | Soleus muscle levels of total glutathione (A), GSH (B) and GSSG (C) in young rats submitted to 14 days of HFD or RCD. Results are presented as 
means ± SD for n = 12–13; * indicates significant difference between the two groups (p < 0.05).
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We observed a significant 4.5 fold increase in the expression 
of interleukin 6 (IL6; adjusted p  =  0.05) in the HFD group, but 
not of its receptor (IL6R; adjusted p  =  0.913) or of any other 
interleukins or their respective receptor (adjusted p  ≥  0.902; 
Figure  4A). Expression levels were also similar for the cytokine 
transforming growth factor β (TGFB; adjusted p ≥ 0.579; Figure 4B) 
superfamily genes. However, we  observed a significant increase in 
the expression of other proteins implicated in pro-inflammatory 
pathways, such as a 5.4 fold increase in angiopoietin-like 4 (ANGPTL4; 
adjusted p = 0.009), a 3 fold increase in cell death activator CIDE-A 
(CIDEA; adjusted p < 0.001), a 4 fold increase in pentraxin-related 
protein PTX3 (PTX3; adjusted p  =  0.006), and a 2.2 fold increase 
in long-chain fatty acid transport protein 1 (SLC27A1/FATP1; 
adjusted p  <  0.001; Figure 4C).
Finally, we  did not observe any difference in the gene 
expression levels of NF-κB (NFKB; adjusted p ≥ 0.801; Figure 5A) 
A B
FIGURE 2 | Soleus muscle GSH:GSSG ratio (A) and glutathione redox potential (B) in young rats submitted to 14 days of HFD or RCD. Results are presented as 
means ± SD for n = 12–13.
A B C
FIGURE 4 | Relative gene expression levels of various interleukins and their respective receptors (A), relative gene expression levels of TGF-β cytokines (B) as well 
as relative gene expression of various pro-inflammatory proteins (C) in the soleus muscle of young rats submitted to 14 days of HFD. Results are presented as mean 
fold change, compared to the RCD group, ±SEM for 5–6 replicates per condition; * indicates significant difference between the two groups (adjusted p < 0.10).
A B
FIGURE 3 | Relative gene expression levels of various enzymes and transcription factors implicated in the glutathione metabolism (A) and relative gene expression 
levels of major antioxidant enzymes (B) in the soleus muscle of young rats submitted to 14 days of HFD. Results are presented as mean fold change, compared to 
the RCD group, ±SEM for 5–6 replicates per condition.
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protein complex members or NADPH oxidase isoforms (NOX; 
adjusted p  ≥  0.801; Figure 5B) between both groups.
DISCUSSION
The present study intended to clarify the effects of a short-
term HFD on the mechanisms regulating glutathione 
metabolism, the development of oxidative stress, and 
inflammation in the soleus (SOL) muscle of young rats. To 
our knowledge, the present results are first to demonstrate 
reduced glutathione levels after such a short exposure to HFD. 
After measuring the expression levels of a host of enzymes 
involved in the regulation of glutathione metabolism, results 
suggest that this decrease in GSH is not due to an alteration 
in de novo synthesis or GSSG recycling via GSR. Further, a 
significant increase in the expression of the pro-inflammatory 
cytokine interleukin 6 (IL-6) in the SOL muscle suggests an 
involvement in early metabolic alterations that can disrupt 
lipid and glucose metabolisms. These alterations precede any 
observable weight gain but could contribute to the mechanisms 
of impaired insulin signaling (Matsuzawa-Nagata et  al., 2008), 
which could ultimately lead to the development of type 2 
diabetes (Wang et al., 2003), as well as other metabolic disorders 
(Lumeng and Saltiel, 2011).
Multiple studies have previously reported HFD-induced 
altered GSH or GSSG levels or ratio in rodent skeletal muscle 
(Anderson et al., 2009; Ritchie and Dyck, 2012; Espinosa et al., 
2013; Yuzefovych et  al., 2013; Gortan Cappellari et  al., 2016; 
Pinho et  al., 2017). However, the expression of both GCL 
subunits (the rate-limiting enzymes in the de novo synthesis 
of GSH), or of GSR (catalyzing the reduction of GSSG into 
GSH), was not altered, as previously reported in mice liver 
(Zhou et  al., 2018). The latter study hypothesized that HFD 
could alter GSH levels via glutathione synthesis-related gene 
promoters hypermethylation. In the same study, a diet 
supplemented with serine, a cysteine precursor, was shown to 
counteract the alterations in GSH production and the 
development of oxidative stress induced by a HFD in hepatic 
tissues. This is of great interest, since cysteine availability is 
the rate-limiting factor of cellular GSH synthesis (Lu, 2013). 
As shown in previous work (Andrich et  al., 2018a), our HFD 
formulation is supplemented with L-cystine, the oxidized dimer 
form of cysteine. Therefore, we conclude that reduced glutathione 
levels observed in this study were not a consequence of decreased 
cysteine availability caused by a lack of nutritional intake, as 
L-cystine supplementation was previously shown to stimulate 
GSH production (Yin et  al., 2016). In that same study, using 
the same diet and protocol, we  observed significantly lighter 
livers in HFD rats (Andrich et  al., 2018a). Glutathione levels 
are at their highest in liver (where it is primarily synthesized), 
which also plays an important role in glutathione inter-organ 
homeostasis (Ookhtens and Kaplowitz, 1998). However, it 
appears that hepatic GSH needs to reach extreme depletion 
before it can affect skeletal muscle GSH concentrations (Burk 
and Hill, 1995). Further, the hepatic cysteine concentration is 
not considered to be  a limiting step of GSH synthesis, as 
methionine is converted to cysteine. Nevertheless, the first 
enzyme in this metabolic cascade, methionine 
adenosyltransferase, can be  inhibited by oxidative molecules 
(Elremaly et  al., 2012, 2016). On the other hand, a more 
recent study hypothesized that skeletal muscle glutamine levels 
could influence hepatic GSH production in the presence of 
oxidative stress (Bilinsky et  al., 2015). Thus, HFD-modulated 
interactions between liver and skeletal muscle glutathione 
metabolism need to be  clarified.
As GSH reduces hydrogen peroxide (H2O2) through GPX, 
the levels of GSSG, a product of that reaction, rise. Under 
cellular stress, GSH levels drop as GSSG accumulates in the 
cell, although it can also react with the free sulfhydryl group 
of a protein to form a mixed disulfide or be  transported 
out of the cell (Lu, 2013). Hence, the GSH:GSSG ratio is a 
good indicator of cellular oxidative stress (Schafer and Buettner, 
2001). We  did not observe any significant HFD-induced 
changes in GSSG levels or in the GSH:GSSG ratio. This, 
combined with the lack of difference in the expression of 
A B
FIGURE 5 | Relative gene expression levels of NF-κB (A) and relative gene expression levels of various NADPH oxidase isoforms (B) in the soleus muscle of young 
rats submitted to 14 days of HFD. Results are presented as mean fold change, compared to the RCD group, ±SEM for 5–6 replicates per condition.
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major antioxidant enzymes GPX, CAT, and MnSOD or in 
various isoforms of NADPH oxidase, a superoxide precursor, 
would suggest that the soleus muscle is not under cellular 
stress, yet. This would confirm earlier findings from our 
group that showed no increase in ROS (H2O2) production 
from permeabilized soleus muscle fibers in rats submitted 
to the same 14-day HFD (Leduc-Gaudet et  al., 2018). 
Nonetheless, in vivo measurements of H2O2 and 
malondialdehyde (MDA), a product of lipid peroxidation and 
widely used marker of oxidative stress (Nielsen et  al., 1997), 
could provide further confirmation of these observations. 
The present results do not show any difference in the glutathione 
redox potential as calculated by the Nernst equation. However, 
this equation’s validity as an indicator of cellular redox 
potential is currently debated in the literature, as it appears 
that the redox potential is highly dependent of GSH but 
not GSSG levels (Flohe, 2013). Moreover, further evidence 
points toward the redox potential, depending predominantly 
on kinetics per se rather than thermodynamic constraints 
(Deponte, 2017). A major consequence of the observed 25% 
drop in GSH levels is a decreased capacity to detoxify 
endogenous peroxides via GPX. Thus, it is appealing to 
postulate that, under exercise-induced physical stress and 
accelerated ROS production (Steinbacher and Eckl, 2015), 
the SOL antioxidant defense system will be  compromised in 
HFD rats due to significantly lower GSH levels. Measurements 
of skeletal muscle glutathione levels following an exercise 
bout could confirm this hypothesis.
The other major finding of this study is the 4.5 fold increase 
in the gene expression of pro-inflammatory cytokine IL-6, 
which has previously been shown to be  increased in the obese 
state (Eder et  al., 2009) and diminished after weight loss 
(Bougoulia et  al., 2006). Further, elevated IL-6 levels are a 
good indicator of an inflamed state, which can play a key 
role in the development of insulin resistance and other associated 
diseases (Yamashita et al., 2018). Its production can be regulated 
by various factors like C/EBPβ (Hungness et  al., 2002) and 
PPARγ-activated proteins ANGPTL4 (Phua et al., 2017), CIDEA 
(Chatterjee et  al., 2015), and FATP1 (Nishiyama et  al., 2018). 
Interestingly, PPARγ has often been associated to Il-6 inhibition 
through STAT3 inactivation (Wang et  al., 2004). However, 
other evidence suggests that PPARγ could trigger IL-6 production 
in skeletal muscle (Assi et  al., 2017) and other cell types and 
tissues (Wanichkul et  al., 2003; Zhang et  al., 2014). Here, our 
data suggest that PPARγ, whose activity has been shown to 
be  modulated by lipid ingestion (den Besten et  al., 2015), 
could stimulate IL-6 expression through the activation of other 
proteins. In turn, IL-6 can induce the production of other 
pro-inflammatory proteins like PTX3 (Figure 6; Atar et  al., 
2017). Co-incidence of elevated IL-6 and lower GSH levels 
was previously reported (Valles et  al., 2013), while obesogenic 
diets were shown to induce both of these effects in mice 
(Han et  al., 2017) and rats (Govindaraj and Sorimuthu Pillai, 
2015). In individuals with type 2 diabetes, increased IL-6 
levels have been suspected as a cause of lowered GSH levels 
(Lagman et  al., 2015). In mice, IL-6 was associated with 
FIGURE 6 | Suggested interplay between HFD, GSH levels and IL-6 expression in rat soleus muscle. The high-fat diet promptly promotes the expression of IL-6. 
This is stimulated by an increase in C/EBPβ (Hungness et al., 2002) and PPARγ activity (den Besten et al., 2015), the latter which yields the upregulation of  
pro-inflammatory proteins ANGPTL4, CIDEA and FATP1. In turn, IL-6 increases the expression of PTX3 and promotes cysteine catabolism (Hack et al., 1996),  
which lowers GSH levels. The latter are also decreased via HFD through a mechanism that was previously proposed to involve glutathione synthesis-related gene 
promoters hypermethylation (Zhou et al., 2018). Ultimately, the present results show that HFD promptly alters the antioxidant defense system while promoting 
inflammation and disruption in skeletal muscle homeostasis.
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glutathione depletion in the skeletal muscle, a mechanism 
possibly involving increased cysteine catabolism (Hack et  al., 
1996). Further, IL-6 has been shown to promote GSH release, 
but not production, from the liver into blood (Obrador et  al., 
2011). It remains to be  seen if such a phenomenon could 
occur in the skeletal muscle. Furthermore, GSH has been 
shown to inhibit IL-6 production in patients with liver cirrhosis 
(Pena et  al., 1999). Induced GSH depletion has also been 
demonstrated to inhibit T helper cell Th1 response in favor 
of Th2 response, which is responsible for IL-6 production 
(Peterson et  al., 1998; Brundu et  al., 2016). Thus, elevated 
IL-6 expression could also be consequential to low GSH levels. 
On the other hand, we  did not observe a different expression 
of the IL-33 gene in the HFD group, which stimulates the 
production of Th2-associated cytokines (Schmitz et  al., 2005). 
In both groups, we  also found similar gene expression of 
other pro-inflammatory cytokines of the interleukin-1 
superfamily, including IL-1β, whose expression has been shown 
to be  stimulated by HFD in the vastus lateralis muscle of 
rats (Collins et  al., 2016). In light of those results, it seems 
appropriate to recommend that the underlying mechanisms 
of glutathione and interleukin interactions should be  further 
investigated in future studies.
In order to better assess the inflammatory status of the 
SOL muscle, the expression of TGF-β cytokine superfamily 
isoforms was also considered, as it was reported to decrease 
GSH levels in multiple cell types, in vitro (Liu and Gaston 
Pravia, 2010), possibly via the suppression of GCLC expression 
(Arsalane et  al., 1997). Further, HFD was shown to induce 
a rise in TGF-β levels in both rats and mice (Yadav et  al., 2011; 
Sousa-Pinto et  al., 2016). We  could not, however, observe 
similar results after submitting young rats to a 2-week HFD. 
Therefore, we cannot postulate that TGF-β influences glutathione 
metabolism at this early stage. As discussed above, a decrease 
in the GSH concentration, as a glutathione peroxidase substrate, 
will result in a lower detoxification of endogenous peroxide, 
allowing an increase in the intracellular concentration of 
H2O2. Because it activates NF-κB, H2O2 could therefore stimulate 
the increase of IL-6. Indeed, NF-κB is a major mediator of 
the inflammation cascade and its activation can be  either 
stimulated or inhibited by GHS, depending on the tissue of 
interest and the experimental model (Hammond et al., 2001). 
Increased NF-κB phosphorylation was also observed in the 
gastrocnemius muscle of rats after 16  weeks of HFD (Sishi 
et  al., 2011). Chronic NF-κB activation may be  involved in 
the development of several diseases, including obesity and 
type 2 diabetes (Lira et  al., 2012). We  could not, however, 
detect any difference in the expression of NF-κB between 
HFD and RCD rats after 2 weeks, underlining that, in our 
model, HFD could impact endogenous metabolism rather 
than gene expression.
Results presented in this study demonstrate that a short-
term high fat diet induces lower GSH levels in the SOL 
muscle of young rats. This effect can neither be  attributed 
to a decrease in the expression of glutathione synthesis-
implicated enzymes nor to observable oxidative stress. However, 
decreased GSH levels suggest a potentially altered antioxidant 
defense system. Moreover, 2  weeks of HFD induced a 
significant increase in IL-6 gene expression, which suggests 
its interaction with skeletal muscle glutathione metabolism. 
It was previously reported that IL-6 mRNA expression is 
increased in response to contractions or to glycogen depletion 
in the skeletal muscle (Munoz-Canoves et  al., 2013). The 
present data, coinciding with our previous results, raise the 
hypothesis that disruptions in the antioxidant defense system, 
coupled to inflammation activation, could play a role in the 
impairment of contractile functions in the soleus muscle of 
young rats submitted to only 14 days of HFD. It was previously 
shown that IL-6 plays a pivotal role in muscle wasting 
mechanisms (Belizario et  al., 2016), although we  could not 
observe evidence of atrophy in neither SOL nor EDL in 
our previous results (Andrich et  al., 2018b). On the other 
hand, GSH has been shown to improve Ca2+ sensitivity in 
rat skeletal muscle, although this was only observed in fast 
twitch fibers (Murphy et  al., 2008) in which fast skeletal 
muscle troponin isoforms are highly expressed. Further, it 
appears as though diets rich in saturated fatty acids could 
alter fast skeletal muscle troponin T (TNNT3 gene) expression 
through alternative splicing of pre-mRNA in rat skeletal 
muscle (Black et  al., 2017), although it remains to be  seen 
if HFD could also alter the expression of other proteins of 
the troponin complex (troponin C and troponin I). Thus, 
further studies are needed to elucidate what role glutathione 
and inflammation could play in impaired oxidative muscle 
contractile functions and to better clarify the mechanisms 
(including the role of the liver and IL-6) underlying the 
reduction of GSH levels observed in the SOL muscle of 
young rats submitted to a short-term HFD.
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Fibroblast growth factor 21 (FGF21) is a hormone that regulates important metabolic
pathways. FGF21 is expressed in several metabolically active organs and interacts with
different tissues. The FGF21 function is complicated and well debated due to its different
sites of production and actions. Striated muscles are plastic tissues that undergo
adaptive changes within their structural and functional properties in order to meet their
different stresses, recently, they have been found to be an important source of FGF21.
The FGF21 expression and secretion from skeletal muscles happen in both mouse
and in humans during their different physiological and pathological conditions, including
exercise and mitochondrial dysfunction. In this review, we will discuss the recent findings
that identify FG21 as beneficial and/or detrimental cytokine interacting as an autocrine
or endocrine in order to modulate cellular function, metabolism, and senescence.
Keywords: FGF21, skeletal muscle, metabolism, regulation, myokine, cytokine, mitochondria
INTRODUCTION
Nearly 40–50% of total body mass in non-obese mammals is composed of skeletal muscle. Striated
muscles are plastic tissues that undergo adaptive changes in their structural or functional properties
in order to meet new challenges. Skeletal muscle tissues have generally been considered to be pure
locomotor organs, but in the 2000s it was recognized a secretory function for these muscles. In 2003
it was proposed that IL-6 and other cytokines were induced and secreted by skeletal muscles into
their circulation during physical activity. In consideration of these findings, the muscle-secreted
molecules were named “myokines.” Increasing evidence underlines that skeletal muscle secretes a
wide variety of molecules like cytokines, miRNA, exosomes, mtDNA during exercise, but also in
different acquired and inherited diseases (Inagaki et al., 2007; Alipoor et al., 2016; Hoffmann and
Weigert, 2017; Delezie and Handschin, 2018; Safdar and Tarnopolsky, 2018). Thus, skeletal muscles
are understood to be a source of myokines, metabolites, and muscle-derived molecules. They
mediate communication between distant organs to adapt whole body metabolism to nutritional and
environmental pressures (Rai and Demontis, 2016; Whitham and Febbraio, 2016). This systemic
regulation helps to explain why physical activity, and thereby muscle contraction, elicits several
beneficial effects in a variety of diseases. However, the nature and the function of most of the
myokines and muscle-derived molecules are still unclear. In this review, we will focus on fibroblast
growth factor 21 (FGF21) and its role as a “myokine.” Several studies have proven that FGF21
stimulates the oxidation of fatty acids, the production of ketone bodies, and the inhibition of
lipogenesis (Fisher and Maratos-Flier, 2016; Staiger et al., 2017). Therefore, the finding that FGF21
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regulates glucose-lipid metabolism has made it a promising
therapeutic target for metabolic disease. However, some studies
have shown that administrating FGF21 prevents diet-induced
obesity and insulin resistance in mice and humans (Fisher and
Maratos-Flier, 2016; Staiger et al., 2017). There is a paradoxically
positive correlation with elevated serum FGF21 levels and
metabolic disorders like obesity, diabetes, mitochondrial diseases,
and aging (Staiger et al., 2017; Tezze et al., 2017). Interestingly,
all these conditions have muscle loss as a common factor. In
addition, several reports have indicated that a pathophysiological
role for FGF21 includes:
(a) the promotion of muscle atrophy (Oost et al., 2019), bone
loss and reduced bone mineral density (Wei et al., 2012;
Fazeli et al., 2015).
(b) that it acts as a stress-induced myokine, which is
released during starvation, ER stress, and mitochondrial
dysfunction (Izumiya et al., 2008; Keipert et al., 2013;
Pereira et al., 2017; Tezze et al., 2017; Rodríguez-Nuevo
et al., 2018).
Thus, FGF21 is a powerful and debatable hormone that
belongs to the list of factors that controls energy homeostasis
and metabolism. As described below, the beneficial and/or
detrimental actions of FGF21 are affected by multiple variables
including tissue source, serum concentration, animal age, and the
presence of synergizing factors.
FGF21 AND METABOLISM
The fibroblast growth factor (FGF) family is a group of
multifunctional signaling molecules that have a wide variety
of functions. The family comprises of 22 related proteins,
each grouped into subfamilies which are based on genetic
and functional similarity. In Nishimura et al. (2000) the
Fgf21 gene was identified in mouse embryos by RT-PCR.
Making it the 21st discovered Fgf gene, which was later to
be included into the FGF19 subfamily (also called endocrine
FGF), together with Fgf15 (mouse ortholog of human FGF19)
and Fgf23. FGF21 function remained completely unknown
until 2005 when it was proposed to be a novel metabolic
regulator and a potential anti-diabetic drug (Kharitonenkov
et al., 2005). Kharitonenkov et al. (2005) demonstrated that
the administration of FGF21 reduced plasma glucose and
triglycerides to an almost normal level in both ob/ob and
db/db mice. These effects persisted for up to 24 h after which
the last FGF21 was administrated. Over the following years,
several groups investigated the metabolic role of FGF21 in
mice. Their results showed that FGF21 mediates the adaptive
starvation response to induce ketogenesis, gluconeogenesis,
lipolysis, and lipid β-oxidation (Inagaki et al., 2007; Izumiya
et al., 2008). In line with Kharitonenkov results, FGF21 treatment
improved metabolic parameters in obese and diabetic animal
models (Coskun et al., 2008; Xu et al., 2009). In humans,
FGF21 is a starvation-induced protein that is elevated after
7 days of fasting and regulates the utilization of fuel to adapt
metabolism in the late phase of the absence of nutrients
(Fazeli et al., 2015). FGF21 is expressed in several tissues such
as liver (Nishimura et al., 2000), adipocytes (Zhang et al.,
2008), pancreas (Johnson et al., 2009), and brain where it
passes the blood-brain barrier (Hsuchou et al., 2007). Other
studies reported the expression of FGF21 mRNA in testes,
gastrointestinal tract, brain, skeletal muscle, brown adipose tissue
(BAT), and heart (Patel et al., 2015). Based on its role in
glucose and lipid metabolism and its wide tissue expression, it
was hypothesized that FGF21 is a fasting-adaptation hormone
in rodents (Fazeli et al., 2015). However, it was recently
demonstrated that FGF21-knockout mice do not exhibit an
impaired response to fasting (Antonellis et al., 2016) suggesting
that FGF21 is not required for the physiological response
to low nutrients.
FGF21 EXPRESSION AND REGULATION
The FGF21 regulation is complicated because of its different
tissue production and action. The liver is considered to be the
main site of FGF21 production (Badman et al., 2007; Inagaki
et al., 2007). Badman and Inagaki independently showed a
cross-talk between FGF21 and PPARα signaling in the liver
during fasting. FGF21 expression was increased in mice that
were either fed with a ketogenic diet or through fasting and
in these conditions, PPARα was recruited in the different
regions of the Fgf21 promoter (Badman et al., 2007; Inagaki
et al., 2007). However, this finding was not confirmed in
other metabolic conditions in which FGF21 was induced,
suggesting that other transcription factors might also regulate
hepatic FGF21 expression. Indeed, Fgf21 was found to be under
the regulation of the Unfolding Protein Response (UPR) in
hepatocytes (Schaap et al., 2013; Kim et al., 2015). Kim et al.
(2015) started from the observation that FGF21 increased in
the liver of patients who were affected by steatosis, and mouse
models of obesity or non-alcoholic fatty liver disease (NAFLD)
while at the same time, observing that an ER stress became
triggered. They found that FGF21 expression was dependent
from PKR-like ER kinase (PERK)–eukaryotic initiation factor
2α (eIF2α)–activating transcription factor 4 (ATF4) pathways
both, in vitro and in vivo (Kim et al., 2015). Moreover,
FGF21-null mice displayed induction of ER stress markers in
genes and observed more lipid accumulation in the liver after
tunicamycin treatment, an inhibitor of glycoprotein biosynthesis
that promotes ER stress (Kim et al., 2015). Several studies have
suggested that other transcription factors are involved in the
regulation of hepatic FGF21 expression. Adams et al. (2010)
reported that thyroid hormone receptor β, which mediates the
action of tri-iodothyronine in the liver, stimulates lipolysis, and
hepatic fatty acid oxidation via FGF21 induction. Moreover,
several researchers have speculated that FGF21 expression is
regulated by RARβ (Wang et al., 2010, p. 21; Berry et al.,
2012; Tsuchiya et al., 2012; Li et al., 2013). This is because
the metabolic effect of the RARb ligand, retinoic acid, on
body weight loss and glucose/lipid metabolism are similar to
FGF21, this has been recently demonstrated in vitro in C2C12
(Hirai et al., 2019) but has not yet been confirmed in vivo.
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Retinoic acid receptor-related orphan receptor (ROR) α has
been implicated in various physiological functions, including
the immune system, inflammation, and circadian rhythms.
In the present study, the synthetic RORα/γ agonist SR1078
stimulated the production and gene expression of FGF21 in
C2C12 myotubes. FGF21, a member of the FGF family, plays an
important role in the regulation of peripheral glucose tolerance
and lipid metabolism while improving metabolic health. The
mRNA expression and secretion of FGF21 were significantly
weaker in RORα-silenced cells than in cells transfected with
non-targeting control siRNA. SR1078 significantly up-regulated
C/EBP homologous protein (CHOP), an established marker of
ER stress, in a dose-dependent manner in C2C12 myotubes,
while CHOP expression was decreased in RORα -silenced
C2C12 cells, suggesting that RORα is involved in the regulation
of FGF21 expression and stimulates ER stress in C2C12
myotubes. The naturally occurring compound baicalein up-
regulated FGF21 expression and secretion in C2C12 myotubes.
Additionally, the up-regulation of CHOP mRNA and protein
expression was observed in C2C12 myotubes after the baicalein
treatment. Furthermore, the knockdown of RORα prevented
the augmentation of FGF21 and up-regulation of CHOP in
response to baicalein in C2C12 cells. Collectively, these results
suggest that baicalein stimulates the ER stress response and
FGF21 expression through a RORα-dependent mechanism in
C2C12 myotubes, and indicates the potential of baicalein as an
effective anti-obesity therapy via its ability to enhance FGF21
production (Hirai et al., 2019). Other reports have shown that
the hepatic expression of FGF21 is either regulated positively or
negatively by glucocorticoid receptor (GR) (Patel et al., 2015),
cAMP-responsive element-binding protein H (CREBH) (Lee
et al., 2017), carbohydrate response element-binding protein
(ChREBP) (Iizuka et al., 2009), PPARγ (Moyers et al., 2007;
Wang et al., 2008), farnesoid X receptor (FXR) (Cyphert
et al., 2012), and liver X receptor (LXR) (Archer et al., 2012;
Uebanso et al., 2012) under various conditions. Extrahepatic
tissues, such as skeletal muscle, white adipose, and brown
adipose tissue regulate FGF21 via different transcription factors.
Indeed, PPARγ activation increases FGF21 production in white
adipose tissue where it acts as an autocrine or endocrine
factor to improve insulin action (Dutchak et al., 2012). Brown
adipose tissue (BAT), FGF21 is regulated by ATF2 (Hondares
et al., 2011) while the skeletal muscle is controlled by ATF4
(Kim et al., 2013) and by the PI3K–AKT signaling pathway
(Izumiya et al., 2008).
FGF21 DOWNSTREAM SIGNALING
The FGF21-dependent signaling downstream FGF receptors
(FGFr) are extremely complicated and well debated. Its
complexity is due to the fact that FGF21 is activated and
released in different conditions such as energy stress, ER stress,
mitochondrial dysfunction, and cold-stress. In vitro studies have
failed to identify a direct interaction of FGF19 subfamily with
their FGF receptor. This negative finding, and the very weak
heparin binding affinity of these family members, implies that
the FGF19 subfamily requires additional cofactors to stably
bind the FGFRs in the target tissue (Gälman et al., 2008).
The aging-suppressor gene Klotho and Beta-Klotho are indeed
the essential co-receptors for the interaction and activation
of FGFRs (Gälman et al., 2008). The complex FGF21-Klotho
binds multiple FGFRs, including FGFR1c, −2c, −3c, and −4
both, in vitro and in vivo (Agrawal et al., 2018). However,
the signaling downstream FGF receptors are tissue specific. In
cultured adipocytes, FGF21 treatment activates Ras/Raf MAPK
and the downstream effector ERK1 and ERK2 (Moyers et al.,
2007; Ge et al., 2011). Transcriptomic analyses on adipocytes
identified that ERK/MAPK signaling pathways are enriched after
FGF21 administration in vivo, a second study showed that
existing ERK1/2- independent pathways in mTOR act on FGF21
activating on adiponectin in adipose tissue in vivo (Minard
et al., 2016). In liver, FGF21 positively controls the PI3K/AKT,
insulin-like growth factor 1 (IGF-1) and mTOR pathways as
well as triglyceride homeostasis, glucose uptake, amino acid
transport, and energy expenditure (Muise et al., 2013). Moreover,
FGF21 inhibits Growth Hormone (GH) action in hepatocytes
resulting in STAT5 inhibition, decreased expression, secretion
of IGF-I, and the reduction of body size (Inagaki et al.,
2008). Finally, FGF21 also induces the expression of IGFBP1,
an inhibitor of IGF1 and suppressor of cytokine signaling 2,
which is a negative modulator of GH signaling, furthering
blocking the GH-IGF1 axis in the liver. It has also been
reported that FGF21 works on the central nervous system and
dorsal vagal complex of the hindbrain to regulate circadian
rhythm, which is important for the adaptive starvation response
(Bookout et al., 2013).
SERUM LEVELS OF FGF21 IN ANIMAL
MODELS
In published studies, the serum FGF21 concentrations measured
in chow-fed mice ranging from 0 to 3000 ng/mL (Badman et al.,
2007; Fisher et al., 2010; Dutchak et al., 2012; Murata et al., 2013;
Tezze et al., 2017; Jimenez et al., 2018). The difference in the
reported FGF21 serum levels may be dependent on the mice
strain, animal age, time of the day in which serum was collected,
as well as the methodology used to quantify the serum levels.
This complicates the interpretation of the data, since basal FGF21
concentration, as well as the increasing degree, may trigger
different metabolic actions. As shown in Table 1, the fold increase
of FGF21 serum in knockout /transgenic versus controls mice
and in different experimental conditions are witness to a range
from 2 to 100. These observations are particularly important
considering that FGF21 is a molecule with a very short half-life
that, in absence of specific stimuli, has been calculated from 1 to
2 h (Kharitonenkov et al., 2007; Xu et al., 2009; Hecht et al., 2012).
This short half-life in the serum is due to enzymatic degradation
and/or renal clearance. In fact, fibroblast activation protein α
(FAP) was recently identified as the serine protease that cleaves
and inactivates FGF21 (Zhen et al., 2016). Interestingly, FAP is
also secreted in human muscle during exercise (Parmar et al.,
2018). Therefore, because FGF21 is secreted from the kidney it
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TABLE 1 | Serum level, absolute and normalize, of FGF21 regarding the transgenic mice, reported into the literature.
Transgenic mouse Paper Basal condition/control
animals serum level (pg/mL)
Transgenic/virus serum level
(pg/mL)




knock-down – liver specific
Badman et al., 2007 Not shown
FGF21 total ko Antonellis et al., 2016 Not shown
FGF21 tg -liver specific Inagaki et al., 2007 Not shown
Virus-mediated FGF21 – liver
specific
Jimenez et al., 2018 1000 (null-chow) 5000
(null-HFD)
Not shown (chow) 6000 –
25000 (HFD)
1–5 (HFD) (HFD)
Virus-mediated Fgf21 – muscle
specific
Jimenez et al., 2018 3000 (fed) 45000(fed) 15 (fed)
atg7 ko – muscle specific Kim et al., 2013 Detectable (fed) – 2000(fasted) 500(fed) – 4000(fasted) Not clear (fed) – 2 (fasted)
Ucp1 tg – muscle specific Keipert et al., 2013 1000(fed) – 2000(fasted) 4000(fed) – 5000(fasted) 4 (fed) – 2 (fasted)
4ebp1 tg – muscle specific Tsai et al., 2015 1000 (fasted) 4000 (fasted) 4 (fasted)
Tsc1 ko – muscle specific Guridi et al., 2015 500 (fed) 1500(fed) 3 (fed)
Opa1 ko – inducible muscle
specific
Tezze et al., 2017 n.d. ( < 50 pg/mL) 4000 (fed) 100 (fed)
Opa1 ko – constitutive muscle
specific
Rodríguez-Nuevo et al., 2018,
p. 1
222 (fed) 544 (fed) 2,4
Opa1 ko – inducible muscle
specific heterozygous
Pereira et al., 2017 1069 (fed) 11500 (fed) 10
Fundc1 ko – muscle specific Fu et al., 2018 400 900 (HFD) 2,24
has a short half-life and its activity is modulated by the presence
of Klotho and FAP, simply monitoring serum levels may not be
enough to claim a direct FGF21 action on targeted tissues without
checking the activation of the pathway downstream FGFr.
FGF21 IN CARDIAC AND SKELETAL
MUSCLE
Originally, the heart was not considered to be an FGF21 source
or target, primarily because β-Klotho mRNA is required to be
co-receptors for cellular responsiveness to FGF21, and this was
only found to be modestly expressed (Fon Tacer et al., 2010).
However, recent studies have demonstrated that FGF21 plays
a key role in cardiac remodeling. In fact, the heart expresses
FGFR1, fibroblast growth factor receptor 1, β-klotho, as well as
FGF21. Moreover, in rodents, it has been reported that FGF21
expression protects against pathologic cardiac hypertrophy,
oxidative stress, and myocardial infarction (Planavila et al.,
2013, 2015; Joki et al., 2015). In the heart, FGF21 acts in the
manner of an autocrine and controls autophagy in obesity-
induced cardiomyopathy (Rupérez et al., 2018). In skeletal
muscle, FGF21 expression was found undetectable or to be
limitedly expressed in basal conditions (Izumiya et al., 2008;
Hojman et al., 2009; Pereira et al., 2017; Tezze et al., 2017;
Rodríguez-Nuevo et al., 2018). However, several physiological
and/or pathological conditions triggered FGF21 expression in
muscle as well as showing a secretion into the blood. This
was first demonstrated in muscle-specific AKT1 transgenic
mice, where the activation of AKT1 brought a reduction of
adipose tissue via FGF21 secretion (Izumiya et al., 2008). In
Kim et al. (2013), it was found that autophagy inhibition,
specifically in skeletal muscle, was protected from obesity and
HFD because FGF21 was dramatically induced in muscles.
As a consequence of the autophagic impairment muscles
accumulate dysfunctional mitochondria, resulting in ER stress,
UPR activation, and FGF21 induction via the transcription
factor of ATF4. Similarly, muscle-specific deletion of Tuberous
sclerosis 1 (TSC1) resulted in the activation of mTOR. At
the same time FGF21 upregulation, via UPR, improved the
insulin sensitivity, leading to an association with a leaner
phenotype when compared with controls (Guridi et al., 2015).
Consistent expression of constitutively active 4EBP1 in skeletal
muscles caused FGF21 secretion into the circulation which
then ameliorates lipid metabolism in WAT via PPARs (Tsai
et al., 2015). Mild mitochondrial dysfunction is a consequent
of UCP1, Uncoupling Protein 1, expression in skeletal muscle
resulting in FGF21 expression and the diminution of the size
of myofibers, but at the same time also improved the metabolic
profile due to the browning of WAT (Keipert et al., 2013).
We have now shown that mitochondrial dysfunction is due
to OPA1 ablation in skeletal muscle and triggers a dramatic
increase of muscle FGF21 transcript and serum levels (Tezze
et al., 2017; Pereira et al., 2017; Rodríguez-Nuevo et al., 2018).
This important FGF21 induction is mediated by mitochondrial-
dependent oxidative stress that had caused UPR activation
(Tezze et al., 2017; Rodríguez-Nuevo et al., 2018). ER stress,
muscle atrophy, and FGF21 upregulation were found in several
muscle-specific OPA1-deficient mice, but the phenotypes of
these knockout mice were different. These discrepancies may
be a consequence to the age of the animal in which OPA1
was deleted, and/or the degree of mitochondrial dysfunction,
and/or the blood levels of FGF21. In Tezze et al. (2017)
the 100-fold (Table 1) showed an increase of FGF21 blood
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FIGURE 1 | Signaling pathways that control FGF21 expression in skeletal muscle and FGF21-mediated metabolic effect on different tissues. UCP1, uncoupling
protein 1; p21, Cdkn1a cyclin-dependent kinase inhibitor 1A; SA-B-gal, senescence-associated beta-galactosidase; Nf-kb, nuclear factor
kappa-light-chain-enhancer of activated B cells; IL-6, interleukin 6; ROS, reactive oxygen species; ATF4, activating transcription factor 4; UPR, unfolded protein
response; FoXO, Forkhead box O.
levels after acute deletion of OPA1 mice at 5 months of age,
causing several detrimental systemic effects. OPA1 inhibition
induces important metabolic changes and a precocious aging
phenotype of epithelial tissues, a systemic inflammatory response
and a premature animal death (Figure 1). Importantly, FGF21
deletion in OPA1-null mice reverted almost all the effects linked
to aging, while muscle and white adipose tissue loss were
attenuated, but still present, in the double FGF21/OPA1 knockout
mice. Interestingly, β klotho and FGFRs were upregulated
in OPA1 deficient skeletal muscles when compared to the
controls supporting the role of this pathway in muscle mass
regulation (Tezze et al., 2017). Similar to Tezze et al. (2017)
also Rodríguez-Nuevo et al. (2018) showed precocious mouse
death and a systemic inflammatory response when OPA1 was
deleted. In this work, the group of Zorzano used a myogenin-
driven Cre transgenic mouse line to delete OPA1 in developing
muscle. The finding that the phenotype of these knockout
mice was not rescued by FGF21 inhibition is probably due
to its reliance on unknown bioenergetics issues. In fact, the
presence of mitochondrial dysfunction in growing muscles is too
bioenergetically detrimental to be counteracted by concomitant
FGF21 ablation. Alternatively, the secretory pattern induced by
a mitochondrial defect in new-born mice is neither the same
of adult muscle nor adequate to promote tissue senescence.
Dale group has also generated an inducible muscle-specific
knockout mouse that shows mild muscle loss and, surprisingly,
several beneficial metabolic changes in terms of resistance to
obesity when the animals were challenged with a high-fat diet.
However, OPA1 deletion was induced in very young mice
(4 weeks of age), and not in adult animals [12 weeks in Tezze
et al. (2017)] and the reduction of OPA1 was partial (around
50–70%). This is probably due to the fact that stem cells
muscles are still fused to myofibers, bringing the OPA1 gene
inside the knockout fibers and causing the partial inhibition
of OPA1 mildly affecting the mitochondrial function. In fact,
mitochondrial respiratory complexes and supercomplexes, as
well as mitochondrial DNA content and citrate synthase, were
unaffected in these knockout mice. The partial OPA1 inhibition
induced morphological changes (swelling) and minor alterations
of respiration. This mild mitochondrial phenotype results in
a minor level of FGF21 serum fold increase (Table 1). This
phenotype differs from our animal model in which OPA1 deletion
occurred in adult mice (3–5 months of age) and resulted in the
decrease of mtDNA, respiratory complexes and supercomplexes
content, complex activity, respiration, mitochondrial membrane
potential and in an increase of ROS production. Altogether these
mitochondrial changes resulted in a dramatic increase of FGF21
in muscle and serum (100 fold, Table 1), its range has been
reported in patients with mitochondrial diseases (Morovat et al.,
2017) and unhealthy aging (Conte et al., 2018). Therefore, the
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beneficial or detrimental effect of FGF21 is age, dose, time, and
context/tissue-dependent.
FGF21 IN HUMANS, A BENEFICIAL OR
DETRIMENTAL MOLECULE?
In healthy humans, a large variation level of serum FGF21 is
shown between individuals, ranging from 5 pg/mL to 5 ng/mL
(Gälman et al., 2008; Zhang et al., 2008; Li et al., 2009; Dushay
et al., 2010; Fazeli et al., 2015). This finding is similar to the
rodents’ data and further underlines a problem in the method of
FGF21 quantification and/or in the variability in terms (Pedersen
et al., 2003). For years the search for the stimulus that initiates
and maintains the change of excitability or sensibility of the
regulating centers in exercise has been progressing. For lack of
more precise knowledge, it has been called the “work stimulus,”
“the work factor,” or “the exercise factor.” In other terms, one
big challenge for muscle and exercise physiologists has been to
determine how muscles signal to central and peripheral organs.
Here, we discuss the possibility that interleukin-6 (IL-6) could
mediate some of the health beneficial effects of exercise. In
resting muscle, the IL-6 gene is silent, but it is rapidly activated
by contractions. The transcription rate is very fast and the
fold changes of IL-6 mRNA is marked. IL-6 is released from
working muscles into the circulation in high amounts. The IL-
6 production is modulated by the glycogen content in muscles,
and IL-6 thus works as an energy sensor. IL-6 exerts its effect
on adipose tissue, inducing lipolysis and gene transcription in
abdominal subcutaneous fat and increases whole body lipid
oxidation. Furthermore, IL-6 inhibits low-grade TNF-alpha-
production and may thereby inhibit TNF-alpha-induced insulin
resistance and atherosclerosis development. We propose that
IL-6 and other cytokines, which are produced and released by
skeletal muscles, exerting their effects in other organs of the
body, should be named “myokines” (Pedersen et al., 2003). Of
the patient’s age, time of the day when the blood is collected,
and nutritional state of the patient (fed or fasted) that may
affect FGF21 secretion or turnover. The Fgf21 gene under basal
conditions is considered to be mainly expressed in the liver,
and to a much lesser extent, also in the brain (Kharitonenkov
and Adams, 2014) and in the pancreas (Fon Tacer et al.,
2010). Similar to rodents, the PPARα response element was
identified in the human FGF21 promoters meaning that they
may regulate FGF21 expression (Lundåsen et al., 2007). However,
there are other tissues contributing to the FGF21 blood levels
in physio-pathological conditions. In skeletal muscle, FGF21 is
expressed in response to insulin stimulation, suggesting that
FGF21 is an insulin-regulated myokine (Hojman et al., 2009) and
an association between chronic hyperinsulinemia and levels of
FGF21 were found in humans (Hojman et al., 2009). Fazeli et al.
(2015) showed that FGF21 works as a fasting-induced hormone
for the adaptive response to starvation and for the utilization
of fuel derived from tissues breakdown. Others claimed that
serum levels of FGF21 are closely related to adiposity, lipid
metabolism, and are used as a biomarker of liver injury but not
of insulin secretion and sensitivity (Li et al., 2009). Despite the
beneficial action of FGF21 in rodents, the literature in humans is
not homogeneous and is supportive of some detrimental effects.
For instance, FGF21 serum levels are increased in patients with
mutations of mitochondrial DNA in skeletal muscles but not
when similar mutations accumulate in other organs. Due to this
specificity to mitochondrial myopathies, FGF21 was proposed
as a biomarker of mitochondrial dysfunction in skeletal muscles
and used as a diagnostic test for these inherited disorders
(Suomalainen et al., 2011, p. 21). In other conditions FG21
serum levels have been used as a predictor of disease progression.
For instance, higher circulating FGF21 levels were associated
with a high mortality rate in end-stage renal disease patients
(Kohara et al., 2017). It was also reported in patients with diastolic
dysfunction of heart failure who have preserved ejection fraction
(Chou et al., 2016), and in those who are serum FGF21 level had
been found to be an independent predictor of coronary heart
disease (Lee et al., 2017). Moreover, circulating FGF21 levels
are elevated in various metabolic disease states, such as obesity,
insulin resistance, and type 2 diabetes mellitus (Zhang et al., 2008;
Chavez et al., 2009). Interestingly, patients with type 2 diabetes
also have elevated circulating levels of FAP, and this is associated
with a diminished ratio of bioactive to total FGF21 in response to
an oral glucose tolerance test (Samms et al., 2017). The increase of
plasma FGF21 levels correlated with the severity of whole-body
mass (primarily muscle) and hepatic insulin resistance (Chavez
et al., 2009). Unexpectedly, in obese humans, the levels of FGF21
did not change after chronic exercise (Besse-Patin et al., 2014)
despite the well-known beneficial effect of physical activity. This
could be related to the level of the myokine FAP, which is known
to increase during exercise (Parmar et al., 2018). Increased FAP
could weaken the ratio of bioactive FGF21 in obesity as well as
in TDM2 patients. Moreover, we found that FGF21 serum levels
positively and significantly correlated with age (Tezze et al., 2017;
Conte et al., 2018). Importantly, the presence of high FGF21
serum levels in association with GDF15 and humanin, which are
two other markers of mitochondrial function, had been found to
be a predictor of morbidity and mortality (Conte et al., 2018).
FINAL CONSIDERATIONS
The understanding that the control of whole-body metabolism
has been greatly advanced in the last years. Impacting these
factors are the different molecules which are secreted by skeletal
muscles in different conditions. In particularly, FGF21 emerged
as an important myokine with several metabolic effects but
whether its action is beneficial or detrimental in physiological
or pathological conditions are still unclear, especially in humans.
There are several issues that should be addressed and clarified
soon. The most problematic and urgent one is related to the great
variability in the measurements of blood levels between different
studies, both in mice and humans. Therefore, a standardization of
the procedure for FGF21 measurement is required to understand
whether a threshold of serum concentrations is a determinant
for its different actions. Nevertheless, we have a clear picture of
the different tissues source and the targets that are involved in
FGF21 effects. We also know the conditions that trigger FGF21
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expression in skeletal muscles (e.g., mitochondrial dysfunction
and ER stress). What is still unclear is the relationship between
FGF21-mediated metabolic changes and the contribution of these
alterations to disease progression/onset. Moreover, the molecules
that synergize, enhance or counteract FGF21-action are still
unknown. Our recent findings are that high versus low serum
levels correlate with mortality in elderly people, underline the
concept that FGF21 actions are dose-dependent. Therefore, first,
it is necessary to better address which concentration, or fold
increase in plasma, is the most relevant for obtaining a beneficial
or detrimental effect. Second, it is important to dissect the
other factors (e.g., cytokines, metabolites) that may modulate
FGF21 action in target tissues and consequently elicit a positive
(healthy) or negative (unhealthy) effect. Finally, the downstream
signaling pathway should be better dissected in beneficial or
detrimental action. In conclusion, FGF21 belongs to a promising
class of cytokines that are induced in response to stress and that
can be used as a drug, drug target, or through a biomarker,
depending on the physio-pathological context. All these findings
will become clear when FGF21 will be used as a therapeutic
molecule, exploiting the beneficial effects of FGF21 for treating
metabolic disease or when it will be blocked to ameliorate disease
progression and the onset of disease.
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Activin negatively affects muscle fibers and progenitor cells in aging (sarcopenia) and
in chronic diseases characterized by severe muscle wasting (cachexia). High circulating
activin levels predict poor survival in cancer patients. However, the relative impact of
activin in mediating muscle atrophy and hampered homeostasis is still unknown. To
directly assess the involvement of activin, and its physiological inhibitor follistatin, in
cancer-induced muscle atrophy, we cultured C2C12 myotubes in the absence or in
the presence of a mechanical stretching stimulus and in the absence or presence
of C26 tumor-derived factors (CM), so as to mimic the mechanical stimulation of
exercise and cancer cachexia, respectively. We found that CM induces activin release
by myotubes, further exacerbating the negative effects of tumor-derived factors. In
addition, mechanical stimulation is sufficient to counteract the adverse tumor-induced
effects on muscle cells, in association with an increased follistatin/activin ratio in the
cell culture medium, indicating that myotubes actively release follistatin upon stretching.
Recombinant follistatin counteracts tumor effects on myotubes exclusively by rescuing
fusion index, suggesting that it is only partially responsible for the stretch-mediated
rescue. Therefore, besides activin, other tumor-derived factors may play a significant
role in mediating muscle atrophy. In addition to increasing follistatin secretion mechanical
stimulation induces additional beneficial responses in myotubes. We propose that in
animal models of cancer cachexia and in cancer patients purely mechanical stimuli
play an important role in mediating the rescue of the muscle homeostasis reported
upon exercise.
Keywords: skeletal muscle atrophy, myokines, mechanotransduction, exercise, C26 colon carcinoma,
FlexCell apparatus
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INTRODUCTION
Cancer cachexia is multifactorial and characterized by tumor-
and host-derived factors leading to muscle wasting (Fearon et al.,
2012). TGF-β family members, including activin and myostatin,
are key regulators of muscle development and homeostasis
(Chen et al., 2016) and have been reported to mediate cachexia
(Costelli et al., 2008; Chen et al., 2014). Since they bind
to activin type IIB receptor (ActRIIB), the latter has been
targeted to counteract muscle wasting (Barreto et al., 2016;
Hatakeyama et al., 2016; Toledo et al., 2016) or to promote
muscle hypertrophy (Morvan et al., 2017) and the regenerative
capacity of muscle (Formicola et al., 2018). Activin induces
muscle catabolism via p38β (Ding et al., 2017) and SMAD2/3
activation (Winbanks et al., 2016). Chemotherapy activates this
pathway too, further worsening muscle atrophy (Barreto et al.,
2016; Coletti, 2018). Follistatin (or activin-binding protein) is a
potent, physiological inhibitor of activin and myostatin (Zheng
et al., 2017). Several organs such as the gonads (Tilbrook
et al., 1996) and skeletal muscle (Ciaraldi et al., 2016) are
sources of follistatin.
Exercise modulates follistatin and other myokines (Yeo et al.,
2012) and the plasma profile of cytokines (Lira et al., 2009;
Donatto et al., 2013), producing marked beneficial effects on
muscle homeostasis (Barone et al., 2016; Coletti et al., 2016; Pigna
et al., 2016). This is the reason why exercise is recommended to
treat cachexia (Lira et al., 2012, 2014).
Even though a high level of circulating activin is an
adverse prognostic factor in cancer patients (Loumaye et al.,
2017), it is yet unknown if activin is a direct player or
only a mere marker of cachexia. Besides, it is not known if
beneficial exercise effects are mediated by purely mechanical
stimuli in the muscle, nor whether exercise itself modulates
the follistatin/activin ratio and its paracrine consequences. To
address these questions, we cultured C2C12 myotubes in the
absence or in the presence of mechanical stretching, and in
the absence or in the presence of tumor-derived factors, so as




C2C12 were seeded at a density of 20000 cells/cm2 in the
multiwell plate of the Flexcell R© FX-6000TM Tension System
designed for unidirectional stretching (collagen coated silicon
membrane, 3.89 cm2). A vacuum was constantly applied to
stretch the membrane by 6%, in order to increase membrane
stiffness, a condition that preliminary experiments showed to
be necessary to allow a proper differentiation of the C2C12
cells into myotubes (data not shown). The following day,
at 80% confluence, GM (DMEM with 15% FBS, 4.5 g/L
of glucose, 2 mM of L-glutamine, 100 µg/mL of penicillin-
streptomycin; Sigma-Aldrich, St. Louis, MO, United States)
was replaced with DM containing 2% Horse Serum (HS,
Carotenuto et al., 2016). A mixed culture of myoblasts and
myotubes was kept for 4 days in DM at 37◦C, 5% of CO2
in the Flexcell apparatus, always under constant stretch. For
the experiments, the initial myotubes cultures were further
cultured for additional 2d under continuous stretching (SC,
Static Condition) or were subjected to 2 daily series of 2 h
cyclic stretching (0,5 Hz, 6% stretch), with a 3 h-pause between
them (DC, Dynamic Condition). As to media composition
during the 2d experimental treatments see figure legends
(Sigma reagents).
In order to obtain a tumor cell conditioned medium (CM),
C26 carcinoma cells (Cell Lines Service) were cultured for 2d
in serum-free DMEM and the supernatant being diluted to 20%
in HS medium. To obtain the control medium, DMEM was
incubated for 2d at 37◦C in the absence of C26 cells.
Immunofluorescence, ELISA
Samples underwent standard procedures (De Arcangelis et al.,
2005; Aulino et al., 2015). Antibodies: MF20 anti-MHC and
F5D anti-myogenin (DSHB); Alexafluor 555 or 488 secondary
Abs (Molecular probes). Regarding the ELISA quantification
of some specific factors secreted in C26 CM or in the
myotube culture media DAC00B Human/Mouse Activin A and
DFN00 Human Follistatin (R&D) systems were used following
manufacturer’s instructions.
Western Blot
Protein extraction and electrophoresis were performed as
previously described (Coletti et al., 2016). In brief: samples
were treated with lysis buffer RIPA containing Tris-Cl 50 Mm
pH = 7.5, 150 Mm NaCl, 1% NP40, 0.5% desoxyclorate
de sodium, EGTA 20 mM, DTT 1 mM, and a protease
inhibitor cocktail. Proteins were denatured with a Bolt kit
(Molecular probes, Invitrogen). Total protein content was
measured by Bradford and GAPDH was used as a loading control.
Membranes of nitrocellulose were incubated with blocking buffer
TBS-Tween with 5% not fat milk. Antibodies: anti-MyoD,
anti Phospho-SMAD2/3, anti-SMAD2/3 (Cell Signalling), anti-
GAPDH (Sigma). The sample size was 9, however, triplicate
independent samples were pooled to obtain a sufficient amount
of proteins to be loaded in each lane. Secondary antibody
fluorescence was detected by using the Odyssey system; for
each band, quantification of the signal was obtained by
ImageJ, following background subtraction, and each value was
normalized by the corresponding GAPDH band intensity; for
SMADs, the ratio between the normalized P-SMAD and SMAD
values was calculated.
Quantitative PCR
Total RNA was isolated with Trizol R© reagent (Invitrogen)
following the manufacturer’s recommendations and
homogenized. RNA concentration was determined by
measuring the absorbance in 260 nm/280 nm in a NanoDrop
spectrophotometer. cDNA synthesis was carried out using the
High capacity applied Reverse Transcription Kit (Biosystem).
Lightcycler 480 was used to detect SYBR Green signal in
Q-PCR. The mRNA levels were determined by the comparative
Ct method; the average 1Ct value of the control group was
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FIGURE 1 | Mechanical stimulation counteracts the negative effect of tumor-derived factors. (A) Myosin (red) localization and nuclei (blue) by immunofluorescence in
C2C12 myotubes at 4d (Aa) and 6d (Ab) of culture in a differentiation medium in the absence (HS) or presence (CM) of C26-conditioned medium, in combination
with the absence (SC) or presence (DC) of cyclic stretching. (B) Morphometric analyses were performed on replicate samples (n = 6). One-way ANOVA performed on
data from 4d and 6d (five groups) followed by Dunnet’s test indicated a significant increase in the fusion index (FI) and in the number of nuclei/myotube (NpM)
between 4d and 6d in any condition except CM. Two-way ANOVA performed on 6d values showed a significant effect for: (Ba) DC on myotube diameter (F = 12.66;
df = 1; p < 0.05); (Bb) CM and interaction with DC (for CM: F = 24.73; df = 1; p < 0.001; for interaction: F = 30.2; df = 1; p < 0.001) on fusion index; #p < 0.05,
##p < 0.01 by Tukey HSD test); (Bc) CM on number of nuclei/myotube (F = 5.64; df = 1; p < 0.05). (C) WB analysis for MyoD (Ca) and relative average density (Cb)
following normalization over the GAPDH signal in the same conditions as above. Two-way ANOVA showed a significant effect for DC (F = 19.47; df = 1; p < 0.001).
(D) Myogenin (red) and nuclei (blue) by IF (Da) in C2C12 myotubes at 6d of culture in the same conditions as above, and quantification of the percentage of
myogenin+ nuclei (Db). Two-way ANOVA showed the significant effect of both CM (F = 13.55; df = 1; p < 0.01) and DC (F = 451.7; df = 1; p < 0.0001), indicating
that the DC rescues myogenin expression. Data are shown as mean ± SEM.
subtracted from the test value to derive a −11Ct value. The
expression of each gene was evaluated by 2−11Ct , according to














Images were acquired by a Zeiss EM S3/SyCoP3 Macro-
apotome equipped with Zen software in the imaging facility
of the Institute of Biology Paris-Seine. The ImageJ software
was used for the morphometric analysis. Fusion index (FI)
was defined as the number of nuclei in myotubes on
total nuclei in 5 fields/sample; myotube diameter (DIA) was
measured in 50 myotubes/sample; nuclei per myotube (NpM)
were counted in 50 randomly chosen myotubes. Myotubes
diameter was measured as the average from three independent
measurements per myotube according to previously published
methods (Trendelenburg et al., 2009; Deane et al., 2013).
At least triplicate samples from two independent experiments
were analyzed for each condition; thus, 6 < n < 10 for
each data group.
Statistical Analysis
Comparisons of quantitative variables were performed
through 2-way ANOVA, after verifying parametric
assumptions. In case these assumptions were violated,
some transformations (square root or arcsin, as appropriate)
were used. Post hoc comparisons were performed through
Tukey’s significant difference method. When a comparison
of each treatment group with a single control group was
necessary, a Dunnett post hoc test was employed. The
significance level was set at 0.05. Statistical analyses were
performed by SPSS 25.0.
RESULTS
Mechanical Stimulation Counteracts the
Negative Effect of Tumor-Derived
Factors on Muscle Cells
C2C12 cultures, following 4d in DM, contained both
multinucleated myotubes and undifferentiated myoblasts
(Figure 1Aa). We further cultured these cells for 2d in control
conditions (i.e., in HS) in the absence (static condition, SC) or
presence (dynamic condition, DC) of mechanical stimulation,
represented by cyclical stretching of the substratum; furthermore,
we treated the cells with C26 tumor-conditioned medium (CM),
in a SC or a DC, and we analyzed 6d cultures undergoing four
combinatorial treatments (Figure 1Ab). The morphometric
analysis focused on myotube diameter (DIA), as a marker of fiber
size, on fusion index (FI), as a marker of the extent of myogenic
differentiation, and on the number of nuclei per myotube (NpM),
as an indication of myotube growth because of the addition of
nuclei deriving from the myoblasts. On day 6 myotube cultures
showed a significant increase in FI and NpM as compared to 4d
cultures, indicating that the myotubes continuously grew in size
by incorporating the nuclei from myoblasts, or, possibly, that
additional newborn myotubes formed (Figure 1B). Two-way
ANOVA on 6d-culture morphological features showed that: CM
decreased, while DC significantly increased, myotube DIA even
in the presence of CM (Figure 1Ba); CM diminished FI, while
DC interfered with CM and rescued FI. Given the significance of
the negative interaction between CM and DC we could perform
post hoc tests, which showed not only that the FI in the presence
of CM is lower compared to all the other treatments, but also that
the DC does not promote fusion per se (Figure 1Bb); indeed CM
had a negative effect on the number of NpM, with no interaction
with the DC, while the latter did not significantly affect the
number of NpM (Figure 1Bc).
Consistently with the previous results, the positive effects of
mechanical stimulation on myogenesis were confirmed by the
significant upregulation of the MyoD level (Figure 1Ca), likely
mirroring a sustained activation of differentiating myoblasts;
we also observed a decreased, albeit not significant, amount
of MyoD protein following CM treatment, with no interaction
between the two variables as shown by ANOVA (Figure 1Cb).
The immunofluorescence analysis of myogenin (Figure 1Da),
which is a later differentiation marker and is required
for terminal myogenic differentiation, revealed statistically
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FIGURE 2 | Follistatin is not sufficient to rescue myotube size in the presence of tumor-derived factors. (A) Quantification of activin (Aa) and follistatin (Ab) by ELISA
in 6d culture supernatant, in differentiation medium in the absence (HS) or presence (CM) of C26-conditioned medium, in combination with the absence (SC) or
presence (DC) of cyclic stretch. The follistatin/activin ratio was calculated (Ac). Two-way ANOVA showed: CM effect and a interaction with DC on activin levels;
interaction between CM and DC on follistatin levels; CM effect and interaction with DC on follistatin/activin ratio. #p < 0.05, ##p < 0.01 by Tukey HSD test. (B) WB
analysis for P-SMAD2/3 and SMAD 2/3 (Ba) and relative average density (Bb) following normalization over the GAPDH. Two-way ANOVA showed a significant effect
for DC (F = 6.25; df = 1; p < 0.05) and interaction of Dc with CM (F = 12.36; df = 1; p < 0.01). #p < 0.05, ##p < 0.01 by Tukey HSD test. (C) Immunofluorescence
for Myosin (green) and nuclei (blue) in C2C12 myotubes at 6d of culture (Ca) in differentiation medium in the absence (HS) or presence (CM) of C26-conditioned
medium and in CM supplemented with 100 ng/ml recombinant follistatin, in the absence of cyclic stretch (SC). The treatments were performed starting on 4d culture
and changing the medium daily. Morphometric analyses (Cb) were performed on replicate samples (n = 6). One-way ANOVA indicated a significant effect of
treatments on myotube diameter and on the number of nuclei/myotube. ∗∗p < 0.01 by Tukey HSD test.
significant, opposite effects of both CM and DC (Figure 1Db) on
the percentage of the myogenin positive nuclei.
Follistatin Is Sufficient to Rescue
Myogenic Differentiation but Not
Myotube Size in the Presence of
Tumor-Derived Factors
To assess the contribution of myokines and putative tumor-
derived factors on myotube size and myoblast recruitment, we
measured both activin and follistatin levels in the 6d culture
media. Worth noting, the C26 CM used throughout this work
contained 2800 ± 380 pg/mL activin (data not shown), implying
that, following a dilution to 20% in the culture medium, the
latter contained 590 ± 76 pg/mL activin of tumor origin
at the beginning of the treatments, i.e., on day 4 (data not
shown). Following 2 days in culture, activin concentration
decreased to 190 ± 18 pg/mL in control conditions (HS SC)
indicating a non-specific or myotube-mediated degradation or
internalization/absorption (Figure 2Aa); on the contrary, in the
presence of CM activin increased about 3 times, which suggests
an activin release from muscle cells (Figure 2Aa). In the DC
activin levels were significantly reduced, both in the absence
or presence of CM, even though they remained higher than in
unstimulated, control cultures (Figure 2Aa).
In order to better understand the novel finding of the release
of activin from muscle cells, we measured activin A expression
in the four culture conditions failing to see any statistically
significant difference, even though we noticed that activin
expression doubled in CM SC (Table 1); this suggests that activin
release from the myotubes could be partially dependent on activin
expression but mostly depends on post-translational events.
We also measured follistatin concentration in the four
conditions above and noticed that it significantly decreased in
the CM SC (Figure 2Ab), consistently with the physiological
role of follistatin as an activin-binding protein, and that its
level was rescued in the presence of mechanical stimulation,
i.e., DC. Worth noting, the CM and the DC have opposite,
significant effects on follistatin expression (Table 1), indicating
that the exposure to tumor-derived factors, including activin,
downregulates follistatin production in muscle cells, while the
mechanical stimulation rescues follistatin expression and release.
Since free activin binds to the activin receptor type-2B
(actRIIB) we could not exclude that mechanical stimulation
counteracted CM effects by affecting the actRIIB expression
as well. Therefore, we measured actRIIB receptor expression
in muscle cell cultures and we found a quasi-significant effect
of both CM and DC on its expression. In addition, we
found that mechanical stimulation interferes with the CM-
induced actRIIB expression increase, further contributing to
the myotube desensitization to activin (Table 1). Altogether,
these data suggest an adverse effect on myotubes of tumor cell-
and muscle-derived activin, which could be counteracted by
the mechanically stimulated secretion of follistatin by myotubes
(Figure 2A). Activin effects are further exacerbated by the
differential modulation of actRIIB by CM and DC (Table 1).
Given the pivotal role of actRIIB in mediating cachexia in vivo
(Zhou et al., 2010) and the negative effects of tumor-derived
TABLE 1 | Mechanical stimulation counteracts the negative effect of tumor-derived factors on P-SMAD transcriptional targets (MRF) and on Follistatin expression.
Gene HS SC CM SC HS DC CM DC ANOVA
ActRIIB 1.00 ± 0.36 5.35 ± 1.52 1.56 ± 0.51 0.99 ± 0.14 DC, CM QS interaction
Activin A 1.00 ± 0.30 2.02 ± 0.53 1.21 ± 0.38 1.18 ± 0.29 NS
Follistatin 1.00 ± 0.17 0.50 ± 0.09 1.77 ± 0.43 1.02 ± 0.25 DC and CM effects
Wnt4 1.00 ± 0.27 2.70 ± 0.74 1.58 ± 0.36 1.23 ± 0.27 interaction
MyoD 1.00 ± 0.09 0.44 ± 0.05 0.70 ± 0.15 0.66 ± 0.15 DC and CM effects interaction
Myogenin 1.00 ± 0.16 0.59 ± 0.08 0.97 ± 0.08 0.92 ± 0.11 DC and CM effects
Gene expression was assessed by Q-PCR in myotubes following 2d culture as indicated in the absence (HS) or presence (CM) of C26-conditioned medium, in combination
with the absence (SC) or presence (DC) of cyclic stretch. Gene expression is shown as fold induction in respect to control (HS SC), following normalization over GAPDH.
Data are shown as mean ± SEM of replicate samples (8 < n < 16). Two-way ANOVA significance is reported in the last column (ANOVA) and ANOVA results are reported
in parentheses for each gene, as follows: ActRIIB, activin Receptor IIB (for DC and for CM: Q.S.; interaction F = 8.67; df = 1; p < 0.01); activin A (NS); Follistatin (for DC:
F = 6.71; df = 1; p < 0.05; for CM: F = 6.09; df = 1; p < 0.05); Wingless-related integration site 4, Wnt4 (F = 4.74; df = 1; p < 0.05); MyoD (For DC: F = 12.58; df = 1;
p < 0.01; for CM: F = 6.85; df = 1; p < 0.05; interaction: F = 6.43; df = 1; p < 0.05); myogenin (for DC: F = 3.97; df = 1; p < 0.05; for CM: F = 4.42; df = 1; p < 0.05;
interaction: QS). NS and QS = not and quasi (p = 0.05) significant, respectively.
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factors on myotubes reported above, we aimed to confirm that
the ActRIIB signaling pathway was differentially activated by CM
and DC. Therefore, we measured SMAD2/3 activation (expressed
as P-SMAD2/3 over total SMADs, following normalization by the
housekeeping gene GAPDH, Figure 2Ba) and found consistent
results, i.e., SMAD2/3 activation by the CM and inhibition
by the DC (Figure 2Bb). To further confirm these results,
we analyzed SMAD2/3 transcriptional targets, including Wnt4
and, noticeably, the MRF MyoD and myogenin (Table 1). As
expected, a negative interaction was found between DC and CM
on Wnt4 expression: the latter was increased by the CM, albeit
not significantly (possibly a false negative result in this case);
in addition, a return to control levels was observed in the DC
(Table 1). As is known, SMAD2/3 transcriptional effects on MRF
are the opposite than those on Wnt4, since their expression is
inhibited by P-SMAD2/3: so, as expected and in line with the
protein levels shown in Figure 1, the CM significantly decreased
both MyoD and myogenin expression, while the DC restored
MyoD and myogenin expression to control levels (Table 1).
The correlation between a high follistatin/activin ratio and the
improvement of myogenesis prompted us to investigate whether
follistatin was sufficient to counteract CM effects upon myotubes.
To this purpose, we incubated myotube cultures in SC with CM in
the absence or presence of recombinant follistatin (Figure 2Ca).
While CM decreased myotube DIA and hampered FI and NpM
increase, follistatin rescued FI but failed to counteract CM effects
on DIA and NpM (Figure 2Cb). Worth noting, in a control
experiment recombinant follistatin alone was able to counteract
the adverse effects of recombinant activin upon myotube DIA
and FI, as a proof of concept of its inhibitory activity on activin
(Supplementary Figure S1).
DISCUSSION
Act receptor ligands are becoming increasingly important as
triggers of muscle wasting and as pharmacological targets to
treat cachexia. The myostatin-activin-SMAD cascade has been
shown to activate FOXO3a, a crucial activator of muscle-atrophy-
related gene expression (Mathew, 2011); ActRIIB antagonism
suffices to revert muscle wasting and prolong survival in animals
affected by cancer cachexia (Zhou et al., 2010). Additional
studies highlighted activin relevance to humans, since increased
circulating concentrations of activin may contribute to the
development of cachexia in cancer patients (Loumaye et al.,
2015). Here we showed that activin is present in the tumor-
conditioned medium, inducing myotube atrophy and inhibiting
the incorporation of myoblasts into nascent myotubes. We found
that a mechanical stimulation-dependent rescue of the myotube
size is indeed associated to an increase in the follistatin/activin
ratio, showing that this is an effective in vitro model to
identify beneficial muscle derived factors. In addition, CM
seems to promote the release of activin from myotubes -
inducing a vicious circle ultimately leading to myotube atrophy
and hampered myotube growth - while mechanical stretching
appears to diminish activin levels and increase the levels of the
activin inhibitor follistatin. However, follistatin per se is not
sufficient to fully revert CM negative effects, since recombinant
follistatin only rescues FI without affecting myotube size (both
in terms of diameter and recruitment of additional nuclei).
As a consequence, additional factors in the tumor CM control
FIGURE 3 | Proposed model of action of tumor-derived factors and
mechanical stimulation on myotubes and myoblasts. Mixed cultures of
myotubes and myoblasts mature in culture by increasing the diameter of
myotubes, the fusion index (i.e., myogenic differentiation tout court, including
the formation of novel myotubes) and the number of nuclei per myotube (i.e.,
myotube accretion by incorporation of myoblasts). C26 tumor-derived factors
include activin and induce further expression and release of activin as well as
a decrease of follistatin expression and its release by muscle cells, ultimately
leading to myotube atrophy, a block of myogenic differentiation and hampered
incorporation of myoblasts into myotubes. On the other hand, mechanical
stimulation counteracts the negative effects exerted by tumor-derived factors
on muscle cells by diminishing the levels of activin available to bind actRIIB:
this is obtained by reducing activin concentration in the medium and by
rescuing follistatin release by muscle cells. Recombinant activin (rActivin A)
mimics tumor CM and its effects are counteracted by recombinant follistatin
(rFollistatin). However, rFollistatin only partially counteracts CM: since, in the
presence of CM, follistatin rescues the fusion index but not myotube diameter
nor the number of NpM, while mechanical stimulation also reverts
CM-mediated effects on myotube size, follistatin is mostly responsible for the
regulation of myogenic differentiation, while mechanical stimulation preserves
myotube size through additional mechanisms. The signaling pathways
downstream of actRIIB involve the activation of SMAD2/3 transcriptional
activity, which is increased by tumor-derived factors and decreased by
mechanical stimulation, resulting in the regulation of MRF expression leading
to myoblast differentiation and fusion.
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myotube size and their negative effects are hampered by
mechanical stimulation independently of follistatin release from
myotubes. A model of the action of mechanical stimulation
combined with tumor-derived factors on the release of activin
and follistatin from myotubes is shown in Figure 3. In this
context, actRIIB plays a major role, since its expression does
not significantly change, through the activin-mediated SMAD2/3
transcriptional activity. The ratio between available activin and
follistatin is likely the major player in these responses, even
though the mechanisms underlying activin availability and the
inhibition of activin by follistatin remain to be elucidated.
In conclusion: (a) the development of novel activin-targeted
therapeutic approaches should consider the existence of further
significant tumor-secreted factors mediating cachexia, even
though activin plays a major role; (b) upon mechanical
stimulation myotubes activate other pathways in addition to
follistatin, which effectively counteract the adverse effect of
tumor-derived factors; (c) in particular, in the presence of
tumor-derived factors follistatin alone is not sufficient to recruit
additional cells (nuclei) toward the myotubes, even though it
increases the fusion index, representing the formation of new
myotubes. In vivo muscle acts as a secretory organ (Pedersen,
2013); our results suggest that the pleiotropic effects of exercise
are not limited to contraction-dependent endocrinological effects
and that pure mechanical stimuli have a direct and relevant effect
on muscle homeostasis.
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FIGURE S1 | (A) Immunofluorescence for Myosin (red) in C2C12 myotubes at 6d
of culture, following 2d of treatment with 10 ng/ml recombinant activin (rActivin),
25 ng/ml recombinant follistatin (rFollistantin) or both, with daily changes of
medium. (B) Morphometric analysis was performed on replicate samples (n = 7)
indicating a significant effect of both treatments and a negative interaction
between them. Two-way ANOVA showed: significant effects on myotube diameter
for activin (F = 7.72; df = 1; p < 0.05), follistatin (F = 4.35; df = 1; p < 0.05) and
an interaction of follistatin with activin (F = 7.91; df = 1; p < 0.01); significant
effects on fusion index for activin (F = 4.68; df = 1; p < 0.05), follistatin (F = 9.1;
df = 1; p < 0.01). #p < 0.05 ##p < 0.01 by Tukey HSD test. # p < 0.05 by Tukey
HSD test.
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The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway 
is a key intracellular mediator of a variety of metabolically relevant hormones and cytokines, 
including the interleukin-6 (IL-6) family of cytokines. The JAK/STAT pathway transmits 
extracellular signals to the nucleus, leading to the transcription of genes involved in multiple 
biological activities. The JAK/STAT pathway has been reported to be required for the 
homeostasis of different tissues and organs. Indeed, when deregulated, it promotes the 
initiation and progression of pathological conditions, including cancer, obesity, diabetes, 
and other metabolic diseases. In skeletal muscle, activation of the JAK/STAT pathway by 
the IL-6 cytokines accounts for opposite effects: on the one hand, it promotes muscle 
hypertrophy, by increasing the proliferation of satellite cells; on the other hand, it contributes 
to muscle wasting. The expression of IL-6 and of key members of the JAK/STAT pathway 
is regulated at the epigenetic level through histone methylation and histone acetylation 
mechanisms. Thus, manipulation of the JAK/STAT signaling pathway by specific inhibitors 
and/or drugs that modulate epigenetics is a promising therapeutic intervention for the 
treatment of numerous diseases. We focus this review on the JAK/STAT pathway functions 
in striated muscle pathophysiology and the potential role of IL-6 as an effector of the cross 
talk between skeletal muscle and other organs.
Keywords: IL-6 cytokine, JAK/STAT pathway, skeletal muscle, organ cross talk, epigenetics
INTRODUCTION
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway 
is a potent signaling cascade, evolutionarily conserved from flies to humans. It is upstream 
of multiple cellular activities such as proliferation, differentiation, migration, apoptosis, 
and cell communication or complex biological processes including inflammation, immune-
system development, immune response, and cancer (Darnell et  al., 1994; O’Shea et  al., 
2002, 2015; Bousoik and Montazeri Aliabadi, 2018). The JAK/STAT pathway was initially 
identified as responsive to interferon-gamma, although a variety of extracellular polypeptide 
signals and their transmembrane receptors were later found to activate it (Schindler et al., 1992; 
Heinrich et  al., 1998; Aaronson and Horvath, 2002; O’Shea and Plenge, 2012).
In mammals, four members of the JAK proteins (JAK1, JAK2, JAK3, and TYK2) and 
seven members of the STAT family (STAT 1–4, STAT 5A/B, and STAT 6) were identified. 
They all share structurally and functionally conserved domains. JAK/STAT proteins are 
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ubiquitously expressed, and different combinations of them 
respond to specific cytokines or growth factor signals, assuring 
a high degree of specificity with distinct in vivo roles 
(Aaronson and Horvath, 2002; Kisseleva et  al., 2002; 
Rawlings  et  al., 2004). The mechanism of IL-6/JAK/STAT 
signaling cascade allows a direct communication between 
transmembrane receptors and the nucleus and can 
be summarized by the following steps: IL-6, the ligand, binds 
the IL-6r-Gp130 receptor complex and activates the JAK 
tyrosine kinases recruited to the intracellular domains of 
their receptors. Once activated, JAK proteins change 
their  conformation, dimerize, phosphorylate, and activate 
their primary substrates, the STAT proteins. Tyrosine-
phosphorylated STAT proteins homo- or hetero-dimerize and 
translocate to the nucleus, where they interact with coactivators 
and bind to specific regulatory elements in the promoter 
regions of thousands of different target protein-coding genes, 
along with microRNAs and long non-coding RNAs. STAT 
activity is regulated by phosphorylation, acetylation, and 
methylation, promoting STAT dimer stabilization, DNA 
binding, interaction with transcriptional coactivators, and 
target gene expression (Zuang, 2013; Yu et al., 2014; Zimmers 
et al., 2016). A further level of control is provided by negative 
regulators of JAK/STAT signaling that guarantee a cytokine-
inducible feedback inhibition of signals from specific cytokine 
receptors (Greenhalgh and Hilton, 2001; Aaronson and 
Horvath, 2002; Linossi et  al., 2013). JAK/STAT signaling 
operates also in response to IL-6 trans-signaling. Indeed, a 
soluble form of IL-6 receptor (sIL-6R), comprising the 
extracellular portion of the receptor, binds to IL-6, and the 
IL-6–sIL-6R complex is able to bind to and activate gp130 
homodimers in cells which lack the membrane bound IL-6R 
(Kallen, 2002; Scheller et  al., 2006). Thus, the JAK/STAT 
signaling cascade provides a remarkable direct and tuned 
translation of extracellular signals into a transcriptional 
response in a vast range of cells.
Primarily identified as functioning in hematopoietic cells, 
the JAK/STAT signaling cascade has been found to play a 
critical role in different cell types and tissues, including skeletal 
muscle. As skeletal muscle contracts, it secretes several cytokines 
into the circulation and the JAK/STAT pathway mediates the 
signaling of many of the myokines secreted by skeletal muscle 
(Pedersen and Febbraio, 2008; Hoffmann and Weigert, 2017).
Here, we  will review the IL-6/JAK/STAT signaling cascade 
in myogenesis and skeletal muscle pathophysiology, focusing 
on its dichotomic role in myogenic cell proliferation and 
differentiation, as well as in muscle growth and muscle wasting. 
We  will also discuss some examples of cross talk 
between muscle and other tissues. Finally, we  will examine 
IL-6/JAK/STAT activity regulation, emphasizing the 
epigenetic mechanisms.
IL-6/JAK/STAT SIGNALING CASCADE IN 
SKELETAL MUSCLE
It is now widely accepted that through IL-6 family signals, 
the JAK/STAT pathway is required for efficient muscle fiber 
adaptation during development and regeneration. It was proposed 
that different combinations of the JAK/STAT pathway members 
have opposite effects on muscle differentiation and myogenesis. 
Indeed, the JAK1/STAT1/STAT3 axis promotes myoblast 
proliferation, preventing the premature differentiation into 
myotubes. Conversely, JAK2/STAT2/STAT3 induces myogenic 
differentiation, suggesting that other intracellular ligands act 
on JAK/STAT factors, to obtain distinct cellular responses at 
each step during development and myogenesis (Sun et  al., 
2007; Wang et  al., 2008; Jang and Baik, 2013; Muñoz-Cánoves 
et  al., 2013). Several studies demonstrated a role of the JAK/
STAT pathway in regulating the myogenic progression of adult 
satellite cells (MuSCs), a population of cells that play a 
fundamental role in skeletal muscle postnatal growth and repair 
upon injury. MuSCs from IL-6 KO mice showed decreased 
proliferative capacity, both in vivo and in vitro. This impairment 
was caused by a lack of IL-6-mediated activation of STAT3 
signaling. STAT3 induces the transcription of downstream genes 
involved in several biological functions, including myoblast 
proliferation, differentiation, and survival (Serrano et  al., 2008; 
Toth et al., 2011). More recently, it has been shown that STAT3 
knock-down (elicited by transient pharmacological or siRNA 
inhibition) in MuSCs, induced their expansion upon regeneration, 
but inhibited their differentiation, thus impairing muscle 
regeneration. Moreover, repeated intermittent administration 
of a STAT3 inhibitor in mdx mice, determined a sustained 
expansion of MuSC, contributing to an overall improvement 
in skeletal muscle repair (Tierney et  al., 2014). Elsewhere, it 
was described that JAK2 or STAT3 KO in isolated MuSCs 
and pharmacological inhibition in vivo promoted symmetric 
satellite cell division and markedly improved their homing 
and repairing ability when transplanted into regenerating muscle 
(Price et al., 2014). However, different evidences were described 
when STAT3 depletion was investigated specifically by genetic 
deletion in MuSCs of mdx mice. By this approach, a progressive 
reduction of MuSC accompanied with aggravated fibrosis and 
muscle inflammation was observed. Then, a permanent knockout 
of STAT3 and a direct and long-term treatment with STAT3 
inhibitors, which causes a gradual depletion of MuSCs, might 
have adverse effects on MuSCs and regeneration in DMD 
patients (Zhu et  al., 2016), in contrast with other approaches 
such as transient inhibition by chemical inhibitors or siRNA, 
shown elsewhere (Price et  al., 2014; Tierney et  al., 2014). It 
may be  speculated that transient and periodic reduction of 
STAT3  in cellular component of the MuSC niche, such as 
macrophages or fibro/adipogenic progenitors, known for playing 
an essential role in muscle regeneration (Bentzinger et  al., 
2013), is responsible for the beneficial effects observed in 
dystrophic muscle. Alternatively, IL-6 downstream effectors 
other than STAT3 could be  active in MuSC in promoting 
muscle regeneration. Nevertheless, studies demonstrated that 
IL-6-mediated immunological responses may promote additional 
Abbreviations: AT, Adipose tissue; C/EBPδ, CCAAT/enhancer binding protein; 
DMD, Duchenne muscular dystrophy; DNMT, DNA methyltransferase; FAP, 
Fibro-adipogenic progenitors; FoxO,  Forkhead box; IL-6, Interleukin 6; JAK, Janus 
kinase; MAFbx, Muscle atrophy F-box; MuRF, Muscle RING finger; MuSC, Muscle 
satellite cell; sIL-6R, Soluble interleukin 6 receptor; STAT, Signal transducer and 
activator of transcription; UPS, Ubiquitin proteasome system.
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muscle fiber damage under conditions of dystrophin deficiency 
in mdx mice (Pelosi et  al., 2015). Accordingly, IL-6 receptor 
blockade with the anti-IL-6 receptor antibody attenuated muscular 
dystrophy via promoting skeletal muscle regeneration in mdx 
and dystrophin-/utrophin-deficient mice (Pelosi et  al., 2015; 
Wada et  al., 2017).
IL-6/JAK/STAT pathway mediates increased proliferation of 
MuSC in other conditions such as acute exercise. Indeed, in 
a model of increasing mechanical loading, muscle hypertrophy 
resulted attenuated in IL-6 KO mice, due to an impaired MuSC 
proliferation and migration (Serrano et  al., 2008). Moreover, 
mRNA expression for STAT3 target genes that regulate MuSC 
proliferation, migration, and differentiation was reduced (Serrano 
et  al., 2008). Acute resistance exercise and resistance training 
activate the IL-6/STAT1/STAT3 signaling pathway in rat skeletal 
muscle (Begue et  al., 2013) and in human (Trenerry et  al., 
2007, 2011), suggesting a potential role for STAT3  in the 
adaptive growth of skeletal muscle mediated by MuSCs. 
Nevertheless, more recent studies in human muscle biopsies 
and in STAT3 KO murine model concluded that STAT3 localized 
to the MuSCs is not required in load-induced skeletal muscle 
hypertrophy (Amorese and Spangenburg, 2017; Perez-Schindler 
et  al., 2017). The cause of this contradictory evidence may 
be  related to the methods for inducing hypertrophy and to 
the cell types where STAT3 activation occurs. Indeed, STAT3 
activation in immune cells or other cells resident in skeletal 
muscle may also play significant roles in regulating muscle 
responses to exercise training (van de Vyver et  al., 2016).
While sudden and acute induction of the IL-6 cascade 
promotes muscle growth, IL-6 sustained and elevated release 
and STAT3 activation have been associated with muscle atrophy 
occurrence in several catabolic conditions, such as obesity, 
diabetes, and age-induced sarcopenia or cancer (Zimmers et al., 
2016). IL-6 overexpression in transgenic mice caused muscular 
atrophy, though entirely reversed by treatment with the membrane 
IL-6 receptor antibody (Tsujinaka et  al., 1996). Interestingly, 
the negative role of IL-6  in the control of muscle mass was 
initially demonstrated using animal models of inflammation 
and cancer-associated cachexia. Cachexia is a muscle wasting 
syndrome accompanying many acute and chronic diseases, 
including cancer (Fearon et  al., 2012; He et  al., 2013; Argiles 
et al., 2014; Pigna et al., 2016). In cachexia experimental models, 
STAT3 expression is induced and correlates with increased 
expression of skeletal muscle ubiquitin E3 ligases. STAT3 
dominant negative activity blocked the skeletal muscle loss 
downstream of IL-6, partly by inhibiting the activity of the 
ubiquitin proteasome system (UPS), in vitro and in vivo 
(Baltgalvis et  al., 2009; Bonetto et  al., 2011, 2012). Coherently, 
treatment with neutralizing antibodies prevented the increase 
of IL-6 concentration, exerting a protective effect on body 
weight loss in cachectic mice and blocking STAT3 activation 
reduced muscle wasting (Strassmann et  al., 1992; Oldenburg 
et al., 1993; Haddad et al., 2005; Zimmers et al., 2016). Moreover, 
treatment of cachectic mice with pharmacological inhibitors 
of the JAK/STAT pathway components, partially prevented 
muscle mass loss (Gilabert et  al., 2014; Pretto et  al., 2015; 
Silva et  al., 2015). JAK/STAT pathway activation is responsible 
for muscle atrophy by several potential mechanisms. In cachexia 
and chronic kidney disease models, both of which exhibit 
muscle mass loss, STAT3 initiated muscle wasting by stimulating 
CCAAT/enhancer binding protein (C/EBPδ) expression and 
activity, which in turn increased myostatin, MAFbx/Atrogin-1, 
and MuRF-1 expression in myofibers (Zhang et  al., 2013). 
Direct UPS activation can be  mediated by STAT3 or indirectly 
via caspase-3 activation (Silva et  al., 2015) or dependent on 
FoxO transcription factors (Hutchins et  al., 2013; Judge et  al., 
2014). Cachexia has been also associated with posttranslational 
modifications of JAK/STAT3 components, such as increased 
muscle phospho-Y705-STAT3 and increased STAT3 localization 
in myonuclei (Bonetto et  al., 2011). Muscle catabolic profile 
may also be  caused by the reduction in ribosomal protein 
kinase S6K1 phosphorylation and the increase of SOCS3 
transcription, an inhibitor of the JAK/STAT pathway (Haddad 
et  al., 2005). Nevertheless, others found that IL-6 does not 
stimulate muscle loss per se (Baltgalvis et  al., 2008), thus 
supposing that other cytokines activate JAK/STAT, which triggers 
skeletal muscle proteolysis (Zhang et  al., 2013). More recently, 
it was also shown that IL-6 trans-signaling works as a novel 
potent inducer of autophagy in myotubes inducing pathway 
that may be important in cancer cachexia development (Pettersen 
et al., 2017). Furthermore, IL-6 trans-signaling/STAT3 axis was 
identified as a therapeutic target in advanced cancer patients 
presenting cachexia (Miller et  al., 2017).
In the muscle microenvironment, a JAK/STAT pathway 
contribution in catabolic conditions can be considered in relation 
to its role in promoting the expansion of the satellite cell pool 
in vitro and in vivo, impairing differentiation and muscle repair 
(He et  al., 2013; Muñoz-Cánoves et  al., 2013; Price et  al., 
2014; Tierney et  al., 2014; Sala and Sacco, 2016; Zhu et  al., 
2016). Other than activation of STAT3  in MuSCs, secreted 
and elevated IL-6 levels and persistent STAT3 activation were 
observed in atrophic conditions in the fibro/adipogenic 
progenitors (FAPs), a population of cells resident in skeletal 
muscle, fundamental for muscular regeneration and inducible 
source of IL-6 (Joe et  al., 2010; Madaro et  al., 2018). IL-6/
STAT3 signaling inactivation in FAPs counteracted muscle 
atrophy and fibrosis in mouse models of acute denervation 
and amyotrophic lateral sclerosis (ALS) (Gurney et  al., 1994). 
This suggests an alternative IL-6/JAK/STAT-mediated mechanism, 
which induces muscle mass loss and represents a possible 
therapeutic target for neurogenic atrophy diseases (Madaro 
et  al., 2018; Marazzi and Sassoon, 2018).
Altogether, the autocrine and paracrine action of the IL-6/
JAK/STAT pathway on skeletal muscle has opposite effects on 
satellite cells differentiation and proliferation, hence on muscle 
homeostasis. Moreover, it causes both deleterious (pro-atrophy) 
and beneficial (pro-repair and pro-growth) effects on muscle 
fiber size (Figure 1). The balance between these opposite 
outcomes may depend on the fine tuning of the JAK/STAT 
pathway. This effect can be  mediated by the interaction of the 
JAK/STAT molecular effectors with the myofibers or with the 
multiple cell types of the muscle niche. Further studies will 
provide new insights to elucidate the molecular mechanism 
underlying this complex regulation.
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IL-6 AS A MEDIATOR OF THE CROSS 
TALK BETWEEN SKELETAL  
MUSCLE AND OTHER ORGANS
Progressive discovery of new myokines by application of new 
technologies contributed to the definition of the muscle secretome 
and to provide new insights regarding their therapeutic potential 
in the treatment of obesity, metabolic disease, and cancer 
(Whitham and Febbraio, 2016).
IL-6 was the first cytokine to be  proposed as a myokine 
(Pedersen et al., 2003), and the first myokine found to be secreted 
during exercise, playing important roles in regulating the 
metabolism of other organs (Goldstein, 1961). One of the main 
paracrine functions of IL-6 is to lead to an increase in hepatic 
glucose production, which works as an energy source for 
contracting muscles (Febbraio et  al., 2004). Furthermore, during 
exercise, skeletal muscle performs also an “energy sensing” role, 
affecting some metabolic processes and, through IL-6, mediates 
the cross talk with insulin-sensitive tissues. By activation of 
AMP-activated protein kinase (AMPK) and/or PI3-kinase, IL-6 
leads to enhanced glucose uptake, lipolysis and fatty acid oxidation, 
which provide energy from skeletal muscle (Keller et al., 2001; 
Al-Khalili et al., 2006). Moreover, IL-6/JAK/STAT plays also a 
major role in mediating communication between skeletal muscle 
and pancreas, enhancing glucose tolerance by activating glucagon-
like peptide 1 (GLP1) in pancreatic islets. This allows adaption 
to changes in insulin demand, reduction of food intake and 
body weight, though having a role in improving metabolic 
homeostasis in obesity and type 2 diabetes (Bouzakri et al., 
2011; Plomgaard et al., 2012; Ellingsgaard et al., 2015).
A direct cross talk between muscle tissue and adipose tissue 
(AT) occurs in obese mice. In this condition, subcutaneous 
adipose tissue does not contribute to IL-6 secretion during 
exercise, so the increased IL-6 produced following prolonged 
exercise probably derives from skeletal muscle (Eder et  al., 
2009). In fact, obese mice exposed to acute exercise showed 
an IL-6 induction, accompanied by increase in STAT3 
phosphorylation, reduction in M1 macrophages, and 
inflammation in infiltrates in AT (Macpherson et  al., 2015).
Skeletal muscle-derived growth factors and cytokines have 
a critical role in maintaining the cardiovascular system. The 
trophic cascade initiated by skeletal muscle JAK/STAT3 signaling 
increases growth factor levels in multiple tissues, leading to 
elevated circulating HGF and VEGF. Their synergistic actions 
FIGURE 1 | Diagram showing the main paracrine and dichotomic autocrine functions of the IL-6/JAK/STAT3 pathway in the pathophysiology of skeletal muscle. 
Skeletal muscle physiological contraction induces IL-6 release (black arrows), with paracrine effects on other organ metabolism. Upon injury or in DMD, IL-6 is 
released (orange arrows) following the inflammatory response and IL-6/JAK/STAT pathway promotes muscle repair by activating pro-myogenic genes (such as 
MyoD) that allow MuSC differentiation and fusion into new or existing myofibers. In catabolic conditions, IL-6 levels are elevated (red arrows) and induce muscle size 
loss, by activation of different pro-atrophic pathways in myofibers. In neurogenic atrophy, FAPs activate the IL-6/JAK/STAT pathway. In response to acute exercise, 
IL-6 is highly produced (blue arrows) and IL-6/JAK/STAT pathway is activated, inducing pro-proliferation and pro-fusion genes that control contribution of MuSC to 
myofiber growth. In the box, the IL-6/JAK/STAT3 signaling model is shown. IL-6 binds the IL-6r-Gp130 receptor complex and activates the JAK tyrosine kinases. 
Once activated, JAK proteins dimerize, phosphorylate, and activate their primary substrates, the STAT proteins. Phosphorylated STAT proteins dimerize and 
translocate to the nucleus, where they activate different target protein-coding genes.
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further activate the myocardial repair mechanisms orchestrated 
by PI3K-AKT, ERK (Shabbir et  al., 2010). The cardioprotective 
events of the IL-6/JAK/STAT3 apparently contradict its activity 
in promoting skeletal muscle wasting, underlying the multiple 
role of JAK-STAT3 signaling in different tissues.
It is known that the myokines mediate direct communication 
from skeletal muscle to bone. Elevated IL-6 induces bone loss 
in IL-6 KO mice (De Benedetti et  al., 2006) and is a systemic 
mediator of the bone loss in dystrophy. In this context, elevated 
levels of IL-6 produced by inflamed skeletal muscle induce 
osteoclast increase, which can be  reduced by treatment with 
an anti-IL-6 antibody (Rufo et  al., 2011). Interestingly, IL-6, 
by affecting the functions of liver, fat, and intestine, induces 
secretion of hepatokines and adipokines to regulate bone 
formation and bone resorption (Rufo et al., 2011; Guo et al., 2017).
Collectively, these data show that IL-6 produced by contracting 
skeletal muscle plays important roles in regulating metabolism 
in other organs (Figure 1). Hence, lack of physical activity 
appears to affect a whole network of organs such as liver, 
pancreas, fat, and bone. From this perspective, the IL-6/JAK/
STAT pathway is nodal in novel therapeutic approaches for 
the preventive treatment of diseases including cardiovascular 
diseases, type 2 diabetes, cancer, and osteoporosis.
EPIGENETIC CONTROL OF  
IL-6/JAK/STAT PATHWAY
Considering that IL-6 mediates cellular response to stress or 
metabolic changes, it is not surprising that the IL-6 pathway 
is also modulated at the epigenetic level, at least by two main 
mechanisms, i.e., DNA methylation and histone modifications 
(Figure 2A). IL-6 gene transcription itself is directly modulated 
by histone acetylation and methylation in macrophages and 
in cancer cell lines (Lee et  al., 2011; Zhang et  al., 2015; Hu 
et  al., 2016; Serresi et  al., 2016; Chen et  al., 2018). Moreover, 
an association between IL6/JAK/STAT DNA altered methylation 
and depression has been recently described (Ryan et  al., 2017). 
JAK and STAT gene hypomethylation might also exert influences 
on erythroid lineage choice by specifically upregulating 
erythropoiesis transcription factors (Liu et  al., 2017). In B cells 
activating pathway, the lysine-specific histone methyltransferase 
KMT2D affected H3K4 methylation and expression of a specific 
set of JAK-STAT genes (Figure 2B; Ortega-Molina et al., 2015).
Interestingly, IL-6 signaling modulates or cooperates with 
epigenetic mechanisms in regulating chromatin accessibility in 
tumorigenesis and development (Figure 2C). For instance, IL-6 
promotes hypermethylation of the miR142-3p promoter in 
glioblastoma cells and of certain tumor suppressor genes in 
oral squamous cell carcinoma (Gasche et al., 2011; Chiou et al., 
2013). IL-6-induced hypermethylation and gene silencing are 
mediated by DNA methyltransferases (DNMTs). IL-6 contributes 
to tumor growth by increasing DNMT expression and 
epigenetically repressing tumor suppressor genes or several 
microRNA in cancer cell lines (Hodge et  al., 2005; Zhang 
et  al., 2005, 2006; Braconi et  al., 2010; Takeuchi et  al., 2015). 
IL-6 also promotes DNA methylation of the promoter-bound 
STAT3, leading to a decrease in STAT3 DNA binding in human 
colon cancer cells (Yang et  al., 2010), or of the Foxp3 gene, 
thus influencing regulatory T cell development (Lal et al., 2009). 
T cells differentiation is also regulated by STAT3-dependent 
histone trimethylation at target gene loci (Durant et  al., 2010).
STAT proteins have also been implicated in epigenetic switches 
involving somatic cell and metabolic reprogramming, inflammation, 
and transformation. JAK/STAT3 activity plays a fundamental 
role in facilitating DNA demethylation/de novo methylation to 
complete reprogramming of pre-iPSC (Tang et  al., 2012). Both 
STAT3 and STAT5 mediate trans-activation and epigenetic 
remodeling of IL-10 through their interaction with the histone 
acetyltransferase p300  in lupus T cells (Hedrich et  al., 2014). 
Furthermore, STAT proteins can recruit and form a repressor 
complex with either the histone methyltransferases, or with NCoR 
associated with histone deacetylases, repressing the transcription 
of genes or microRNA promoters (Nakajima et al., 2001; Litterst 
et  al., 2003; Wang et  al., 2004; Mandal et  al., 2011; 
Chang et  al., 2015).
To date, no evidence about the epigenetic control of IL-6 
pathway has been reported in skeletal muscle. Identification 
of the epigenetic mechanisms regulating IL-6 gene expression, 
or the expression of the IL-6 pathway downstream effectors, 
as well as STAT protein interaction studies in specific muscle 
cell types or during muscle differentiation and their effects 
on muscle cell biology remain puzzling.
CONCLUSION AND PERSPECTIVES
The IL-6/JAK/STAT signaling cascade plays a dominant role 
in skeletal muscle pathophysiology. IL-6 autocrine, paracrine, 
and endocrine functions assign to its downstream effectors 
pivotal importance in skeletal muscle-wasting-associated diseases 
and other multiple system diseases where muscle acts in 
communication with other organs. Targeting the components 
of the JAK/STAT pathway recently emerged as a strategic 
approach for the treatment of inflammatory diseases and 
human cancer.
This review highlights the opposite outcomes on muscle 
biology caused by the amount of local and systemic release 
of IL-6. Transient release and short-term acute action have 
positive effects, by increasing the source of progenitors for 
regeneration and growth in skeletal muscle. This also affects 
metabolic processes in other organs, since it stimulates glucose 
production. In different circumstances, chronically elevated levels 
of IL-6 have negative consequences, promoting muscle atrophy 
through different mechanisms not completely yet elucidated. 
These antithetical effects can also be  a key to the several 
discrepancies observed with different experimental approaches 
aimed to decipher the IL-6/JAK/STAT role in skeletal muscle 
functions. Moreover, the different cell and tissue compartments 
where IL-6 is produced and acts can account for the conflicting 
effects observed on muscle repair, growth, and wasting. 
Additionally, a role in these dichotomous outcomes can also 
be carried out by the combined action of the IL-6 trans-signaling, 
which is pro-inflammatory and the classic IL-6 signaling via 
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FIGURE 2 | (A) DNA methylation and histone modifications are involved in epigenetic modulations of IL-6/JAK/STAT pathway members. They induce chromatin 
conformational transitions, altering accessibility of the transcriptional machinery (transcriptional active chromatin—blue arrow; transcriptional inactive chromatin – red 
arrow). DNA methylation is a process by which methyl groups are added to the cytosine of the DNA molecule and acts to repress gene transcription. Histone 
acetylation transfers acetyl groups to the histones and increases gene expression. Histone deacetylation removes acetyl groups from histones, allowing the histone 
to wrap more tightly the DNA and preventing transcription. Histone methylation adds methyl groups to the amino acids of the histones. Methylation of histones can 
either increase (i.e., H3K79, H3K4) or decrease (i.e. H3K9, H3K27) gene transcription. (B) Epigenetic modifications of IL-6/JAK/STAT pathway member genes that 
lead to gene repression (red) or gene activation (blue). (C) Epigenetic switches involving IL-6/JAK/STAT pathway members that lead to gene repression (red) or gene 
activation (blue) in tumorigenesis and development.
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the membrane bound IL-6R, which instead is needed for 
regenerative or anti-inflammatory activities of the cytokine 
(Scheller et  al., 2011; Rose-John, 2012; Belizário et  al., 2016).
Development of specific inhibitors or neutralizing antibodies 
against IL-6/JAK/STAT pathway factors may be  proposed for 
diseases that cause muscle wasting, including DMD, cancer 
cachexia, and diabetes. Indeed, many studies demonstrated that 
they could ameliorate muscle wasting in mice (Zhang et  al., 
2013; Pretto et  al., 2015; Silva et  al., 2015). Nevertheless, they 
can act by nonspecific mechanisms and on cells and tissues 
other than myofibers.
In the light of this evidence, any therapeutic approach for 
skeletal muscle-wasting diseases targeting IL-6/JAK/STAT 
pathway should ideally consider the rate and the site of IL-6 
production, in order to promote the benefits and avoid the 
detrimental effects.
Future studies on the mechanisms of action underlying the 
IL-6/JAK/STAT signaling cascade will provide new insights to 
tailor therapeutic strategies for each physiopathological condition. 
Further investigation of epigenetic mechanisms regulating and 
involving IL-6/JAK/STAT signaling cascade may identify 
epigenetics modification of IL-6 and its effectors as biomarkers 
of several diseases. Moreover, the IL-6/JAK/STAT molecular 
factors may represent new targets of the evolving epigenetics 
therapies directed to systemic pathologies and neuromuscular 
diseases, where combinations of epigenetic modulators may 
provide a tool to discriminate among alternative therapeutic effects.
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Eccentric contractions, characterized by the lengthening of the muscle-tendon complex,
present several unique features compared with other types of contractions, which may
lead to unique adaptations. Due to its specific physiological and mechanical properties,
there is an increasing interest in employing eccentric muscle work for rehabilitation and
clinical purposes. However, unaccustomed eccentric exercise is known to cause muscle
damage and delayed pain, commonly defined as “Delayed-Onset Muscular Soreness”
(DOMS). To date, the most useful preventive strategy to avoid these adverse effects
consists of repeating sessions involving submaximal eccentric contractions whose
intensity is progressively increased over the training. Despite an increased number
of investigations focusing on the eccentric contraction, a significant gap still remains
in our understanding of the cellular and molecular mechanisms underlying the initial
damage response and subsequent adaptations to eccentric exercise. Yet, unraveling
the molecular basis of exercise-related muscle damage and soreness might help
uncover the mechanistic basis of pathological conditions as myalgia or neuromuscular
diseases. In addition, a better insight into the mechanisms governing eccentric training
adaptations should provide invaluable information for designing therapeutic interventions
and identifying potential therapeutic targets.
Keywords: skeletal muscle, eccentric contraction, exercise-induced muscle damage (EIMD), delayed-onset
muscle soreness (DOMS), eccentric muscle training
INTRODUCTION
An eccentric (lengthening) muscle contraction occurs when a force applied to the muscle exceeds
the momentary force produced by the muscle itself, resulting in the forced lengthening of the
muscle-tendon system while contracting (Lindstedt et al., 2001). During this process, the muscle
absorbs energy developed by an external load, explaining why eccentric action is also called
“negative work” as opposed to concentric (shortening) contraction or “positive work” (Abbott et al.,
1952). Although not always obvious, eccentric muscle contractions are an integral part of most
movements during daily or sport activities. Skeletal muscles contract eccentrically to support the
weight of the body against gravity and to absorb shock or to store elastic recoil energy in preparation
for concentric (or accelerating) contractions (LaStayo et al., 2003b). The slowing-down role of such
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contractions is classically illustrated by downhill running or
walking down the stairs during which the eccentric work of the
knee extensor muscles is accentuated (Gault and Willems, 2013).
Compared to concentric or isometric (constant length)
contractions, eccentric muscle actions possess several unique
features that may be responsible for unique adaptations (Guilhem
et al., 2010; Duchateau and Baudry, 2014). Greater forces
are generated during eccentric contraction compared to other
contraction types for a given angular velocity (Hortobagyi and
Katch, 1990). In addition, eccentric contractions require less
motor unit activation and consume less oxygen and energy
for a given muscle force than concentric contractions (Abbott
et al., 1952). Indeed, the metabolic cost required for eccentric
exercise is approximately fourfold lower than for the same
exercise performed concentrically. Reduced cardiorespiratory
and hemodynamic responses have been reported following
eccentric exercise when compared to concentric exercise at
the same absolute workload (Overend et al., 2000; Meyer
et al., 2003). While many questions remains unanswered,
it is well accepted that neural strategies controlling eccentric
contractions considerably differ from concentric or isometric
contractions (Duchateau and Baudry, 2014). Differences are
detected on the level of the contracting muscle as well as
on the cortical level. Most studies indicate a reduced central
activation (evidenced by a lower EMG amplitude) during
maximal eccentric contractions than maximal concentric or
isometric contractions. This has implications on eccentric
coordination: fine motor control in eccentrically biased actions
appears more difficult as fewer motor-units are required for the
same work (Hoppeler, 2016). The twitch interpolation technique
also revealed a greater voluntary deficit in eccentric compared
to concentric contractions, such that untrained individuals are
usually unable to fully activate their muscles during maximal
eccentric muscle contractions. Further characteristics of eccentric
contraction are a greater cortical excitability but a lower motor
units discharge. Collectively, the mechanisms underpinning the
unique features of eccentric contraction are not well understood
(Hoppeler and Herzog, 2014).
Due to its specific physiological and mechanical properties,
the eccentric contraction has gained a growing interest in several
fields. Besides its interest in sport training or in physical medicine
and rehabilitation (Croisier et al., 2002; Kjaer and Heinemeier,
2014; Vogt and Hoppeler, 2014), evidence is accumulating
regarding the benefits of eccentric exercise in special populations
of aged individuals or patients with chronic health diseases
such as neuromuscular pathologies (Roig et al., 2008; Gault and
Willems, 2013; Isner-Horobeti et al., 2013; Hyldahl and Hubal,
2014). Indeed, the two main defining properties of eccentric
contraction “highest forces and lower energy requirement” makes
this contraction regime a judicious alternative to conventional
muscle training. To date, it is well accepted that the benefits
of eccentric exercise transcend improved muscle function,
as this mode of training has been shown to induce a number
of favorable repercussions on neural drive or health-related
factors (Paschalis et al., 2010, 2013). For many years, eccentric
regime has been largely used in sport training to improve
maximal muscular strength, power as well as coordination during
eccentric tasks. Robust evidence support its wide prescription
in the sport rehabilitation field, notably in the treatment
of tendinopathies (Croisier et al., 2007; Kaux et al., 2013).
In addition, implementing eccentric exercise in athletes showed
its effectiveness to prevent sport injuries such as hamstring strain
(Croisier et al., 2002). While research has mainly focused on
the functional outcomes following eccentric resistance training
using high-loads, the potential of low/moderate load regimes
received much attention over the last decade (LaStayo et al.,
2014; Hoppeler, 2016). With the increasing consideration of
the physical activity in numerous medical fields over the last
decades, a novel training modality based on low to moderate load
ECC exercise has emerged. This modality, referred as RENEW
(Resistance Exercise via Eccentric Work) by LaStayo et al. (2014),
appears to result in similar gains in muscle strength and volume
as traditional strength training. Since eccentric modality provides
a strong mechanical stress at a lower metabolic cost (Lastayo et al.,
1999), it appears particularly suitable for training individuals with
medical conditions associated to muscle wasting and reduction
in muscle strength, mobility and aerobic capacity (Hoppeler,
2016). Eccentric training is increasingly proposed to patients
with cardiorespiratory problems, sarcopenia of old age, cachexia,
diabetes type 2, neurological and musculoskeletal diseases (Julian
et al., 2018). Along with the positive effects on the muscle
function, aerobic eccentric exercise induces specific effects on
muscle energetic metabolism, insulin resistance and blood lipid
profile, reducing disease risks. It is thus recognized as a promising
lifestyle factor to combat obesity and dyslipidemias (Paschalis
et al., 2010; Julian et al., 2018, 2019).
However, despite the above-mentioned advantages, the use
of eccentric exercise in clinical conditions has been frequently
the object of contrasting opinions, because of its potential
undesirable associated effects. Indeed, eccentric exercise induces
greater muscle damage and negative functional consequences in
an healthy naïve muscle than other types of exercise (Friden and
Lieber, 1992). Indeed, the combination of high force and reduced
recruitment of fiber number during eccentric contractions
causes a high mechanical stress on the involved structures that
may lead to focal microlesions of the muscle fibers (Lieber
and Friden, 1999). Numerous histological studies described
widespread Z-line streaming with myofibrillar disruption and
necrosis following intense and/or unaccustomed eccentric
exercise (Friden and Lieber, 1998; Crameri et al., 2007; Lauritzen
et al., 2009). The sarcomeric disorganization has been associated
with disruptions to the sarcolemma and the extracellular
matrix, swelling of mitochondria, dilation of the transverse
tubule system and fragmentation of the sarcoplasmic reticulum
(Takekura et al., 2001; Crameri et al., 2004). Sarcolemmal
disruption may be highlighted by the appearance of sarcoplasmic
proteins into the blood (as creatine kinase, CK and myoglobin,
Mb) or by the cytoplasmic accumulation of proteins that
are normally not present in muscle fibers (as albumin and
immunoglobulins) (McNeil and Khakee, 1992; Clarkson and
Hubal, 2002). Vital dye such as Evans blue is also used in
rodents to demonstrate increased sarcolemmal permeability
(Hamer et al., 2002). Damage to extracellular matrix and
connective tissue components also occur following a novel
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eccentric exercise (Brown et al., 1997; Crameri et al., 2007).
Morphological abnormalities observed immediately after exercise
gradually extent to a larger number of muscle fibers and appear
exacerbated 2–3 days post-exercise (Friden et al., 1983a). These
observations have led authors to define primary and secondary
damage phases (Morgan and Allen, 1999). Both human and
animal studies supported that Type II (in particular IIb) muscle
fibers are more damaged after eccentric exercise than Type I fibers
(Friden et al., 1983b; Jones et al., 1986; Lieber and Friden, 1988).
Several hypotheses could explain the higher susceptibility of Type
II fibers to exercise-induced muscle damage (EIMD). Among
these are differences in their structural composition (Z-line, fiber
type specific protein isoforms such as titin), a reduced oxidative
capacity, a lower ability to regulate calcium homeostasis or a
selective recruitment of fast-twitch muscle fibers during eccentric
contraction (Lieber and Friden, 1999; McHugh et al., 1999a;
Byrne et al., 2004).
The EIMD manifests itself by a range of clinical symptoms
including delayed-onset muscle soreness (DOMS), stiffness,
swelling and various functional deficits such as a loss in
force generating capacity or decreased proprioceptive function
(Clarkson, 1992). To avoid the invasive nature of muscle
biopsies, these clinical manifestations as well as the plasma CK
activity are frequently used to indirectly assess the presence
of muscle damage (Warren et al., 1999; Clarkson and Hubal,
2002). The magnitude of changes in EIMD indirect markers
(in particular, the plasma CK activity) shows a marked inter-
individual variability even when subjects are submitted to
standardized eccentric protocols (Clarkson et al., 1992; Nosaka
and Clarkson, 1996; Hody et al., 2013c). Multiple factors as
muscle architecture, muscle typology, individual fitness, age, sex,
and genetic variability may contribute to the wide inter-subject
variability in the response to eccentric exercise (Vincent and
Vincent, 1997; Clarkson and Hubal, 2002; Yamin et al., 2007;
Hody et al., 2009; Hyldahl and Hubal, 2014). Even if DOMS
and associated clinical symptoms spontaneously disappear after
few days, these negative consequences can delay or disturb
rehabilitation and/or training programs. Exercise is necessary to
maintain a good health and to prevent physical inactivity-related
diseases, but unpleasant sensations resulting from unaccustomed
exercise can discourage people to continue physical activity.
Moreover, due to the mechanical fragility, the risk of further
injuries (e.g., muscle tears or ligament rupture) increases if
intense physical activities are performed during a DOMS episode
or the following days (Nicol et al., 2006). It is worth noting that
muscle soreness disappears before the full recovery of muscle
function, further elevating the injury incidence (Strojnik et al.,
2001). Although exceptional, extreme CK and Mb elevations
associated with EIMD could be severe enough to provoke a
kidney tubulopathy (Sayers et al., 1999).
Given the risks and drawbacks related to the occurrence
of EIMD described above, the development of strategies to
prevent or reduce the intensity of its clinical manifestations
has become a primary goal of many studies. The most
commonly used approaches include stretching, cryotherapy,
electric or manual therapies, whole-body vibration or nutritional
and pharmacological interventions (Cheung et al., 2003;
Barnett, 2006; Bloomer, 2007; Howatson and van Someren,
2008). Despite the large number of clinical trials, there are
very few evidence-based guidelines for the application of these
interventions. The inconsistencies in the dose and frequency
of the investigated interventions may account for the lack
of consensus regarding their efficacy. Conversely, there is
unequivocal evidence that a first bout of eccentric exercise confers
protection against EIMD following a subsequent bout of the
similar exercise. This muscle adaptation process, commonly
called “the repeated-bout effect” (RBE), is characterized by
reduced increases in muscular proteins in the blood, attenuated
DOMS, less muscle swelling, reduced abnormality in echo
intensity of B-mode ultrasound and/or magnetic resonance
images and faster recovery of muscle strength and range of
motion following the repeated bout (McHugh, 2003; Nosaka
and Aoki, 2011). Although a significant protective effect occurs
after a single eccentric bout (Clarkson et al., 1992; Nosaka and
Clarkson, 1995), the adaptive process appears more complete
after several sessions (Croisier et al., 1999; Hody et al., 2011).
The RBE seems to imply long-lasting adaptation since it
persists for several weeks and even up to 6 months but
the magnitude of the protection decreases over time (Nosaka
et al., 2001, 2005). It is interesting to note that the magnitude
of the protective effect is not necessarily dependent on the
severity of the initial muscle damage. It has been demonstrated
that repeating bouts of “non-damaging” eccentric exercise can
provide strong protective adaptations against subsequent bouts
of maximal eccentric exercise (Chen et al., 2013). Therefore, to
date, performing repeated sessions with submaximal eccentric
contractions appears to be the most efficient strategy to induce
eccentric training-induced adaptations that would prevent
further EIMD and DOMS. The demonstration that eccentric
actions can be performed without damage and soreness allowed
considering the potential of eccentric trainings in medical
conditions. Studies conducted first with healthy subjects and
then, with patient populations, have supported the application
of eccentric trainings as a safe, feasible and efficient strategy for
rehabilitation purposes (LaStayo et al., 2000; Hoppeler, 2016).
Numerous studies have attempted to elucidate the mechanisms
underlying the RBE, but this feature of the skeletal muscle is
not fully understood (McHugh et al., 1999a; McHugh, 2003;
Nosaka and Aoki, 2011).
Despite considerable amount of available data at the clinical
and histological levels, a significant gap still remains in the
understanding of the mechanisms that mediate morphological,
cellular, and molecular responses to muscle damaging eccentric
exercise (Hoppeler and Herzog, 2014). In addition, the
molecular events underlying the specific eccentric training
muscle adaptations are not fully understood (McHugh, 2003;
Nosaka and Aoki, 2011). This review begins by describing the
potential mechanisms leading to muscle damage and soreness
following unaccustomed eccentric exercise. Then, are discussed
the current knowledge of the eccentric training-induced
adaptations including the main hypotheses of the protective effect
against EIMD. Finally, the multiple applications of eccentric
training, justifying the need of an improved understanding of its
underlying molecular and cellular mechanisms, are exposed.
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It is generally accepted that the damage process is initiated
due to a lack of homogeneity in sarcomeres stretching
(asymmetric lengthening). This theory initially proposed by
Morgan (1990) suggests that during eccentric contractions, the
weakest sarcomeres or even half-sarcomeres will absorb most
of the length change (Morgan, 1990). These may be stretched
beyond the point of myofilament overlap resulting in disrupted
or “popped” sarcomeres. In line with this proposal, several
studies have clearly shown that the length of the muscle during
eccentric contraction is a critical factor in determining the extent
of damage (Talbot and Morgan, 1998). Eccentric contractions
performed at longer muscle length results in greater symptoms
of damage than similar contractions at shorter muscle length
(Lieber and Friden, 1993).
The initial mechanical damage would trigger a cascade of
events leading to more severe secondary damage (Figure 1).
Loss of calcium homeostasis, possible inflammatory reaction
and reactive oxygen species (ROS) production are thought to
contribute to the secondary damage phase. The disturbances in
Ca2+ homeostasis observed following unaccustomed eccentric
exercise may be the consequence of membrane damage
(Friden and Lieber, 2001) or opening of stretch-activated
channels (Overgaard et al., 2002). Abnormal increase in
calcium concentration inside muscle cells is responsible for
the activation of muscle proteases, named calpains. Since these
proteases cleave important structural proteins in charge of
myofibril integrity (as desmin and alpha-actinin), they have been
suggested to contribute to EIMD. The degradation of proteins
released from myofibrillar structures by the calpains could
be enhanced by other proteolytic pathways as the ubiquitin–
proteasome system (Raastad et al., 2010). Activation of calpains
may also result in the destruction of membrane constituents,
which in turn, will increase calcium entry. Elevated calcium
concentrations in skeletal muscle mitochondria, which can
alter mitochondrial respiratory function, also occur following
unaccustomed eccentric exercise (Rattray et al., 2011, 2013).
This calcium overload may be associated with the opening
of the mitochondrial permeability transition pore (mPTP)
leading to the activation of cell death signaling or with the
increased calpain proteolytic activity which is capable of targeting
proteins resulting in mitochondrial dysfunction. Furthermore,
the increased calpains activity can promote neutrophils and
macrophages activation, leading to ROS production (Powers and
Jackson, 2008). Besides the clinical symptoms associated with
EIMD (such as DOMS and decline in muscle strength), EIMD
have been reported to induce metabolic consequences at the acute
phase: decreased glucose uptake and insulin sensitivity, impaired
glycogen synthesis, elevated metabolic rate and a shift toward
non-oxidative metabolism (Tee et al., 2007).
Inflammatory and Immune Responses
to Eccentric Exercise
While the development of an inflammatory reaction after
eccentric exercise has been debated (Yu et al., 2002; Malm and Yu,
2012), many studies have now provided clear evidence of systemic
and local inflammatory responses in both rodents and humans
following various types of eccentric exercise (Peake J. et al., 2005;
Paulsen et al., 2012). However, in contrast to extensive works
describing the histological and clinical signs associated to EIMD,
the mechanisms underlying the inflammation-immune responses
and the subsequent regenerative events are less well understood
(Peake J. et al., 2005; Paulsen et al., 2012). The inflammation
processes following damaging exercise was initially considered as
a detrimental event due to its association with muscle damage,
soreness and delayed recovery but it is now well accepted that
the inflammatory stages are crucial for functional recovery of the
muscle to EIMD. The inflammation would ensure the removal of
tissue debris from the injured area and promote muscle repair
by activating muscle cells. Over the last decade, more studies
FIGURE 1 | Summary of the main specific features of eccentric contraction, its multi-target beneficial effects and potential risks associated with unaccustomed
and/or maximal eccentric exercise.
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have focused on the implication of multiple immune cell types
interacting with the muscle and emphasized the undeniable role
of satellite cells for muscle regeneration following one bout of
eccentric exercise (Crameri et al., 2004; Paulsen et al., 2012).
Early accumulation of leukocytes, primarily neutrophils, has
been observed in micro-blood vessels of the damaged muscle,
as well as in the perimysium, immediately after exercise.
In case of moderate to severe EIMD, histological studies
have consistently shown that neutrophils infiltrate into the
muscle and accumulate in the damaged area from 1 and
24 h after eccentric exercise (Paulsen et al., 2010). It is
likely that secretion and/or passive release of chemoattractant
proteins due to modifications to membrane permeability are
involved in the recruitment of circulating inflammatory cells.
They initiate the pro-inflammatory stage through phagocytosis
and by releasing proteolytic enzymes (such as elastase or
myeloperoxidase) and reactive species. At later time points,
when neutrophils are cleared from muscle, pro-inflammatory
macrophages start to accumulate. This type of macrophages,
referred as M1, contribute to the phagocytosis of the damaged
tissue by secreting pro-inflammatory cytokines (e.g., TNF-α,
IL-6, and IL-1β) and secretory leukocyte protease inhibitor.
Tissue-resident monocytes may also become activated after
exercise, in addition to the leukocytes originating from the
blood circulation. Neutrophils and M1 macrophages interact
with each other to regulate the proinflammatory response
of muscle damage. Their influx inside injured myofibers
appears to be dependent on the magnitude of EIMD and
may lead to an exacerbation of the initial cellular alterations.
Conversely, M2 macrophages that appear later generally produce
anti-inflammatory cytokines and signaling molecules involved
in the muscle recovery and regeneration. Large variations
across healthy individuals are observed, some presenting
substantial leukocyte accumulation whereas others displayed
very little leukocytes invasion. Furthermore, the magnitude of
the inflammation response appears to be dependent on the
initial perturbations induced by the exercise. It is assumed
that minor perturbations result in a cell-signaling-mediated
adaptive response, whereas intense eccentric actions seem to
generate a more severe response leading to secondary damage
to myofibers and increased risk of necrosis. While significant
necrosis is observed after electrically stimulated contractions,
segmental myofiber necrosis may occur without affecting the
whole myofiber, even in severe cases of EIMD. Interestingly,
the degree of leucocyte accumulation seems to be related to the
changes in force-generating capacity of the muscle (Paulsen et al.,
2010). Therefore, measuring the decline of muscular strength
following exercise, which is recognized as the best indirect marker
of EIMD, may inform on the status of the muscle. In contrast,
the level of leukocyte invasion into injured myofibers is not
necessarily related to DOMS.
The muscle inflammatory response appears to intimately
coregulate with muscle regeneration. Indeed, additionally to their
immune functions, macrophages also participate to myogenesis
and contribute to the extracellular matrix remodeling.
M1 macrophages stimulate satellite cells proliferation whereas
M2 macrophages interact with differentiating satellite cells
(Paulsen et al., 2012). The latter can also promote general protein
synthesis within muscle fibers. The replacement of macrophages
M1 to anti-inflammatory M2 macrophages is a key stage for
the transition from proinflammatory to anti-inflammatory
stages. This process is regulated by different signals including
the phagocytosis of cell debris, IL10 and AMP-activated protein
kinase (Chazaud, 2016). While a large body of research has
primarily focused on neutrophils and macrophages, other
cell types interact with the muscle and are important in the
inflammation and muscle regeneration processes. These include
notably mast cells, T lymphocytes, eosinophils, fibro-adipogenic
progenitors, and pericytes (Paulsen et al., 2012).
The inflammation and immune responses are mediated by
various growth factors and the actions of exercise-responsive
cytokines (i.e., IL-6, CCL2, and interferon-γ), pro-inflammatory
cytokines (TNF-α and IL-1β) and the anti-inflammatory cytokine
IL-10. Collectively, all these cytokines appear to activate myoblast
proliferation and some of them are involved in myoblast
differentiation (Peake J. et al., 2005). Interestingly, the satellite
cells activity is differentially affected by the contraction mode
in human muscle following exercise of the same work load.
Resistance eccentric, but not concentric, exercise has been
shown to elicit the proliferation of satellite cells immediately
after exercise, suggesting that EIMD is the main stimulus for
activating the satellite cells pool (Hyldahl and Hubal, 2014;
Hyldahl et al., 2014).
The precise source of production for cytokines found in the
circulation during and after exercise is not well established.
Indeed, the cytokines can be produced not only by leucocytes, but
also by myofibers and peri-tendinous tissue (Paulsen et al., 2010).
The term “myokines” has been introduced to refer to muscle
derived-cytokines and chemokines. Myokines are secreted by
the skeletal muscle in order to communicate with non-muscle
tissues and act as auto-, para- and endocrine mediators. These
might be molecular mediators which link muscle exercise and
the whole body physiology (Schnyder and Handschin, 2015).
While research to date has focused primarily on the biological
functions of the myokines in regulating metabolism, much less
attention has been made regarding their role in inflammatory
and adaptation to EIMD (Paulsen et al., 2010). Nevertheless,
studies investigating the cytokine responses to eccentric exercise
demonstrated increased activity of some cytokines such as MCP-1
and IL-10 after eccentric but not concentric exercise (Hyldahl and
Hubal, 2014). The anti-inflammatory cytokine IL-10 may attract
T lymphocytes, which activate muscle cell proliferation and
muscle regeneration. Systemic increase of IL-8 and upregulation
in intramuscular IL-8 mRNA expression and plasma levels after
downhill running and eccentric actions of the quadriceps has also
been reported (Hubal et al., 2008; Buford et al., 2009). IL-8 plasma
levels are also increased after eccentric muscle contractions,
but unchanged following concentric exercise. IL-8 is known to
attract primary neutrophils but this chemokine may also promote
neovascularization of muscle tissue through its association with
CXCR2 (Schnyder and Handschin, 2015). Some studies also
showed an increase in plasma concentration of IL-1ra and
G-CSF (granulocyte-colony stimulating factor) in the hours after
eccentric exercise (Peake J. et al., 2005; Peake J.M. et al., 2005).
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A large body of science has focused on IL-6. This myokine,
considered as one “exercise factor,” is regulated by exercise and
acts both locally within the muscle and on distal organs in an
endocrine-like fashion (Catoire and Kersten, 2015). IL-6 has
initially been characterized as a prototypical pro-inflammatory
cytokine by contributing to neutrophil mobilization and
activation and promoting impaired peripheral insulin resistance.
In contrast, anti-inflammatory properties of IL-6 have been
proposed later. Indeed, its exercise-induced systemic increase
generates the elevation of plasma level of several anti-
inflammatory cytokines (IL-1ra and IL-10) and inhibits the
production of the pro-inflammatory cytokine TNF-α (Pedersen
and Febbraio, 2008; Pedersen, 2012). Various cell types secrete
IL-6, including the skeletal muscle fibers during and after
exercise. Alongside the systemic increase, IL-6 mRNA levels are
augmented in contracting muscle fibers. IL-6 is considered as an
energy sensor of the muscle (Pedersen, 2012) since its secretion
from the exercising muscles increases glucose uptake and fatty
acid oxidation locally and improves insulin secretion, which
further increases glucose uptake into muscle fibers. Hepatic
glucose delivery and fatty acid release from adipose tissue are also
stimulated supporting the maintenance of metabolic homeostasis
during exercise (Febbraio and Pedersen, 2002). Muscle derived
IL-6 was first thought to be related to injury but “non-damaging
exercise” has been shown to lead to substantial IL-6 increase
(Croisier et al., 1999). Nevertheless, IL-6 contributes with TNF-α
and MCP-1 to muscle regeneration after EIMD by stimulating
the proliferation and differentiation of myoblasts (Schnyder and
Handschin, 2015). Moreover, the transforming growth factor-
beta is another cytokine involved in muscle recovery and
repair after muscle damage that regulates extracellular matrix
remodeling and promotes fibrosis (Kim and Lee, 2017).
Delayed-Onset Muscle Soreness
Delayed-onset muscle soreness (DOMS) refers to unpleasant,
dull, aching pain, usually felt during palpation, contraction
or stretching of the affected muscle. Such muscle soreness
typically appears 12–24 h after unaccustomed eccentric exercise,
peaks at between 24 and 72 h before progressively subsiding
and disappearing within 5–7 days post-exercise. Interestingly,
DOMS intensity is poorly correlated with other EIMD indirect
markers and seems thus not to reflect the magnitude of muscle
damage (Nosaka et al., 2002). Although DOMS is an extremely
common symptom, why DOMS occurs with a delay, and why
eccentric contraction but not shortening contraction induces
DOMS is not clearly understood. Several hypotheses have been
put forward to explain the mechanism of DOMS. These include
lactic acid release, spasm, connective tissue damage, muscle
damage, inflammation and oxidative stress (Hyldahl and Hubal,
2014). For many years, the most widely supported hypothesis was
that the biochemical, thermal and mechanical changes associated
with the inflammatory response sensitize small diameter muscles
afferents (types III and IV) that may then be at the origin
of the sensation of muscle soreness (Friden and Lieber, 1992).
It was only in 2010 that Murase and coworkers provided new
insights into the molecular mechanisms of DOMS generation.
They highlighted bradykinin and nerve growth factor (NGF)
as important players in the development of DOMS following
eccentric contractions (Figure 1). Using a rodent model, they
demonstrated that a bradykinin-like substance released from
the muscle during eccentric exercise triggers the process of
muscular mechanical hyperalgesia by upregulating NGF through
B2 receptors in exercised muscle of rats. In humans, NGF has
been shown to be involved in the generation and potentiation
of pain following eccentric exercise (Nie et al., 2009). Another
pathway proposed to be involved in the development of
DOMS is the activation of the COX-2-glial cell line-derived
neurotrophic factor (GDNF) (Murase et al., 2013; Mizumura
and Taguchi, 2016). Similarly to NGF pathway, this agent likely
generates muscle mechanical hyperalgesia directly by stimulating
muscle nociceptors, or by binding to extracellular receptors.
While myofibers micro-damage were believed to be necessary
to initiate inflammation and DOMS, some studies reported
mechanical hyperalgesia after eccentric exercises without any
signs of muscle damage. This supports the crucial roles of
NGF and GDNF in DOMS and suggests that the mechanical
hyperalgesia development may be associated with inflammation
in the extracellular matrix (Peake J. M. et al., 2017). NGF
and GDNF are also known to play a role in pathological pain
conditions and are increasingly recognized as active players in the
whole pain process and upregulated in ischemic skeletal muscle
(Turrini et al., 2002). NGF is increasingly regarded as an active
player in the whole pain process (McKelvey et al., 2013). Thus,
advances in the understanding of the mechanisms and cellular
origins of muscle soreness could lead to development of effective





The distinct features of the eccentric contraction compared
to other contraction modes are the source of specific training
adaptations. A significant body of evidence suggests that
compared to concentric contractions, chronically performed
eccentric contractions promote greater gains in strength, muscle
mass and neural adaptations (Reeves et al., 2009; Roig et al.,
2009). The mechanisms responsible for these adaptations are
underlined by modifications in gene expression. Indeed the
process of exercise-induced adaptations in skeletal muscle
involves multiple signaling mechanisms initiating transcription
of specific genes that enable subsequent translation into a series
of new proteins (Coffey and Hawley, 2007). Several studies have
reported that eccentric and concentric actions activate distinct
muscular molecular pathways in humans (Kostek et al., 2007)
and in rats (Chen et al., 2002). It has been shown that eccentric
exercise triggers a progressive activation of genes responsible
for cellular growth and development, involved in muscular cell
hypertrophy processes. The expression levels of these genes
are more stimulated by eccentric actions than by isometric
or concentric actions (Chen et al., 2002; Barash et al., 2004;
Kostek et al., 2007), presumably due to the unique mechanical
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FIGURE 2 | Schematic representation of the potential mechanisms associated with eccentric exercise-induced muscle damage and involved in the development of
DOMS. BD, bradykinin; CK, creatine kinase; DOMS, delayed-onset muscle soreness; E–C, excitation–contraction; GDNF, glial cell line-derived neurotrophic factor;
IL, interleukin; NGF, nerve growth factor; ROS/RNS, reactive oxygen and nitrogen species; TNF, tumor necrosis factor.
stress placed on the eccentrically contracted muscles. For
example, in skeletal muscle, the effect of eccentric training was
greater than concentric training for liver-type insulin-like growth
factor I and mechano-growth factor (positive regulators of
muscle growth) (Barash et al., 2004). Such modifications in gene
expression profiles are thought to be regulated by mechanical
signaling pathways involving proteins that are sensitive to the
mechanical status of muscle cell (i.e., Microtubules-Associated
Proteins or MAP proteins) (Hentzen et al., 2006). Transcriptome
analyses in eccentric-exercised muscles also revealed substantial
transcriptional activity related to the presence of leukocytes,
immune-related signaling and adaptive remodeling of the
intramuscular extracellular matrix until 96 h after exercise
(Neubauer et al., 2014). In comparison to concentric or isometric
contractions, eccentric contractions appear to upregulate muscle
cell activity and anabolic signaling pathway to a greater extent
(Douglas et al., 2017).
Specific Muscle Adaptations to
Chronic Eccentric Exercise
Because the eccentric contraction differs from other contraction
types notably in terms of force generation, maximum force
produced and energy cost, it could provide different stimuli
leading to distinct muscular and functional adaptations
(Figure 2) (Franchi et al., 2017a). A significant body of evidence
have suggested the superiority of eccentric resistance training in
terms of muscular hypertrophy over concentric or conventional
strength trainings (Julian et al., 2018). Some studies also reported
earlier increments in muscle mass with eccentric-based resistance
training when compared with concentric training. However, the
findings appear extremely variable to clearly confirm greater
gains in muscle mass following eccentric modalities (Julian
et al., 2018). Indeed, in their review, Franchi et al. (2014) draw
the conclusion that the changes in muscle size are similar
between eccentric and concentric training when matched for
load or work. A systematic review and meta-analysis about the
contribution of the different muscle actions to muscle growth
showed a greater muscle mass gain with eccentric contractions
but the results did not reach significance (Schoenfeld et al., 2017).
Nevertheless, taking into account the energy demand to produce
similar force or work, eccentric exercise may be considered as
more efficient (Julian et al., 2018). Interestingly, contraction type
tends to induce a region-specific hypertrophy. Greater increase
in distal muscle size has been observed following eccentric
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training, while concentric training favors median-muscle
hypertrophy (Franchi et al., 2014). In addition, the hypertrophic
responses to eccentric versus concentric contractions might be
obtained by different structural adaptations mediated by distinct
myogenic and molecular responses. While both training regimes
appeared to increase muscle fascicle length and pennation
angle (Blazevich et al., 2007), conventional strength training
would increase pennation angle more than eccentric training.
In contrast, eccentric-only resistance training seems to favor
fascicle length increase (Reeves et al., 2009), with the implication
that eccentric training is able to shift the optimum of the
length-tension relationship to longer muscle length (Hoppeler,
2016). This muscle architectural change appears thus particularly
interesting for injury prevention and athletic performance
(Brughelli and Cronin, 2007). Regarding muscle thickness,
similar increases have been observed with both training modes.
There are evidence that eccentric training promotes significantly
greater increase in muscle strength, whereas the differences
in isometric and concentric measures seems less significant
(Roig et al., 2009). Findings also showed that the increase in
eccentric strength after eccentric training is greater than the
gain in concentric strength after concentric training (Vikne
et al., 2006). The systematic review of Douglas et al. (2017)
also reported mode-specific strength increase and revealed that
greater overall strength increases can be achieved after eccentric
training than concentric or traditional training. Furthermore,
in comparison with concentric exercise, eccentric actions have
been reported to induce a greater cross-education effect. Only
few studies examined changes in muscle power. Performance in
actions involving muscle power or stretch-shortening cycle (such
as vertical jump) appeared to be improved to a greater extent
with eccentric training compared with concentric or traditional
resistance training (Liu et al., 2013; Douglas et al., 2017).
The Repeated-Bout Effect (RBE)
Skeletal muscle exhibits an intriguing plasticity to repeated
bouts of eccentric exercises. Among the adaptations specifically
triggered by the eccentric contraction, some contribute to the
RBE, aiming thus to protect muscle against EIMD. A large
number of theories have been proposed to explain the RBE,
suggesting a multifactorial origin of this adaptive process.
Potential adaptations have been categorized as (Lindstedt et al.,
2001) neural, (Abbott et al., 1952) mechanical and (LaStayo et al.,
2003b) cellular theories (McHugh et al., 1999a; McHugh, 2003).
However, although many studies have attempted to elucidate the
mechanisms behind the RBE, a unified theory is not yet available.
According to the neural theory, the EIMD results from
the high mechanical stress imposed on a small number of
active muscle fibers during intense eccentric contractions.
Although not commonly accepted, this theory also supports
a preferential recruitment of fast-twitch motor units during
eccentric contractions to explain the higher susceptibility to
disruption of the fast muscle fibers. Therefore, it has been
postulated that changes in neural activation may contribute
to reduce subsequent myofibrillar damage (McHugh, 2003).
Suggested neural adaptations involve improved motor units
(MUs) synchronization and activation of a large pool of MUs,
mainly by recruiting a greater number of slow-twitch fibers
(Warren et al., 2000; Chen, 2003; Starbuck and Eston, 2012). Such
mechanisms would allow a better distribution of the workload
over a greater number of active muscle fibers in repeated bouts
(Nosaka and Clarkson, 1995). The fast-setting adaptations but
also the existence of contralateral protective effect (Howatson
and van Someren, 2007; Starbuck and Eston, 2012; Hody et al.,
2013b) support the contribution of neurophysiologic processes
in the RBE. Indeed, some studies have reported that an initial
bout of eccentric exercise in one limb provides protection from
the symptoms of EIMD during a second eccentric bout in the
contralateral limb. Nevertheless, the magnitude of protection
in the contralateral limb is lower than that observed in the
ipsilateral limb, indicating that neural adaptations cannot entirely
explain the RBE (Howatson and van Someren, 2007). Moreover,
the demonstration of RBE with electrically stimulated eccentric
contractions (Black and McCully, 2008) suggests that the RBE
can occur independently of neural adaptations and involves thus
a peripheral and/or muscular adaptation.
The mechanical origin of initial muscle damage has led
authors to suggest that changes in mechanical properties of the
musculoskeletal system could render the muscle more resilient
to EIMD. With respect to this hypothesis, both the passive
and dynamic stiffness of the muscle-tendon complex has been
shown to increase after eccentric training (Howell et al., 1993;
Reich et al., 2000). These modifications have been, respectively,
attributed to an increase in intramuscular connective tissue
improving the ability to withstand myofibrillar stress and to
a reinforcement of intermediate filament system, in charge of
maintaining the alignment and structure of the sarcomeres
(i.e., titin, desmin) (McHugh, 2003). In agreement with the
reorganization of cytoskeletal proteins, the level of certain
structural proteins, such as desmin, was found to increase in
the days following eccentric exercise (Feasson et al., 2002; Lehti
et al., 2007). This suggests that muscle-specific cytoskeletal
remodeling could play a role to protect from future sarcomere
disruption. Desmin, the major protein of the muscle intermediate
filament, would act as mechanical integrator for the repair of
the filaments (Yu et al., 2002). Its reinforcement secondary to
transcriptional upregulation may provide mechanical protection
from future sarcomere disruption (Peters et al., 2003). However,
some studies showing that stiffer muscles are more prone to
damage questioned the mechanical theory (McHugh et al.,
1999b). Moreover, desmin knockout (KO) mice have been
found to exhibit less exercise-induced than wild-type mice (Sam
et al., 2000). This finding was, however, imputed to more
compliant muscles of KO mice. Recent works have suggested
that in addition to their function of structural support to
the cell, the intermediate filaments may play an active role
in biological processes such as signaling, mechanotransduction
and gene regulation. The mechanisms behind these processes
are not well understood. Desmin, which is responsible for
transmission of stress among myofibrils appears to be required
for the maintenance of myofiber alignment, nuclear deformation,
stress production and JNK-mediated stress sensing (Palmisano
et al., 2015). Growing evidence supports the role of the
skeletal muscle intermediate filaments as a stress-transmitting
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and stress-signaling network. Notably, cytoskeletal proteins help
mitochondria not only in their movement and proper cellular
positioning, but also to maintain their biogenesis, morphology,
function, and regulation of energy fluxes. The functionality of
these cytoskeletal proteins may thus influence the mitochondria
functions, including the regulation of Ca2+ signals and apoptosis
(Mado et al., 2019). Remodeling of the intermediate filaments
network may also impact cell migratory behaviors important to
development (Sanghvi-Shah and Weber, 2017).
Another group of theories explaining the RBE relies on
cellular adaptation. Given the focal feature of muscle damage,
speculation has been made that the muscle becomes more
resistant to EIMD thanks to the removal of stress-susceptible
fibers or sarcomeres resulting from the initial eccentric bout
(Armstrong, 1984; Newham et al., 1987). However, this is
inconsistent with the fact that the initial bout does not have to
cause appreciable damage to confer a protective effect. Several
works provided evidence that eccentric exercise promotes an
increase in series sarcomeres (Lynn and Morgan, 1994; Yu et al.,
2004). Such longitudinal addition of sarcomeres is thought to
contribute to the protective effect as it would avoid the sarcomere
stretching beyond their overlap and thus, their disruption. The
sarcolemma and sarcoplasmic reticulum would also become
stronger following the initial bout of eccentric exercise (McHugh,
2003). This may limit perturbations of calcium homeostasis and
thus, may prevent the calpain activation and the degradation
of cytoskeletal proteins. The reduced calpain activity could
then explain the attenuation of mitochondrial dysfunction
following chronic exposure of eccentric exercise. Other potential
adaptations such a decreased susceptibility to calcium-induced
mPTP (mitochondrial permeability transition pore) opening or
upregulation of heat shock proteins, in particular Hsp70, may also
be contribute to protect mitochondrial function (Rattray et al.,
2013). In addition, changes in the inflammatory response, such as
a reduced activation of the monocytes and neutrophils, have been
described after repeated eccentric bouts and may also be related
to the RBE (Pizza et al., 1996). Nevertheless, whether adaptation
in the inflammatory process is the cause or a consequence
of reduced muscle damage is not elucidated. Adaptation
may also rely on the monocyte chemoattractant protein 1
(MCP-1), a chemokine involved in activation and attraction of
inflammatory cells. Indeed, MCP-1 is dramatically overexpressed
at the transcript level after a single bout of eccentric exercise and
it appeared even more upregulated after a second bout (Hubal
et al., 2008). Authors have thus suggested that MCP-1 enhances
muscle recovery after a repeated bout of eccentric exercise via
improved signaling between macrophages and satellite cells.
Other chemokines may contribute to the protective adaptation
to exercise-induced muscle damage. Upregulation of CCL2 and
a decreased of NF-kB DNA-binding activity occur following
repeated bouts of eccentric exercise. These observations supports
the hypothesis that the immune response becomes more efficient
to promote the regeneration of muscle tissue after an initial
bout of eccentric exercises, notably through enhancement in
inflammatory cell infiltration into the muscle and myoblast
proliferation (Peake J. et al., 2005). Furthermore, a remodeling
of the surrounding extracellular matrix might also occur during
the RBE. A strengthening of the extracellular matrix such as
an improved integrin support may help to recover faster after
eccentric contractions (Hyldahl et al., 2015).
Other potential cellular adaptations include increased protein
synthesis, adaptation in the excitation-contraction coupling and
increased stress proteins (i.e., heat shock proteins) (McHugh,
2003). In particular, the role of heat shock proteins (HSPs) in
protection against muscle damage constitutes an exciting new
area of research. The small HSPs (sHSPs) named HSPB1 (Hsp27)
and alphaB-crystallin, seem to play important roles in cellular
adaptation as they have been implicated in the chaperoning of
unfolded proteins, the stabilization of the cytoskeleton as well
as in the regulation of the cellular redox state and inhibition
of apoptosis (Orejuela et al., 2007). Following one bout of
eccentric exercise, the sHSPs translocate from the cytosol to the
cytoskeletal/myofibrillar compartment, presumably to stabilize
and protect the myofibrillar filament organization (Paulsen et al.,
2007, 2009; Frankenberg et al., 2014). Such an observation was
not found after concentric exercise (Frankenberg et al., 2014).
AlphaB-crystallin interacts with desmin intermediate filaments
and, Hsp27, together with alphaB-crystallin, has been suggested
to interact with various microfilaments (Orejuela et al., 2007).
These data strongly support the idea that alphaB-crystallin and
Hsp27 are crucial for the maintenance and the remodeling of
myofibrillar structures. Therefore, in line with the reinforcement
of the cytoskeletal/myofibrillar structures, appropriate adaptation
in the protection systems of HSPs might be important as
well (Paulsen et al., 2007). Moreover, because the HSPs are
involved in the development of stress tolerance against several
stressful insults, it is likely that the HSPs response elicited
by an initial damaging bout bestows resistance to a second
potentially damaging exercise. Only few studies investigated the
HSPs response to repeated bouts of eccentric exercise. Paulsen
et al. (2009) revealed that two bouts of maximal eccentric exercise
separated by 3 weeks resulted in comparable increased levels of
HSPs in the cytoskeletal fraction, despite less damage inflicted
during the second bout. The large amount of Hsp27, alphaB-
crystallin, and Hsp70 in the cytoskeletal compartment after the
repeated bout suggests that a more efficient translocation of
these HSPs is plausibly a mechanism behind the RBE. Similarly,
Thompson et al. (2002) reported a similar relative increase of
Hsp27 and Hsp70 2 days after the first and second eccentric bouts,
but, intriguingly, the basal levels of these HSPs appeared to be
lower before the second bout. This finding casts doubt on the
HSPs as important players in the RBE. Contrary to these findings,
results from a study by Vissing et al. (2009) did not point out a
role for the HSPs in reducing EIMD, as they observed a blunted
translocation of HSPs after the second bout. In this latter study,
the low degree of muscle damage inflicted during the exercise
and/or the long duration between bouts (8 weeks) could explain
the lack of HSPs movement following the second bout. Future
studies appear thus to be necessary to delineate the HSPs response
after repeated eccentric bouts.
Finally, using a proteomic approach, a short isokinetic
eccentric training in human quadriceps was found to induce
proteome modifications that suggest an isoform shift in fiber
type components (Hody et al., 2011). Indeed, a decreased
Frontiers in Physiology | www.frontiersin.org 9 May 2019 | Volume 10 | Article 5361 6
fphys-10-00536 May 2, 2019 Time: 17:45 # 10
Hody et al. Eccentric Exercise
expression of several glycolytic enzymes coupled with a lower
expression of the fast isoforms of some contractile and structural
proteins was observed after five sessions of submaximal eccentric
contractions. Adaptation in the muscle fiber typology following
eccentric training was further supported by a study in mice.
This highlighted significant changes in the size and number
of muscle fiber types following eccentrically biased trained in
comparison with untrained or concentrically biased trained
mice: the eccentric training specifically resulted in an increased
proportion of slow and fast oxidative muscle fibers (Hody et al.,
2013a). Nevertheless, whether a shift to a more oxidative muscle




Eccentric training has sparked a growing interest over the
last decade, particularly in light of the emerging health-
related benefits of improved muscle mass. Moreover, because
a greater volume of exercise can be done at less metabolic
and cardiorespiratory cost, eccentric muscle work constitutes
a promising training strategy, not only to improve athletes’
performances, but also to help maintain or restore the exercise
capacity and quality of life in individuals with reduced tolerance
for physical activity (i.e., the elderly or patients with chronic
disabilities) (Gault and Willems, 2013; Hyldahl and Hubal, 2014;
LaStayo et al., 2014). The lower perceived exertion to perform
eccentric exercises helps to increase the adherence of patients to
exercise programs. As eccentric contractions have traditionally
been associated with muscle damage, the prescription of eccentric
training programs in clinical practice has been discouraged
for a long time. Nowadays, it is well accepted that when
the duration, frequency and intensity of the eccentric training
sessions are progressively increased, symptoms of damage can
be minimized and even avoided (Croisier et al., 1999; Chen
et al., 2013). Additionally, it is now accepted that neither muscle
damage nor inflammation are prerequisites for stimulating
positive muscle adaptations as protection against EIMD or
increased muscle mass (LaStayo et al., 2007). Eccentric training
interventions are thus considered as a safe and suitable alternative
to traditional resistance exercise. Before discussing the numerous
applications of eccentric training, it should be mentioned that
the identification of its specific effects in comparison to the
other training modalities remain difficult due to methodological
reasons. First, the training programs used in several studies
involved usual daily movements that do not isolate eccentric
and concentric contractions. Secondly, a limited number of
studies employed an appropriate calibration of the eccentric
and concentric exercises, making conclusive comparison between
the contraction modes impossible. Since they imply different
metabolic cost for the same mechanical work, eccentric and
concentric exercises must be matched for similar mechanical
output, metabolic rate or oxygen consumption level, or similar
total training load. Additionally, the techniques and equipment
to perform eccentric exercises is often sophisticated, require
specific experience and may represent financial constraints. These
reasons may contribute to the few number of studies comparing
eccentric training with other modalities and the difficulty to draw
definitive conclusions (Julian et al., 2018).
Competitive Sports
While few studies have been devoted to the effects of eccentric
training in elite athletes compared to untrained subjects, the
systematic inclusion of eccentric-based protocols into training
programs is recommended for most competitive sports for
performance enhancement or injury prevention purposes (Isner-
Horobeti et al., 2013; Vogt and Hoppeler, 2014). Indeed, because
of its distinct characteristics, eccentric training modalities can
further enhance maximal muscular strength and optimize
improvements to power, optimal muscle length for strength
development, as well as coordination during eccentric tasks
(LaStayo et al., 2003a). Eccentric training may also be especially
efficient in enhancing speed performance or in rebound activities
such as jump (Franchi et al., 2017b; Chaabene et al., 2018).
This has notably been demonstrated in basketball players. Those
subjected to eccentric training for 6 weeks exhibited a significant
improvement in jumping height of 8% while the performance
of the players that performed traditional weight-lifting was
unchanged (Lindstedt et al., 2002). A change in titin protein
isoform has been proposed to explain the increased stiffness of
the muscle-tendon unit and enhanced recovery of elastic strain
energy (Hoppeler, 2016). These functional adaptations in skeletal
muscles are based on increases in muscle mass, fascicle length,
number of sarcomeres, and cross-sectional area of type II fibers.
In terms of injury prevention, the isokinetic assessment of muscle
function, in particular through the eccentric mode, appears to
be of great importance for detecting athletes at high risk of
injuries before the start of the season (Croisier et al., 2002;
Forthomme et al., 2013). Moreover, preventive interventions
with controlled eccentric exercises have been shown to decrease
the risk of hamstring injury in professional soccer players
(Croisier et al., 2008) or of shoulder pain in volleyball players
(Forthomme et al., 2013).
Rehabilitation
Over the last 20 years, eccentric muscle actions have been
frequently integrated in the treatment of several pathologies of
the locomotor system (Croisier et al., 2009). In particular, chronic
eccentric exercise has become a mainstay in the treatment
of tendinopathies mainly of the Achilles, patellar and lateral
epicondylar tendonitis (Croisier et al., 2007; Hoppeler and
Herzog, 2014; Kjaer and Heinemeier, 2014). To justify the
relevance of eccentric exercise for strengthening tendon tissues,
a stimulating impact of such exercise on collagen synthesis and
an increase in blood flow around tendon cells after eccentric
actions have been proposed (Guilhem et al., 2010). Eccentric
intervention has also been shown to be safe and effective after
anterior cruciate ligament reconstruction (ACLR). The studies of
Gerber et al. (2007, 2009) reported superior short and long-term
results in strength, performance and activity level after surgery
when eccentric exercise is part of the rehabilitation after ACL-R
in comparison to standard rehabilitation programs. Otherwise,
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ipsilateral eccentric training has been demonstrated to increase
muscles’ strength in the contralateral homologous muscle group,
and this in a greater extent than concentric training (Higbie et al.,
1996; Hortobagyi et al., 1997). Thus, implementing unilateral
eccentric contractions in rehabilitation programs could improve
the muscle function of the opposite injured limb without it
being solicited.
Sarcopenia
Given the ever-increasing aging population, the development
of strategies to improve the quality of life of the elderly has
become a major concern. One of the most evident and disabling
consequences of aging is sarcopenia, a process characterized
by a progressive and steady loss of lean skeletal muscle mass.
Muscle loss is also associated with an increase in intramuscular
fat and connective tissue, a reduction in muscle strength, in
addition to cardiovascular dysfunction reducing aerobic capacity
(Gault and Willems, 2013). Such changes contribute to a
decline in functional independence and severely compromise
the function, quality of life, and life expectancy in older
individuals. Multiple lines of evidence suggest that exercise
training can prevent or reverse muscle aging. Indeed, studies
comparing muscle characteristics of highly trained young and
senior athletes demonstrated that trained subjects can maintain
and improve muscle function regardless of their age (Roig et al.,
2008; Dickinson et al., 2013). However, the implementation of
conventional resistance training programs in the elderly may be
hampered by the difficulty of such programs as reduced initial
levels of force and cardiovascular dysfunction are frequent in
old adults. Conversely, eccentric training programs can massively
overload the muscular system with a low cardiopulmonary
stress. Interestingly, numerous studies reported that older
individuals exhibit a relatively preserved capacity of producing
eccentric strength. Indeed, when compared to concentric or
isometric strength, the magnitude of the age-related decline in
eccentric strength is less pronounced. This provides an additional
advantage for eccentric exercises to initiate resistance training
and rehabilitation programs (LaStayo et al., 2003b; Roig et al.,
2010). In addition to the suitability of eccentric training in old
individuals, it is important to emphasize that resistance training
with eccentric contractions induces greater beneficial effects than
concentric training to improve mobility and independence of
the elderly. As in young individuals, high-intensity eccentric
resistance training has been shown to be more effective than
concentric training in increasing muscle strength and mass in
older adults (LaStayo et al., 2003a; Reeves et al., 2009). Other
appreciable benefits resulting from eccentric training in old
individuals are the improved ability to complete functional tasks
and the decreased risk of fall (Gault and Willems, 2013). LaStayo
et al. (2003a) demonstrated that using eccentric modality in
very frail elderly (mean age, 80 years) was more efficient to
reverse sarcopenia and its related functional limitations than
traditional weight training. Indeed, the elderly who performed
10–20 min of eccentric resistance exercise 3 times per week
over 11 weeks showed significant improvements in strength
(60%), balance (7%), stair descent (21%) abilities and a reduced
risk of fall. These positive outcomes were not found in the
elderly subjects submitted to traditional resistance exercises.
Additionally, the subjects of the eccentric group reported the
training to be relatively effortless. Besides resistance training,
eccentric endurance exercise involving large muscle groups (ECC
cycling, downhill treadmill walking, and stepping) seems to
be particularly convenient for the elderly (in particular for
frail elderly). This training modality minimizes the substantial
mechanical stress on single joints occurring during resistance
training and provides benefits for strength, muscle mass and
potentially aerobic adaptations (Gault and Willems, 2013;
LaStayo et al., 2014). The study of Mueller et al. (2009) compared
the effects of a moderate load eccentric exercise on an eccentric
ergometer to a conventional resistance exercise training. Both
trainings were carried out for 12 weeks with 2 sessions per
week. A significant increase in maximal isometric strength (8.4%)
was observed only for the eccentric group (Mueller et al.,
2009). Improvements in body composition characterized by a
decrease in intramyocellular lipid content concomitantly with
total body fat have also been observed in the elderly after
12 weeks of eccentric ergometer training (Mueller et al., 2011).
In contrast, tight lean mass increased similarly after both training
modalities. Interestingly, the gain in muscle mass in the elderly
following eccentric training was not paralleled by an increase in
muscle fiber cross-sectional area (hypertrophy) as observed with
traditional exercise training (Mueller et al., 2011). Muscle growth
after eccentric training thus seem to occur by the addition of
sarcomeres in series or by hyperplasia. While available evidence
suggest that eccentric training protocols are well tolerated in
elderly individuals, it should kept in mind that old adults show
an increased vulnerability to exercise-related muscle damage.
Indeed, biopsies from the human m. vastus lateralis immediately
after a bout of eccentric cycling showed disorganization of
sarcomeres, with a higher percentage of disorganization in
older (59–63-years) compared to younger adults (20–30-years)
(Manfredi et al., 1991). Therefore, careful and safe progression of
the intensity of eccentric training is thus strongly advised when
initiating eccentric programs in the elderly.
Chronic Diseases
Musculoskeletal dysfunction is relatively common in patients
with chronic conditions such as chronic obstructive pulmonary
disease, chronic heart failure or stroke (Hyldahl and Hubal,
2014). Although the exact etiology of the muscle function
decline in these patients is not yet clear, it is believed that
the lack of physical activity contributes at least to some
of the deleterious changes in muscle function (Roig et al.,
2008). Moreover, the ability of exercise to maintain mobility
and minimize muscle wasting in most people with chronic
conditions is commonly accepted. Until now, only few studies
explored the use of eccentric-biased programs in persons with
chronic health conditions. Nevertheless, current evidence exists
regarding the effectiveness and safety of eccentric exercise in
restoring musculoskeletal function in patients with different
chronic conditions. For instance, compared to conventional
training programs, judicious eccentric-based protocols result in
greater strength gains and enhancement of functional capacity
in cancer survivors, Parkinson disease patients or total knee
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replacement patients (Hyldahl and Hubal, 2014). However,
such favorable effects were not observed in individuals with
multiple sclerosis (Hayes et al., 2011). Studies exploring the
use of resistance training in individuals recovering from a
stroke revealed that eccentric contractions were more effective
for improving neuromuscular activation, strength, and walking
speed than concentric contractions (Engardt et al., 1995; Clark
and Patten, 2013). Since eccentric training seems to provide
greater central neural adaptation than concentric modes of
exercise, the use of eccentric exercise may be particularly
effective for patients with central nervous system diseases. The
physiologic characteristics of eccentric contraction (attenuated
cardiopulmonary stress, low metabolic cost) seem to be well
suited for their incorporation into the revalidation of patients
intolerant to intense cardiac and respiratory efforts (i.e., patients
with heart disorders or lung pathologies) (Meyer et al., 2003; Roig
et al., 2008). Eccentric training has been suggested to attenuate
reductions in arterial compliance, thus potentially limiting the
risks commonly associated with resistance training in patients
with coronary disease (Okamoto et al., 2006). Steiner et al. (2004)
compared concentric and eccentric training at similar heart
rate (85% of HR) in patients suffering from cardiac problems.
Training was carried out 3 times per week during 8 weeks,
with a progressive increase of the exercise intensity the first
5 weeks. The authors showed a significant gain in muscle torque
following the eccentric training. Both training modalities induce
a small 3% increase in leg muscle mass but leg and whole
body fat mass appeared to decrease only in patients trained
eccentrically. Interestingly, despite working at fourfold higher
mechanical loads, the eccentric group did not show different
changes in cardiovascular variables (such as heart rate, mean
arterial pressure, or vascular resistance) than the concentrically
trained subjects (Meyer et al., 2003). Collectively, all studies
reported eccentric exercise to be a safe training modality for
patients with various cardiac conditions.
Eccentric exercise may also be useful in the prevention or
treatment of metabolic diseases given its rapid and favorable
effects on health related parameters (Roig et al., 2008;
Paschalis et al., 2010; Isner-Horobeti et al., 2013). For instance,
eccentric training is more effective to improve glucose tolerance
than concentric training. Additionally, Paschalis et al. (2010)
demonstrated that a weekly bout of intense eccentric exercise –
and not concentric exercise – is sufficient to improve health risk
factors. They found that only 30 min of eccentric exercise per
week for 8 weeks markedly increased resting energy expenditure
and lipid oxidation as well as decreased insulin resistance
and blood lipid profile. The study of Marcus et al. (2008)
compared the effects of a 16-week aerobic exercise training
alone to aerobic exercise combined with moderate load eccentric
exercise in diabetes type 2 patients. While glycemic control and
physical performance were similarly improved in all patients, the
improvements in tight lean mass and body mass index were larger
when eccentric exercise was performed.
In regard with muscular dystrophy pathology, no human
study investigated the potential effects of eccentric training in
this disease. It is likely that eccentric contractions may accelerate
the degenerative process given that the degenerative nature of
dystrophic muscle can partially be accounted for by exhaustive
regenerative cycles (Hyldahl and Hubal, 2014). Nevertheless,
some recent animal studies indicate a favorable adaptation to
moderate exercise in dystrophic animals (Lovering and Brooks,
2014). In fact, despite the increased vulnerability of dystrophic
(mdx) muscles to eccentric contractions, young mdx mice were
found to recover from and adapt more quickly to EIMD than
wild-type mice (Ridgley et al., 2009; Call et al., 2011). However,
such increased regenerative capacity was lost in older animals
(Carter et al., 2002) and it is still unclear whether an eccentric-
based training program would be helpful or detrimental to the
long-term health of the muscle.
Notwithstanding recent evidence demonstrate the benefits of
eccentric training interventions in several fields, there is a real
need to further study the physiology of eccentric contraction.
Indeed, it is still unclear whether this high specificity of
eccentric training adaptations compromises the transferability
of strength gains to more functional movements (Roig et al.,
2010). Moreover, long-term implications of eccentric training
in old individuals or in patients with chronic diseases should
be explored in more details. Likewise, further investigations
are required to optimize parameters as intensity, duration, and
modes of eccentric training leading to the favorable effects on
muscle performance, health and quality of life.
PRACTICAL CONSIDERATIONS
Eccentric actions can be integrated in different types of
muscle training. Plyometric exercises, such as drop jump, is
frequently used to improve speed and jumping ability in athletes.
The literature recommends specific habituation training and
knowledgeable supervision due to the inherent risk of injuries
in such exercises (Hoppeler, 2016). Eccentric based resistance
training, characterized by high muscle loads at low metabolic
cost, has been increasingly prescribed for individuals with
a centrally limited exercise tolerance (LaStayo et al., 2014).
However, in most patient populations, the use of high mechanical
loads may constrain their adherence to resistance muscle
training. Therefore, the new modality “moderate load eccentric
exercise” represents an attractive choice in various medical
conditions (Hoppeler, 2016). Over the last decades, various
motorized ergometers or similar devices allowing safe and
controlled application of eccentric loads, have been developed for
rehabilitation and performance purposes.
The prescription of eccentric muscle training require specific
experience. Practitioners must respect fundamental precepts
and consider important safety considerations concerning the
applications of eccentric muscle training, especially during
the initial implementation phase. Exercise professionals should
be aware of the potential detrimental effects of eccentric
contractions as well as the ways to prevent their occurrence.
Nowadays, it is well accepted that repeated exposure to eccentric
exercises confers protective adaptations against potential further
damage (McHugh, 2003; Nosaka and Aoki, 2011). Even if
the magnitude of this “repeated-bout effect” appeared larger
if the initial eccentric bout involved high workloads, this
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strategy could be problematic, especially for those undergoing
rehabilitation or elite athletes. Indeed, DOMS and the functional
consequences associated with EIMD may frequently disturb the
progress of rehabilitation and/or training programs. Moreover,
the uncomfortable sensations may discourage people to continue
exercise training. Therefore, an initial phase consisting of
submaximal eccentric muscle actions with incremental loading
over multiple sessions should be used to introduce individuals
to eccentric muscle training (LaStayo et al., 2003b). Flann et al.
(2011) demonstrated that a 3-week gradual “ramp up” eccentric
protocol was effective at promoting muscle hypertrophy in
the absence of demonstrable markers of muscle damage. In
clinical interventions, the progressive ramping eccentric protocol
typically starts with load of 50–75 W to reach the target
training load of 400–500 W. Higher loads, over 1,200 W, can
be achieved in competitive athletes (Hoppeler, 2016). A period
of 2–4 days between the exposure stimulus and progressively
higher levels of loading has been suggested as optimal (Hoppeler,
2016). Guidelines to design ramping protocols in rehabilitation
conditions are described in more details by LaStayo et al. (2014).
The exercise duration generally increases from 5–10 min to
20–30 min over the sessions. When using higher load trainings,
four bouts of 5 min seems to be equally effective and less tiring
for subjects (Steiner et al., 2004; Vogt and Hoppeler, 2014).
A training frequency of two sessions per week seems to be the
lower limit to induce measurable gains (Mueller et al., 2009).
When conceiving eccentric interventions, practitioners should
also take into account the parameters affecting the extent and
duration of EIMD and/or slower recovery. Exercises performed at
high vs. low eccentric torque, at long vs. short muscle length and
increasing numbers of eccentric contractions appear to result in
more severe EIMD (Nosaka and Newton, 2002). Skeletal muscles
do not display the same vulnerability to EIMD. The upper limb
muscles appear mostly more affected than lower limb muscles
and the knee flexors more than the knee extensors (Chen et al.,
2011). The untrained status, genetic variations, aging and chronic
diseases are other factors increasing the severity of potential
EIMD (Tidball, 2011; Gault and Willems, 2013; Baumert et al.,
2016). Special attention should thus be given to these populations
when establishing the initial eccentric exercise prescription in
rehabilitation settings.
Even if trained athletes are generally less affected by EIMD
than untrained people when submitting to the same eccentric
protocol, they might not escape to the detrimental effects of
eccentric contractions in some circumstances. They might be
particularly vulnerable to EIMD at the start of the season,
or when they return to competition after injury or following
an unaccustomed eccentric session (Cheung et al., 2003). The
occurrence of EIMD associated with unaccustomed eccentric
exercise could be problematic in athletes because of the
associated negative consequences on locomotor biomechanics
and sport performance within the short term (Cheung et al.,
2003; Assumpcao Cde et al., 2013). Moreover, when athletes
suffered from DOMS, they are frequently unable to train at
their maximal intensity which can compromise the quality
of the training programs. Even if the negative functional
consequences of EIMD are transitory, it seems important to
avoid their onset even in healthy athletes. If EIMD have not
been avoided, it is recommended not to perform high intensity
exercises, particularly explosive efforts. Indeed, the risk of
injuries such as muscle tears or ligament rupture has been
shown to increase due to the disturbed muscle function and
mechanical fragility. Accordingly, it should be kept in mind
that even when muscle hyperalgesia is resolved, a decrease in
muscle function may persist. Care must thus be exerted in
the days following an episode of DOMS (Damas et al., 2016).
When experiencing EIMD, stretching should also be avoided
since it could interfere with recovery. Since EIMD triggers
inflammation response, some practitioners have used non-steroid
anti-inflammatory drugs (NSAIDs) in an attempt to attenuate
the clinical symptoms (Paulsen et al., 2012). Nevertheless, studies
demonstrated that reducing or blocking potential inflammation
response may negatively perturb the muscle cell activity and
hinder the hypertrophy and regenerative processes (Mackey
et al., 2007). Therefore, NSAIDs should be avoided in healthy
subjects (Paulsen et al., 2012). Contrary to this, evidence suggests
that NSAIDs may be beneficial for subjects characterized by
a low-grade systemic inflammation contributing to sarcopenia
(Bautmans et al., 2005; Rieu et al., 2009). In the elderly or in
individuals with chronic disease, the use of NSAIDs may help to
maintain muscle mass (Rieu et al., 2009).
CONCLUSION
The study of eccentric contraction is no longer confined to
muscle physiology and sport sciences but is becoming central
in clinical medicine and is likely to expand in the near future.
Indeed, due to its unique neural, mechanical and metabolic
properties, the eccentric mode has gained a growing interest in
several fields. In addition to its efficiency in sports performance
and rehabilitation, the eccentric training interventions constitute
an attractive strategy to prevent muscle wasting in sarcopenia
or in many chronic diseases. Increasing evidence also support
the beneficial effects of eccentric exercises on body composition
and other health-related parameters, making this contraction
mode a promising tool for various patient populations. However,
unaccustomed eccentric exercise is well known to induce muscle
damage that manifests by a range of clinical symptoms including
DOMS and decreased muscle function. Up to now, there is no
equivocal therapeutic approach allowing a significant attenuation
in the symptoms of damage. Conversely, it has been clearly
demonstrated that repeated exposures to eccentric actions with
progressively increasing loads can prevent the occurrence of
muscle damage or DOMS.
FUTURE PERSPECTIVES
Although the eccentric contraction has received more attention
over the last decade, many questions remain unanswered with
regard to both the initial damaging response to unaccustomed
eccentric contraction and the subsequent adaptations. Further-
more, the mechanisms behind the protective effect conferred
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by a repeated eccentric bout are still in great part speculative.
Yet, the numerous practical applications of eccentric exercise
in sports, rehabilitation and pathological conditions justify the
need to elucidate the mechanisms underlying the acute and
chronic effect of eccentric exercise on the skeletal muscle.
In addition, a better knowledge of the transient eccentric induced
damage and subsequent adaptations on a mechanistic level
may help to further understand the degeneration/regeneration
cycles in healthy skeletal muscle and to identify abnormalities in
these processes in pathological conditions as in neuromuscular
diseases. Given some similarities in the histopathological
alterations that follow unaccustomed eccentric actions with
those observed in muscular dystrophy pathology, further
investigations on the eccentric exercise may unravel crucial issues
in molecular mechanisms frequently involved in neuromuscular
diseases. Investigations employing rigorous standardization of
the experimental conditions in the eccentric and other training
groups are necessary to determine the specific multi-target and to
draw guidelines for eccentric activity prescriptions. In particular,
more efforts should be devoted to develop intensity, duration and
modes of eccentric training optimizing efficiency of this method.
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Movement and regular physical activity are two important factors that help the human
body prevent, reduce and treat different chronic diseases such as obesity, type
2 diabetes, heart diseases, hypertension, sarcopenia, cachexia and cancer. During
exercise, several tissues release molecules into the blood stream, and are able to
mediate beneficial effects throughout the whole body. In particular, contracting skeletal
muscle cells have the capacity to communicate with other organs through the release
of humoral factors that play an important role in the mechanisms of adaptation
to physical exercise. These muscle-derived factors, today recognized as myokines,
act as endocrine and paracrine hormones. Moreover, exercise may stimulate the
release of small membranous vesicles into circulation, whose composition is influenced
by the same exercise. Combining the two hypotheses, these molecules related to
exercise, named exer-kines, might be secreted from muscle cells inside small vesicles
(nanovesicles). These could act as messengers in tissue cross talk during physical
exercise. Thanks to their ability to deliver useful molecules (such as proteins and miRNA)
in both physiological and pathological conditions, extracellular vesicles can be thought
of as promising candidates for potential therapeutic and diagnostic applications for
several diseases.
Keywords: exercise, muscle cells, exocytosis, extracellular bodies, exosomes
INTRODUCTION
Skeletal muscle is the largest organ of our body, responsible for our posture and our movement.
It is equivalent to 2/5 of the whole body weight and it is responsible for more than 3/4 of the
total human metabolism. It is mainly composed of proteins and a fine balance between protein
synthesis and protein degradation regulates its mass. An unbalance in one of these two processes
can lead to the establishment and progression of pathological conditions (Bowen et al., 2015) such
as sarcopenia (slow and normal loss of muscle due to aging, in absence of other diseases) and
cachexia (multifactorial syndrome, characterized by a severe and involuntary loss of muscle mass,
with or without loss of fat mass) (Fearon et al., 2011).
A sedentary lifestyle, physical inactivity and malnutrition (reduction or hyper-caloric intake),
are among the causes that emphasize the accumulation of visceral fat. Therefore, a lifestyle based
on a greater physical activity and a lower energy intake, helps to decrease visceral fat mass content
(Miyatake et al., 2002; Shojaee-Moradie et al., 2007), inflammation (Petersen and Pedersen, 2005;
Mathur and Pedersen, 2008; Nilsson et al., 2019) and the risk of several chronic diseases such as
obesity (Roh and So, 2017), type 2 diabetes (Hu et al., 1999) and cancer (Hojman et al., 2011;
Barone et al., 2016).
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Muscle fiber is the principal unit of skeletal muscle and it
is able to shorten its length because of nervous stimulation.
Its development requires the involvement of several proteins
and it is promoted by the differentiation and fusion of muscle
cell progenitors into myotubes (Mauro, 1961). During physical
activity, these cells are subjected to energetic (metabolic) and
mechanical (contractile) stimuli that improve metabolic health
of skeletal muscle and promote the release of specific molecules
(called myokines), that can alter the function of other tissues
(Stanford and Goodyear, 2018).
Recently, physical activity has also been associated with
the release of extracellular vesicles (EVs) into the circulation
(Fruhbeis et al., 2015). These are nano-sized vesicles that appear
to be involved into cell-to-cell communication and may probably
bring cytokines to distal organs, such as the heart (Bei et al.,
2017). Communication is an essential process in multicellular
organisms, both in physiological and pathological conditions
and it is actuated by the exchange of information through
different mechanisms: direct contact between cells (Cartwright
and Arnold, 1980; Kalimi and Lo, 1988; Franke, 2009), secretion
of soluble factors (Sicard, 1986; Lukacs et al., 1995) or interaction
ligand-receptor (Qi et al., 2001). They are spherical organelles
(originating from intracellular lipid compartments and released
into the extracellular space and the systemic circulation) that
have been discovered as new protagonists of intercellular
communication (Pap et al., 2009; Zomer et al., 2010; Desrochers
et al., 2016; Verweij et al., 2019).
Extracellular vesicles were first considered as cell waste
products, but several studies revealed that they can transfer
signaling molecules among cells in an autocrine, paracrine or
endocrine manner (Lobb et al., 2015). They play a crucial role
in regulating physiological processes (Schweitzer, 1973; Ratajczak
et al., 2006; Kurachi et al., 2016; Niu et al., 2016; Bidarimath et al.,
2017), inducing local and systemic changes that can develop, in
some cases, into the progression of some diseases like cancer
(Becker et al., 2016; Ohyashiki et al., 2018), neurodegenerative
diseases (Vella et al., 2007; Danzer et al., 2012; Guix et al., 2018)
and viral infections (Jaworski et al., 2014; Kalamvoki et al., 2014).
Interest in EVs has grown exponentially in the last 30 years, in
part because most of the cells are able to secrete them. Skeletal
muscle, the organ most represented in our organism, with its
mechanical and secretory activities (Pedersen, 2013) may be
responsible for the release of most of the circulating EVs during
exercise. In fact, our research group has recently demonstrated
that a single bout of exercise induces an increase in the release
of EVs in the blood of healthy mice (Barone et al., 2016). While
another paper described how an event of injury in response to
exercise alters the composition of circulating EVs such as the
content of some micro-RNAs (mi-Rs) (Guescini et al., 2015;
Lovett et al., 2018).
MYOKINES AND THE
CONTRACTING MUSCLE
Physical activity is known to exert beneficial effects on
the prevention of chronic diseases (Zheng et al., 2006;
Mikus et al., 2010; Pedersen and Saltin, 2015), this may
be due to the release of contraction-regulated molecules
(cytokines and myokines) that play a crucial role in the
communication between muscle and other tissues (such as
adipose tissue, liver, and pancreatic cells) (Ahima and Park,
2015). Despite the term “myokine” is generally referred
to any secreted protein synthesized by the skeletal muscle
tissue, it should be effectively used to describe only those
proteins secreted by muscle cells. In fact, the skeletal muscle
also comprise fibrous connective tissue and endothelial
and nerve cells.
Several myokines are synthesized and secreted during
contraction (Pourteymour et al., 2017) like Fibroblast Growth
Factor 21 (FGF-21) (Kim and Song, 2017), Interleukin-6 (IL-
6) (Brown et al., 2018), Interleukin-8 (IL-8) (Covington et al.,
2016), Interleukin-15 (IL-15) (Hingorjo et al., 2018), Leukemia
Inhibitory Factor (LIF) (Broholm et al., 2011), irisin (Lu et al.,
2016), Myostatin (Hjorth et al., 2016), Angiopoietin-like 4
(ANGPTL4) (Norheim et al., 2014), Brain-Derived Neurotrophic
Factor (BDNF) (Fortunato et al., 2018), Follistatin-like 1 (FSTL1)
(Xi et al., 2016) and Vascular Endothelial Growth Factor (VEGF)
(Gomes et al., 2017). Their expression in skeletal muscle is
generally very low, but the levels of some of these myokines
increase considerably during muscle contraction (FGF-21, IL-6,
IL-15, irisin and BDNF among others) (Table 1). Moreover, the
use of different exercise-based protocols (aerobic or resistance
exercise training) can affect their secretion (Guescini et al.,
2015; Schild et al., 2016; Abd El-Kader and Al-Shreef, 2018;
Brown et al., 2018).
FGF-21 is an endocrine hormone belonging to the family
of fibroblast growth factors (FGFs), which plays an important
role in response to liver starvation, in lipolysis and glucose
uptake in adipose tissues and skeletal muscle. It enhances the
utilization of energy substrates (fatty acids, ketones and glucose)
and meddles with energy consuming processes (lipogenesis
and growth). Moreover, under certain conditions (such as
cold), it can stimulate the activation of brown adipocytes and
promote adaptive thermogenesis (Wu et al., 2013). It is also
involved in mechanisms related to physical activity; in fact, its
levels increase in acute exercise (in both human and mice),
enhancing the phosphorylation of protein kinase B (Akt) and
the translocation of Glucose Transporter Type 4 (GLUT4) to
the muscle cell membrane, with consequent glucose uptake
(Tanimura et al., 2016). Some results are controversial. For
example, Cuevas-Ramos et al. (2012) proved that its serum levels
increase only after 2 weeks of daily physical activity and no
change was observed after a single bout of exercise. Chronic
exercise and FGF-21 also induces the expression of Peroxisome
proliferator-activated receptor Gamma Coactivator -1α (PGC-
1α), a transcriptional protein factor that interacts with various
DNA-binding proteins resulting in increased gluco-neogenesis,
fatty acid oxidation, ketogenesis and mitochondrial biogenesis
(Barone et al., 2016, 2017).
Interleukins are another important class of molecules released
during exercise, especially IL-6, IL-8 and IL-15 (Ostrowski et al.,
1999; Peake et al., 2015). They are small molecules belonging
to the class of cytokines and constitute one of the most
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TABLE 1 | Principal myokines and exerkines released and regulated during physical activity.
Contracting Exerkines Levels of myokine Reference
FGF-21 Increase Cuevas-Ramos et al., 2012; Kim and Song, 2017
IL-6 Increase Papanicolaou et al., 1996
IL-8 Increase Mucci et al., 2000; Covington et al., 2016
IL-15 Increase Nielsen et al., 2007; Hingorjo et al., 2018
Irisin Increase Kraemer et al., 2014
BDNF Increase Gomez-Pinilla et al., 2002; Fortunato et al., 2018
ANGPTL4 Increase Norheim et al., 2014
LIF Increase Broholm et al., 2011
FSTL-1 Increase Xi et al., 2016
VEGF Increase Gustafsson et al., 2001; Gomes et al., 2017
Myostatin Decrease Hittel et al., 2010
important communication systems among cells, defending the
body (Nelson and Summer, 1998).
IL-6 is a pleiotropic cytokine, able to work as a pro- and
anti-inflammatory molecule (Petersen and Pedersen, 2006; Yao
et al., 2014), cardiovascular risk factor and regulator of lipid
metabolism (Bao et al., 2015). It also acts as a myokine and its
concentration increases up to 100-fold in response to muscle
contraction (Agarwal et al., 2017), mediating anti-inflammatory
responses and metabolic adaptations. It may reduce the incidence
of cardiovascular diseases through lipid and glucose metabolism
and the suppression of pro-inflammatory cytokines. During
exercise, it acts both locally (inside the muscle) and peripherally
(in several organs, such as white adipose tissue WAT) acting as
a hormone. In WAT, it affects adipose tissue metabolism and
lipolysis, with the release in the circulation and oxidation of fatty
acids (Knudsen et al., 2017) while in skeletal muscle, it activates
5′-Adenosine Monophosphate-activated Protein (AMP) and/or
Phosphatidylinositol 3-kinase (PI3 kinase) to increase glucose
uptake and fat oxidation (Pedersen, 2009).
IL-15 is one of the most abundantly expressed cytokines
in human muscle, involved in the regulation of adiposity,
muscle mass, exercise capacity and mitochondrial activity in
muscle cells (Thornton et al., 2016). Historically studied as an
activator of Natural Killer (NK) cells (with anti-tumorigenic and
anti-inflammatory properties) (Gosselin et al., 1999), its levels
strongly increase after resistance exercise, promoting muscle
growth (Nielsen et al., 2007). Similar to IL-6, its activity is
strongly correlated to the AMP-protein kinase (AMPK), a central
regulator of metabolism; indeed, it was shown that lacking muscle
AMPK reduces serum IL-15, causing the acceleration of skin
aging (Crane et al., 2015). IL-15 has also anti-tumorigenic effects;
in fact, Carbo et al. (2000) showed that, in tumorigenic rats
treated with IL-15, it partly inhibits skeletal muscle wasting
protein rates (eight-fold) to values even lower than those
observed in non-tumor-bearing animals.
Irisin is a secreted myokine that originates from the
cleavage of its precursor fibronectin type III domain-containing
protein 5 (FNDC5) (Huh et al., 2012). Firstly known as a
molecule responsible for the browning of WAT (Giralt and
Villarroya, 2013), it was also shown that its levels strongly
increase after resistance exercise (Miyamoto-Mikami et al., 2015;
Zhao et al., 2017), but not in aerobic training (Kim et al., 2016).
Moreover, it was also recently proposed as a novel marker for
patients with cardiac cachexia (Kalkan et al., 2018). Even if it
was shown that it can mediate those beneficial effects that follow
exercise (inducing the expression of pro-myogenic genes in
myotubes), its role in physical activity still remain controversial.
In fact, on one hand, Blizzard Leblanc et al. (2017) shown a
significant increase in irisin plasma levels after an acute bout
of aerobic exercise, also associated with the improvement in
insulin sensitivity. These data were also confirmed by Nygaard
et al. (2015), which further showed that single sessions of intense
endurance exercise and heavy strength training led to transient
increase of plasma concentration, without an increase in FNDC5
expression (Pang et al., 2018). However, on the other hand, a
pivot study in hemo-dyalised patients proved that there was no
correlation between intense intra-dialytic strength exercise and
the increase of circulating irisin (Esgalhado et al., 2018). Also,
the research group of Biniaminov et al. (2018) investigated the
association among resting irisin concentrations, regular physical
activity and physical fitness in serum of healthy humans; they
found that nor physical activity level, neither fitness status were
related to resting irisin concentrations in healthy humans.
Considering its potential beneficial effects during training,
Reza et al. (2017) investigated its capability to act as an exercise
mimetic. They injected wild-type mice with irisin and observed
an increase in body weight, skeletal muscle mass and muscle
strength, suggesting that irisin induces fiber hypertrophy and
enhances regeneration of injured muscle cells, through the
activation of satellite cells and protein synthesis.
Overall, the way irisin works is still largely unknown. However,
it may be that it exerts its activity in a way similar to that of
interleukins, through AMP kinase.
Another important myokine released during physical exercise
is the BDNF (Gomez-Pinilla et al., 2002), a type of neurotrophic
molecule mainly involved in memory and cognitive development
(Heldt et al., 2007). This molecule is the product of the proteolytic
cleavage of its precursor protein (proBDNF) (Koshimizu et al.,
2009). BDNF and proBDNF often have opposing actions; in
fact, while BDNF promotes synaptic long-term potentiation
and stress resistance, proBDNF enhances longterm depression
(Teng et al., 2005).
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Brain-derived neurotrophic factor has neurobiological and
metabolic effects, regulating the survival (Hofer and Barde, 1988),
growth (Kalcheim and Gendreau, 1988) and maintenance of
neurons (Griesbeck et al., 1995). Its association with physical
activity is already known (Almeida et al., 2016; Church et al.,
2016); in fact, its expression not only increases after exercise (Park
and Kwak, 2017) but also depends on the intensity of exercise
(Jeon and Ha, 2017). Previous studies demonstrated that its
mRNA and protein expression levels increase in human skeletal
muscle after exercise without any release into the circulation
(Matthews et al., 2009). Indeed, it acts as a contraction-inducible
protein that enhances fatty acid oxidation through the activation
of AMPK in the skeletal muscle. Thus, it does not act in a
hormone like manner, but as an autocrine and/or paracrine
molecule within the skeletal muscle tissue (Matthews et al., 2015).
EXTRACELLULAR VESICLES: ORIGINS
AND FUNCTIONS
First characterized in 1967 in hematopoietic cells (Wolf, 1967),
EVs are small particles composed of a lipid bi-layer containing
multiple molecules derived from the cytosol and from the
cellular membrane of the donor cell (Akers et al., 2013).
They constitute a heterogeneous population that differs in
cellular origin, size, morphology, antigenic composition and
functional properties (Table 2). Isolated from different body
fluids (including blood, urine, saliva, breast milk, amniotic fluid,
ascites, cerebrospinal fluid, bile and seminal fluid) (Colombo
et al., 2014), these vesicles are involved in the communication
of both prokaryotes and eukaryotes. Despite the fact that their
name originally referred to their size (apoptotic bodies > 800 nm,
microparticles in a range of 0.1–1 µm and exosomes with
diameter of 40–150 nm), their tissue of origin (prostasomes,
oncosomes) and their function or their presence outside the cells
(exosomes), one of the last classifications of EVs, focused on
their biogenesis pathways (Kalra et al., 2016). However, there
is still no consensus on specific EV subtypes markers, such
as endosome-origin “exosomes” and plasma membrane-derived
“ectosomes” (microparticles/microvesicles); therefore, assigning
an EV to a particular biogenesis pathway remains difficult unless
the EV is caught during its release in live imaging techniques.
Hence, in order to classify a particular vesicle to a specific EV
subtype, MISEV 2018 suggested considering several parameters
such as: size [“small EVs” (sEVs) and “medium/large EVs” (m/l-
EVs)], density (low, middle, high), biochemical composition
(CD63+, CD81+, Annexin A5), description of their tissue of
origin (prostasomes, oncosomes), their function or their presence
outside the cells, or their biogenesis pathway (Théry et al., 2018).
Extracellular vesicles obtained from differential
ultracentrifugation have been classified into: large EVs, pelleted
at low speed; medium-sized EVs, pelleted at intermediate speed
and small EVs (sEVs), pelleted at high speed. The latter were
further subdivided into four sub-categories: (1) sEVs rich in
tetraspanines CD63, CD9 and CD81 and endosomal markers
(better known as exosomes); (2) sEVs without CD63 and CD81,
but rich in CD9; (3) sEVs without CD63/CD9/CD81; (4) sEVs
rich in extracellular matrix or serum factors. The last two-listed
sEV are not associated with exosomes (Kowal et al., 2016).
Their molecular composition reflects the specific functions
of the cells from which they originate and, for this reason,
their cargo is defined as cell-type specific. They generally
carry several molecules, such as proteins, nucleic acids (largely
represented by mRNA and miRNA) and lipids, and their protein
composition is similar to that of the plasma membrane and of
the endocytotic and subcellular compartments of the budding cell
(Gutierrez-Vazquez et al., 2013). In particular, exosome protein
content is mainly divided in four categories: transmembrane
or lipid bound extracellular proteins (tetraspaninins like CD9,
CD81, CD63), cytosolic proteins normally involved in their
biogenesis (RAB proteins, Hsp70, Hsp90), intracellular proteins
unique of cellular organelles and typically absent in exosomes
(calnexin, Golgi and ER proteins) and extracellular proteins,
such as acetylcholinesterase (ACHE). When characterizing these
particles, at least one protein of each category should be identified
(Lotvall et al., 2014). Therefore, membrane and cytoskeletal
proteins, lysosomal markers enzymes, death receptors (FasL,
TRAIL), cytokines, HLA class I and II proteins, and some HSPs
can be part of these vesicles. As well as their molecular content,
even their functions are closely related to their cellular origin,
being involved in several mechanisms such as immune response
and inflammation (Zhang et al., 2014).
Despite the fact that the lipid composition of these
nanovesicles is still not well known, we know that EVs are mainly
composed of sphyngolipids, phosphatidyl serine, cholesterol
(possibly involved in exosomes release), saturated fatty acids and
ceramide (Pfrieger and Vitale, 2018).
The mechanisms underlying the biogenesis of EVs are
different among various types of vesicles. Apoptotic bodies
(>800 nm) are particles that cells produce during the apoptotic
process. During programmed cell death, membrane protrusion
known as apoptopodia (Atkin-Smith et al., 2015) release (in the
extracellular space) vesicles (apoptotic bodies) resulting from
the fragmentation of the apoptotic cell (Coleman et al., 2001).
Ectosomes (0.1–1 µm), also known as shedding vesicles or
microparticles, originate from plasma membrane through an
outward budding of the membrane; in this process, the increase
of intracellular Ca2+, induced by an external signal, causes
changes in lipid distribution and membrane blebbing, through
the alteration of the enzymatic activity of flippases, translocases
and scramblases (Willms et al., 2018). This increment of internal
Ca2+ enhances the activation of cytosolic proteases (such
as calpain and gelsolin), which re-organize the cytoskeleton
(through the deconstruction of the actin cytoskeletal protein
network) and causing plasma membrane protrusion with
consequent detachment of these vesicles (Turturici et al., 2014;
Cocucci and Meldolesi, 2015).
Exosomes (<150 nm) are the most studied small vesicles,
especially because of their small size and internal content that
reflects that of the cell of origin. They are mostly defined by
their size and their protein content, despite the fact that in
literature the term “exosome” is improperly used to refer to small
EVs (Wang et al., 2017). Their biogenesis is a well-organized
process, mainly characterized by exocytosis through an active
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TABLE 2 | Types of extracellular vesicles and most common markers.
Apoptotic Bodies Microvesicles-Ectosomes Exosomes
(small-medium-large)
Size >800 nm 0.1 nm–1 µm 30–150 nm
Biogenesis Apoptosis Outward budding of plasma membrane Endocytosis
Common Markers Chemokine (C-X3-C motif) ligand 1 X3CL1













Reference Groves and Ellwood, 1985; Catchpoole and
Stewart, 1995
Surman et al., 2017 Kowal et al., 2016
FIGURE 1 | Cells releasing extracellular vesicles. Representation of different extracellular vesicles. Brown particles represent Apoptotic Bodies (>500 nm), forming
during the apoptotic process; while the yellow and orange vesicles represent Microparticles (>150 nm) and Exosomes (30–150 nm) generated respectively by
outward budding of the membrane and endocytosis.
involvement of the membrane. The process starts with the
invagination of the plasma membrane and the development of
the early endosome (EE), a membrane bounded compartment
within the cell. Subsequently, the inner budding of the membrane
of the early endosome replaces the already existing endosomal
luminal space with small intraluminal vesicles (ILVs) and forms a
body called Multi-Vescicular Body (MVB) or late endosome (LE).
The latter is filled with proteins, lipids, and cytoplasm specifically
sorted (Gutierrez-Vazquez et al., 2013; Hessvik and Llorente,
2018). At this point vesicles within the MVB can undergo three
different fates: merge with the lysosomes and be degraded in their
protein content; constitute a momentary deposit compartment
or merge with the plasma membrane, releasing its intraluminar
vesicles in the extracellular space as exosomes (Figure 1) (Caruso
Bavisotto et al., 2017; Sutaria et al., 2017). The development of
ILVs and MVBs is a process that requires the participation of the
Endosomal Sorting Complex Required for Transport (ESCRT),
a complex composed by almost 30 proteins assembled into 4
components: ESCRT 0, ESCRT I, ESCRT II and ESCRT III.
ESCRT 0 is involved in the recognition and the sequestration
of ubiquitinated transmembrane proteins into the endosomal
membrane; ESCRT II and I are responsible for the membrane
deformation into buds with specific cargo; the last complex
is implicated into the detachment of the formed vesicle. Even
though the mechanism involved in exosomes secretion is still
not well understood, it is likely that the increase of internal
Ca2+, followed by a cytoskeleton remodeling, is involved in their
release. Once in the extracellular space, these vesicles can be either
internalized by the receiving cell through endocytosis processes,
or they act as transmembrane signals by binding receptors on the
plasma membrane and activate specific cellular pathways (Feng
et al., 2010; Mulcahy et al., 2014). It was also thought that their
uptake can be due by a “passive endocytosis” which occurs during
the natural recycling of the plasma membrane and could passively
take up exosomes attached to the surface of a cell.
Currently, the characterization of these vesicles is a
combination of several methods that include microscopy
(TEM, SEM, CrioTEM), Western Blot, Flow Cytometry,
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Nanoparticle Tracking Analysis (NTA), Tunable Resistive Pulse
Sensing (TRPS), Dynamic Light Scattering (DLS) and immuno-
histochemical analysis of specific EVs markers, used to describe
their morphology, biochemical composition and the receptors
localized on these vesicles (Szatanek et al., 2015) (Table 3).
However, one of the main issue when purifying these particles
is that, currently, there is no consensus for a unique standard
isolation protocol. Ideally, the method used for their isolation
should be simple, fast and inexpensive.
Overall, there are three main methodologies used for
their isolation: differential centrifugation/ultracentrifugation
with/without a sucrose gradient/cushion, adsorption to
magnetic/non-magnetic micro-beads and size exclusion
chromatography. Each has its own advantages and the choice
of one method rather than another can result in different EV
subpopulations with different properties (Konoshenko et al.,
2018). Hence, one important challenge is the absence of a
unique method able to minimize co-isolating protein aggregates
and other membranous particles from a pure sample of EVs.
Currently, the gold standard for pure exosome preparation is
differential ultracentrifugation coupled with sucrose/iodixanol
density gradient. Van Deun et al. (2014) isolated EVs with 4
commonly used methods (ultracentrifugation, density gradient,
exo-kit and total exosome isolation) for the evaluation of
yield, size, morphology, protein and RNA content of exosome.
They demonstrated that density gradient ultracentrifugation
gave the purest exosome preparations, while the other three
techniques also co-isolate contaminating factors. Similarly,
Skottvoll et al. (2019) evaluated the performance of different
isolation methods based on differential ultracentrifugation and
a commercial isolation kit (total exosome isolation reagent).
These results shown that the two isolation methods had
similar performance with only some differences based on
the origin of the cell. In another study, the results published
by Gamez-Valero et al. (2016) suggested that size-exclusion
chromatography (SEC) is capable of eliminating most of the
abundant proteins contained in a body fluid, also maintaining
the EVs vesicular structure and conformation, thus making this
procedure ideal for biomarker discovery as well as for therapeutic
applications. Benedikter et al. (2017) also confirmed these data,
demonstrating that ultrafiltration followed by size exclusion
chromatography (UF-SEC), provides well-concentrated EVs
for proteomic and functional analysis. Indeed, because of
its efficient capability to separate EVs from contaminant
proteins (especially from large initial volumes) UF-SEC gives
a higher yield of pure vesicles if compared to those isolated by
simple ultracentrifugation.
Interest on EVs is growing very fast over the years. Thanks to
their characteristics (specifically their non-immunogenic nature
due to the similar composition to the cell from which they
originate) they were recently taken into consideration for their
use as drug delivery vehicles (Batrakova and Kim, 2015).
Actually, liposomes are used as drug delivery vehicles, but
their biocompatibility and their safety are still unknown. Unlike
these synthetic systems, exosomes have long circulating half-life,
promise to be biocompatible and stable, and have minimal or no
inherent toxicity issues. Moreover, thanks to their small size, they
are able to cross the blood-brain barrier (BBB), thus providing a
useful carrier for the delivery of small drugs across this area.
Ninety-eight percent of drugs potentially important for the
central nervous system cannot cross the BBB and their conceptual
efficacy shown in labs has not a counterpart in clinical trials
(Haney et al., 2015). Moreover, thanks to their capability to
carry different molecules (protein and miRNA among others),
they can also eliminate problems related to the instability of
nucleic acid based drugs (Liang et al., 2018). Furthermore, the
possibility to isolate them from all biological fluids, suggests
their use for diagnostic applications, providing a non-invasive
diagnostic method. For instance, they can be used for diagnosis
since circulating exosomes can be correlated to specific diseases
(Aryani and Denecke, 2016). For these reasons, if compared with
their synthetic counterparts, they seem to be a better choice,
TABLE 3 | Most common extracellular vesicles isolation and characterization methods.
Isolation References Characterization References
Ultracentrifugation Thery et al., 2006 Electron Microscopy: TEM; SEM;
cryo-EM
Escola et al., 1998; Poliakov




Zhang et al., 2014 Dynamic Light Scattering (DLS);
Nanoparticle Tracking Analysis (NTA);
Tunable Resistive Pulse Sensing (TRPS)
Kesimer and Gupta, 2015
Gercel-Taylor et al., 2012
Maas et al., 2014
Size Exclusion
Chromatography (SEC)




Logozzi et al., 2009; Pedersen et al., 2017 Flow cytometry Pospichalova et al., 2015
Polymer-based precipitation Brown and Yin, 2017 Omics analysis: Proteomic; Lipidomic Schey et al., 2015; Haraszti
et al., 2016
Flow-field-flow fractionation Sitar et al., 2015
Commercial Kits ExoQuick
Total Exosomes Isolation (TEI)
Exo-Spin (ExoS)
Ding et al., 2018
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exceeding those synthetic nanoparticles limitations. That’s why
they have aroused a lot of interest as a drug delivery system for
the treatment of several chronic and neurodegenerative diseases
(Ha et al., 2016).
Nowadays their use as a drug delivery system for small
molecules, proteins and nucleic acids is already a true reality;
Alvarez-Erviti et al. (2011) showed that intravenously injected
Rabies Virus Glycoprotein (RVG) targeted exosomes delivered
GAPDH siRNA specifically in the brain, resulting in a specific
gene knockdown. A similar result was also confirmed by Liu
et al. (2015), showing that exogenous siRNA transfected into
cells can be packaged by exosomes and delivered into recipient
cells to regulate gene silencing, indicating that exosomes can
serve as siRNA delivery vesicles in gene therapy for cancer
and other diseases. In another study, large size plasmid DNA
encapsulated into exosomes was successfully transferred to
MSCs (Lin et al., 2018). Sun et al. (2010) treated mice with
curcumin carrying exosomes, demonstrating that they were
protected against lipopolysaccharide (LPS)-induced septic shock.
Curcumin was more stable both in vitro and in vivo. In a similar
study, Gomari et al. (2018) encapsulated doxorubicin (a drug
currently used for breast and solid cancer) into exosomes to
increase local dosage of the molecule and reduce its adverse
effects on other organs. Considering their ability to deliver large
molecules (such as proteins), Khatua et al. (2009) demonstrated
that human cytidine deaminase APOBEC3G (A3G), a cellular
defense system against human immunodeficiency virus type 1
(HIV-1) and other retroviruses, can be secreted in exosomes
conferring an antiviral phenotype to target cells, also limiting
replication of the virus in recipient cells.
However, despite several evidences of their potential as drug
delivery system, one of the principal obstacles for the application
of exosomes in clinic is their final yield from donor cells, which is
often very limited and strongly related to the protocol of isolation
(Van Deun et al., 2014). In addition, they may act as vehicles
for the replication and propagation of transmissible pathogens,
since exosomes derived from bacteria, or virus-infected cells,
might contain pathogen-derived factors that activate a pro-
inflammatory pathway. Plus exosomes have also a different
effect on health and diseases; indeed, despite some of them can
prevent tumor development (Naseri et al., 2018; Rosenberger
et al., 2019), others provide a communication system between
tumor cells and the surrounding tissues (Haga et al., 2015;
Keklikoglou et al., 2019).
In the last few years, researchers have started to combine
exosomes with synthetic nanoparticles, developing engineered
particles more efficiently than their natural counterparts do.
For instance, Sato et al. (2016), to control and modify the
performance of exosomal nanocarriers, realized hybrid exosomes
fusing them with polyethylene glycol (PEG) liposomes. This
modification facilitated cellular uptake of the PEG modified
exosomes, reducing also their circulation time in the blood.
Other researchers created exosome-mimetic nanovesicles by
serial extrusions through polycarbonate membranes with pore
sizes of 10, 5, and 1 µm, for their utilization in tissue repair and
regeneration. These exosome-mimetic nanovesicles (NVs) had a
final yield almost 100 times higher than exosomes and promoted
cell proliferation and liver regeneration similar to that induced by
exosomes (Wu et al., 2018).
EVs AND EXERCISE: EVs CHANGES
INDUCED BY EXERCISE
The capacity of myokines to positively influence the metabolism
and homeostasis of the body, makes them promising targets
for treatment of several diseases. However, little is known
about the mechanisms that regulate the release of these
factors, especially regarding the final steps in recruitment
and exocytosis of specific secretory vesicles. In fact, despite
muscle cells express several secretory vesicle transport proteins
(Romancino et al., 2013), the mechanisms that target containing
vesicles to particular regions in the plasma membrane to
control myokine secretion are largely unknown. Some studies
demonstrated that glucose receptor GLUT4 is translocated to the
plasma membrane in Vesicle-Associated Membrane Protein 2
(VAMP2) labeled vesicles and, its translocation, requires an active
remodeling of actin filament which can be induced by insulin
(Giudice and Taylor, 2017).
Exercise triggers the release of exerkines (EXs) into the
circulation, possibly through their encapsulation within EVs
(Gorgens et al., 2015; Lombardi et al., 2016) that mediates the
systemic benefits of physical exercise, in both physiological and
pathological conditions (Safdar et al., 2016). In fact, it was shown
that in patients with cardio-metabolic risk factors, acute exercise
promoted a large release of plasma EVs (Bei et al., 2017). A similar
mechanism of communication among cells was already seen
during high energy demand related to exercise; in this case,
cells released enzymes of the glycolytic pathway into the EVs,
that probably influenced the glycolytic rate in the recipient cells
(Garcia et al., 2016; Zhao et al., 2016).
Whitham et al. (2018) analyzed (by means of the Nano-
UHPLC followed by mass spectrometry) the proteome of the
EVs of human plasma (before and after exercise), demonstrating
how the EV trafficking was involved in tissue cross talk during
physical activity. Indeed, exercise induces an increase of more
than 300 proteins in the circulation, many of them associated with
the biogenesis and function of “small vesicles” and exosomes.
They identified 35 new myokine candidates, supporting the
idea that the skeletal muscle is one of the major distributors
of secreted molecules during exercise (Deshmukh et al., 2015).
Some of these molecules were also found in EVs collected from
myotubes conditioned medium (Forterre et al., 2014), but also
from plasma and serum of participants who had walking speed
decline (Suire et al., 2017). Another interesting data obtained
by Petersen et al. (2011), showed the amino acid sequences of
each protein transported inside these vesicles. Using the SignalP
4.0 server, they revealed that these proteins were deprived of
the signal peptide sequence, typical of the classical secretion
pathway. According to the obtained results, they postulated that
the increase of EVs into the circulation (induced by exercise),
can be related to the mechanism by which the skeletal muscle
releases myokines, in a way independent of the classic secretory
pathway. Moreover, exosome release is generally associated with
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an increase of intracellular calcium (Savina et al., 2003); since
the motoneuron stimulates skeletal muscle fibers (causing an
immediate release of Ca2+ from the sarcoplasmic reticulum)
(Melzer et al., 1984), it may be plausible that the release of muscle
small vesicles is faster than in other organs. However, uptake
of the EVs in the recipient cells during exercise is a necessary
step to talk about tissue cross talk and the reduction of the
amount of proteins within the EVs (4 h after exercise), suggests
that these proteins are partially removed from the circulation by
tissue absorbing.
Therefore, exosomes and sEVs may act as communicator
factors among cells, through the packaging of proteins
inside their lumen.
CONCLUSION
Even though it has been widely proved that, during exercise,
muscle cells release several myokines into the circulation with
a potential role in whole-body homeostasis (Aswad et al., 2014),
the mechanisms underlying this secretion process are still vaguely
known. Since calcium is an essential ion involved in both
extracellular vesicles secretion and contraction of skeletal muscle
fibers, it may be possible that, during exercise, the stimulation
of muscle cells from motoneurons enhances the release of
small vesicles potentially carrying myokines. However, there
are almost no studies about that, hence, further analysis are
needed in order to better understand the relationship between
nanovesicles and myokines.
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Exercise and supplementation with conjugated linoleic acid (CLA) are used to reduce
body weight and to improve health. Applied together, they may exert a synergistic
effect. However, the effects of exercise and CLA supplementation on liver metabolism
are poorly understood. The aim of this study was to examine the influence of exercise
and CLA supplementation on fatty acids (FA) composition in mouse liver. We analyzed
44 of known FAs of this organ by gas chromatography-mass spectrometry. Our results
demonstrated that exercise contributed to a decrease in odd-chain FA and an increase
in n-6 polyunsaturated FA contents. In turn, CLA stimulated an increase in branched-
chain FAs and n-3 polyunsaturated FAs. Exercise combined with CLA supplementation
caused a substantial increase in branched-chain FA content and a slight increase in n-6
polyunsaturated FAs. The elevated liver content of branched-chain FAs after the exercise
combined with CLA supplementation, as well as the increase in n-3 polyunsaturated
FAs after CLA may be favorable since both these FA groups were previously shown to
produce health benefits. However, the expression pattern of enzymes involved in fatty
acid synthesis did not match the changes in FA composition. Thus, the mechanism of
exercise- and CLA-induced changes in liver FA profile is yet to be established. Also, the
consequences of CLA- and/or exercise-induced changes in the composition of liver FAs
need to be elucidated.
Keywords: fatty acid, liver, exercise, myokine, conjugated linoleic acid
INTRODUCTION
The hepatic fat composition is determined by a number of processes, e.g., de novo lipogenesis,
delivery of lipids to the liver from diet or adipose tissue, hepatic lipid oxidation and secretion
of intrahepatic lipids to the circulation (Lira et al., 2012; Brouwers et al., 2016). Alterations of
these processes are responsible for deposition of the intrahepatic lipids and development of non-
alcoholic fatty liver (Brouwers et al., 2016), a condition associated with obesity, insulin resistance
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and metabolic syndrome (Mika et al., 2017). The hepatic
fat composition may also be modified by extrinsic factors,
including physical exercise and supplementation with various
FAs. While the beneficial effects of exercise on skeletal muscle
metabolism have been described in detail, little is known on
the influence of physical training on liver metabolism (Brouwers
et al., 2016). Previous studies demonstrated that moderate
exercise might prevent accumulation of fat in the liver through
diminished delivery of lipids to this organ, enhanced hepatic
oxidation and increased incorporation of triacylglycerol (TG)
into very low-density lipoprotein (VLDL) (Lira et al., 2012;
Brouwers et al., 2016; Oh et al., 2017). Conjugated linoleic acid
(CLA) has been advertised and promoted as a pro-health and
weight loss promoting supplement since the mid-1990s. While
supplementation with CLA, indeed, leads to a decrease in body
adiposity (Barone et al., 2013; Macaluso et al., 2013), it was
also shown to induce hepatic steatosis and to reduce the levels
of n-3 and n-6 polyunsaturated FAs (PUFAs) in mouse liver,
although these effects seem to be CLA isomer-specific (Vyas
et al., 2012). Furthermore, the results of another study involving
rats suggest that CLA may, in fact, attenuate liver steatosis
(Purushotham et al., 2007).
The aim of the present study was to explore and discuss,
using preliminary data, the effects of physical exercise
and supplementation with CLA, applied either alone or in
combination, on the composition of FAs in mouse liver. Various
FAs exert different effects on cell metabolism; for example, n-3
PUFAs are anti-inflammatory fatty acids (FA), whereas saturated
FAs (SFAs) induce inflammation (Mika and Sledzinski, 2017).
Both physical exercise and supplementation with CLA are used
to reduce body weight and to improve health. The effect of both
treatments on FA composition in the liver may be vital for the
functioning of this organ.
MATERIALS AND METHODS
Animals and Treatment
The study included 32 young (7-week-old) male mice
(BALB/cAnNHsd) obtained from Harlan Laboratories S.r.l.
(Italy). The mice were maintained under a constant 12:12-h
light-dark cycle with free access to food and water. The protocols
of all animal experiments were approved by the Committee on
the Ethics of Animal Experiments at the University of Palermo
(Italy), and compliant with the Guide for the Care and Use of
Laboratory Animals of the National Institute of Health (NIH).
The study mice were randomized into four groups, eight
animals each: placebo sedentary (PLA-SED), CLA sedentary
(CLA-SED), placebo trained (PLA-TR), and CLA trained (CLA-
TR). Through the 6-week experiment period, animals from both
CLA groups (CLA-SED and CLA-TR) were gavaged with 35 µl
d-1 of Tonalin R© FFA 80 food supplement (Cognis Nutrition
and Health, Germany) containing CLA, whereas mice from the
placebo groups (PLA-SED and PLA-TR) received 35 µl d-1 of
sunflower oil via the same route (Macaluso et al., 2012; Barone
et al., 2013, 2017). The gavaged quantities correspond to the
0.5% of food ingested, approximately 4 g (Barone et al., 2013).
Tonalin R© FFA 80 is derived from safflower oil and contains a 50:50
ratio of the active CLA isomers (C18:2 c9, t11 and C18:2 t10, c12).
Animals from both trained groups (PLA-TR and CLA-TR)
were trained on a motorized Rota-Rod (Ugo Basile, Biological
Research Apparatus, Italy) 5 days/week over a period of 6 weeks.
The endurance training began at 3.2 m/min for 5 days/week;
during week 1, the mice exercised for 15 min, and the time and
speed were systematically increased until week 6, where they
were training at 4.8 m/min for 60 min (Di Felice et al., 2007;
Barone et al., 2016a). Mice from the sedentary groups (PLA-SED
and CLA-SED) did not perform any controlled physical activity
throughout the period of the experiment. At 48 h from the end
of the last exercise session, all mice were sacrificed by cervical
dislocation, and their livers were harvested and weighed (Barone
et al., 2016b). The liver was frozen in liquid nitrogen and stored
at −80◦C for further analyses.
GCMS Analysis of Fatty Acid
Composition in the Liver
The liver samples were extracted in a chloroform-methanol
mixture (2:1, v/v) (Folch et al., 1957). Extracted lipids were
hydrolyzed with 0.5 M KOH, and the profile of FA methyl
esters were determined by gcms using Zebron 5MSi capillary
column and electron ionization source, as described previously
(Sledzinski et al., 2013).
Analysis of mRNA Levels
Total mRNA was isolated from 25 mg of mouse liver using
GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich,
MO, United States), in line with the manufacturer’s instructions.
The quality of the resulting RNA was assessed by automated
gel electrophoresis (Experion, Bio-Rad Laboratories). Reverse
transcription and quantitative real-time PCR were conducted as
described previously (Czumaj et al., 2018). The primer sequences
are presented in Supplementary Table 1.
Immunofluorescence and Confocal
Analysis
For immunofluorescence, deparaffinised sections were incubated
in the antigen unmasking solution (10 mM tri-sodium citrate,
0.05% Tween-20) for 8 min at 75◦C, and treated with a blocking
solution (3% BSA in PBS) for 30 min. The primary antibody
(anti-BCKDHA, diluted 1:50 in PBS, rabbit polyclonal ab90691,
Abcam; Cambridge, United Kingdom; anti-BCKDHA (phospho
S293), diluted 1:50 in PBS, rabbit polyclonal ab200577, Abcam;
anti-ELOVL6, diluted 1:200 in PBS, rabbit polyclonal ab69857,
Abcam) was applied and the sections were incubated in a
humidified chamber overnight at 4◦C. Then, the sections were
incubated for 1 h at room temperature with a conjugated
secondary antibody (anti-rabbit IgG-FITC antibody produced in
goat, diluted 1:100 in PBS, F0382, Sigma-Aldrich, St. Louis, MO,
United States). Nuclei were stained with Hoechst Stain Solution
(diluted 1:1000 in PBS, Hoechst 33258, Sigma-Aldrich). The
slides were treated with PermaFluor Mountant (Thermo Fisher
Scientific, Inc., Waltham, MA, United States) and cover slipped.
The images were captured using a Leica Confocal Microscope
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TABLE 1 | Fatty acid composition of livers in the studied groups of mice.
The group of fatty acids Fatty acid PLA SED (% of total
tissue FA ± SEM)
CLA SED (% of total
tissue FA ± SEM)
PLA TR (% of total
tissue FA ± SEM)
CLA TR (% of total
tissue FA ± SEM)
Even-chain saturated FA (ECFA) C10:0 Traces 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
C12:0 0.09 ± 0.03 0.12 ± 0.04 0.09 ± 0.03 0.09 ± 0.01
C14:0 0.42 ± 0.07 0.35 ± 0.30 0.43 ± 0.02 0.52 ± 0.13
C16:0 26.77 ± 0.73 26.29 ± 1.70 26.13 ± 0.61 27.36 ± 0.56
C18:0 10.74 ± 1.23 10.99 ± 0.82 9.46 ± 0.34 8.73 ± 0.66∗
C20:0 0.39 ± 0.03 0.50 ± 0.20 0.28 ± 0.05∗ 0.30 ± 0.01#
C22:0 0.20 ± 0.02 0.24 ± 0.08 0.18 ± 0.03 0.17 ± 0.00#
C24:0 0.09 ± 0.02 0.10 ± 0.02 0.07 ± 0.02 0.06 ± 0.00
Total ECFA 38.70 ± 1.92 38.54 ± 1.62 36.64 ± 0.81 37.23 ± 1.07
ODD-chain saturated FA (OCFA) C11:0 Traces 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
C13:0 0.01 ± 0.00 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00
C15:0 0.11 ± 0.02 0.12 ± 0.02 0.09 ± 0.01 0.14 ± 0.00$#
C17:0 0.27 ± 0.04 0.29 ± 0.04 0.22 ± 0.02 0.26 ± 0.03
C19:0 0.10 ± 0.01 0.11 ± 0.02 0.08 ± 0.01∗ 0.10 ± 0.01
C21:0 1. ± 0.01 Traces 0.01 ± 0.00 0.01 ± 0.00
C23:0 2. ± 0.01 0.03 ± 0.01 0.02 ± 0.02 0.03 ± 0.01
Total OCFA 0.52 ± 0.05 0.57 ± 0.08 0.43 ± 0.02∗ 0.55 ± 0.04$
Branched-chain saturated FA (BCFA) iso C15:0 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
anteiso C15:0 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
iso C16:0 0.04 ± 0.01 0.06 ± 0.01$ 0.03 ± 0.00∗ 0.06 ± 0.00#
iso C17:0 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.00 0.05 ± 0.00
anteiso C17:0 0.03 ± 0.00 0.04 ± 0.0 0.03 ± 0.00 0.13 ± 0.06∗$#
anteiso C19:0 0.04 ± 0.01 0.05 ± 0.01 0.05 ± 0.02 0.08 ± 0.00∗#
anteiso C21:0 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
Total BCFA 0.17 ± 0.00 0.22 ± 0.03$ 0.16 ± 0.02 0.35 ± 0.06∗$#
CPOA2H 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01
Monounsaturated FA (MUFA) C12:1 Traces 0.04 ± 0.05 0.01 ± 0.01 0.01 ± 0.01
C14:1 0.02 ± 0.00 0.16 ± 0.23 0.02 ± 0.01 0.03 ± 0.01
C16:1 2.87 ± 0.40 3.17 ± 0.16 2.59 ± 0.39 3.25 ± 0.55
C17:1 0.09 ± 0.01 0.12 ± 0.01$ 0.09 ± 0.01 0.15 ± 0.00∗$#
C18:1 19.10 ± 1.75 17.10 ± 1.42 20.59 ± 0.90 19.49 ± 1.00
C19:1 0.01 ± 0.00 0.01 ± 0.01 0.01 ± 0.00 0.02 ± 0.01
C20:1 0.44 ± 0.03 0.46 ± 0.08 0.50 ± 0.09 0.54 ± 0.05#
C22:1 0.07 ± 0.01 0.08 ± 0.01 0.07 ± 0.01 0.06 ± 0.00∗
C24:1 0.06 ± 0.03 0.05 ± 0.01 0.05 ± 0.02 0.06 ± 0.01
Total MUFA 22.67 ± 2.12 21.19 ± 1.33 23.93 ± 1.12 23.58 ± 1.61
n-3 polyunsaturated FA (n-3 PUFA) C18:3n-3 0.17 ± 0.02 0.12 ± 0.01$ 0.25 ± 0.04∗ 0.16 ± 0.01∗$
C20:3n-3 0.03 ± 0.01 0.05 ± 0.01$ 0.03 ± 0.01 0.04 ± 0.01
C20:5n-3 0.43 ± 0.06 0.47 ± 0.01 0.44 ± 0.08 0.36 ± 0.03∗
C22:5n-3 0.62 ± 0.09 0.79 ± 0.11 0.60 ± 0.05 0.69 ± 0.08
C22:6n-3 7.83 ± 0.30 9.34 ± 0.52$ 7.33 ± 0.76 7.04 ± 0.45∗#
Total n-3 PUFA 9.07 ± 0.26 10.76 ± 0.53$ 8.65 ± 0.77 8.29 ± 0.56∗
n-6 polyunsaturated FA (n-6 PUFA) C16:2n-6 0.01 ± 0.01 0.01 ± 0.00 0.02 ± 0.01 0.03 ± 0.01∗
C18:2n-6 19.41 ± 1.37 18.77 ± 1.01 21.67 ± 1.55 22.21 ± 0.40∗#
C20:2n-6 0.26 ± 0.03 0.34 ± 0.03$ 0.23 ± 0.04 0.32 ± 0.01$#
C20:3n-6 1.03 ± 0.12 1.07 ± 0.15 0.83 ± 0.07 0.85 ± 0.08
C20:4n-6 7.80 ± 1.07 8.11 ± 1.00 7.14 ± 0.45 6.29 ± 0.35∗
C22:4n-6 0.21 ± 0.04 0.23 ± 0.02 0.16 ± 0.04 0.21 ± 0.04
C22:5n-6 0.13 ± 0.03 0.16 ± 0.05 0.11 ± 0.03 0.11 ± 0.01
Total n-6 PUFA 28.86 ± 0.26 28.68 ± 0.67 30.16 ± 1.02∗ 30.00 ± 0.00∗#
18:1/18:0 desaturation index 1.78 ± 0.38 1.56 ± 0.24 2.17 ± 0.17 2.23 ± 0.28
18:0/16:0 elongation index 0.40 ± 0.04 0.42 ± 0.03 0.36 ± 0.01 0.32 ± 0.02∗#
CPOA2H – Cyclopropaneoctanoic acid 2-hexyl; PLA – placebo, SED – sedentary, TR – trained, ∗p < 0.05 trained compared to corresponding sedentary group; $p < 0.05
CLA treated compared to corresponding placebo group #p < 0.05 comparing PLA SED to CLA TR.
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TCS SP8 (Leica Microsystems). The staining intensity was
expressed as the mean value pixel intensity (PI) using the software
Leica application suite advanced fluorescences software.
Statistical Analysis
The results are presented as means ± SEM for each study group, if
not otherwise specified. The significance of intergroup differences
was verified with one-way analysis of variance (ANOVA), or
ANOVA on ranks for not normally distributed data, followed
by an appropriate post hoc test. The threshold of statistical
significance for all tests was set at P < 0.05. All analyses were
carried out with STATISTICA 12 package (StatSoft).
RESULTS
The results documenting the effects of CLA supplementation and
endurance exercise on body weight, skeletal muscle strength, and
endurance performance in the study groups have been published
elsewhere (Barone et al., 2013). Endurance training or CLA
supplementation did not exert a statistically significant effect on
the liver weight [PLA-SED: 0.058 ± 0.020 g (liver weight/body
weight ± Standard Deviation – SD), PLA-TR: 0.041 ± 0.003 g,
CLA-SED: 0.055 ± 0.022 g, CLA-TR: 0.046 ± 0.003 g], however,
we observed a trend to decrease of liver weight/body weight
ratio after exercise.
Fatty Acid Composition in Liver After
Exercise and CLA Supplementation
The analysis of FA composition in mouse livers demonstrated
that physical exercise and supplementation with CLA applied
either alone or in combination, induced significant changes in
the contents of various FA (Table 1). The training contributed
to a significant increase in n-6 PUFAs and a decrease in odd
chain FAs (OCFAs), with the latter effect observed solely in PLA-
TR mice. Moreover, a tendency for higher values of 18:1/18:0
desaturation index (DI) and lower values of 18:0/16:0 elongation
index (EI) was observed in trained animals, but the results
did not differ significantly from those for sedentary animals
(Table 1). Supplementation with CLA contributed to a significant
increase in branched-chain FA (BCFA) and n-3 PUFA contents
in sedentary mice. The exposure to both physical exercise and
CLA supplementation resulted in a significant increase in BCFA
content and a slight increase in n-6 PUFAs. However, the trained
TABLE 2 | Relative mRNA levels of liver enzymes of fatty acid metabolism.
Enzyme PLA SED CLA SED PLA TR CLA TR
BHKDHA 1.00 6.63 ± 1.45$ 2.32 ± 0.15 3.81 ± 1.27#∗
SCD1 1.00 2.97 ± 0.23$ 1.83 ± 0.18∗ 1.76 ± 0.57#∗
ELOVL6 1.00 7.68 ± 2.2$ 3.67 ± 1.2∗ 1.14 ± 0.47∗
PLA – placebo, SED – sedentary, TR – trained, BHKDHA – alpha subunit of
branched-chain alpha-keto acid dehydrogenase enzyme complex, SCD1 – stearoil-
CoA desaturase, ELOVL6 – fatty acid elongase 6, ∗p < 0.05 trained compared
to corresponding sedentary group; $p < 0.05 CLA compared to corresponding
placebo group, #p < 0.05 comparing PLA SED to CLA TR.
and CLA-supplemented mice did not show an increase in n-
3 PUFA content, which was observed in PLA-TR animals. The
combination of CLA supplementation and exercise contributed
also to a non-significant increase in DI values and a significant
decrease in EI values (Table 1).
The Expression of the Enzymes of Fatty
Acid Metabolism in Liver After Exercise
and CLA Supplementation
To verify if the training- and supplementation-induced
differences in liver FA composition resulted from changes in
the synthesis, elongation, and desaturation of FA in the liver,
we measured the expressions of some enzymes known to be
involved in these processes. As the combination of exercise
and CLA supplementation exerted the most evident effect
on BCFA content, we measured the expression of the alpha
subunit of branched-chain alpha-keto acid dehydrogenase
enzyme complex (BCKDHA), an enzyme responsible for
BCFA synthesis. Moreover, we determined the expression of
another two enzymes, stearoyl-CoA desaturase (SCD1), and
FA elongase 6 (ELOVL6). Although the analysis demonstrated
that both CLA supplementation and physical exercise exerted
an effect on BHKDHA, SCD1, and ELOVL6 expressions
(Table 2), the pattern of changes in mRNA levels in hepatocytes
of trained and supplemented mice did not match with the
changes in their BCFA content or 18:1/18:0 and 18:0/16:0 index
values (Tables 1, 2).
Confocal microscopy analyses are showed in Figure 1,
which indicated that BCKDHA is localized mainly in the
mitochondrion matrix and minimally in the nucleus, while
phospho-BCKDHA is localized only in the nucleus. The protein
level of BCKDHA was significantly higher in CLA-TR group
than in PLA-SED, while no differences were observed among the
others groups. The endoplasmic reticulum membrane protein,
ELOVL6, was significantly higher in PLA-TR group than in
PLA-SED, while no differences were observed among the others
groups. Thus, changes in protein levels were consistent with
the mRNA levels.
DISCUSSION
This study revealed that physical exercise, supplementation
with CLA and combination thereof might induce significant
changes in FA composition of mouse liver. The most spectacular
change was observed in the case of BCFA content in CLA-
TR mice, which was twice as high as in the untreated
controls. It should be emphasized that such a significant
increase in BCFAs was not observed after either the exercise
or the CLA supplementation alone. The effect of exercise and
CLA supplementation on BCFA content should probably be
considered a favorable finding since elevated levels of FA from
this group were previously shown to be associated with some
health benefits (Wongtangtintharn et al., 2004, 2005, Ran-Ressler
et al., 2011), and their serum levels correlated inversely with
hypertriglyceridemia, inflammation and insulin concentration
(Mika et al., 2016). Moreover, Garcia Caraballo et al. (2014)
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FIGURE 1 | Confocal microscopy analyses. Representative images of immunofluorescence stain for BCKDHA, phospho-BCKDHA and ELOVL6 in liver sections of
placebo sedentary (PLA-SED), placebo trained (PLA-TR), CLA sedentary (CLA-SED), and CLA trained (CLA-TR). The staining intensity for BCKDHA,
phospho-BCKDHA, and ELOVL6 was expressed as the mean value pixel intensity (PI) using the software Leica application suite advanced fluorescences software.
Data are presented as the means ± SD. Bar = 25 µm for all panels.
found an inverse correlation between liver contents of BCFAs
and TG in mice maintained on a high-protein diet, and
suggested that the elevated BCFA content may predispose to a
decrease in hepatic TG level and lesser steatosis. In mammals,
BCFA can be synthesized from branched-chain amino acids
(Garcia Caraballo et al., 2014), and the rate-limiting step of
these amino acids catabolism is catalyzed by branch chain
keto-acid dehydrogenase (BCKDHA) enzyme complex (Crown
et al., 2015). However, the patterns of post-treatment changes
in BCKDHA mRNA and protein level and BCFA content in
our trained and CLA-supplemented mice did not match. We
also did not find any differences in phosphorylated (inactive)
BCKDHA levels. This implies that the increase in BCFA content
observed after exercise and CLA supplementation might have
been mediated by other mechanisms (i.e., increased influx of
BCFA into hepatocyte).
Another beneficial effect of CLA supplementation
documented in our study was an increase in n-3 PUFA content.
Previous studies demonstrated that n-3 PUFA might exert
anti-inflammatory, insulin-sensitizing, and cardioprotective
effects (Mika and Sledzinski, 2017). However, in our study,
the beneficial effect of CLA supplementation on n-3 PUFA
content was counterbalanced by physical exercise, since
we did not find a statistically significant difference in the
levels of these FA in supplemented and non-supplemented
mice subjected to the Rota-Rod training. In turn, the liver
content of n-6 PUFAs increased after training but remained
unchanged after CLA supplementation. n-6 PUFAs are
precursors of many proinflammatory molecules (Mika and
Sledzinski, 2017). Physical exercise is known to attenuate
inflammation and oxidative stress in the liver (de Castro
et al., 2017). However, the inflammatory response may be
triggered by many various factors, and the elevated content
of n-6 PUFAs might not be enough to induce inflammation
in liver tissues.
We also found that physical exercise resulted in an increase
of 18:1/18:0 DI values and in a decrease in 18:0/16:0 EI values.
DI and EI are calculated based on the contents of some specific
FAs and are considered the measures of SCD1 and ELOVLs
activities, respectively (Murakami et al., 2008; Popeijus et al.,
2008). However, when we analyzed the profiles of exercise- and
supplementation-induced changes in both indices against the
patterns of changes in SCD1 mRNA and ELOVL6 mRNA or
protein levels, they seemed to be unrelated. This implies that
DI and EI values in trained and CLA-supplemented mice did
not depend on the expressions of SCD1 and ELOVL6 genes, but
were rather influenced by other processes, such as FA oxidation,
supply of dietary lipids or release thereof from adipose tissue,
and secretion of hepatic lipids to the circulation in the form
of lipoproteins.
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An important issue that needs to be addressed is the
mechanism through which CLA and exercise modulate liver
profiles of FAs. A proteomic study showed that some specific CLA
isomers might influence the activities of enzymes involved in
beta-oxidation and fructose metabolism (Della Casa et al., 2016).
Furthermore, exercising muscles release various myokines, and
many of them have already been shown to influence the liver
metabolism (Carson, 2017). This problem should be elucidated
during future research.
In conclusion, this study demonstrated that both
supplementation with CLA and physical exercise might induce
significant changes in FA profile of the liver. However, the
mechanisms and the consequences of CLA- and/or exercise-
induced changes in the composition of liver FAs need
to be elucidated.
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Rationale: Low physical activity is frequent in end stage renal disease. We evaluated
the longitudinal change in physical activity and its barriers in hemodialysis (HD) patients
and the association between the patterns of physical activity change, body composition,
and beta-aminoisobutyric acid (BAIBA), as circulating myokine.
Methods: This is an observational study, where HD patients were considered in
a 24-month follow-up. We assessed overtime the change of physical inactivity
and its barriers by validated questionnaires, body composition by bioimpedance
analysis, muscle strength by hand-dynamometer, and plasma BAIBA levels by
liquid chromatography spectrometry. Parametric and non-parametric analyses were
performed, as appropriate.
Results: Out of the 49 patients studied at baseline, 39 completed the first-year follow-
up, and 29 completed the second year. At month 12, active patients had higher
intracellular water (ICW) (P = 0.001) and cellular mass (P < 0.001), as well as at month
24 (P = 0.012, P = 0.002; respectively) with respect to inactive. A significant reduction
in ICW was shown at month 12 (P = 0.011) and month 24 (P = 0.014) in all patients.
The barrier “reduced walking ability” was more frequent in inactive patients with respect
to active at month 12 (P = 0.003) and at month 24 (P = 0.05). At month 24, plasma
BAIBA levels were higher among active patients with respect to inactive (P = 0.043)
and a correlation was seen between muscle strength and ICW (r = 0.51, P = 0.005);
normalizing BAIBA per body mass index, we found it lower with respect to baseline
(P = 0.004), as well as after correcting per ICW (P = 0.001), as marker of muscle mass.
Conclusion: A high prevalence of physical inactivity persisted during a 24-month follow-
up in this cohort. We found an association between physical activity and a decline in
marker of muscularity and reduced plasma BAIBA levels.
Keywords: hemodialysis, physical activity, body composition, beta-aminoisobutyric acid, longitudinal study
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INTRODUCTION
The assessment of physical activity among hemodialysis (HD)
patients is a crucial clinical aspect which has improved the
understanding of the association between frailty and poor
outcomes (Sy and Johansen, 2017). This assessment allows to
recognize that inactive patients with end-stage renal disease
(ESRD) undergoing maintenance HD are at higher risk for
morbidity and mortality (Sy and Johansen, 2017; Ku et al.,
2018). Physical inactivity is associated with the risk of falls,
hospitalizations, cognitive impairment, vascular access failure,
and poor quality of life among HD patients (Johansen et al.,
2013a; Sy and Johansen, 2017) and exercise may be effective
to reduce this risk (Johansen et al., 2013b). We recently
investigated the presence of physical inactivity and its barriers
among a cohort of HD patients and the association with
the myokine beta-aminoisobutyric acid (BAIBA) (Molfino
et al., 2017), which is formed by the catabolism of valine,
determining several beneficial effects on muscle metabolism in an
autocrine/paracrine manner (Molfino et al., 2017; Huh, 2018). In
particular, BAIBA secretion increases with exercise and induces
browning of white fat and hepatic beta-oxidation having potential
implication in the physiological mechanisms of physical activity
(Roberts et al., 2014).
Although low physical activity accompanies ESRD
progression (Robinson-Cohen et al., 2014), few studies
have documented the time course and the features of
physical activity changes that occur with ESRD progression
(Johansen et al., 2000).
The patterns of change in physical activity and barriers appear
clinically relevant because they may provide insights into an
appropriate timing of diagnosis and intervention to achieve the
greatest impact on outcomes among HD patients. In addition,
to date few data are available on the role of exercise-induced
myokines, as possible biomarkers of physical activity and its
variation in humans and in particular among HD patients who
are known to be extremely sedentary (Johansen et al., 2000).
In this light, research on possible novel biomarker(s), such as
BAIBA, to easily assess and monitor muscularity associated or not
to low physical activity, appears clinically important.
In this study, we first aimed to determine the longitudinal
changes (up to 24 months) in physical activity levels among
patients on HD, including barriers to physical activity. We
next analyzed the association between these patterns of
physical activity changes, BAIBA levels, body composition, and
muscle strength.
PATIENTS AND METHODS
This longitudinal study was performed on patients from the
Dialysis Unit of “Fatebenefratelli” Hospital, Isola Tiberina, in
Rome, Italy. Women and men ≥18 years chronically maintained
on HD, participating on a study investigating the role of nutrition
and quality of life, whose baseline characteristics were previously
described (Molfino et al., 2017), underwent to a follow-up of
24 months. In summary, 52 patients are chronically treated at
the HD center and the inclusion criteria consisted in enrolling
the entire HD cohort with the exception of patients with highly
catabolic diseases, such as cancer, chronic infections, and AIDS,
and the absence of informed consent, as previously shown
(Molfino et al., 2017). The sample size we used was representative
of the entire number of patients, respecting the inclusion criteria,
treated at the single Dialysis Unit.
The study was approved by the local ethics committee. Written
informed consent was obtained from all patients. Patients were
maintained on a regular HD prescription, three times a week, for
4-h sessions during the 2-year follow-up.
Patient Clinical Characteristics
Participants’ demographic and clinical characteristics, including
age, gender, weight, height, body mass index (BMI), dialysis
vintage, and Kt/V were recorded, and comorbidities and
current therapies were collected. Nutritional and inflammatory
biomarkers were assessed at baseline (Molfino et al., 2017),
at 12 and 24 months.
Body Composition Analysis
Body impedance analysis (BIA) was performed in all HD
patients to assess body composition overtime (Model 101, single-
frequency BIA, Akern, Florence, Italy). Blinded research staff
performed BIA 1 h after the end of the second HD session of
the week. As previously shown, the patient maintained a supine
position during this period (Jankowska et al., 2006; Molfino
et al., 2017). The pairs of electrodes were placed on the non-
access side of the body on the hand to the foot for injecting
current and on the wrist to the ankle for measuring voltage. Total
body water was estimated using the resistance extrapolated to
frequency and parameters, including intracellular water (ICW)
and cellular mass, as the metabolically active component of lean
tissue mass, were calculated using a program provided by the
producer (Jankowska et al., 2006; Molfino et al., 2017).
Physical Activity Level
As for baseline (Molfino et al., 2017), at month 12 and
month 24, we asked enrolled patients to answer questions
on the self-reported frequency of physical activity, including
recreational walking, running, and so on, during leisure
time. This questionnaire was shown to be reliable in
large cohorts of dialysis patients (Tentori et al., 2010;
Delgado and Johansen, 2012).
A second questionnaire was used to evaluate the barriers to
physical activity in general or to lower physical activity levels
than desired, investigating 23 barriers, designed on the basis
of previously validated questionnaire in the HD population
(Delgado and Johansen, 2012; Johansen et al., 2014b).
Patients who experienced exercise at least once a week
were considered active, those who never exercised or reported
physical exercise less than once a week were considered inactive
(Delgado and Johansen, 2012; Johansen et al., 2014b).
Muscle Strength
The muscle function was assessed on the same day of the
recruitment immediately before starting the HD session by
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handgrip strength measurement, using a handle dynamometer
(JAMAR, Sammons Preston Rolyan, Bolingbrook, IL,
United States). The test was performed conducting three
attempts with each hand, and the mean of the strongest hand
was used to determine muscle strength (Johansen et al., 2014a;
Molfino et al., 2017).
Plasma BAIBA Levels Assay
Blood samples were obtained from the HD patients immediately
before the second HD session of the week and kept at room
temperature for 1 h before the plasma was isolated. Aliquots
of plasma were stored at −80◦C until analysis. Taking into
account the expected association between the myokine BAIBA
and body size and body composition, in particular muscularity,
we also used BAIBA/BMI and more specifically BAIBA/ICW (%)
ratio (ICW, as marker of muscularity) (Johansen et al., 2014a)
in our analyses. Data presented here utilize the mean of
two measurements.
Plasma BAIBA levels were assessed by a Liquid
chromatography–tandem mass spectrometry (LC–MS/MS)
method, as previously described (Molfino et al., 2017). Briefly,
40 µL of plasma samples were added to 160 µL of internal
standard in acetonitrile. The samples were vortex-mixed,
centrifuged and 100 µL of clean upper layer were then diluted
with 100 µL of 0.1% formic acid and transferred in autosampler
vials. Chromatographic separation was achieved using a
Phenomenex Luna HILIC column (100 × 2.0 mm, 3 µm;
Phenomenex, Torrance, CA, United States), with an elution
gradient (Molfino et al., 2017). The HPLC-MS/MS analysis
were performed using an Agilent Liquid Chromatography
System series 1100 (Agilent Technologies, Santa Clara, CA,
United States) coupled with a 3200 triple quadrupole system
(Applied Biosystems, Foster City, CA, United States), with a
Turbo Ion Spray source. Data were acquired and processed by
Analyst 1.5.1 Software.
Statistical Analyses
Patient characteristics were described using mean (±SD)
for continuous normally distributed variables and percent
for dichotomous variables. Variables that were not normally
distributed were described using median with 25th and 75th
percentiles. The proportion of patients self-reporting each barrier
and the average number of barriers perceived per patient were
calculated. Chi-square, Mann–Whitney, and Kruskall–Wallis
tests were used to study the association between reported barriers
to physical activity and patient characteristics, the association
between barriers and reported levels of physical activity, between
barriers and time (baseline, 12, 24 months) and between BAIBA,
levels of physical activity and its barriers, body composition
and muscle strength overtime. Spearman’s correlation index was
used to assess associations between continuous measurements.
A linear mixed-effect model was used to evaluate the change
of body composition overtime, as well as a model to evaluate
changes of clinical parameters and biomarkers overtime. The
model included physical activity, categorical time point, physical
activity level per time point interaction as fixed effect and subject
as a random effect.
A standard two-tailed a (P < 0.05) was considered statistically
significant. Statistical analysis was performed in R v.3.4.3.
RESULTS
Patient Characteristics
Characteristics of the participants are reported in Table 1.
In summary, 49 patients (13 women) were studied at baseline
with a mean age of 66.6 ± 15.5 years. Median dialysis vintage
was 37 months [interquartile range (IQR), 13–92] with a mean
Kt/V of 1.3 ± 0.3 (Molfino et al., 2017) and 20% of patients
were on hemodiafiltration.
At 12-month follow-up, 7 patients died, 2 were transferred
to another dialysis facility and 1 patient received renal
transplantation. Therefore, 39 patients were considered, with a
mean age of 66 ± 15.1 years and a median dialysis vintage
of 40.5 months (IQR, 25–70.2) (Table 1).
At 24-month follow-up, 5 patients died, 2 were transferred
to another dialysis facility and 3 patients received renal
transplantation. A total of 29 patients were studied, with a
mean age of 66.9 ± 14.7 years and a median dialysis vintage of
50 months (IQR, 37–77) (Table 1).
During the entire follow-up period, as for baseline (Molfino
et al., 2017), more than 50% of the patients were treated
with antihypertensive therapies, statins, vitamin supplements,
erythropoietin, and potassium, and phosphate binders and
supplemented with folic acid.
Physical Activity Level and Its Change
At baseline, inactive patients were 51 and 88% reported having
barriers to physical activity (Molfino et al., 2017). Similarly, at
12 months 51% of the patients reported performing physical
activity during leisure time less than once per week, almost
never, or never, and therefore were considered inactive, and 90%
TABLE 1 | Patient characteristics.
Month 12 Month 24
Patients N = 39 Patients N = 29 P
Sex (male) 31 23
Age, years 66 ± 15.2 66.9 ± 14.7 0.85
BMI, weight (kg)/height 2 (m) 24.5 ± 5.3 25.0 ± 5.82 0.87
Hb, g/dl 11.2 ± 1.3 11.4 ± 1.22 0.96
Albumin, g/l 39.7 ± 3.04 37.4 ± 4.08 0.49
Urea#, mg/dl 118.6 ± 31.8 132.6 ± 36.1 0.68
Creatinine, mg/dl 9.1 ± 2.5 8.9 ± 2.4 0.41
CRP, mg/dl 0.4 (0.2; 1.3) 0.37 (0.19; 0.9) 0.97
Dialysis vintage, months 40.5 (25; 70.2) 50 (37; 77) 0.21
nPCR, g/kg/d 0.92 ± 0.2 0.94 ± 0.17 0.97
Kt/V 1.29 ± 0.24 1.34 ± 0.26 0.39
Physical inactivity (yes) 20 (51%) 19 (63%) 0.27
#Urea levels are 2.14 times the corresponding BUN levels. BMI, body mass
index; BUN, blood urea nitrogen; CRP, C-reactive protein; Hb, hemoglobin; nPCR,
normalized protein catabolic rate.
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reported barriers to physical activity. Four patients, who were
active at baseline, resulted inactive at month 12 months.
At month 24, 65% of patients resulted inactive and 96%
reported having barriers to physical activity. From baseline to
month 24, according to the questionnaire, 7 active patients
resulted inactive. In the entire cohort of the enrolled patients,
the median number of barriers endorsed at baseline (n = 4),
month 12 (n = 3), and month 24 (n = 3) did not significantly
change overtime (P = 0.30). From baseline to 24-month follow-
up, the type of barriers did not significantly change in all HD
patients and also when considering active and inactive patients
separately. We did not observe differences between active and
inactive patients in terms of type and numbers of comorbidities,
and in nutritional and inflammatory biomarkers. In addition, we
did not find a significant association between inactivity at baseline
and mortality (P = 0.114).
During the entire follow-up, the most frequently endorsed
barrier was “fatigue on dialysis days.” The barrier “reduced
walking ability” was confirmed to be more frequent in inactive
patients with respect to active patients at month 12 (P = 0.003)
and month 24 (P = 0.05).
Body Composition and Physical Activity
Change
Differences in body composition parameters between active and
inactive patients during the follow-up are reported in Table 2.
As for baseline (Molfino et al., 2017), at month 12, we found
that active patients had higher ICW (%) (P = 0.001) and cellular
mass (%) (P < 0.001) with respect to inactive patients. Similarly,
at month 24 active patients showed compared to inactive
patients higher ICW (%) (P = 0.012) and cellular mass (%)
(P = 0.002) (Table 2).
Independent of the presence of physical inactivity, our cohort
of HD patients showed, compared to baseline, a significant
reduction in ICW (%) at month 12 (P = 0.011) and at
month 24 (P = 0.014).
This trend overtime was confirmed after adjusting for
the presence of physical inactivity, although at the limit of
significance (at month 12, P = 0.046 and at month 24,
P = 0.059, respectively).
BAIBA, Physical Activity Level and Its
Barriers, Body Composition and Muscle
Strength Overtime
In all the participants, at baseline BAIBA (µM) median value
was 0.40 (IQR, 0.21–0.61) (Molfino et al., 2017) and at month
24 was 0.21 (IQR, 0.10–0.32). During the 24-month follow-
up, BAIBA median level did not significantly change among
all the participants; however, at month 24, median BAIBA
level was higher among active patients with respect to inactive
(Figure 1) (P = 0.043).
No significant association was found between plasma BAIBA
levels and the number and type of barriers at month 24.
Independent of the presence of physical inactivity, when
considering BAIBA normalized per BMI (BAIBA/BMI), we found
this ratio at month 24 significantly lower with respect to baseline
(P = 0.004) (Figure 2A). Similarly, when BAIBA was normalized
per ICW (BAIBA/ICW), we documented this ratio lower with
respect to baseline (P = 0.001) (Figure 2B).
At month 24, median values of hand-grip measurement
were not different between active (21 mmHg) and inactive
patients (21 mmHg). Moreover, no association was documented
overtime between muscle strength and BAIBA levels, physical
inactivity and its barriers. However, at month 24, a significant
correlation was observed between muscle strength and ICW
(r = 0.51, P = 0.005).
DISCUSSION
There have been robust data on physical inactivity and its
association with frailty during HD and how this condition
may affect patient’s prognosis (Johansen et al., 2013b, 2016;
Sy and Johansen, 2017). This suggests to physicians to
evaluate physical activity level to prevent clinical deterioration
and functional dependence during ESRD (Rodríguez-Mañas
et al., 2013). The prevalence of HD patients physically
inactive and sedentary is high (Johansen et al., 2007, 2014b),
and its percentage depends on how physical activity is
defined (Delgado and Johansen, 2012; Bossola et al., 2014;
Johansen et al., 2016).
TABLE 2 | Biompendance analysis parameters.
Baseline 12-month follow-up 24-month follow-up
Active patients Inactive patients P Active patient Inactive patients P Active patient Inactive patients P
N = 24 (49%) N = 25 (51%) N = 19 (49%) N = 20 (51%) N = 10 (35%) N = 19 (65%)
Body weight (Kg) 69.9 ± 18.4 69.2 ± 14.7 0.88 66.6 ± 18.0 71.2 ± 13.7 0.38 62.25 ± 13.8 73.65 ± 16.9 0.07
Biompendance analysis
Fat mass
(%) 33.2 ± 8.9 31.6 ± 8.0 0.52 30.3 ± 8.2 30.5 ± 6.9 0.94 32.4 ± 9.1 32.7 ± 7.4 0.98
(kg) 23.3 ± 9.2 21.0 ± 7.2 0.58 20.35 ± 8.07 20.83 ± 7.87 0.85 20.37 ± 7.54 24.2 ± 8.12 0.21
Intracellular water (%) 51.2 ± 7.3 44.5 ± 9.5 0.008 52.4 ± 5.98 43.1 ± 9.4 0.001 53.1 ± 5.97 45.4 ± 7.7 0.012
Cellular mass (%) 42.3 ± 7.3 35.9 ± 7.8 0.005 43.1 ± 4.02 33.04 ± 9.4 <0.001 43.08 ± 4.2 35.9 ± 6.3 0.002
Body mass cell index (kg/m2) 6.7 ± 1.9 5.6 ± 1.8 0.04 6.88 ± 1.9 5.65 ± 1.9 0.059 6.18 ± 1.72 6.95 ± 4.2 0.58
Phase angle (◦) 5.2 ± 1.2 4.1 ± 1.1 <0.001 5.2 ± 1.0 4.0 ± 1.1 <0.001 5.4 ± 1.1 4.3 ± 1.2 0.02
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FIGURE 1 | Plasma BAIBA levels in hemodialysis inactive and active patients at month 24. Box plot of BAIBA levels (µM) stratified by inactive or active patients.
BAIBA levels were significantly higher in active with respect to inactive patients (P = 0.043). Lines represent the median, 25th and 75th percentiles, and the whiskers
(error bars) below and above the box indicate the 10th and 90th percentiles. BAIBA, beta-aminoisobutyric acid.
We previously confirmed in a cohort of HD patients a high
prevalence of physical inactivity, defined using self-reported
physical function (Molfino et al., 2017). The majority of
the data available in the literature on this topic have been
obtained in cross-sectional studies (Johansen et al., 2014a, 2016).
Novel information may be obtained by longitudinal studies by
comparing the timing of changes in body composition with the
development of several conditions, including low muscle mass
and frailty (Johansen et al., 2014a). In this light, longitudinal
data are important to ascertain whether modifications in body
composition are strictly related with physical activity changes
and whether possible biomarker(s) of muscularity may identify
or predict changes in body composition and in physical activity
level which are associated with adverse outcomes.
In the present study, we evaluated overtime (up to 24 months)
in a single-center cohort of HD patients, being representative of a
homogenous population, the physical activity level during leisure
time. We administered, as for baseline (Molfino et al., 2017),
a first questionnaire on the self-reported frequency of physical
activity and a second questionnaire regarding barriers to physical
activity in general or to lower physical activity levels than desired.
The participation in physical activity, already low at baseline
(Molfino et al., 2017), was confirmed to be reduced after the
24-month follow-up, as 63% of the patients reported participating
in light activity never, almost never, or less than once per week,
and 96% of patients reported endorsing barriers to physical
activity. Interestingly, although not statistically different, the
median number of barriers at month 24 was lower than baseline.
Considering that low level of physical activity is associated with
reduced survival, we believe that those patients in our cohort
who survived at month 24 may be less inactive. The most
frequent barriers observed at month 12 and 24 were “fatigue on
dialysis day” and “reduced walking ability.” The barrier “reduced
walking ability” was more frequently reported by inactive
patients with respect to active during the entire follow-up at
month 12 and 24. This highlights the importance of walking
difficulty in conditioning reduced mobility in HD patients.
Moreover, results of a recent multicenter study documented that
barriers to physical activity and non-proactive health-care staff ’s
attitude reduced the implementation of physical activity in the
HD population and that patients not reporting barriers were
those who showed greater beneficial effects from a proactive
staff ’s attitude (Regolisti et al., 2018).
Physical inactivity may be the cause and/or the effect of
body composition derangements. In fact, low activity level may
determine and/or worsen low muscle mass; on the other hand,
lower muscularity may reduce physical performance. In this light,
it appears advisable to evaluate body composition overtime in
association with the level of physical activity.
During our follow-up, we found that lower ICW, a proxy
of muscle mass (Johansen et al., 2014a), was associated with
physical inactivity at month 12 and 24. A significant decline
in ICW was observed from baseline to month 24 in the entire
cohort. This is in line with the results obtained in a larger cohort
of HD patients where lower ICW was associated with frailty
(Johansen et al., 2014a).
When performing a multivariable analysis accounting for
physical activity, the trend of ICW reduction overtime was
confirmed in the inactive group, suggesting the possibility
that the time-altered body composition association might be
explained, at least in part, by physical inactivity.
In addition, we focused on the possible relationship between
changes overtime of body composition, physical activity, and
BAIBA, as circulating biomarker of muscularity during HD.
This aspect appears relevant considering that BAIBA seems
to present different actions within skeletal muscle, including
attenuation of insulin resistance, inflammation and inducing
fatty acid oxidation (Jung et al., 2015). Not conclusive data
are yet available on the physiology/pathophysiology of BAIBA
and we do not have information on BAIBA removal from HD.
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FIGURE 2 | Plasma BAIBA levels normalized per BMI and per ICW in hemodialysis patients at baseline and at month 24. In panel (A) Box plot of BAIBA/BMI ratio at
baseline vs. month 24 (P = 0.004). Lines represent the median, 25th and 75th percentiles, and the whiskers (error bars) below and above the box indicate the 10th
and 90th percentiles. BAIBA, betaaminoisobutyric acid; BMI, body mass index. In panel (B) Box plot of BAIBA/ICW ratio at baseline vs. month 24 (P = 0.001). Lines
represent the median, 25th and 75th percentiles, and the whiskers (error bars) below and above the box indicate the 10th and 90th percentiles. BAIBA,
betaaminoisobutyric acid; ICW, intracellular water.
However, Roberts et al. showed robust data in humans
documenting that BAIBA levels increased with physical
activity and were inversely related with metabolic risk factors
(Roberts et al., 2014).
In the present study, at the end of the follow-up (month 24),
inactive patients showed lower plasma BAIBA levels with respect
to active patients and, independent of the level of physical
activity, we found lower BAIBA/BMI ratio with respect to
baseline. This trend was confirmed when BAIBA was corrected
per marker of muscle mass. Although not at baseline, a
correlation was present at month 24 between muscle mass
and its function (muscle strength). However, as for baseline,
no correlation was seen between BAIBA and muscle function
indicating a possible different mechanism(s) regulating BAIBA
expression and muscle mass and its function. In particular, our
results did not allow us to ascertain a cause-effect relationship
between plasma BAIBA levels and changes of physical activity
and muscularity overtime. However, our data give us the
perspective to possibly use BAIBA as a muscle-specific biomarker
that might help physicians in monitoring muscularity in
the HD population.
Our study has several limitations, including the patient
sampling (single center study) and, in particular, the reduced
sample size at month 12 and 24, possibly affecting the investigated
associations, and the study group is highly variable including a
wide range of dialysis vintage. As for baseline, physical activity
is only subjectively assessed by the patients and not by more
objective instruments such as accelerometers or pedometers,
and the tool used to evaluate physical activity did not include
questions on potential additional activities (Molfino et al.,
2017). The association found between physical inactivity and
body composition does not imply a clear causality in one or
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other direction, as previously suggested by others (Johansen
et al., 2014a). We could not determine if low ICW caused
physical inactivity or if being more sedentary determined
body composition derangements. Using BIA, possible errors
in estimating body composition and fluid distribution remain
(Kyle et al., 2004). Moreover, the biomarker BAIBA has not
yet been validated in HD population, with poor availability of
information regarding its accumulation in HD patients and its
removal with dialysis.
CONCLUSION
In conclusion, we observed in our cohort of HD patients
a high prevalence of physical inactivity during a 24-month
follow-up and a clinically relevant number of endorsed
barriers. These conditions were associated with a decline in
markers of muscularity overtime. The levels of the myokine
BAIBA after 24-month follow-up were significantly lower
among inactive patients and, independent of the level of
physical activity, BAIBA levels significantly reduced overtime
when corrected per index of muscularity. Larger clinical
investigations are essential to clarify the role of BAIBA and
body composition changes overtime in HD, as well as to
assess BAIBA levels evaluating its changes after interventional
studies by administering nutritional support and/or physical
activity interventions.
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Hepatocyte growth factor (HGF) is well known for its role in the migration of embryonic 
muscle progenitors and the activation of adult muscle stem cells, yet its functions during 
the adult muscle regeneration process remain to be elucidated. In this study, we showed 
that HGF/c-met signaling was activated during muscle regeneration, and that among 
various infiltrated cells, the macrophage is the major cell type affected by HGF. 
Pharmacological inhibition of the c-met receptor by PHA-665752 increased the expression 
levels of pro-inflammatory (M1) macrophage markers such as IL-1β and iNOS while 
lowering those of pro-regenerative (M2) macrophage markers like IL-10 and TGF-β, 
resulting in compromised muscle repair. In Raw 264.7 cells, HGF decreased the RNA 
level of LPS-induced TNF-α, IL-1β, and iNOS while enhancing that of IL-10. HGF was 
also shown to increase the phosphorylation of AMPKα through CaMKKβ, thereby 
overcoming the effects of the LPS-induced deactivation of AMPKα. Transfection with 
specific siRNA to AMPKα diminished the effects of HGF on the LPS-induced gene 
expressions of M1 and M2 markers. Exogenous delivery of HGF through intramuscular 
injection of the HGF-expressing plasmid vector promoted the transition to M2 macrophage 
and facilitated muscle regeneration. Taken together, our findings suggested that HGF/c-met 
might play an important role in the transition of the macrophage during muscle repair, 
indicating the potential use of HGF as a basis for developing therapeutics for muscle 
degenerative diseases.
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INTRODUCTION
Resolution of tissue damage requires tight interaction between the immune system and the target 
tissue undergoing repair. Immune cells detect the injury, remove damaged tissues, and then promote 
repair mechanisms to restore tissue integrity. In addition, they strongly influence the growth and 
differentiation of stem cells and progenitors to repair the inflicted damage (Wynn and Vannella, 
2016). Upon muscle injury, macrophages have been reported to play critical roles in this process 
as they occupy major cell population infiltrated in injured muscle. They are responsible for the 
removal of damaged myofibers and also contribute to subsequent regrowth and differentiation of 
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muscle progenitors (Tidball, 2017). These procedures are tightly 
regulated by the coordinated transition of macrophage between 
pro-inflammatory (M1) and pro-regenerative (M2) phenotypes 
in the immune environment (Wang et  al., 2014).
Hepatocyte growth factor (HGF) is a multifunctional protein 
which contains mitogenic, morphogenic, motogenic, and 
angiogenic activities by interacting with its cellular receptor, 
c-met (Nakamura and Mizuno, 2010). This interaction 
subsequently turns on a variety of signaling pathways depending 
on cell types. HGF has been shown to play important roles 
in the regeneration process of various tissues by stimulating 
the proliferation and migration of respective progenitor cells 
(Kawaida et  al., 1994; Huh et  al., 2004; Wu et  al., 2004; 
Watanabe et  al., 2005). For example, HGF has been implicated 
in both skeletal muscle development and its regeneration after 
injury (Sisson et  al., 2009).
The interaction between HGF and c-met is required for 
migration of myogenic progenitors into the limb buds during 
embryogenesis (Dietrich et  al., 1999). Upon muscle injury, 
HGF activates muscle stem cells that reside in muscle fiber, 
rendering them to make a myogenic commitment (Jennische 
et  al., 1993; Allen et  al., 1995; Tatsumi et  al., 1998; Sheehan 
et  al., 2000). Exogenously added recombinant HGF protein 
was reported to increase myoblast proliferation while inhibiting 
differentiation, resulting in delayed regeneration of damaged 
muscle (Miller et al., 2000). However, recent studies have shown 
that HGF activated by urokinase plasminogen activator (uPA) 
promotes muscle regeneration (Sisson et  al., 2009), and its 
receptor, c-met, is responsible for the transition of quiescent 
muscle stem cells into GAlert, a cellular state in which they 
have an increased ability to participate in tissue repair (Rodgers 
et  al., 2014). Thus, the role of HGF in muscle regeneration 
remains to be  clarified. In particular, although the immune 
system plays an instrumental role in the muscle regeneration 
process, the effect of HGF on immune cells infiltrated in injured 
muscle tissue is not yet clearly understood.
Here, we report the role of HGF in the transition of infiltrated 
macrophages during muscle regeneration. HGF expression was 
upregulated following muscle injury. When mice were treated 
with PHA-665752, an inhibitor of the c-met receptor, muscle 
regeneration was delayed. Consistently, the population of M1 
and M2 macrophages during muscle regeneration was 
deregulated. HGF overexpression by intramuscular (i.m.) injection 
of plasmid expression vector facilitated muscle regeneration. 
Data from experiments involving Raw 264.7 cells indicated 
that HGF might regulate the transition of macrophage to the 
M2 phenotype through CaMKKβ-AMPK signaling. Taken 
together, our data suggested that HGF might be  used as a 
platform for developing therapeutic agents to treat diseases 
associated with defects in muscle regeneration.
MATERIALS AND METHODS
Animal Cares
Ten-week-old male C57BL/6 mice were purchased from Orient 
Bio Inc. (Seongnam, Korea) for animal studies. Mice were 
housed at 24°C with a 12  h light-dark cycle. All experiments 
were performed in compliance with the guideline set by the 
International Animal Care and Use Committee at Seoul 
National University.
Surgical Procedures
All surgical protocols were approved by the International Animal 
Care and Use Committee at Seoul National University. For 
muscle injury, ten-week-old male C57BL/6 mice were anesthetized 
with isoflurane, and the TAs were injected with 50  μl CTX 
(Latoxan, Valence, France), diluted to 10  μM in phosphate 
buffered saline (PBS). Sham treatment was performed by 
following the same procedure except injecting TAs with PBS. 
PHA-665752 (Tocris Bioscience, MO), a c-met inhibitor, was 
dissolved in DMSO (Sigma Aldrich, MO) and i.p. administered 
in each mouse on a daily basis with a dose of 20  mg/kg. For 
i.m. injection, 0.3  mm needle size, 0.5  ml insulin syringe (BD, 
NJ) was used. pCK or pCK-HGF-X7 plasmid expression vector 
was dissolved in 50  μl PBS (2  μg/μl). The injection procedure 
was performed by injecting the needle parallel to the tibia 
and then delivering plasmid into the middle of the TA.
Immunohistochemistry
Immunohistochemical analyses were performed as previously 
described (Ahn et  al., 2014). Briefly, TAs were isolated and 
fixed in 4% paraformaldehyde in PBS and cryo-sectioned to 
6  μm thickness. Sections were washed in 0.1  M PBS (pH 7.4) 
twice, then blocked for 1  h with PBS containing 5% fetal 
bovine serum (Corning, NY), 5% donkey serum (Jackson 
ImmunoResearch Laboratories, PA), 2% BSA (Sigma Aldrich, 
MA) and 0.1% Triton X-100 (Sigma Aldrich, MA). Samples 
were incubated with primary antibodies diluted in blocking 
buffer overnight at 4°C. Sections were washed 4 times in PBS 
and incubated for 1  h at room temperature with secondary 
antibodies (Invitrogen, CA) diluted in PBS. Immunostained 
samples were further washed 6 times and counterstained with 
DAPI (Sigma Aldrich, MA) for nuclear staining. The fluorescence 
images were obtained using a Zeiss LSM 700 confocal microscope 
(Zeiss, Oberkochen, Germany).
Hematoxylin and Eosin Staining and 
Morphometric Analysis
TAs were fixed in 10% normalized buffered formalin (Sigma 
Aldrich, MA) and dehydrated with a gradient series of ethanol 
from 70 to 100%. Samples were embedded in the paraffin 
block and sectioned to 6  μm thickness. A paraffin section of 
the TA was stained by hematoxylin and eosin, and the morphology 
of each cross-section was analyzed by Image J software (National 
Institutes of Health, MD). More than 300 myofibers were 
assessed from four individual mice in each group.
RNA Isolation and RT-qPCR
TAs were prepared and mechanistically homogenized using 
Bullet Blender Storm (Next Advance, NY), and total RNA was 
extracted from homogenized TA or cultured cells with RNAiso 
(Takara, Kusatsu, Japan) following the manufacturer’s instructions. 
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One microgram of RNA was converted to cDNA using oligo 
dT primers (Qiagen, Hilden, Germany) and Reverse Transcriptase 
XL (AMV) (Takara, Kusatsu, Japan). Gene expression was 
assessed using quantitative real-time PCR with Thermal Cycler 
Dice Real Time System TP800 (Takara, Kusatsu, Japan) and 
SYBR Premix Ex Taq (Takara, Kusatsu, Japan). Primers used 
in this study are listed in Supplementary Table S1A.
ELISA
TAs were prepared and mechanistically homogenized using 
Bullet Blender Storm (Next Advance, NY), and total proteins 
were extracted in RIPA lysis buffer (Sigma Aldrich, MO) 
containing a protease inhibitor (Roche, Basel, Switzerland), 
phosphatase inhibitor (Roche, Basel, Switzerland), and PMSF 
(Sigma Aldrich, MO). Samples were centrifuged at 12,000  rpm 
for 15 min at 4°C, and the supernatants containing total protein 
were subjected to mHGF ELISA (R&D systems, MN) following 
the manufacturer’s protocol.
Western Blot
For immunoblotting, TAs or cultured cells were prepared and 
homogenized in RIPA lysis buffer (Sigma Aldrich, MO) containing 
a protease inhibitor (Roche, Basel, Switzerland) and phosphatase 
inhibitor (Roche, Basel, Switzerland) using Bullet Blender Storm 
(Next Advance, NY). Equal amounts of protein were then 
separated by 10% SDS-polyacrylamide gel and electrophoretically 
transferred to polyvinylidene fluoride membranes (Millipore, 
MA). The membranes were blocked with 5% BSA (Gibco, 
MA) in TBST (1  M Tris-HCl, pH 7.4, 0.9% NaCl and 0.1% 
Tween-20) for 1  h and probed with antibodies diluted in 3% 
BSA blocking solution overnight at 4°C. Membranes were then 
incubated with HRP-conjugated anti-mouse or anti-rabbit IgG 
(1:100,000; Sigma Aldrich, MO) for 1 h, and the protein bands 
were visualized with the enhanced chemiluminescence system 
(Millipore, MA). Antibodies used in this study are listed in 
Supplementary Table S1B.
Cell Culture and Reagents
Raw 264.7 cells (American Type Culture Collection, VA) were 
grown in DMEM (Welgene, Gyeongsan, Korea) supplemented 
with 10% FBS (Corning, NY) and antibiotics [100 U/ml penicillin 
and 100 μg/ml streptomycin (Sigma Aldrich, MO)]. Recombinant 
human HGF protein (R&D systems, MN) and LPS (Sigma 
Aldrich, MO) were used at appropriate concentrations. STO-609 
(CaMKKβ inhibitor, Tocris Bioscience, MO) was used at 5 or 
20  μM for experiments.
siRNA Transfection
Raw 264.7 cells were transfected with siRNA specific to AMPKα 
or scramble siRNA (Santa Cruz Biotechnology, TX) using 
RNAiMAX (ThermoFisher Scientific, MA) according to the 
manufacturer’s protocol. Briefly, Raw 264.7 cells were plated at 
1  ×  106 cells per well in 6-well culture plates. Twenty-four hours 
later, 25  pmol (2.5  μl, 10  μM) of AMPKα or scramble siRNA 
was diluted into 125  μl of Opti-MEM (Gibco, MA), and 5  μl 
of RNAiMAX was diluted in 125 μl of Opti-MEM. Diluted siRNA 
and RNAiMAX were then combined and incubated at room 
temperature for 5  min. Subsequently, 250  μl of the siRNA-
RNAiMAX mixtures were added to each well of a 6-well plate. 
Twenty-four hours after transfection, cells were subjected to the 
analysis. Knock-down efficiency was evaluated by western blot 
using antibodies against AMPKα (Cell Signaling Technology, MA).
Statistical Analysis
All values are represented as mean  ±  SEM from two or more 
independent experiments. Statistical significance was determined 
using unpaired student’s t test or one way ANOVA followed 
by Bonferroni’s multiple comparison tests, provided by the 
GraphPad Prism 7 (GraphPad, CA) software.
RESULTS
HGF/c-Met Signaling Was Upregulated 
During Muscle Regeneration
To investigate the possible involvement of HGF during muscle 
regeneration, cardiotoxin (CTX)-induced muscle injury model 
was used. Injection of CTX provides homogenous damage to 
the whole muscle and induces the infiltration of various immune 
cells including monocytes and macrophages into the regenerating 
muscle until the repair is completed (Arnold et al., 2007). Tibialis 
anterior (TA) muscle of a 10-week-old C57BL/6 mouse was 
injected with CTX or PBS (sham), and total proteins were prepared 
from the TA at appropriate time points followed by ELISA. The 
basal level of the HGF protein in the sham (PBS-injected) muscle 
was maintained at 120–160  pg/mg of total cellular protein in 
the TA (Figure 1A). After muscle injury, the level of the HGF 
protein in the injured side was gradually increased, reaching a 
peak at approximately 1.1  ng  mg of total cellular protein at day 
4, and then steadily decreased before returning to the sham 
level at day 12. A similar magnitude of HGF RNA induction 
was observed during muscle regeneration as measured by RT-qPCR 
(Figure 1B). These data suggested that HGF expression was 
highly induced after muscle injury at both RNA and protein levels.
c-met is the only known receptor for HGF. When HGF is 
expressed, the c-met protein becomes phosphorylated to 
be  activated. Therefore, the level and content of the c-met 
protein was analyzed after muscle injury. Total proteins were 
prepared from the TA followed by western blot using antibodies 
to total c-met or phosphorylated form (Figure 1C). During 
muscle regeneration, the level of total c-met protein rapidly 
increased and the phosphorylated form of the c-met protein 
was also upregulated in the damaged muscle.
To identify the cell types that express c-met, cells known 
to be  infiltrated in the injured muscle were analyzed by 
IHC using antibodies to phosphorylated c-met, CD11b for 
macrophages, CD31 for endothelial cells, and Ly6G for 
neutrophils, 3 days after muscle injury. As shown in Figure 1D, 
the major cell type containing activated c-met was 
macrophages. In sham-treated muscle, there were no cells 
expressing phosphorylated c-met (Supplementary 
Figure  S1A). Since macrophages are known to be  a primary 
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source of HGF after injury (Sisson et  al., 2009), these data 
indicated that in an injured muscle, HGF might act on 
macrophage in an autocrine manner.
Inhibition of c-Met Signaling Delayed 
Muscle Regeneration
It was tested whether increased expression of HGF would 
contribute to or inhibit muscle regeneration using an inhibitor 
specific to the c-met receptor, PHA-665752. After CTX injection, 
mice were intraperitoneally (i.p.) injected with PHA-665752 
on a daily basis. We have previously reported that i.p. injection 
of PHA-665752 could effectively inhibit the phosphorylation 
of c-met in vivo including in the muscle tissue (Choi et  al., 
2018; Ko et  al., 2018). Treatment with PHA-665752 also 
suppressed c-met phosphorylation in macrophages infiltrating 
the injured muscle (Supplementary Figure S2A). Seven days 
after CTX injection, TA mass from vehicle (DMSO)-treated 
animals was found to be  reduced by 12% from 38.7  ±  0.7 to 
33.9  ±  0.9  mg, compared to that of the sham-operated group, 
while PHA-665752 treated mice showed a larger reduction, 
by 19% (Figure 2A). The skeletal muscle cross-section was 
analyzed by hematoxylin and eosin (H&E) staining of the TA 
(Figure 2B). In vehicle-treated mice, muscle fiber size was 
decreased by 40  ±  3% from 1,690  ±  134 to 1,014  ±  55  μm2 
A B C
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FIGURE 1 | HGF/c-met signaling is activated during muscle regeneration. (A) Expression kinetics of HGF protein during muscle injury by CTX and regeneration. 
The muscle was isolated at 2, 4, 7, and 12 days after CTX injection, and total proteins were analyzed by ELISA to measure the protein levels of HGF. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 versus sham-treated muscles (unpaired student’s t test), n = 4 per group. (B) Expression kinetics of the RNA levels of HGF 
during muscle injury and regeneration. RNA was prepared from TAs 1, 3, and 7 days after CTX injection followed by RT-qPCR, *p < 0.05, **p < 0.01 versus sham-
treated muscles (unpaired student’s t test), n = 4 per group. The values were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (C) Expression 
kinetics of total and phosphorylated c-met proteins in CTX-injured TAs. Muscles were isolated at 3 and 7 days postinjury, and total proteins were prepared followed 
by western blot using specific antibodies to total or phosphorylated c-met. β-tubulin was used as a loading control. Each lane represents a sample from an individual 
mouse. Two representative mice are shown here. Two independent experiments were performed (with a total of four mice), and similar results were obtained. Arrow 
indicates the protein of interest in blots. (D) Identification of cell types expressing c-met. CTX-injured TA was isolated 3 days postinjury and subjected to 
immunofluorescence assay using antibodies to CD11b for macrophages, CD31 for endothelial cells, Ly6G for neutrophils (all red), and phosphorylated c-met (green). 
Nuclei were counterstained with DAPI (blue). n = 4 per group. Scale bars, 20 μm. All data are presented as mean ± SEM. See also Supplementary Figure S1.
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compared with that of the sham-operated animals. In PHA-665752 
treated mice, it was further reduced, by 60  ±  3% compared 
to the sham-operated group (Figure 2C). In addition, the 
number of necrotic or damaged phagocytic fibers in PHA-treated 
animal was significantly higher in comparison to the vehicle-
treated group (Figure 2D). These data indicated that the 
inhibition of c-met signaling could delay the restoration of 
muscle mass and muscle fiber regeneration, suggesting that 
HGF might play a positive role(s) in muscle repair.
It was reported that defects in the process of removing 
damaged muscle fibers are associated with the improper transition 
of macrophage from M1 toward M2 phenotype (Mounier et al., 
2013). Therefore, the effect of PHA-665752 on the expression 
of M1 and M2 macrophage markers were tested. Three days 
after muscle injury, RNAs were isolated from TAs of mice 
when the RNA level of M1 and M2 macrophage markers were 
greatly induced. In animals treated with PHA-665752, the level 
of IL-1β, iNOS, and CCL2 (M1 markers) further increased 
(Figure 3A), while that of IL-10, TGF-β, arginase 1 (Arg1), 
CD163, and resistin-like alpha (Retnla) (M2 markers) was 
reduced, in comparison to the vehicle-treated group (Figure 3B).
To identify whether the regulation of M1 and M2 marker 
genes was caused by the changes in the population of macrophage, 
injured muscle was analyzed by immunofluorescence assay 
using antibodies to iNOS for M1 macrophages, and CD206 
for M2 macrophages. Three days after muscle injury, the number 
of iNOS-positive macrophages was highly increased and was 
further enhanced in animals treated with PHA-665752 
(Figure  3C). The number of CD206-positive macrophages was 
also increased upon injury, but PHA-665752 treatment 
significantly reduced it (Figure 3D). These results indicated 
that the HGF/c-met signaling pathway might be  involved in 
the transition of macrophages to an appropriate type during 
muscle regeneration.
Muscle regeneration is controlled by spatiotemporal regulation 
of various myogenic regulatory factors (MRFs) during which 
A B
C D
FIGURE 2 | Effects of c-met inhibitor PHA-665752 on muscle regeneration. After CTX injury, mice were i.p. injected with 20 mg/kg of PHA-665752 on a daily basis 
until sacrificed. CTX injured TAs were analyzed 7 days postinjury. (A) Effect on muscle weight. Muscle mass was normalized with the weight of mice. PHA,  
PHA-665752. ns, not significant, **p < 0.01, ***p < 0.001 (one-way ANOVA), n = 4 per group. (B) H&E staining of regenerating muscle. Crosses (x) and asterisks (*) 
indicate necrotic and phagocyted myofibers, respectively. Scale bars, 200 μm. (C) Effect on cross-sectional areas of muscle fibers. Mean value of area sizes is 
indicated in the graph. **p < 0.01, ***p < 0.001 (one-way ANOVA), n = 4 per group. (D) Quantification of necrotic or phagocyted fibers expressed as a percentage of 
total myofibers. At least 300 muscle fiber areas were counted per sample. **p < 0.01, ***p < 0.001 (unpaired student’s t test), n = 4 per group. All data are presented 
as mean ± SEM. See also Supplementary Figure S2.
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infiltrated immune cells play key roles (Di Marco et  al., 2005; 
Tidball and Villalta, 2010). Therefore, the expression of myoD, 
the key player in the regulation of myogenic commitment, 
was tested. Three days after muscle injury, the RNA level of 
myoD was markedly increased in CTX-injured TA, but treatment 
with PHA-665752 inhibited injury-induced myoD expression 
(Figure 3E). The protein level of myoD showed a similar 
pattern (Figure 3F). Taken together, our results implied that 
HGF/c-met signaling would act to regulate macrophage M1-M2 
transition, thereby contributing to regeneration of injured muscle.
HGF Promotes M2 Macrophage Transition 
via CaMKKβ-AMPK Signaling
To understand the mechanism(s) underlying the effect of HGF 
on macrophage transition at the molecular and cellular levels, 
Raw 264.7 cells, a murine macrophage line, was used. 
Lipopolysaccharide (LPS) was used to activate these cells to the 
pro-inflammatory phenotype (M1) in order to mimic in vivo 
muscle injury. Cells were treated with various concentrations 
of the recombinant human HGF (hHGF) protein in the presence 
of 100  ng/ml of LPS for 24  h. When Raw 264.7 cells were 
treated with LPS only, the expression level of M1 markers (IL-1β, 
iNOS, and TNFα) was greatly induced compared to the untreated 
control. Co-treatment with HGF inhibited an LPS-mediated 
increase in the level of M1 maker genes in a dose-dependent 
manner resulting in an approximate 40% decrease compared 
to the LPS only group (Figure 4A). On the other hand, LPS 
stimulation increased the expression level of IL-10 and Arg1, 
representative M2 marker genes, and HGF treatment further 
increased it in a dose-dependent manner (Figure 4B), suggesting 
that HGF might indeed control macrophage M2 transition.
The transition of macrophages from M1 to M2 during muscle 
regeneration is known to be controlled by two different pathways; 
CREB-C/EBPβ pathway (Ruffell et al., 2009) or AMPK signaling 
(Mounier et  al., 2013). HGF had little or no effect on the 
former, since treatment with HGF did not affect the 




FIGURE 3 | Effects of c-met inhibitor PHA-665752 on macrophage population infiltrated in the muscle. After CTX injury, mice were i.p. injected with 20 mg/kg of 
PHA-665752 on a daily basis until sacrificed. (A) Effects on the RNA levels of M1 markers (iNOS, IL-1β, and CCL2). (B) Effects on the RNA levels of M2 markers 
(IL-10, TGF-β, Arg1, CD206, CD163, Ym1, and Retnla). The RNA level of these genes isolated from TAs 3 days after injury was determined by RT-qPCR.  
The relative expression level of sham-operated, vehicle-treated mice is presented as 1. (C) Effect on iNOS-positive macrophages and (D) CD206-positive 
macrophages. CTX-injured TA was isolated 3 days postinjury and subjected to immunofluorescence assay using antibodies to CD11b (red) and iNOS or CD206 
(green). Nuclei were counterstained with DAPI (blue). Percentage of iNOS+ or CD206+ macrophages was indicated in the graph. *p < 0.05, **p < 0.01 (unpaired 
student’s t test), n = 4 per group. Scale bars, 20 μm. (E) Effects on MyoD RNA. *p < 0.05 (unpaired student’s t test), n = 4 per group. (F) Effects on MyoD protein. 
Two representative results are shown here, n = 4 per group. All data are presented as mean ± SEM.
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(Figure 4C, Supplementary Figure S3B). To test whether HGF 
regulates the macrophage transition through AMPK, Raw 264.7 
cells were treated with 50  ng/ml of the hHGF protein and 
100  ng/ml LPS for 30  min, followed by western blot, using 
antibodies to total or phosphorylated AMPKα. LPS stimulation 
decreased the level of phosphorylated AMPKα as previously 
reported (Sag et  al., 2008), but the presence of HGF restored 
the phosphorylation of AMPKα to the normal level. The level 
of total AMPKα remained unchanged in all conditions 
(Figure 4C).
To test if AMPK is involved in the effects of HGF on 
inflammatory cytokines production, Raw 264.7 cells were 
transfected with siRNA against AMPKα followed by treatment 
with LPS and HGF. The protein level of AMPKα was highly 
reduced by siRNA transfection (Supplementary Figure S3A). 
Raw 264.7 cells transfected with siAMPKα had no effect on 
the HGF-mediated control of M1 and M2 marker gene expressions 
(Figure 4D). These results indicated that HGF controlled the 
expression of M1 markers (IL-1β and iNOS) and IL-10 by 
upregulating AMPK phosphorylation.
AMPK phosphorylation is known to be regulated by upstream 
effectors such as LKB1 and CaMKKβ (Carling et  al., 2008). 
It was tested as to which upstream effectors would be  involved 
in the phosphorylation of AMPK mediated by HGF. LKB1 
did not seem to play a role as HGF did not induce the 
phosphorylation of LKB1  in Raw 264.7 cells (Figure 4C). 
However, treatment with HGF induced the phosphorylation 
of CaMKKβ and treatment with STO-609, CaMKKβ inhibitor, 
lowered the level of HGF-mediated phosphorylation of AMPKα 
(Figure 4E). Therefore, in Raw 264.7 cells, CaMKKβ, but not 
LKB1, appeared to act as an upstream effector of HGF-mediated 
control of AMPK.
Finally, it was investigated whether the phosphorylation of 
AMPK was regulated by HGF during skeletal muscle regeneration. 
At day 3 postinjury, TAs were isolated and subjected to western 






FIGURE 4 | Roles of CaMKKβ-AMPKα on HGF-mediated control of the expression of M1 and M2 markers in Raw 264.7 cells. Raw 264.7 cells were cultured in the 
presence or absence of LPS and recombinant HGF proteins. Total RNA and proteins were prepared and analyzed by RT-qPCR and western blot, respectively.  
(A) Effects of HGF on the RNA levels of M1 markers (IL-1β, iNOS, and TNFα). *p < 0.05, **p < 0.01 (unpaired student’s t test), n = 3 per group. (B) Effects of HGF 
on RNA levels of M2 markers (IL-10 and Arg1). Values were normalized to GAPDH. *p < 0.05, **p < 0.01 (unpaired student’s t test), n = 3 per group. (C) Effects of 
HGF on signaling pathways related to macrophage polarization. (D) Effects of AMPKα knockdown on HGF-mediated regulation of the RNA level of IL-1β, iNOS, and 
IL-10, marker genes of M1 and M2. Raw 264.7 cells were transfected with AMPKα or control siRNAs, and then treated with LPS and HGF. Values were normalized 
to GAPDH. *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired student’s t test), n = 3 per group. (E) Effects of CaMKKβ inhibitor, STO-609, on the HGF-mediated 
phosphorylation of AMPKα. Arrow indicates the protein of interest in blots. In western blot hybridization, GAPDH was used as a loading control. All data are 
presented as mean ± SEM. See also Supplementary Figure S2 and S3.
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AMPKα was highly increased in CTX-injured TA, and treatment 
with PHA-665752 had no significant effect (Supplementary 
Figure S2B). When the phosphorylation of AMPK was measured 
in situ specifically in macrophages, however, a completely 
different picture emerged; PHA-665752 treatment significantly 
reduced the injury-mediated phosphorylation of AMPK in 
macrophages (Supplementary Figure S2C). Taken together, 
these data suggested that HGF/c-met pathway regulate M2 
macrophage transition by regulating CAMKKβ and AMPK.
Exogenous Delivery of HGF Facilitated 
Muscle Regeneration
Based on the above results indicating a positive role(s) of 
HGF in macrophage transition during muscle regeneration, 
we  tested the effects of the exogenous addition of HGF in 
the same CTX muscle injury model. Since HGF has a very 
short half-life, less than 5  min in serum (Kawaida et  al., 
1994), we  delivered HGF in the form of a plasmid DNA 
expression vector. pCK-HGF-X7 (or VM202) is a plasmid 
designed to produce two isoforms of human HGF, HGF723 
(or dHGF), and HGF728 (or cHGF), at high levels in vivo 
(Cho et  al., 2008; Pyun et  al., 2010; Hahn et  al., 2011), and 
it has been known to work in a variety of clinical studies 
and animal models (Cho et  al., 2008; Pyun et  al., 2010; Hahn 
et  al., 2011; Kessler et  al., 2015; Kibbe et  al., 2016). The in 
vivo protein expression kinetics of this plasmid in the muscle 
have been well established previously (Supplementary 
Figure S4A) (Cho et al., 2008; Pyun et al., 2010; Hahn et al., 2011; 
Nho et  al., 2018).
Three days prior to the muscle injury, 100 μg of pCK-HGF-X7 
or pCK control vector lacking the HGF sequence was i.m. 




FIGURE 5 | Effects of HGF overexpression by intramuscular injection of HGF expressing plasmid on muscle regeneration. pCK or pCK-HGF-X7 was i.m. injected 
3 days prior to the CTX injection. TAs were prepared at appropriate times after injury. (A) Effect on TA weight. Representative TAs from 7 days postinjury are shown in 
the photos. *p < 0.05 versus CTX + pCK group (one-way ANOVA), n = 4 per group. Scale bar, 1 mm. (B) Effects on cross-sectional areas of regenerating fibers. 
CTX-injured TA was isolated 3 days postinjury and subjected to immunofluorescence assay using antibodies to eMHC (red) for regenerating myofibers. Percentage of 
eMHC+ myocytes was indicated in the graph. ***p < 0.001 (one-way ANOVA), n = 4 per group. Scale bar, 50 μm. (C–E) Three days after injury, the TA was isolated, 
and total RNAs were analyzed by RT-qPCR. (C) Effects on the expression of Myh3. *p < 0.05 (one-way ANOVA), n = 4 per group. (D) Effects on the RNA levels of 
M1 markers (IL-1β, iNOS, and CCL2). *p < 0.05 (one-way ANOVA), n = 4 per group. (E) Effects on RNA levels of M2 markers (IL-10, TGF-β, Arg1, and CD163). 
*p < 0.05 (one-way ANOVA), n = 4 per group. Values were normalized to GAPDH. All data are presented as mean ± SEM. See also Supplementary Figure S4.
241
Choi et al. HGF Regulates Muscle Macrophage Transition
Frontiers in Physiology | www.frontiersin.org 9 July 2019 | Volume 10 | Article 914
by injecting CTX to the TA of a 10-week-old C57BL/6 mouse. 
The TA was isolated, and muscle mass was quantitated at 
different time points after muscle injury. As shown in Figure 5A, 
in CTX-injured mice injected with pCK control vector, muscle 
mass was decreased by 18 and 22% at days 3 and 7, respectively. 
When mice were injected with pCK-HGF-X7, the restoration 
of muscle weight was facilitated, to 17 and 13% decrease, 
compared to the control at days 3 and 7, respectively.
The regenerating muscle fibers were analyzed by 
immunostaining embryonic myosin heavy chain (eMHC), 3 days 
after muscle injury. In pCK-treated animals, the percentage 
of eMHC+ myocytes was about 20%, while it increased to 
37% when treated with pCK-HGF-X7 (Figure 5B). Similar 
patterns were observed when the RNA level of eMHC (Myh3) 
was measured by qRT-PCR (Figure 5C). Overall, our data 
showed that the exogenous addition of HGF, delivered in the 
form of plasmid expression vector, could facilitate 
muscle regeneration.
The effects of i.m. injection of pCK-HGF-X7 on M1 and 
M2 markers were also measured. Muscle injury was induced, 
and pCK or pCK-HGF-X7 was i.m. injected into the TA. Three 
days after muscle injury, TA was isolated, and the RNA level 
of M1 and M2 markers were measured using RT-qPCR. The 
level of M1 markers, IL1β, iNOS, and CCL2 was highly increased 
after muscle injury, but pCK-HGF-X7 injection reduced the 
expression of these genes (Figure 5D). The level of M2 markers, 
IL-10, Arg1, and CD163, also increased upon muscle injury 
and further increased in animals treated with PCK-HGF-X7 
(Figure 5E). These data strongly indicated that HGF 
overexpression by gene transfer technology could trigger 
transition of macrophages to the M2 phenotype to promote 
muscle regeneration.
DISCUSSION
In this report, we  demonstrated that HGF/c-met signaling 
plays a key role in the regulation of macrophage transition 
during muscle regeneration after necrotic injury. The 
HGF/c-met signaling was highly activated after muscle damage, 
and the macrophage was the major cell type affected by 
HGF among cells that infiltrated the muscle. Treating 
CTX-injured mice with PHA-665752, a specific inhibitor for 
c-met, deregulated the population of macrophages and delayed 
muscle regeneration. Exogenous supply of the HGF protein 
to the affected region through i.m. injection of a highly 
efficient plasmid expression vector promoted the transition 
of macrophage to the M2 phenotype and facilitated muscle 
regeneration. Data from Raw 264.7 cells showed that HGF 
controls macrophage transition via CaMKKβ-AMPK signaling. 
Taken together, HGF/c-met signaling plays a key role in 
the transition of the macrophage infiltrated during 
muscle regeneration.
HGF is secreted by a variety of cell types in cases of muscle 
injury. Relevant to our work is that fact that, macrophages 
are known to be  the primary source of HGF during muscle 
regeneration (Sisson et  al., 2009). Consistent with previous 
reports, we  found that the kinetics of the RNA and protein 
levels of HGF paralleled the curve of macrophagic appearance 
in regenerating muscle (Mounier et  al., 2013). However, the 
underlying mechanism by which macrophages produce HGF 
has not yet been understood. One possibility is that HGF 
may be  secreted when these cells are exposed to apoptotic 
neutrophils. It was previously reported that when macrophages 
encounter apoptotic cells, HGF is produced via a RhoA-
dependent signal in vitro (Park et  al., 2011). Interestingly, our 
study showed that the expression level of HGF peaked at 
3–4  days postinjury, and this is the time when neutrophils 
induce an early immune response and became apoptotic and 
cleared by macrophages (Arnold et  al., 2007; Nguyen et  al., 
2011). It remains to be  elucidated whether HGF expression 
in macrophages would indeed be  regulated by their exposure 
to apoptotic neutrophils in vivo.
We found that HGF regulated phosphorylation of AMPK 
through the CaMKKβ upstream regulator. Since HGF/c-met 
signaling promotes the influx of calcium ions into a variety 
of cells, it is possible that calcium-dependent kinases are 
activated (Baffy et  al., 1992; Tyndall et  al., 2007; Gomes et  al., 
2008). In our study involving Raw 264.7 cells, another well-
known upstream regulator, LKB1, was not phosphorylated by 
HGF. This is different from the previous study showing that 
HGF regulates the phosphorylation of AMPK through LKB1 in 
primary hepatocytes (Vázquez Chantada et  al., 2009). In cases 
of muscle injury, however, it was previously reported that mice 
lacking LKB1 in their myeloid cells did not show any significant 
defects during muscle regeneration (Mounier et  al., 2013). 
Therefore, LKB1  in macrophages may play a negligible role 
in the HGF/AMPK-mediated regulation of macrophage transition 
during muscle repair. These data imply that HGF might regulate 
the phosphorylation of AMPK through a different pathway 
depending on cell type.
In this study, we focused on the role of HGF/c-met signaling 
on macrophages during muscle regeneration, as they are the 
major cell type infiltrated after muscle injury. We  found that 
HGF regulated the transition of the macrophage phenotype 
to promote muscle repair; while others reported that when 
c-met is knocked out specifically in muscle stem cells, mice 
showed delayed stem cell activation, decreased myoblast motility, 
abnormalities in myocyte fusion, and impaired muscle 
regeneration (Webster and Fan, 2013). These results suggest 
that HGF/c-met signaling could act on various cell types, 
including muscle progenitors and invading immune cells, to 
coordinate muscle repair during muscle regeneration. Also, 
HGF may be able to produce multiple positive effects in various 
cells during muscle regeneration.
In summary, HGF/c-met signaling appears to play a role(s) 
in muscle repair by promoting macrophage transition to the 
M2 phenotype. Various muscle diseases, including muscular 
dystrophy or myositis, are accompanied by a high inflammatory 
burden, leading to tissue lysis and compromising of the 
regeneration process. Currently, no drug can discriminate 
between the different phenotypes of the macrophage. Without 
such specificity, there is a chance of indiscriminate macrophage 
depletion, which can lead to undesirable systemic side effects 
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(Balaban et  al., 2005). Given the safety and efficacy records 
of pCK-HGF-X7 (VM202) observed in several clinical studies 
for other indications, further studies are warranted to 
investigate the possibility of using HGF, and in particular 
the plasmid DNA vector expressing HGF, for various muscle 
degenerative diseases.
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Skeletal muscle is composed of a large and heterogeneous assortment of cell
populations that interact with each other to maintain muscle homeostasis and
orchestrate regeneration. Although satellite cells (SCs) – which are muscle stem
cells – are the protagonists of functional muscle repair following damage, several
other cells such as inflammatory, vascular, and mesenchymal cells coordinate muscle
regeneration in a finely tuned process. Fibro–adipogenic progenitors (FAPs) are a muscle
interstitial mesenchymal cell population, which supports SCs differentiation during tissue
regeneration. During the first days following muscle injury FAPs undergo massive
expansion, which is followed by their macrophage-mediated clearance and the re-
establishment of their steady-state pool. It is during this critical time window that FAPs,
together with the other cellular components of the muscle stem cell niche, establish a
dynamic network of interactions that culminate in muscle repair. A number of different
molecules have been recently identified as important mediators of this cross-talk, and
its alteration has been associated with different muscle pathologies. In this review, we
will focus on the soluble factors that regulate FAPs activity, highlighting their roles in
orchestrating the inter-cellular interactions between FAPs and the other cell populations
that participate in muscle regeneration.
Keywords: FAPs, fibrosis, cytokine – immunological terms, muscle regeneration, stem cell
INTRODUCTION
Skeletal muscle is the most abundant tissue in healthy humans, accounting for 40% of body weight.
It is composed of multinucleated contractile cells called myofibers, which are formed during
development by fusion of differentiated mononuclear muscle cells, and their number remains
constant during post-natal growth. The regenerative potential of skeletal muscle relies primarily
on satellite cells (SCs), the prototypical muscle stem cells. Upon muscle injury SCs enter the cell
cycle, proliferate, and differentiate to repair damaged myofibers, while self-renewing to repopulate
the reserve pool (Feige et al., 2018).
Recently, several studies have indicated that the establishment of functional cross-talk between
SCs and other cell types within the muscle niche, including motor neurons, endothelial cells,
immune cells, fibrogenic cells, and adipogenic precursors, is crucial for muscle repair and
homeostasis (Tatsumi et al., 2009; Joe et al., 2010; Uezumi et al., 2010; Heredia et al., 2013;
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Saccone et al., 2014; Kuswanto et al., 2016; Verma et al., 2018;
Giordani et al., 2019; Lukjanenko et al., 2019). Indeed, different
stem/progenitor cell types are recruited to the regenerative
niche and influence muscle regeneration either by directly
differentiating into muscle cells or by releasing paracrine factors
(i.e., growth factors, cytokines) that control the regenerative
response of SCs (Pannérec et al., 2012). Among the non-
cellular components of the SCs niche the extra-cellular matrix
(ECM) plays a crucial role by undergoing a transient remodeling
during acute injury, followed by a prompt termination to avoid
pathological fibrosis and tissue degeneration. Although recent
findings have shown that myogenic cells can produce ECM
components (Fry et al., 2017b; González et al., 2017; Baghdadi
et al., 2018), and a recently identified population of interstitial
tenocytes has been implicated in ECM deposition in vivo
(Giordani et al., 2019), the main cellular sources of ECM proteins
are fibroblasts, myo-fibroblast, and fibro–adipogenic progenitors
(FAPs) (Serrano and Muñoz-Cánoves, 2010; Lemos et al., 2015;
Contreras et al., 2016; Mueller et al., 2016).
Since their discovery FAPs have attracted a considerable
attention (Joe et al., 2010; Uezumi et al., 2010), in particular, their
phenotypical plasticity, which appears critical for efficient muscle
repair. FAPs have been defined as multi-potent progenitors,
having the ability to differentiate into fibroblasts, adipocytes,
and possibly into osteoblasts and chondrocytes, although not
into myoblasts (Joe et al., 2010; Uezumi et al., 2010). They
share the expression of cell surface markers, such as Sca-1 and
PDGFRα with mesenchymal stem cells and can therefore be
broadly defined as mesenchymal precursors (Joe et al., 2010;
Mueller et al., 2016; Judson et al., 2017; Malecova et al., 2018;
Giordani et al., 2019).
Under quiescent conditions FAPs frequently localize close
to blood vessels but unlike pericytes FAPs reside outside
the capillary basement membrane and do not express NG2
(Joe et al., 2010).
However, upon muscle injury, FAPs become activated,
proliferate and expand, and provide a transient favorable
environment to promote SCs-mediated regeneration (Joe et al.,
2010; Heredia et al., 2013; Mozzetta et al., 2013). FAPs
expansion is critical during regeneration in order to sustain SCs
differentiation in a paracrine manner and to maintain the SCs
pool (Wosczyna et al., 2019). Indeed, in vivo depletion of FAPs
clearly established their absolute requirement for regeneration
and long-term maintenance of skeletal muscle (Wosczyna et al.,
2019). However, as regeneration proceeds, FAPs are cleared from
the regenerative niche by apoptosis (Lemos et al., 2015) and
failure in doing so has been associated with their pathological
accumulation and with a number of muscle dysfunctions. In fact,
beyond their supportive role in muscle regeneration, FAPs have
been identified as the major source of infiltrating fibroblasts and
adipocytes in degenerating dystrophic muscles (Uezumi et al.,
2010, 2011; Mozzetta et al., 2013; Kopinke et al., 2017). Similarly,
in chronic atrophic conditions, caused by moto-neurons deficits,
increased fibrosis is associated with accumulation of FAPs in
the interstitium of denervated muscles (Contreras et al., 2016;
Fry et al., 2017a; Madaro et al., 2018; Rebolledo et al., 2019).
Likewise, intra-muscular fatty infiltration and obesity-associated
muscle dysfunctions have been also linked to FAPs accumulation
and fibro–adipogenic differentiation (Dammone et al., 2018;
Gorski et al., 2018; Kang et al., 2018; Pagano et al., 2018;
Buras et al., 2019).
These findings emphasize that the FAPs lineage decisions
are dramatically influenced by signals released in their
microenvironment, whose pathological alteration might
culminate in excessive ECM accumulation (Lemos et al.,
2015; Contreras et al., 2016; Dammone et al., 2018; Madaro
et al., 2018), acquisition of altered cell fates, as in the case
of heterotypic ossification (Lees-Shepard et al., 2018), and
impaired myogenesis. In physiological conditions, FAPs’ cross-
talk with other cell populations is emerging as an important
and finely orchestrated process crucial for a successful muscle
regeneration. While it is now well established that a cross-talk
between SCs and fibrogenic cells is necessary for efficient SCs
expansion in response to injury, and to prevent interstitial
fibrosis accumulation (Murphy et al., 2011; Fry et al., 2017b;
Lukjanenko et al., 2019), increasing evidence indicates that FAPs
also actively interact with immune cells in a finely tuned manner
(Heredia et al., 2013; Lemos et al., 2015; Malecova et al., 2018;
Moratal et al., 2018).
Taken together, these observations demonstrate that FAPs
orchestrate a plethora of processes involved in regenerative
myogenesis, which have been recently reviewed elsewhere
(Wosczyna and Rando, 2018). In this mini-review, we will
instead specifically focus on the secreted signals, cytokines,
and paracrine factors controlling FAPs function and those
released by FAPs monitoring the different cell types involved
in muscle repair. We will first describe the signals secreted by
the various cell populations present in the regenerative niche
known to directly influence FAPs activity and then discuss the
signals released by FAPs themselves, highlighting their cellular
targets and functions (Table 1).
THE SECRETOME THAT REGULATES
FAPS ACTIVITIES
IL-4 and IL-13 Family
Interleukin-4 (IL-4) and IL-13 are Th2 cytokines, which have
been implicated as mediators in the cross-talk between the
immune system and FAPs (Heredia et al., 2013). The innate
immune system is activated rapidly upon muscle injury and
triggers the recruitment of Th2 lymphocytes, macrophages, mast
cells, and eosinophils to the injured sites (Tidball and Villalta,
2010; Heredia et al., 2013).
Interleukin-4/IL-13 signaling is crucial for skeletal muscle
repair, as demonstrated by studies showing a complete absence
of regenerated myofibers, persistence of cellular debris, and
an inflammatory infiltrate, in the muscles of IL-4/IL-13−/−
mice following cardiotoxin-induced injury (Heredia et al.,
2013). Although activation of type 2 immune responses has
been classically associated with alternatively activated (M2)
macrophages (Allen and Wynn, 2011; Palm et al., 2012),
eosinophils have been recently identified as the dominant
cell source of IL-4 and IL-13 (Heredia et al., 2013) during
Frontiers in Physiology | www.frontiersin.org 2 August 2019 | Volume 10 | Article 1074246
fphys-10-01074 August 20, 2019 Time: 15:34 # 3
Biferali et al. FAPs Social Network
TABLE 1 | Schematic table illustrating the principal molecules, the producing and target cells, and the corresponding biological effects, that have been shown to act on,




Target Effects References Experimental
conditions
TGF-β Macrophages FAPs TGF-β induces FAPs fibrogenic differentiation and blocks
TNF-induced FAPs apoptosis.
Uezumi et al., 2011; Lemos
et al., 2015; Davies et al.,
2016
In vitro and in vivo
IL-15 Muscle
fibers
FAPs IL-15 stimulates FAPs proliferation and prevents adipogenic
differentiation in vitro and in vivo and promotes
FAPs-induced SC differentiation.
Kang et al., 2018 In vitro and in vivo
IL-4 Eosinophils FAPs IL-4 inhibits adipogenic differentiation of FAPs and
increases FAPs ability to remove cellular debris enhancing
regeneration.
Heredia et al., 2013; Dong
et al., 2014
In vitro and in vivo
IL-13 FAPs IL-13 promotes FAPs proliferation that supports
myogenesis, while inhibits FAPs differentiation into
adipocytes.
Heredia et al., 2013 In vitro and in vivo
TNF-α Macrophages FAPs TNF-α induces FAPs apoptosis preventing excessive
deposition of extracellular matrix during regeneration.
Lemos et al., 2015 In vitro and in vivo
IL-6 FAPs Myotubes IL-6 promotes myogenic differentiation. Joe et al., 2010 In vitro
FAPs IL-6 promotes pro-atrophic FAPs phenotype during
denervation.
Madaro et al., 2018 In vitro and in vivo
IL-33 FAPs Regulatory
T cells
IL-33 increases Treg cells proliferation promoting muscle
repair.
Kuswanto et al., 2016 In vitro and in vivo
Follistatin FAPs Satellite
cells
FAPs-secreted follistatin promotes multinucleated
myotubes formation.
Mozzetta et al., 2013 In vitro
IL-10 FAPs Myotubes IL-10 is upregulated in FAPs during muscle regeneration. Its
role is still unknown but the hypothesis is that the secretion
of IL-10 facilitates myoblast differentiation by preventing the
antimyogenic activity of TNF and IL-1β.
Lemos et al., 2012 n/a
BMP1-
MMP14
FAPs Macrophages FAPs-secreted BMP1 and MMP14 activate TGF-β
produced by macrophages in fibrotic DMD muscle.
Juban et al., 2018 In vitro
WISP1 FAPs Satellite
cells
FAPs-secreted WISP1 regulates satellite cell expansion and
asymmetric differentiation. FAPs-derived WISP1 is lost
during aging impairing muscle regeneration.
Lukjanenko et al., 2019 In vitro and in vivo
References relative to the evidence described are shown together with the experimental conditions (in vivo or in vitro) used to identify the described mechanisms. Where
experimental evidence is lacking we indicated the experimental procedure with n/a.
skeletal muscle regeneration. Specifically, it has been shown
that eosinophils secrete IL-4 to activate the regenerative actions
of FAPs. Indeed, Heredia et al. (2013) identified FAPs as the
cells specifically expressing the IL-4Rα, demonstrating, both
in vitro and in vivo, that FAPs are the cellular targets of
IL-4/IL-13 signaling during muscle regeneration. Intriguingly,
they also unveiled a previously unrecognized function of FAPs:
their capacity to phagocytoze necrotic debris, a crucial process
for successful completion of muscle repair (Heredia et al.,
2013). In addition, IL-4/IL-13 signaling, via activation of STAT6,
promotes FAPs proliferation to support myogenesis, while
inhibiting their differentiation into adipocytes (Heredia et al.,
2013). Accordingly, in the injured muscles of IL-4-knockout
mice, the levels of adipocytes are increased, while in vitro
and in vivo administration of IL-4 inhibits FAPs adipogenesis
(Heredia et al., 2013; Dong et al., 2014). In agreement with these
observations, glucocorticoids (GCs)-induced repression of IL-4
leads to intramuscular adipogenic accumulation by promoting
FAPs proliferation and differentiation into adipocytes (Dong
et al., 2014). Since GCs are known to suppress eosinophils, it is
likely that they inhibit IL-4 signaling by reducing the number of
infiltrating eosinophils upon muscle injury (Dong et al., 2014).
Yet, IL-4-polarized, anti-inflammatory macrophages have been
shown to induce adipogenesis of human FAPs isolated from
dystrophic muscles (Moratal et al., 2018), suggesting that IL-4
signaling might govern more complex cellular interactions than
previously expected.
IL-15
Interleukin-15 is expressed in human skeletal muscle and it has
been identified as an anabolic factor involved in muscle growth
(Quinn et al., 2002; Furmanczyk and Quinn, 2003). Indeed,
IL-15 can decrease protein degradation in muscle (Busquets
et al., 2005) and modulate muscle–adipose tissues interactions
(Quinn et al., 2005). A recent work identified IL-15 as a myokine
able to prevent intramuscular fatty infiltration, likely affecting
FAPs differentiation capacities (Kang et al., 2018). In this work,
the authors showed that IL-15 stimulates FAPs proliferation
and it directly inhibits their adipogenic differentiation, both
in vitro and in vivo, ultimately facilitating myofibers regeneration
(Kang et al., 2018). Moreover, intramuscular administration of
a recombinant IL-15 prevented fat accumulation in the murine
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model of glycerol-induced fatty degeneration (Kang et al., 2018).
Accordingly, in vitro treatment of FAPs with IL-15 impaired their
capacity to differentiate into adipocytes (Kang et al., 2018), likely
through the induction of desert Hedgehog (DHH) signaling, a
known repressor of FAPs adipogenesis (Kopinke et al., 2017).
Although these results suggest a positive role for IL-15 in
muscle regeneration, the evidence that IL-15 administration, and
expression, correlates with increased collagen deposition in vivo
after muscle damage (Kang et al., 2018), poses several unresolved
issues that warrant further investigation. Indeed, whether IL-
15 directly promotes FAPs differentiation into fibroblasts has
not been tested yet. Furthermore, even though FAPs expansion
and regenerative fibrogenesis have a positive impact on acute
muscle regeneration (Heredia et al., 2013; Fiore et al., 2016),
the evidence that IL-15 expression is positively correlated with
the number of FAPs and collagen deposition in subjects with
rotator cuff tear indicates that IL-15 might serve, instead, as
a signal to sustain FAPs pathogenic fibrogenesis in chronically
fibrotic muscles.
TNF-α
Tumor necrosis factor-alpha (TNF-α) is a pleiotropic
cytokine secreted rapidly upon muscle damage by infiltrating
inflammatory cells and its impact on muscle regeneration is
still under debate. Indeed, while pharmacological blockade
of TNF-α has been associated with reduced muscle necrosis
and amelioration of the histological profile of dystrophic
muscles (Hodgetts et al., 2006; Huang et al., 2009; Piers et al.,
2011; Ermolova et al., 2014). More recently, TNF-α has been
implicated in preventing FAPs aberrant accumulation (Lemos
et al., 2015; Fiore et al., 2016), suggesting that anti-TNF therapies
might instead exert a pro-fibrotic effect.
During acute injury, TNF-α has been reported to promote
muscle repair by activating promyogenic p38 signaling (Chen
et al., 2007), thus inducing SCs differentiation (Palacios et al.,
2010). Recently, it has been suggested that TNF-α regulates
matrix production during acute damage, thus unveiling a crucial
function for TNF-α in mediating FAPs apoptosis and clearance
(Lemos et al., 2015; Fiore et al., 2016). Specifically, TNF-
α was found to be predominantly expressed and produced
by infiltrating monocytes that rapidly differentiate into pro-
inflammatory macrophages (M1) that accumulate in close
proximity to expanding FAPs. By using a mouse model unable
to recruit circulating monocytes to damaged muscles [the C–
C chemokine receptor type 2 (Ccr2)−/− mouse strain (Warren
et al., 2005)], Lemos et al. (2015) elegantly demonstrated that
in the absence of infiltrating TNF-a-producing macrophages,
FAPs accumulate in the sites of damage and aberrantly
differentiate into fibrogenic cells. Inflammatory cell-derived
TNF-α production is therefore required for FAPs clearance
to prevent pathological ECM accumulation. Of note, this
physiological role is altered in chronically damaged muscles,
such as those of dystrophic mice, where the abundance of
transforming growth factor beta 1 (TGF-β1) signaling impairs
the pro-apoptotic effects of TNF-α on FAPs (Lemos et al., 2015).
These data might offer a possible explanation for the apparent
controversial results reporting a positive effect of anti-TNF-α
therapies on dystrophic mice (Hodgetts et al., 2006; Huang et al.,
2009; Piers et al., 2011; Ermolova et al., 2014). Indeed, when
TGF-β1 is abundant, as in chronic degenerating muscles, the
anti-fibrotic role of TNF-α is irrelevant and pharmacological
approaches aimed at inhibiting its activity most likely exert
their beneficial effects through targeting of the pro-myogenic,
SC-mediated function of TNF-α.
TGF-β
The transforming growth factor beta (TGF-β) superfamily
comprises pleiotropic and multifunctional secreted peptides
implicated in a wide range of cell functions, including tissue
homeostasis and repair, immune and inflammatory responses,
ECM deposition, cell differentiation, and growth (Biernacka et al.,
2011; Meng et al., 2016). Studies in a wide range of experimental
models have firmly established TGF-β1 as a crucial mediator
of fibrinogenesis and inhibition of its activity has consistently
been associated with reduced fibrosis (Biernacka et al., 2011;
Meng et al., 2016).
In the context of skeletal muscle, inhibition of TGF-β1
has been linked to improvement in muscle regeneration and
decreased fibrosis (Davies et al., 2016; Song et al., 2017;
Zhang et al., 2019), consistent with the importance of the
TGF-β1 signaling in regulating both regeneration and matrix
production. Several works have elucidated the detrimental,
cell-autonomous, impact of TGF-β signaling on muscle stem
cells by inhibiting their activation (Carlson et al., 2008; Wang
et al., 2016) and terminal differentiation (Carlson et al., 2008)
while promoting a fibrogenic switch in chronically degenerating
muscles (Biressi et al., 2014).
Nonetheless, recent findings point toward a prominent role
for inflammatory cell-derived TGF-β signaling in the survival
and fibrotic differentiation of FAPs. Specifically, during chronic
muscle damage, macrophages express and secrete high levels of
TGF-β1, antagonizing the TNF-mediated apoptosis of FAPs, and
instead induce their fibrogenic differentiation and consequent
ECM deposition (Lemos et al., 2015; Davies et al., 2016;
Fiore et al., 2016; Juban et al., 2018). Thus, in conditions
of chronic muscle damage, TGF-β1 acts as a dominant, pro-
survival signal that overrides the beneficial effect of the pro-
inflammatory cell-derived, and anti-fibrotic cytokine, TNF-α.
Thus, treatment with nilotinib, via specific inhibition of TGF-
β1-induced p38 signaling, restores FAPs apoptosis and prevents
fibrotic accumulation in dystrophic mice (Lemos et al., 2015).
Of note, FAPs from chronic fibrotic dystrophic muscles have
been identified as the main source of TGF-β-activating enzymes
(Juban et al., 2018). Indeed, once released, latent TGF-β1 must
be activated, either via enzymatic or mechanical mechanisms,
to exert its properties and to bind to its receptors (Travis and
Sheppard, 2014). FAPs exhibit high expression of a series of
latent TGF-β1 activators, among which matrix metallo proteinase
14 (MMP14) and bone morphogenetic protein 1 (BMP1) are
able to activate the latent TGF-β1 released by pro-inflammatory
macrophages (Juban et al., 2018). Notably, pharmacological
inhibition of BMP1 or MMP14 reduced muscle fibrosis in
dystrophic mice resulting in increased muscle fiber size and
reduced necrosis (Juban et al., 2018).
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In summary, these data support a model through which
chronic inflammation and fibrosis reciprocally sustain
themselves in degenerating dystrophic muscles, by reinforcing a
regulatory cross-talk between inflammatory cells and FAPs.
MOLECULES SECRETED BY FAPS
IL-6
In skeletal muscle, IL-6 is classified as a myokine produced and
released by muscle fibers in response to contraction (Pedersen
and Febbraio, 2008). It promotes lipolytic and anti-inflammatory
beneficial effects during exercise (Pedersen et al., 2003), working
as an energy sensor and exerting both local and endocrine
metabolic effects.
Interleukin-6 regulates both muscle hypertrophy and
regeneration (Muñoz-Cánoves et al., 2013). Indeed, IL-6
knockout mice show a reduced hypertrophic response to
overloading, ascribed to impaired myonuclei incorporation as
a consequence of the defective proliferation and migration of
SCs. Treatment with IL-6 promotes murine SCs proliferation, via
regulation of cell-cycle associated genes, Cyclin D1 and c-Myc
(Serrano et al., 2008), while during regeneration the IL-6/STAT3
axis controls SCs fate (Tierney et al., 2014). Interestingly, FAPs
were identified as one of the main source of IL-6 during
muscle regeneration. Upon muscle injury, IL-6 expression
remains constant in myogenic progenitors but increases nearly
10-fold in FAPs and in vitro co-culture experiments have
shown that IL-6 mediates the pro-myogenic activity of FAPs
(Joe et al., 2010).
The positive effect of IL-6, and others myokines, is normally
associated with transient production and short-term action.
By contrast, persistent inflammatory conditions, denervation,
and some types of cancer and other chronic diseases have
been associated with long-lasting elevated IL-6 levels. In
agreement with this notion, IL-6 has been shown to promote
skeletal muscle atrophy (Haddad et al., 2005). Accordingly,
in denervated muscles, FAPs show a persistent activation of
IL-6, thus promoting muscle atrophy without other systemic
effects (Madaro et al., 2018). Notably, in vivo pharmacological
inhibition of IL-6 effectively counteracts denervation-mediated
muscle atrophy (Madaro et al., 2018) and accumulation of FAPs
with hyper-activation of IL-6 signaling has also been found in
mouse models of amyotrophic lateral sclerosis (ALS) (Contreras
et al., 2016; Madaro et al., 2018).
Taken together, these observations suggest two apparently
opposing effects of FAPs-derived IL-6 during muscle
regeneration or in denervation-induced muscle wasting,
and further studies are needed to shed light on the molecular
mechanisms behind these apparently contradictory roles.
IL-33
Interleukin-33 is a nuclear chromatin-associated cytokine,
belonging to the IL-1 family, and constitutively expressed in
the nucleus of a wide variety of cell types, including fibroblasts,
epithelial cells, and endothelial cells (Carriere et al., 2007). IL-33
appears to function as an alarmin (alarm signal) that is rapidly
released upon cellular damage and stress (Liew et al., 2016) and
mediates a potent effect on the activation of regulatory T cell
lymphocytes (Treg) (Matta et al., 2014; Alvarez et al., 2019).
In skeletal muscle, the major IL-33-producing cell type has
been identified within the FAP cell population (Kuswanto et al.,
2016). FAPs start to express IL-33 within 6–12 h after acute
injury, inducing proliferation of muscle resident Treg (Kuswanto
et al., 2016). As previously demonstrated, Treg cells promote
muscle repair, accumulating in both acutely and chronically
injured skeletal muscles (Burzyn et al., 2013; Castiglioni et al.,
2015; Panduro et al., 2018). Interestingly, a severe decline in
Treg accumulation, caused by an impairment in IL-33-producing
FAPs, has been linked to regeneration defects in aged muscles
(Kuswanto et al., 2016). On the other hand, in vivo treatment with
IL-33 restored the Treg population in injured muscles of old mice,
enhancing tissue regeneration.
Intriguingly, IL-33-expressing FAPs have been found in
close association with muscle spindles (Kuswanto et al., 2016),
which are stretch-sensitive mechanoreceptors that lie within
the skeletal muscle and comprise both sensory and motor
neurons. This finding raises the possibility that FAPs might
function as mechano-cellular sensors that modulate the cross-
talk between neural and immune cells to facilitate proper
homeostatic reorganization of skeletal muscle and neural circuits
upon injury. In agreement with this possibility, IL-33 expression
is increased in fibroblasts upon mechanical stress (Kakkar et al.,
2012) and PDGFRα+ mesenchymal precursors, found within the
endoneurium of peripheral nerves, have been recently implicated
in tissue repair and regeneration (Carr et al., 2019).
WISP1
Wnt family member 1 (WNT1) inducible signaling pathway
protein 1 (WISP1) is encoded by the cellular communication
network factor 4 (CCN4) gene, a member of the CCN family
of matricellular proteins that are involved in diverse biological
processes, such as ECM remodeling, tissue repair, and tumor
growth. CCN4/WISP1 is important in the musculoskeletal
system, where it regulates osteogenesis and chondrogenesis, as
well as skin repair (Ono et al., 2011, 2018; Maeda et al., 2015).
A recent study showed that in young mice CCN4/WISP1
is upregulated in FAPs following muscle injury, but this
induction is lost in FAPs of old muscles (Lukjanenko et al.,
2019). The FAP-secreted WISP1 plays an important role in
SCs expansion and asymmetric commitment to myogenic
differentiation. Indeed, similar to aging, the loss of WISP1 in
knockout mice affects SCs function and impairs myogenesis.
In agreement with this, the transplantation of young, but not
aged or WISP−/− FAPs, rescues the myogenic dysfunction of
aged SCs and their regeneration ability (Lukjanenko et al., 2019).
Even better, systemic treatment with recombinant WISP1 mimics
rejuvenation beneficial effects, opening new prospects in the use
of this approach as a strategy to counteract aging and associated
muscular diseases.
Interestingly, these findings together with the reported
impaired interplay between FAPs and Treg during aging
(Kuswanto et al., 2016), the sensitivity of FAPs to muscle
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FIGURE 1 | Schematic illustration showing the known mediators that govern the interaction between FAPs, muscle stem cells (MuSCs), and the different immune
cells in skeletal muscle homeostasis. Green arrows (TGF-β, IL-13, IL-4, and IL-15) indicate the molecules that positively regulate FAPs expansion. Blue arrows (IL-33,
IL-6, Follistatin, IL-10, WISP1, MMP-14, and BMP-1) represent the molecules secreted by FAPs that act on the different cell targets. Red lines (TNF-α, IL-4, IL-13,
and IL-15) show the factors that inhibit the fibro-adipogenic differentiation of FAPs.
denervation (Madaro et al., 2018), and the recently reported
atrophic phenotype of FAPs-depleted skeletal muscles (Wosczyna
et al., 2019) clearly point toward FAPs as promising new
cellular targets for the treatment of muscle defects associated
with sarcopenia.
Follistatin
Follistatin is a potent natural antagonist of myostatin and activin
A, two TGF-β superfamily cytokines implicated in muscle growth
inhibition, and it is therefore a potent pro-myogenic factor (Lee,
2007; Nakatani et al., 2008; Guo et al., 2009; Kota et al., 2009;
Rodino-Klapac et al., 2009; Winbanks et al., 2012).
In the context of skeletal muscle regeneration, follistatin
expression is induced 12 h after muscle injury (Iezzi et al., 2004)
and remains elevated for 5 days, concurrent with SCs
activation. Of note, FAPs have been described as the major
source of follistatin, displaying 10-fold higher expression
levels than SCs (Mozzetta et al., 2013; Formicola et al.,
2019). Follistatin is considered the central mediator of the
fusogenic effects exerted by histone deacetylase inhibitors
(HDACi) on skeletal muscles (Iezzi et al., 2004; Minetti
et al., 2006; Mozzetta et al., 2013). Indeed, HDACi treatment
in dystrophic mice induces the upregulation of follistatin
in muscle progenitor cells, promoting the formation of
multinucleated myotubes. In agreement with its pro-
myogenic activity, follistatin knock-down in FAPs reduced
the ability of HDACi to stimulate SCs-mediated formation of
myotubes, suggesting a crucial role of FAP-derived follistatin
as a mediator of the pro-differentiative activity of FAPs
(Mozzetta et al., 2013).
A proper balance between follistatin and its antagonists is
crucial to preserve reciprocal functional interactions between
FAPs and SCs and to preserve muscle homeostasis (Baccam et al.,
2019; Formicola et al., 2019). Indeed, pharmacological inhibition
of the activin receptor type-2B pathway (AcvR2B), which
blocks both myostatin and activin A activity, reverses muscle
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atrophy in SC-depleted skeletal muscles, while also restoring
stem cells regenerative potential (Formicola et al., 2019). Of
note, beneficial effects of AcvR2B targeting in SCs-depleted
muscles are accompanied by an increased number of FAPs
(Formicola et al., 2019), an observation that further supports the
notion that restoration of a proper balance of regulatory factors
between the different cells within the regenerative niche is key
for muscle repair.
Once again, a role of FAPs emerges not only in regulating
muscle regeneration but also in mediating signaling pathways
associated with maintaining muscle mass. Future experiments
should elucidate the possible use of FAPs as a source of
trophic factors.
IL-10
Interleukin is a broadly expressed anti-inflammatory cytokine
that inhibits the activation of the innate immune system
and Th1 activation, preventing inflammatory and autoimmune
pathologies (Saraiva and O’Garra, 2010; Ouyang et al., 2011).
Like IL-6, IL-10 is also considered a myokine expressed in
skeletal muscle in a wide range of conditions. It influences
different aspects of muscle biology, such as regeneration, exercise,
metabolism, and aging (Furmanczyk and Quinn, 2003; Nunes
et al., 2008; Villalta et al., 2011; Deng et al., 2012; Dagdeviren et al.,
2016, 2017). Its anti-inflammatory activity has been investigated
in different muscle-related disorders (Hong et al., 2009; Nitahara-
Kasahara et al., 2014; Villalta et al., 2014; Dagdeviren et al.,
2016, 2017; Zhang et al., 2018). The main source of IL-10 in
regenerating skeletal muscle is macrophages and Tregs (Villalta
et al., 2011, 2014; Deng et al., 2012) although it has also been
demonstrated that FAPs increase IL-10 expression upon muscle
damage (Lemos et al., 2012). This evidence is in line with the
crucial pro-myogenic activity of FAPs, which likely contribute to
muscle repair also through the secretion of an anti-inflammatory
cytokine, such as IL-10, to counteract the anti-myogenic activity
of TNF-α. Although the function of IL-10 released by FAPs has
not yet been demonstrated in vivo, this work underscores the
complexity of the interplay between inflammatory cells and the
other players in muscle regeneration. Future studies are needed
to better understand this mechanism.
CONCLUDING REMARKS
In conclusion, the available evidence reviewed above clearly
indicates that FAPs act as crucial regulators of skeletal muscle
homeostasis (Figure 1). However, several critical issues need
to be addressed before defining them as the co-star of
skeletal muscle repair. First, their molecular heterogeneity
makes it difficult to target them genetically, to uniquely assess
their requirement, and to define the function of FAP-specific
expression of the different factors described above. Future
single-cell transcriptomic approaches will help identify sub-
populations differently altered during the diverse stages of muscle
regeneration and, more importantly, in pathological situations.
Finally, the evidence of the association of FAPs with nerve
structures (Kuswanto et al., 2016), and the ability of FAPs to
respond to nerve lesions (Contreras et al., 2016; Madaro et al.,
2018), suggest a mechano-sensitivity of FAPs and emphasize
the urgency to improve our understanding of the molecular
regulation governing FAPs activity during muscle adaptation.
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